U.S. patent application number 15/994901 was filed with the patent office on 2018-12-06 for ire1 small molecule inhibitors.
The applicant listed for this patent is QUENTIS THERAPEUTICS, INC.. Invention is credited to Sarah BETTIGOLE, Dansu LI, Joseph P. VACCA.
Application Number | 20180346446 15/994901 |
Document ID | / |
Family ID | 64455585 |
Filed Date | 2018-12-06 |
United States Patent
Application |
20180346446 |
Kind Code |
A1 |
VACCA; Joseph P. ; et
al. |
December 6, 2018 |
IRE1 SMALL MOLECULE INHIBITORS
Abstract
Provided herein are small molecule inhibitors for the targeting
or IRE1 protein family members. Binding may be direct or indirect.
Further provided herein are methods of using IRE1 small molecule
inhibitors for use in treating or ameliorating cancer in a subject.
Moreover, IRE1 small molecule inhibitors described herein are for
the treatment of cancer, where the cancer is a solid or hematologic
cancer.
Inventors: |
VACCA; Joseph P.; (New York,
NY) ; LI; Dansu; (New York, NY) ; BETTIGOLE;
Sarah; (New York, NY) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
QUENTIS THERAPEUTICS, INC. |
New York |
NY |
US |
|
|
Family ID: |
64455585 |
Appl. No.: |
15/994901 |
Filed: |
May 31, 2018 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
62513929 |
Jun 1, 2017 |
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
A61P 35/00 20180101;
C07D 417/04 20130101; C07D 401/12 20130101; C07D 239/84 20130101;
C07D 413/04 20130101; C07D 401/04 20130101; C07D 217/22 20130101;
C07D 403/04 20130101 |
International
Class: |
C07D 403/04 20060101
C07D403/04; C07D 239/84 20060101 C07D239/84; C07D 401/04 20060101
C07D401/04; C07D 417/04 20060101 C07D417/04; C07D 413/04 20060101
C07D413/04; C07D 217/22 20060101 C07D217/22; C07D 401/12 20060101
C07D401/12; A61P 35/00 20060101 A61P035/00 |
Claims
1. A compound of Formula (I), or a pharmaceutically acceptable
salt, or solvate thereof: ##STR00294## wherein, ##STR00295## is a
substituted C.sub.3-C.sub.10 cycloalkyl that is substituted with
1-3R.sup.1 and 0-3R.sup.2; each R.sup.1 is independently
--OR.sup.6, --SR.sup.6, --S(.dbd.O)R.sup.7,
--S(.dbd.O).sub.2R.sup.7, or --N(R.sup.6).sub.2; each R.sup.2 is
independently H, halogen, --CN, --OR.sup.8, --SR.sup.8,
--S(.dbd.O)R.sup.9, --S(.dbd.O).sub.2R.sup.9,
--S(.dbd.O).sub.2N(R.sup.8).sub.2,
--NR.sup.8S(.dbd.O).sub.2R.sup.9, --C(.dbd.O)R.sup.9,
--OC(.dbd.O)R.sup.9, --CO.sub.2R.sup.8, --CO.sub.2R.sup.9,
--N(R.sup.8).sub.2, --OC(.dbd.O)N(R.sup.8).sub.2,
--NR.sup.8C(.dbd.O)R.sup.9, --NR.sup.8C(.dbd.O)OR.sup.9, optionally
substituted C.sub.1-C.sub.4alkyl, optionally substituted
C.sub.1-C.sub.4fluoroalkyl, optionally substituted
C.sub.1-C.sub.4heteroalkyl, optionally substituted
C.sub.3-C.sub.6cycloalkyl, optionally substituted aryl, or
optionally substituted heteroaryl; each R.sup.6 is independently H,
optionally substituted C.sub.1-C.sub.4alkyl, optionally substituted
C.sub.1-C.sub.4heteroalkyl, optionally substituted
C.sub.1-C.sub.4fluoroalkyl, --X-optionally substituted
C.sub.1-C.sub.4alkyl, --X-optionally substituted
C.sub.1-C.sub.4heteroalkyl, --X-optionally substituted
C.sub.1-C.sub.4fluoroalkyl, optionally substituted
C.sub.3-C.sub.6cycloalkyl, optionally substituted
C.sub.2-C.sub.10heterocycloalkyl, optionally substituted aryl, or
optionally substituted heteroaryl; or two R.sup.6 are taken
together with the N atom to which they are attached to form an
optionally substituted heterocycle; X is --(C.dbd.O)--; each
R.sup.7 is independently optionally substituted
C.sub.1-C.sub.4alkyl, optionally substituted
C.sub.1-C.sub.4heteroalkyl, optionally substituted
C.sub.1-C.sub.4fluoroalkyl, optionally substituted
C.sub.3-C.sub.6cycloalkyl, optionally substituted
C.sub.2-C.sub.10heterocycloalkyl, optionally substituted aryl, or
optionally substituted heteroaryl; each R.sup.8 is independently H,
optionally substituted C.sub.1-C.sub.4alkyl, optionally substituted
C.sub.1-C.sub.4heteroalkyl, optionally substituted
C.sub.1-C.sub.4fluoroalkyl, optionally substituted
C.sub.3-C.sub.6cycloalkyl, optionally substituted
C.sub.2-C.sub.10heterocycloalkyl, optionally substituted aryl, or
optionally substituted heteroaryl; or two R.sup.8 are taken
together with the N atom to which they are attached to form an
optionally substituted heterocycle; each R.sup.9 is independently
optionally substituted C.sub.1-C.sub.4alkyl, optionally substituted
C.sub.1-C.sub.4heteroalkyl, or optionally substituted
C.sub.1-C.sub.4fluoroalkyl, optionally substituted
C.sub.3-C.sub.6cycloalkyl, optionally substituted
C.sub.2-C.sub.10heterocycloalkyl, optionally substituted aryl, or
optionally substituted heteroaryl; A.sup.2 is N or CR.sup.A;
R.sup.A, R.sup.A1, R.sup.A2, and R.sup.A3 are each independently H,
halogen, optionally substituted C.sub.1-C.sub.4alkyl, optionally
substituted C.sub.1-C.sub.4fluoroalkyl, optionally substituted
aryl, or --OR.sup.10; R.sup.10 is independently H, optionally
substituted C.sub.1-C.sub.4alkyl, optionally substituted
C.sub.1-C.sub.4fluoroalkyl, optionally substituted
C.sub.1-C.sub.4heteroalkyl, optionally substituted
C.sub.3-C.sub.6cycloalkyl, optionally substituted
C.sub.2-C.sub.10heterocycloalkyl, optionally substituted aryl, or
optionally substituted heteroaryl; ring A is a monocyclic
carbocycle or a monocyclic heterocycle; each R.sup.3 is
independently H, halogen, --CN, --OR.sup.11, --SR.sup.11,
--N(R.sup.11).sub.2, optionally substituted C.sub.1-C.sub.4alkyl,
optionally substituted C.sub.1-C.sub.4fluoroalkyl, optionally
substituted C.sub.1-C.sub.4heteroalkyl, optionally substituted
C.sub.3-C.sub.6cycloalkyl, optionally substituted
C.sub.2-C.sub.10heterocycloalkyl, optionally substituted aryl, or
optionally substituted heteroaryl; each R.sup.11 is independently
H, optionally substituted C.sub.1-C.sub.4alkyl, optionally
substituted C.sub.1-C.sub.4fluoroalkyl, optionally substituted
C.sub.1-C.sub.4heteroalkyl, optionally substituted
C.sub.3-C.sub.6cycloalkyl, optionally substituted
C.sub.2-C.sub.10heterocycloalkyl, optionally substituted aryl, or
optionally substituted heteroaryl; n is 0, 1, 2, 3, or 4; R.sup.4
and R.sup.5 are each independently H, halogen, --CN, --OR.sup.12,
--SR.sup.12, --N(R.sup.12).sub.2, optionally substituted
C.sub.1-C.sub.4alkyl, optionally substituted
C.sub.1-C.sub.4fluoroalkyl, optionally substituted
C.sub.1-C.sub.4heteroalkyl, optionally substituted
C.sub.3-C.sub.6cycloalkyl, optionally substituted
C.sub.2-C.sub.10heterocycloalkyl, optionally substituted aryl, or
optionally substituted heteroaryl; and R.sup.12 is independently H,
optionally substituted C.sub.1-C.sub.4alkyl, optionally substituted
C.sub.1-C.sub.4fluoroalkyl, optionally substituted
C.sub.1-C.sub.4heteroalkyl, optionally substituted
C.sub.3-C.sub.6cycloalkyl, optionally substituted
C.sub.2-C.sub.10heterocycloalkyl, optionally substituted aryl, or
optionally substituted heteroaryl.
2. (canceled)
3. The compound of claim 1, or a pharmaceutically acceptable salt,
or solvate thereof, wherein ##STR00296## and q is 0, 1, 2, or
3.
4. (canceled)
5. The compound of claim 3, or a pharmaceutically acceptable salt,
or solvate thereof, wherein ##STR00297## and q is 0, 1, 2, or
3.
6. (canceled)
7. The compound of claim 5, or a pharmaceutically acceptable salt,
or solvate thereof, wherein each R.sup.6 is independently H,
optionally substituted C.sub.1-C.sub.4alkyl, optionally substituted
C.sub.1-C.sub.4heteroalkyl, optionally substituted
C.sub.1-C.sub.4fluoroalkyl, --X-optionally substituted
C.sub.1-C.sub.4alkyl, --X-optionally substituted
C.sub.1-C.sub.4heteroalkyl, or --X-optionally substituted
C.sub.1-C.sub.4fluoroalkyl; and each R.sup.2 is independently H,
optionally substituted C.sub.1-C.sub.4alkyl, optionally substituted
C.sub.1-C.sub.4heteroalkyl, or optionally substituted
C.sub.1-C.sub.4fluoroalkyl.
8. The compound of claim 7, or a pharmaceutically acceptable salt,
or solvate thereof, wherein each R.sup.6 is independently H.
9. (canceled)
10. The compound of claim 5, or a pharmaceutically acceptable salt,
or solvate thereof, wherein ##STR00298## R.sup.6 is H, optionally
substituted C.sub.1-C.sub.4alkyl, optionally substituted
C.sub.1-C.sub.4heteroalkyl, optionally substituted
C.sub.1-C.sub.4fluoroalkyl, --X-optionally substituted
C.sub.1-C.sub.4alkyl, --X-optionally substituted
C.sub.1-C.sub.4heteroalkyl, or --X-optionally substituted
C.sub.1-C.sub.4fluoroalkyl; q is 0 or 1; and R.sup.2 is H,
optionally substituted C.sub.1-C.sub.4alkyl, optionally substituted
C.sub.1-C.sub.4heteroalkyl, or optionally substituted
C.sub.1-C.sub.4fluoroalkyl.
11. The compound of claim 10, or a pharmaceutically acceptable
salt, or solvate wherein R.sup.6 is optionally substituted
C.sub.1-C.sub.4alkyl, optionally substituted
C.sub.1-C.sub.4heteroalkyl, optionally substituted
C.sub.1-C.sub.4fluoroalkyl, --X-optionally substituted
C.sub.1-C.sub.4alkyl, --X-optionally substituted
C.sub.1-C.sub.4heteroalkyl, or --X-optionally substituted
C.sub.1-C.sub.4fluoroalkyl.
12. The compound of claim 1, or a pharmaceutically acceptable salt,
or solvate thereof, wherein A.sup.2 is N.
13.-16. (canceled)
17. The compound of claim 1, or a pharmaceutically acceptable salt,
or solvate thereof, wherein R.sup.A1 is H.
18. The compound of claim 1, or a pharmaceutically acceptable salt,
or solvate thereof, wherein R.sup.A2 is H, optionally substituted
C.sub.1-C.sub.4alkyl, or optionally substituted
C.sub.1-C.sub.4fluoroalkyl.
19.-20. (canceled)
21. The compound of claim 1, or a pharmaceutically acceptable salt,
or solvate thereof, wherein R.sup.A3 is H, halogen, optionally
substituted C.sub.1-C.sub.4alkyl, optionally substituted
C.sub.1-C.sub.4fluoroalkyl, or --OR.sup.10.
22. The compound of claim 21, or a pharmaceutically acceptable
salt, or solvate thereof, wherein R.sup.A3 is optionally
substituted C.sub.1-C.sub.4alkyl.
23.-26. (canceled)
27. The compound of claim 1, or a pharmaceutically acceptable salt,
or solvate thereof, wherein: ##STR00299##
28.-30. (canceled)
31. The compound of claim 1, or a pharmaceutically acceptable salt,
or solvate thereof, wherein: ##STR00300##
32. The compound of claim 31, or a pharmaceutically acceptable
salt, or solvate thereof, wherein: ##STR00301##
33.-39. (canceled)
40. The compound of claim 1, or a pharmaceutically acceptable salt,
or solvate thereof, wherein each R.sup.3 is independently H,
halogen, --CN, --OR.sup.11, --SR.sup.11, optionally substituted
C.sub.1-C.sub.4alkyl, or optionally substituted
C.sub.1-C.sub.4fluoroalkyl; and n is 1, 2, or 3.
41. The compound of claim 40, or a pharmaceutically acceptable
salt, or solvate thereof, wherein R.sup.3 is optionally substituted
C.sub.1-C.sub.4alkyl.
42.-48. (canceled)
49. The compound of claim 1, or a pharmaceutically acceptable salt,
or solvate thereof, wherein R.sup.4 is halogen or optionally
substituted C.sub.1-C.sub.4alkyl.
50.-57. (canceled)
58. The compound of claim 1, or a pharmaceutically acceptable salt,
or solvate thereof, wherein R.sup.5 is H.
59.-94. (canceled)
95. The compound of claim 1, or a pharmaceutically acceptable salt,
or solvate thereof, wherein the compound has the structure of
formula (Id) ##STR00302## and R.sup.A3 is optionally substituted
C.sub.1-C.sub.4 alkyl.
96. The compound of claim 95, or a pharmaceutically acceptable
salt, or solvate thereof, wherein the compound has the structure of
formula (Ie) ##STR00303##
97. The compound of claim 95, or a pharmaceutically acceptable
salt, or solvate thereof, wherein the compound has the structure of
formula (If) ##STR00304##
98. (canceled)
99. The compound of claim 97, or a pharmaceutically acceptable
salt, or solvate thereof, wherein R.sup.4 and R.sup.5 are each
independently H, halogen, --CN, --OR.sup.12, --SR.sup.12,
--N(R.sup.12).sub.2, optionally substituted C.sub.1-C.sub.4alkyl,
or optionally substituted C.sub.1-C.sub.4fluoroalkyl.
100. The compound of claim 1, or a pharmaceutically acceptable
salt, or solvate thereof, wherein the compound is a compound
selected from:
N-(5-(2-(((1r,4r)-4-aminocyclohexyl)amino)quinazolin-6-yl)-1-methyl-1H-py-
razol-3-yl)-2-chlorobenzenesulfonamide;
N-(4-(2-(((1r,4r)-4-aminocyclohexyl)amino)quinazolin-6-yl)-3-methylphenyl-
)-2-chlorobenzenesulfonamide; N-(4-(2-(((1
r,4r)-4-aminocyclohexyl)amino)-8-ethylquinazolin-6-yl)-3-methylphenyl)-2--
chlorobenzenesulfonamide; N-(5-(2-(((1
r,4r)-4-aminocyclohexyl)amino)-8-ethylquinazolin-6-yl)-4-methylpyridin-2--
yl)-2-chlorobenzenesulfonamide; N-(5-(2-(((1
r,4r)-4-aminocyclohexyl)amino)quinazolin-6-yl)-4-methylpyridin-2-yl)-2-ch-
lorobenzenesulfonamide; N-(5-(2-(((1
r,4r)-4-aminocyclohexyl)amino)-8-ethylquinazolin-6-yl)-1-methyl-1H-pyrazo-
l-3-yl)-2-chlorobenzenesulfonamide; N-(4-(2-(((1
r,4r)-4-aminocyclohexyl)amino)-8-ethylquinazolin-6-yl)-3-methylphenyl)-2--
(trifluoromethyl)benzenesulfonamide; N-(4-(2-(((1
r,4r)-4-aminocyclohexyl)amino)-8-ethylquinazolin-6-yl)-3-methylphenyl)-2--
(trifluoromethoxy)benzenesulfonamide; N-(4-(2-(((1
r,4r)-4-aminocyclohexyl)amino)-8-ethylquinazolin-6-yl)-3-methylphenyl)-2,-
5-dichlorobenzenesulfonamide; N-(4-(2-(((1
r,4r)-4-aminocyclohexyl)amino)-8-ethylquinazolin-6-yl)-3-methylphenyl)-2--
fluorobenzenesulfonamide;
N-(4-(2-(((1r,4r)-4-aminocyclohexyl)amino)quinazolin-6-yl)-3-methylphenyl-
)-3-chlorobenzenesulfonamide; N-(4-(2-(((1
r,4r)-4-aminocyclohexyl)amino)-8-ethylquinazolin-6-yl)-3-methylphenyl)-4--
chlorobenzenesulfonamide; N-(4-(2-(((1
r,4r)-4-aminocyclohexyl)amino)-8-ethylquinazolin-6-yl)-3-methylphenyl)-2--
methoxybenzenesulfonamide; N-(4-(2-(((1
r,4r)-4-aminocyclohexyl)amino)-8-ethylquinazolin-6-yl)-3-(trifluoromethyl-
)phenyl)-2-chlorobenzenesulfonamide; N-(4-(2-(((1
r,4r)-4-aminocyclohexyl)amino)-8-ethylquinazolin-6-yl)-3-methylphenyl)ben-
zenesulfonamide; N-(5-(2-(((1
r,4r)-4-aminocyclohexyl)amino)-8-ethylquinazolin-6-yl)-6-methylpyridin-2--
yl)-2-chlorobenzenesulfonamide; N-(4-(2-(((1
r,4r)-4-aminocyclohexyl)amino)-8-ethylquinazolin-6-yl)-3-chlorophenyl)-2--
chlorobenzenesulfonamide; N-(4-(2-(((1
r,4r)-4-aminocyclohexyl)amino)-8-ethylquinazolin-6-yl)phenyl)-2-chloroben-
zenesulfonamide; N-(4-(2-(((1
r,4r)-4-aminocyclohexyl)amino)-8-ethylquinazolin-6-yl)-3-methoxyphenyl)-2-
-chlorobenzenesulfonamide;
N-(6-(2-(((1r,4r)-4-aminocyclohexyl)amino)-8-ethylquinazolin-6-yl)-5-meth-
ylpyridin-3-yl)-2-chlorobenzenesulfonamide; N-(4-(2-(((1
r,4r)-4-aminocyclohexyl)amino)-8-ethylquinazolin-6-yl)-2-fluoro-5-methylp-
henyl)-2-chlorobenzenesulfonamide; or N-(4-(2-(((1
r,4r)-4-aminocyclohexyl)amino)-8-ethylquinazolin-6-yl)-2,3-dimethylphenyl-
)-2-chlorobenzenesulfonamide.
101.-143. (canceled)
144. A pharmaceutical composition comprising: a compound according
to claim 1, or a pharmaceutically acceptable salt or solvate
thereof; and one or more pharmaceutically acceptable
excipients.
145. (canceled)
146. A method for treating or ameliorating the effects of a disease
associated with altered IRE1 signaling, the method comprising
administering to a subject in need thereof a pharmaceutical
composition, wherein the pharmaceutical composition comprises a
compound of claim 1.
147. The method of claim 146, wherein the disease is cancer.
148. (canceled)
149. The method of claim 147, wherein the cancer is ovarian cancer,
breast cancer, or triple negative breast cancer (TNBC).
150.-154. (canceled)
155. The compound of claim 1, or a pharmaceutically acceptable
salt, or solvate thereof, wherein: ##STR00305## and q is 0, 1, 2,
or 3; each R.sup.6 is independently H, optionally substituted
C.sub.1-C.sub.4alkyl, optionally substituted
C.sub.1-C.sub.4heteroalkyl, optionally substituted
C.sub.1-C.sub.4fluoroalkyl, --X-optionally substituted
C.sub.1-C.sub.4alkyl, --X-optionally substituted
C.sub.1-C.sub.4heteroalkyl, or --X-optionally substituted
C.sub.1-C.sub.4fluoroalkyl; each R.sup.2 is independently H,
optionally substituted C.sub.1-C.sub.4alkyl, optionally substituted
C.sub.1-C.sub.4heteroalkyl, or optionally substituted
C.sub.1-C.sub.4fluoroalkyl; A.sup.2 is N; R.sup.A1 is H; R.sup.A3
is methyl, ethyl, propyl or butyl; R.sup.4 is --Cl, --Br, --F, or
--I; R.sup.5 is hydrogen; R.sup.A2 is H; ring A is pyridinylene; n
is 1, 2, or 3; and R.sup.3 is methyl, ethyl, propyl, or butyl; or
R.sup.3 is --OR.sup.11 and R.sup.11 is methyl, ethyl, propyl, or
butyl; or R.sup.3 is --OR.sup.11 and R.sup.11 is CF.sub.3 or
--CH.sub.2CF.sub.3.
Description
CROSS-REFERENCE
[0001] This application claims benefit of U.S. Provisional Patent
Application No. 62/513,929 filed on Jun. 1, 2017, which is
incorporated herein by reference in its entirety.
SEQUENCE LISTING
[0002] The instant application contains a Sequence Listing which
has been submitted electronically in ASCII format and is hereby
incorporated by reference in its entirety. Said ASCII copy, created
on May 23, 2018, is named 51089-711_201_SL.txt and is 23,840 bytes
in size.
BACKGROUND
[0003] Aggressive tumors have evolved strategies that enable them
to thrive under constant adverse conditions. For example, cancer
cells respond to hypoxia, nutrient starvation, oxidative stress,
and high metabolic demand by adjusting their protein folding
capacity via the endoplasmic reticulum (ER) stress response
pathway. There exists a need for improved methods and compositions
to target cancer cells and counter their mechanisms of
survival.
BRIEF SUMMARY
[0004] Provided in one aspect is a compound of Formula (I), or a
pharmaceutically acceptable salt, or solvate thereof:
##STR00001##
wherein,
##STR00002##
is a substituted C.sub.3-C.sub.10 cycloalkyl that is substituted
with 1-3R.sup.1 and 0-3R.sup.2; [0005] each R.sup.1 is
independently --OR.sup.6, --SR.sup.6, --S(.dbd.O)R.sup.7,
--S(.dbd.O).sub.2R.sup.7, or --N(R.sup.6).sub.2; [0006] each
R.sup.2 is independently H, halogen, --CN, --OR.sup.8, --SR,
--S(.dbd.O)R.sup.9, --S(.dbd.O).sub.2R.sup.9,
--S(.dbd.O).sub.2N(R.sup.8).sub.2,
--NR.sup.8S(.dbd.O).sub.2R.sup.9, --C(.dbd.O)R.sup.9,
--OC(.dbd.O)R.sup.9, --CO.sub.2R.sup.8, --OCO.sub.2R.sup.9,
--N(R.sup.8).sub.2, --OC(.dbd.O)N(R.sup.8).sub.2, --NR
C(.dbd.O)R.sup.9, --NR.sup.8C(.dbd.O)OR.sup.9, optionally
substituted C.sub.1-C.sub.4alkyl, optionally substituted
C.sub.1-C.sub.4fluoroalkyl, optionally substituted
C.sub.1-C.sub.4heteroalkyl, optionally substituted
C.sub.3-C.sub.6cycloalkyl, optionally substituted aryl, or
optionally substituted heteroaryl; [0007] each R.sup.6 is
independently H, optionally substituted C.sub.1-C.sub.4alkyl,
optionally substituted C.sub.1-C.sub.4heteroalkyl, optionally
substituted C.sub.1-C.sub.4fluoroalkyl, --X-optionally substituted
C.sub.1-C.sub.4alkyl, --X-optionally substituted
C.sub.1-C.sub.4heteroalkyl, --X-optionally substituted
C.sub.1-C.sub.4fluoroalkyl, optionally substituted
C.sub.3-C.sub.6cycloalkyl, optionally substituted
C.sub.2-C.sub.10heterocycloalkyl, optionally substituted aryl, or
optionally substituted heteroaryl; [0008] or two R.sup.6 are taken
together with the N atom to which they are attached to form an
optionally substituted heterocycle; [0009] X is --(C.dbd.O)--;
[0010] each R.sup.7 is independently optionally substituted
C.sub.1-C.sub.4alkyl, optionally substituted
C.sub.1-C.sub.4heteroalkyl, optionally substituted
C.sub.1-C.sub.4fluoroalkyl, optionally substituted
C.sub.3-C.sub.6cycloalkyl, optionally substituted
C.sub.2-C.sub.10heterocycloalkyl, optionally substituted aryl, or
optionally substituted heteroaryl; [0011] each R.sup.8 is
independently H, optionally substituted C.sub.1-C.sub.4alkyl,
optionally substituted C.sub.1-C.sub.4heteroalkyl, optionally
substituted C.sub.1-C.sub.4fluoroalkyl, optionally substituted
C.sub.3-C.sub.6cycloalkyl, optionally substituted
C.sub.2-C.sub.10heterocycloalkyl, optionally substituted aryl, or
optionally substituted heteroaryl; [0012] or two R.sup.8 are taken
together with the N atom to which they are attached to form an
optionally substituted heterocycle; [0013] each R.sup.9 is
independently optionally substituted C.sub.1-C.sub.4alkyl,
optionally substituted C.sub.1-C.sub.4heteroalkyl, or optionally
substituted C.sub.1-C.sub.4fluoroalkyl, optionally substituted
C.sub.3-C.sub.6cycloalkyl, optionally substituted
C.sub.2-C.sub.10heterocycloalkyl, optionally substituted aryl, or
optionally substituted heteroaryl; [0014] A.sup.2 is N or CR.sup.A;
[0015] R.sup.A, R.sup.A1, R.sup.A2, and R.sup.A3 are each
independently H, halogen, optionally substituted
C.sub.1-C.sub.4alkyl, optionally substituted
C.sub.1-C.sub.4fluoroalkyl, optionally substituted aryl, or
--OR.sup.10; [0016] R.sup.10 is independently H, optionally
substituted C.sub.1-C.sub.4alkyl, optionally substituted
C.sub.1-C.sub.4fluoroalkyl, optionally substituted
C.sub.1-C.sub.4heteroalkyl, optionally substituted
C.sub.3-C.sub.6cycloalkyl, optionally substituted
C.sub.2-C.sub.10heterocycloalkyl, optionally substituted aryl, or
optionally substituted heteroaryl; [0017] ring A is a monocyclic
carbocycle or a monocyclic heterocycle; [0018] each R.sup.3 is
independently H, halogen, --CN, --OR.sup.11, --SR.sup.11,
--N(R.sup.11).sub.2, optionally substituted C.sub.1-C.sub.4alkyl,
optionally substituted C.sub.1-C.sub.4fluoroalkyl, optionally
substituted C.sub.1-C.sub.4heteroalkyl, optionally substituted
C.sub.3-C.sub.6cycloalkyl, optionally substituted
C.sub.2-C.sub.10heterocycloalkyl, optionally substituted aryl, or
optionally substituted heteroaryl; [0019] each R.sup.11 is
independently H, optionally substituted C.sub.1-C.sub.4alkyl,
optionally substituted C.sub.1-C.sub.4fluoroalkyl, optionally
substituted C.sub.1-C.sub.4heteroalkyl, optionally substituted
C.sub.3-C.sub.6cycloalkyl, optionally substituted
C.sub.2-C.sub.10heterocycloalkyl, optionally substituted aryl, or
optionally substituted heteroaryl; [0020] n is 0, 1, 2, 3, or 4;
[0021] R.sup.4 and R.sup.5 are each independently H, halogen, --CN,
--OR.sup.12, --SR.sup.12, --N(R.sup.12).sub.2, optionally
substituted C.sub.1-C.sub.4alkyl, optionally substituted
C.sub.1-C.sub.4fluoroalkyl, optionally substituted
C.sub.1-C.sub.4heteroalkyl, optionally substituted
C.sub.3-C.sub.6cycloalkyl, optionally substituted
C.sub.2-C.sub.10heterocycloalkyl, optionally substituted aryl, or
optionally substituted heteroaryl; and [0022] R.sup.12 is
independently H, optionally substituted C.sub.1-C.sub.4alkyl,
optionally substituted C.sub.1-C.sub.4fluoroalkyl, optionally
substituted C.sub.1-C.sub.4heteroalkyl, optionally substituted
C.sub.3-C.sub.6cycloalkyl, optionally substituted
C.sub.2-C.sub.10heterocycloalkyl, optionally substituted aryl, or
optionally substituted heteroaryl.
[0023] In some embodiments,
##STR00003##
is substituted C.sub.4-C.sub.7 cycloalkyl that is substituted with
1-3R.sup.1 and 0-3R.sup.2.
[0024] In some embodiments
##STR00004##
and
[0025] q is 0, 1, 2, or 3.
[0026] In some embodiments,
##STR00005##
and [0027] q is 0, 1, 2, or 3.
[0028] In some embodiments,
##STR00006##
and [0029] q is 0, 1, 2, or 3.
[0030] In some embodiments, q is 0 or 1. In some embodiments, each
R.sup.6 is independently H, optionally substituted
C.sub.1-C.sub.4alkyl, optionally substituted
C.sub.1-C.sub.4heteroalkyl, optionally substituted
C.sub.1-C.sub.4fluoroalkyl, --X-optionally substituted
C.sub.1-C.sub.4alkyl, --X-optionally substituted
C.sub.1-C.sub.4heteroalkyl, or --X-optionally substituted
C.sub.1-C.sub.4fluoroalkyl. In some embodiments, each R.sup.6 is
independently H. In some embodiments, each R.sup.2 is independently
H, optionally substituted C.sub.1-C.sub.4alkyl, optionally
substituted C.sub.1-C.sub.4heteroalkyl, or optionally substituted
C.sub.1-C.sub.4fluoroalkyl.
[0031] In some embodiments
##STR00007##
R.sup.6 is H, optionally substituted C.sub.1-C.sub.4alkyl,
optionally substituted C.sub.1-C.sub.4heteroalkyl, optionally
substituted C.sub.1-C.sub.4fluoroalkyl, --X-optionally substituted
C.sub.1-C.sub.4alkyl, --X-optionally substituted
C.sub.1-C.sub.4heteroalkyl, or --X-optionally substituted
C.sub.1-C.sub.4fluoroalkyl; q is 0 or 1; and R.sup.2 is H,
optionally substituted C.sub.1-C.sub.4alkyl, optionally substituted
C.sub.1-C.sub.4heteroalkyl, or optionally substituted
C.sub.1-C.sub.4fluoroalkyl.
[0032] In some embodiments, R.sup.6 is H. In some embodiments,
A.sup.2 is N. In some embodiments, A.sup.2 is CR.sup.A. In some
embodiments, R.sup.A is H, optionally substituted
C.sub.1-C.sub.4alkyl, or optionally substituted
C.sub.1-C.sub.4fluoroalkyl. In some embodiments, R.sup.A is H. In
some embodiments, R.sup.A1 is H, optionally substituted
C.sub.1-C.sub.4alkyl, or optionally substituted
C.sub.1-C.sub.4fluoroalkyl. In some embodiments, R.sup.A1 is H. In
some embodiments, R.sup.A2 is H, optionally substituted
C.sub.1-C.sub.4alkyl, or optionally substituted
C.sub.1-C.sub.4fluoroalkyl. In some embodiments, R.sup.A2 is H. In
some embodiments, R.sup.A3 is H, halogen, optionally substituted
C.sub.1-C.sub.4alkyl, optionally substituted
C.sub.1-C.sub.4fluoroalkyl, optionally substituted aryl, or
--OR.sup.10. In some embodiments, R.sup.A3 is H, halogen,
optionally substituted C.sub.1-C.sub.4alkyl, optionally substituted
C.sub.1-C.sub.4fluoroalkyl, or --OR.sup.10. In some embodiments,
R.sup.A3 is optionally substituted C.sub.1-C.sub.4alkyl. In some
embodiments, R.sup.A3 is methyl, ethyl, propyl or butyl. In some
embodiments, R.sup.A3 is --OR.sup.10 and R.sup.10 is methyl, ethyl,
propyl or butyl. In some embodiments, ring A is phenylene or a
monocyclic C.sub.3-C.sub.8cycloalkylene that is selected from
cyclopropylene, cyclobutylene, cyclopentylene, cyclohexylene,
cycloheptylene, and cyclooctylene. In some embodiments, ring A is
phenylene.
[0033] In some embodiments,
##STR00008##
[0034] In some embodiments, ring A is a monocyclic
C.sub.1-C.sub.8heteroarylene containing 1-4 N atoms, and 0 or 1 O
or S atom, or a monocyclic C.sub.1-C.sub.5heteroarylene containing
0-4 N atoms, and 1 O or S atom. In some embodiments, ring A is a
monocyclic 6-membered heteroarylene selected from pyridinylene,
pyrimidinylene, pyrazinylene, and pyridazinylene. In some
embodiments, ring A is pyridinylene.
[0035] In some embodiments,
##STR00009##
[0036] In some embodiments,
##STR00010##
[0037] In some embodiments, ring A is a monocyclic 5-membered
heteroarylene selected from furanylene, thienylene, pyrrolylene,
oxazolylene, thiazolylene, imidazolylene, pyrazolylene,
triazolylene, tetrazolylene, isoxazolylene, isothiazolylene,
oxadiazolylene, and thiadiazolylene. In some embodiments, ring A is
oxazolylene, thiazolylene, imidazolylene, pyrazolylene, or
oxadiazolylene. In some embodiments, ring A is pyrazolylene.
[0038] In some embodiments,
##STR00011## ##STR00012##
[0039] In some embodiments,
##STR00013##
[0040] In some embodiments,
##STR00014##
[0041] In some embodiments, ring A is a ring A is a monocyclic
C.sub.2-C.sub.8heterocycloalkylene containing at least 1 N atom in
the ring that is selected from aziridinylene, azetidinylene,
pyrrolidinylene, piperidinylene, piperazinylene, and azepanylene.
In some embodiments, each R.sup.3 is independently H, halogen,
--CN, --OR.sup.11, --SR.sup.11, optionally substituted
C.sub.1-C.sub.4alkyl, or optionally substituted
C.sub.1-C.sub.4fluoroalkyl; and n is 1, 2, or 3. In some
embodiments, R.sup.3 is optionally substituted
C.sub.1-C.sub.4alkyl.
[0042] In some embodiments, R.sup.3 is methyl, ethyl, propyl, or
butyl. In some embodiments, R.sup.3 is --OR.sup.11. In some
embodiments, R.sup.11 is H, optionally substituted
C.sub.1-C.sub.4alkyl, or optionally substituted
C.sub.1-C.sub.4fluoroalkyl. In some embodiments, R.sup.11 is
methyl, ethyl, propyl, or butyl. In some embodiments, R.sup.11 is
--CF.sub.3 or --CH.sub.2CF.sub.3. In some embodiments, R.sup.4 is
H, halogen, --CN, --OR.sup.12, --SR.sup.12, --N(R.sup.12).sub.2,
optionally substituted C.sub.1-C.sub.4alkyl, or optionally
substituted C.sub.1-C.sub.4fluoroalkyl. In some embodiments,
R.sup.4 is H. In some embodiments, R.sup.4 is halogen. In some
embodiments, R.sup.4 is --Cl, --Br, --F, or --I. In some
embodiments, R.sup.4 is --OR.sup.12. In some embodiments, R.sup.12
is H, optionally substituted C.sub.1-C.sub.4alkyl, or optionally
substituted C.sub.1-C.sub.4fluoroalkyl. In some embodiments,
R.sup.4 is optionally substituted C.sub.1-C.sub.4alkyl. In some
embodiments, R.sup.4 is methyl, ethyl, propyl, or butyl. In some
embodiments, R.sup.4 is optionally substituted
C.sub.1-C.sub.4fluoroalkyl. In some embodiments, R.sup.4 is
--CF.sub.3 or --CH.sub.2CF.sub.3. In some embodiments, R.sup.5 is
H, halogen, --CN, --OR.sup.12, --SR.sup.12, --N(R.sup.12).sub.2,
optionally substituted C.sub.1-C.sub.4alkyl, or optionally
substituted C.sub.1-C.sub.4fluoroalkyl. In some embodiments,
R.sup.5 is H. In some embodiments, R.sup.5 is halogen. In some
embodiments, R.sup.5 is --Cl, --Br, --F, or --I. In some
embodiments, R.sup.5 is --OR.sup.12. In some embodiments, R.sup.12
is H, optionally substituted C.sub.1-C.sub.4alkyl, or optionally
substituted C.sub.1-C.sub.4fluoroalkyl. In some embodiments,
R.sup.5 is optionally substituted C.sub.1-C.sub.4alkyl. In some
embodiments, R.sup.5 is methyl, ethyl, propyl, or butyl. In some
embodiments, R.sup.5 is optionally substituted
C.sub.1-C.sub.4fluoroalkyl. In some embodiments, R.sup.5 is
--CF.sub.3 or --CH.sub.2CF.sub.3.
[0043] In some embodiments, the compound has the structure of
formula (Ia)
##STR00015##
[0044] In some embodiments, the compound has the structure of
formula (Ib)
##STR00016##
[0045] In some embodiments, the compound has the structure of
formula (Ic)
##STR00017##
[0046] In some embodiments,
##STR00018##
and q is 0 or 1.
[0047] In some embodiments, each R.sup.6 is independently H,
optionally substituted C.sub.1-C.sub.4alkyl, optionally substituted
C.sub.1-C.sub.4heteroalkyl, optionally substituted
C.sub.1-C.sub.4fluoroalkyl, --X-optionally substituted
C.sub.1-C.sub.4alkyl, --X-optionally substituted
C.sub.1-C.sub.4heteroalkyl, or --X-optionally substituted
C.sub.1-C.sub.4fluoroalkyl. In some embodiments, each R.sup.6 is
independently H. In some embodiments, each R.sup.2 is independently
H, optionally substituted C.sub.1-C.sub.4alkyl, optionally
substituted C.sub.1-C.sub.4heteroalkyl, or optionally substituted
C.sub.1-C.sub.4fluoroalkyl. In some embodiments, A.sup.2 is N. In
some embodiments, A.sup.2 is CR.sup.A. In some embodiments, R.sup.A
is H, optionally substituted C.sub.1-C.sub.4alkyl, or optionally
substituted C.sub.1-C.sub.4fluoroalkyl. In some embodiments,
R.sup.A is H. In some embodiments, R.sup.A1 is H, optionally
substituted C.sub.1-C.sub.4alkyl, or optionally substituted
C.sub.1-C.sub.4fluoroalkyl. In some embodiments, R.sup.A1 is H. In
some embodiments, R.sup.A2 is H, optionally substituted
C.sub.1-C.sub.4alkyl, or optionally substituted
C.sub.1-C.sub.4fluoroalkyl. In some embodiments, R.sup.A2 is H. In
some embodiments, R.sup.A3 is H, halogen, optionally substituted
C.sub.1-C.sub.4alkyl, optionally substituted
C.sub.1-C.sub.4fluoroalkyl, optionally substituted aryl, or
--OR.sup.10. In some embodiments, R.sup.A3 is H, halogen,
optionally substituted C.sub.1-C.sub.4alkyl, optionally substituted
C.sub.1-C.sub.4fluoroalkyl, or --OR.sup.10. In some embodiments,
R.sup.A3 is optionally substituted C.sub.1-C.sub.4alkyl. In some
embodiments, R.sup.A3 is methyl, ethyl, propyl, or butyl. In some
embodiments, R.sup.A3 is ethyl. In some embodiments, ring A is
phenylene. In some embodiments, ring A is a monocyclic 6-membered
heteroarylene selected from pyridinylene, pyrimidinylene,
pyrazinylene, and pyridazinylene. In some embodiments, ring A is
pyridinylene. In some embodiments, ring A is a monocyclic
5-membered heteroarylene selected from furanylene, thienylene,
pyrrolylene, oxazolylene, thiazolylene, imidazolylene,
pyrazolylene, triazolylene, tetrazolylene, isoxazolylene,
isothiazolylene, oxadiazolylene, and thiadiazolylene. In some
embodiments, ring A is pyrazolylene. In some embodiments, each
R.sup.3 is independently H, --OR.sup.11, optionally substituted
C.sub.1-C.sub.4alkyl, or optionally substituted
C.sub.1-C.sub.4fluoroalkyl; and n is 1, 2, or 3. In some
embodiments, R.sup.11 is H, optionally substituted
C.sub.1-C.sub.4alkyl, or optionally substituted
C.sub.1-C.sub.4fluoroalkyl. In some embodiments, R.sup.4 and
R.sup.5 are each independently H, halogen, --CN, --OR.sup.12,
--SR.sup.12, --N(R.sup.12).sub.2, optionally substituted
C.sub.1-C.sub.4alkyl, or optionally substituted
C.sub.1-C.sub.4fluoroalkyl.
[0048] In some embodiments, the compound has the structure of
formula (Id)
##STR00019##
and R.sup.A3 is optionally substituted C.sub.1-C.sub.4 alkyl.
[0049] In some embodiments, the compound has the structure of
formula (Ie)
##STR00020##
[0050] In some embodiments, the compound has the structure of
formula (If)
##STR00021##
[0051] In some embodiments, ring A is phenylene, pyridinylene,
pyrazolylene, thiazolylene, imidazolylene, oxazolylene, or
oxadiazolylene. In some embodiments, R.sup.4 and R.sup.5 are each
independently H, halogen, --CN, --OR.sup.12, --SR.sup.12,
--N(R.sup.12).sub.2, optionally substituted C.sub.1-C.sub.4alkyl,
or optionally substituted C.sub.1-C.sub.4fluoroalkyl.
[0052] In another aspect, provided herein is a compound, or a
pharmaceutically acceptable salt, or solvate thereof, selected
from: [0053]
N-(6-(2-(((1r,4r)-4-aminocyclohexyl)amino)-8-ethylquinazolin-6-yl)-
-4-ethylpyridazin-3-yl)-2-chlorobenzenesulfonamide; [0054]
2-chloro-N-(5-(8-ethyl-2-(((1r,4r)-4-hydroxycyclohexyl)amino)quinazolin-6-
-yl)-6-methoxypyridin-2-yl)benzenesulfonamide; [0055]
N-(5-(2-(((1r,4r)-4-aminocyclohexyl)amino)-7-methylquinazolin-6-yl)-6-met-
hoxypyridin-2-yl)-2-cyanobenzenesulfonamide; [0056]
N-(5-(2-(((1r,4r)-4-aminocyclohexyl)amino)-8-ethylquinazolin-6-yl)-6-meth-
oxypyridin-2-yl)-2-methylbenzenesulfonamide; [0057]
N-(5-(2-(((1r,4r)-4-aminocyclohexyl)amino)-7-methylquinazolin-6-yl)-6-met-
hoxypyridin-2-yl)-2-chlorobenzenesulfonamide; [0058]
N-(5-(2-(((1r,4r)-4-aminocyclohexyl)amino)-7-methylquinazolin-6-yl)-6-eth-
ylpyridin-2-yl)-2-chlorobenzenesulfonamide; [0059]
N-(5-(2-(((1r,4r)-4-aminocyclohexyl)amino)-7-methylquinazolin-6-yl)-6-met-
hylpyridin-2-yl)-2-chlorobenzenesulfonamide; [0060]
N-(5-(2-(((1r,4r)-4-aminocyclohexyl)amino)-8-ethylquinazolin-6-yl)-6-(tri-
fluoromethoxy)pyridin-2-yl)-2-chlorobenzenesulfonamide; [0061]
N-(5-(2-(((1r,4r)-4-aminocyclohexyl)amino)-8-ethylquinazolin-6-yl)-6-meth-
oxypyridin-2-yl)-2-methoxybenzenesulfonamide; [0062]
N-(5-(2-(((1r,4r)-4-aminocyclohexyl)amino)-7-ethylquinazolin-6-yl)-6-meth-
oxypyridin-2-yl)-2-chlorobenzenesulfonamide; [0063]
N-(5-(2-(((1r,4r)-4-aminocyclohexyl)amino)-8-ethylquinazolin-6-yl)-6-meth-
ylpyridin-2-yl)benzenesulfonamide; [0064]
N-(5-(2-(((1r,4r)-4-aminocyclohexyl)amino)-8-ethylquinazolin-6-yl)-6-meth-
ylpyridin-2-yl)-2-methylbenzenesulfonamide; [0065]
N-(5-(2-(((1r,4r)-4-aminocyclohexyl)amino)-8-ethylquinazolin-6-yl)-6-meth-
ylpyridin-2-yl)-3-methylbenzenesulfonamide; [0066]
N-(5-(2-(((1r,4r)-4-aminocyclohexyl)amino)-5-methylquinazolin-6-yl)-6-met-
hoxypyridin-2-yl)-2-chlorobenzenesulfonamide; [0067]
N-(5-(2-(((1r,4r)-4-aminocyclohexyl)amino)-8-methylquinazolin-6-yl)-6-met-
hoxypyridin-2-yl)-2-chlorobenzenesulfonamide; [0068]
2-chloro-N-(4-(2-(((1r,4r)-4-(dimethylamino)cyclohexyl)amino)-8-ethylquin-
azolin-6-yl)-2-fluoro-5-methoxyphenyl)benzenesulfonamide; [0069]
2-chloro-N-(4-(8-ethyl-2-(((1r,4r)-4-(methylamino)cyclohexyl)amino)quinaz-
olin-6-yl)-2-fluoro-5-methoxyphenyl)benzenesulfonamide; [0070]
N-(5-(2-(((1
r,4r)-4-aminocyclohexyl)amino)-8-(1,1-difluoroethyl)quinazolin-6-yl)-6-me-
thoxypyridin-2-yl)-2-chlorobenzenesulfonamide; [0071]
N-(5-(2-(((1r,4r)-4-aminocyclohexyl)amino)-8-(methoxymethyl)quinazolin-6--
yl)-6-methoxypyridin-2-yl)-2-chlorobenzenesulfonamide; [0072]
N-(5-(2-(((1r,4r)-4-aminocyclohexyl)amino)-8-(trifluoromethyl)quinazolin--
6-yl)-6-methoxypyridin-2-yl)-2-chlorobenzenesulfonamide; [0073]
2-chloro-N-(5-(2-((4-(dimethylamino)bicyclo[2.2.2]octan-1-yl)amino)-8-eth-
ylquinazolin-6-yl)-6-ethylpyridin-2-yl)benzenesulfonamide; [0074]
N-(5-(2-(((1s,4s)-4-aminocyclohexyl)amino)-8-methylquinazolin-6-yl)-6-met-
hoxypyridin-2-yl)-2-chlorobenzenesulfonamide; [0075]
N-(5-(2-(((1s,4s)-4-aminocyclohexyl)amino)-8-ethylquinazolin-6-yl)-6-meth-
oxypyridin-2-yl)-2-chlorobenzenesulfonamide; and [0076]
N-(5-(2-(((1s,4s)-4-aminocyclohexyl)amino)-8-methylquinazolin-6-yl)-3-flu-
oro-6-methoxypyridin-2-yl)-2-chlorobenzenesulfonamide.
[0077] In some embodiments, the compound or pharmaceutically
acceptable salt, or solvate thereof, selectively binds to IRE1a at
one or more binding sites. In some embodiments, the IRE1a comprises
an RNase domain, a kinase domain, or any combination thereof. In
some embodiments, the kinase domain is an auto-transphosphorylation
kinase domain. In some embodiments, the kinase domain comprises an
ATP-binding pocket. In some embodiments, the kinase domain
comprises an activation loop. In some embodiments, at least one
binding site is within the RNase domain. In some embodiments, at
least one binding site is within the kinase domain. In some
embodiments, the at least one binding site is within the
ATP-binding pocket of the kinase domain. In some embodiments, In
some embodiments, the at least one binding site is within the
activation loop of the kinase domain. In some embodiments, binding
occurs at a first binding site. In some embodiments, the first
binding site is located within the RNase domain, kinase domain,
ATP-binding pocket, or activation loop. In some embodiments, the
first binding site comprises at least one amino acid residue of
within amino acid residues 465-977 of SEQ ID NO: 1. In some
embodiments, the first binding site comprises at least one amino
acid residue within amino acid residues 568-833 of SEQ ID NO: 1. In
some embodiments, the first binding site comprises at least one
amino acid residue within amino acid residues 577-586, 597, 599,
626, 642-643, 645, 648, 688, 692-693, 695, or 711 of SEQ ID NO: 1.
In some embodiments, the first binding site comprises at least one
amino acid residue within amino acid residues 710-725 or 729-736 of
SEQ ID NO: 1. In some embodiments, the first binding site comprises
at least one amino acid residue within amino acid residues 835-963
of SEQ ID NO: 1. In some embodiments, binding further occurs at a
second binding site. In some embodiments, the second binding site
is located within the RNase domain, the kinase domain, the
ATP-binding pocket, or the activation loop. In some embodiments,
the second binding site comprises at least one amino acid residue
of within amino acid residues 465-977 of SEQ ID NO: 1. In some
embodiments, the second binding site comprises at least one amino
acid residue within amino acid residues 568-833 of SEQ ID NO: 1. In
some embodiments, the second binding site comprises at least one
amino acid residue within amino acid residues 577-586, 597, 599,
626, 642-643, 645, 648, 688, 692-693, 695, or 711 of SEQ ID NO: 1.
In some embodiments, the second binding site comprises at least one
amino acid residue within amino acid residues 710-725 or 729-736 of
SEQ ID NO: 1. In some embodiments, the second binding site
comprises at least one amino acid residue within amino acid
residues 835-963 of SEQ ID NO: 1. In some embodiments, binding
occurs when the IRE1a is in a homo-dimerized conformation. In some
embodiments, binding occurs when the IRE1a is in an oligomerized
conformation. In some embodiments, binding occurs when the IRE1a is
in a non-oligomerized or non-dimerized conformation. In some
embodiments, binding occurs when the IRE1a is in an ATP-bound
state. In some embodiments, binding occurs when the IRE1a is in a
non-ATP-bound state. In some embodiments, the compound selectively
binds to a first IRE1a. In some embodiments, selectively binding to
the first IRE1a blocks dimerization of the first IRE1a to a second
IRE1a. In some embodiments, selectively binding to the first IRE1a
blocks auto-transphosphorylation of the first IRE1a. In some
embodiments, selectively binding to the first IRE1a blocks
auto-transphosphorylation of a second IRE1a to which the first
IRE1a is dimerized. In some embodiments, selectively binding to the
first IRE1a blocks activation of the first IRE1a. In some
embodiments, selectively binding to the first IRE1a blocks
activation a second IRE1a to which the first IRE1a is dimerized. In
some embodiments, selectively binding to the first IRE1a blocks
kinase activity of the first IRE1a. In some embodiments,
selectively binding to the first IRE1a blocks kinase activity of a
second IRE1a to which the first IRE1a is dimerized. In some
embodiments, selectively binding to the first IRE1a blocks RNase
activity of the first IRE1a. In some embodiments, selectively
binding to the first IRE1a blocks RNase activity of a second IRE1a
to which the first IRE1a is dimerized.
[0078] In another aspect, provided herein is a compound that
selectively binds a first IRE1a at two or more sites, wherein when
the compound is bound to the first IRE1a protein, the compound
binds to an ATP-binding pocket of the first IRE1a and blocks the
binding of ATP to the first IRE1a. In some embodiments, the ATP
binding pocket is comprised within a kinase domain. In some
embodiments, the ATP binding pocket is comprised within amino acid
residues 465-977 of SEQ ID NO: 1. In some embodiments, the ATP
binding pocket is comprised within amino acid residues 568-833 of
SEQ ID NO: 1. In some embodiments, the ATP binding pocket comprises
one or more of amino acid resides 577-586, 597, 599, 626, 642-643,
645, 648, 688, 692-693, 695, or 711 of SEQ ID NO: 1.
[0079] In another aspect, provided herein is a pharmaceutical
composition comprising any one of the compounds described herein,
or a pharmaceutically acceptable salt or solvate thereof. In some
embodiments, the pharmaceutical composition further comprises one
or more pharmaceutically acceptable excipients.
[0080] In another aspect, provided herein is a method for treating
or ameliorating the effects of a disease associated with altered
IRE1 signaling, the method comprising administering to a subject in
need thereof a pharmaceutical composition, wherein the
pharmaceutical composition comprises the compound of any one of the
compounds described herein. In some embodiments, the disease is
cancer. In some embodiments, the cancer is a solid cancer or a
hematologic cancer. In some embodiments, the cancer is ovarian
cancer, breast cancer, or triple negative breast cancer (TNBC).
[0081] In another aspect, provided herein is a method for treating
or ameliorating a cell proliferative disorder, the method
comprising administering a pharmaceutical composition comprising a
compound, or a pharmaceutically acceptable salt, or solvate
thereof, that selectively binds to at least one amino acid residue
of a IRE1 family protein comprising an RNase domain and kinase
domain. In some embodiments, the IRE1 family protein is IRE1a. In
some embodiments, the compound binds to an ATP-binding site of
IRE1a. In some embodiments, the cell proliferative disorder is
cancer. In some embodiments, the cancer is a solid cancer or a
hematologic cancer, lung cancer, or bladder cancer.
BRIEF DESCRIPTION OF THE DRAWINGS
[0082] The novel features of the invention are set forth with
particularity in the appended claims.
[0083] A better understanding of the features and advantages of the
present invention will be obtained by reference to the following
detailed description that sets forth illustrative embodiments, in
which the principles of the invention are utilized, and the
accompanying drawings of which:
[0084] FIG. 1 shows an example diagram of the domain structure of
IRE1a. A signal peptide (P) and transmembrane (TM) region are
indicated.
[0085] FIG. 2 shows an example alignment of the C-terminal half
IRE1 orthologues from yeast (ScIre1) (SEQ ID NO: 4), human (HsIre1)
(SEQ ID NO: 5), mouse (MmIre1) (SEQ ID NO: 6), and rat (RnIRE1)
(SEQ ID NO: 7). Stars indicate kinase domain dimer interface
residues. Circles indicate Kinase extension nuclease (KEN) domain
dimer interface residues. Triangles indicate putative nuclease
active site residues. Yellow highlighted residues are highly
conserved in Ire1 orthologues. Green highlighted residues are
invariant in all analyzed Ire1 orthologues. Blue highlighted
residues are invariant in analyzed RNaseL and Ire1 orthologues.
[0086] FIG. 3 depicts the bioavailability of Compound 3 and
Compound 37 in vivo. Mice were dosed with Compound 3 or Compound 37
intravenously, orally, and intraperitoneally.
[0087] FIG. 4 shows suppression of IRE1a-dependent splicing of
X-box binding protein 1 (XBP1). The bottom left panel shows the
unspliced (XBP1u) and spliced XBP1(s) protein with varying
combinations of Compound 3 and TM, where mpk is mg/kg.
[0088] FIG. 5 shows that Compound 3 can inhibit IRE1a-dependent
signaling in various cell types in the tumor microenvironment.
DETAILED DESCRIPTION
Certain Terminology
[0089] Unless otherwise stated, the following terms used in this
application have the definitions given below. The use of the term
"including" as well as other forms, such as "include", "includes,"
and "included," is not limiting. The section headings used herein
are for organizational purposes only and are not to be construed as
limiting the subject matter described.
[0090] As used herein and in the appended claims, the singular
forms "a," "and," and "the" include plural referents unless the
context clearly dictates otherwise. Thus, for example, reference to
"an agent" includes a plurality of such agents, and reference to
"the cell" includes reference to one or more cells (or to a
plurality of cells) and equivalents thereof known to those skilled
in the art, and so forth. When ranges are used herein for physical
properties, such as molecular weight, or chemical properties, such
as chemical formulae, all combinations and subcombinations of
ranges and specific embodiments therein are intended to be
included. The term "about" when referring to a number or a
numerical range means that the number or numerical range referred
to is an approximation within experimental variability (or within
statistical experimental error), and thus the number or numerical
range may vary between 1% and 15% of the stated number or numerical
range. The term "comprising" (and related terms such as "comprise"
or "comprises" or "having" or "including") is not intended to
exclude that in other certain embodiments, for example, an
embodiment of any composition of matter, composition, method, or
process, or the like, described herein, may "consist of" or
"consist essentially of" the described features.
Definitions
[0091] As used in the specification and appended claims, unless
specified to the contrary, the following terms have the meaning
indicated below.
[0092] "Amino" refers to the --NH.sub.2 radical.
[0093] "Cyano" refers to the --CN radical.
[0094] "Nitro" refers to the --NO.sub.2 radical.
[0095] "Oxa" refers to the --O-- radical.
[0096] "Oxo" refers to the .dbd.O radical.
[0097] "Thioxo" refers to the .dbd.S radical.
[0098] "Imino" refers to the .dbd.N--H radical.
[0099] "Oximo" refers to the .dbd.N--OH radical.
[0100] As used herein, C.sub.1-C.sub.x includes C.sub.1-C.sub.2,
C.sub.1-C.sub.3 . . . C.sub.1-C.sub.x. By way of example only, a
group designated as "C.sub.1-C.sub.4" indicates that there are one
to four carbon atoms in the moiety, i.e. groups containing 1 carbon
atom, 2 carbon atoms, 3 carbon atoms or 4 carbon atoms. Thus, by
way of example only, "C.sub.1-C.sub.4 alkyl" indicates that there
are one to four carbon atoms in the alkyl group, i.e., the alkyl
group is selected from among methyl, ethyl, propyl, iso-propyl,
n-butyl, iso-butyl, sec-butyl, and t-butyl.
[0101] An "alkyl" group refers to an aliphatic hydrocarbon group.
The alkyl group is branched or straight chain. In some embodiments,
the "alkyl" group has 1 to 10 carbon atoms, i.e. a
C.sub.1-C.sub.10alkyl. Whenever it appears herein, a numerical
range such as "1 to 10" refers to each integer in the given range;
e.g., "1 to 10 carbon atoms" means that the alkyl group consist of
1 carbon atom, 2 carbon atoms, 3 carbon atoms, 4 carbon atoms, 5
carbon atoms, 6 carbon atoms, etc., up to and including 10 carbon
atoms, although the present definition also covers the occurrence
of the term "alkyl" where no numerical range is designated. In some
embodiments, an alkyl is a C.sub.1-C.sub.6alkyl. In one aspect the
alkyl is methyl, ethyl, propyl, iso-propyl, n-butyl, iso-butyl,
sec-butyl, or t-butyl. Typical alkyl groups include, but are in no
way limited to, methyl, ethyl, propyl, isopropyl, butyl, isobutyl,
sec-butyl, tertiary butyl, pentyl, neopentyl, or hexyl.
[0102] An "alkylene" group refers refers to a divalent alkyl
radical. Any of the above mentioned monovalent alkyl groups may be
an alkylene by abstraction of a second hydrogen atom from the
alkyl. In some embodiments, an alkelene is a
C.sub.1-C.sub.6alkylene. In other embodiments, an alkylene is a
C.sub.1-C.sub.4alkylene. In certain embodiments, an alkylene
comprises one to four carbon atoms (e.g., C.sub.1-C.sub.4
alkylene). In other embodiments, an alkylene comprises one to three
carbon atoms (e.g., C.sub.1-C.sub.3 alkylene). In other
embodiments, an alkylene comprises one to two carbon atoms (e.g.,
C.sub.1-C.sub.2 alkylene). In other embodiments, an alkylene
comprises one carbon atom (e.g., C.sub.1 alkylene). In other
embodiments, an alkylene comprises two carbon atoms (e.g., C.sub.2
alkylene). In other embodiments, an alkylene comprises two to four
carbon atoms (e.g., C.sub.2-C.sub.4 alkylene).
[0103] Typical alkylene groups include, but are not limited to,
--CH.sub.2--, --CH(CH.sub.3)--, --C(CH.sub.3).sub.2--,
--CH.sub.2CH.sub.2--, --CH.sub.2CH(CH.sub.3)--,
--CH.sub.2C(CH.sub.3).sub.2--, --CH.sub.2CH.sub.2CH.sub.2--,
--CH.sub.2CH.sub.2CH.sub.2CH.sub.2--, and the like.
[0104] The term "alkenyl" refers to a type of alkyl group in which
at least one carbon-carbon double bond is present. In one
embodiment, an alkenyl group has the formula --C(R).dbd.CR.sub.2,
wherein R refers to the remaining portions of the alkenyl group,
which may be the same or different. In some embodiments, R is H or
an alkyl. In some embodiments, an alkenyl is selected from ethenyl
(i.e., vinyl), propenyl (i.e., allyl), butenyl, pentenyl,
pentadienyl, and the like. Non-limiting examples of an alkenyl
group include --CH.dbd.CH.sub.2, --C(CH.sub.3).dbd.CH.sub.2,
--CH.dbd.CHCH.sub.3, --C(CH.sub.3).dbd.CHCH.sub.3, and
--CH.sub.2CH.dbd.CH.sub.2.
[0105] The term "alkynyl" refers to a type of alkyl group in which
at least one carbon-carbon triple bond is present. In one
embodiment, an alkenyl group has the formula --C.ident.C--R,
wherein R refers to the remaining portions of the alkynyl group. In
some embodiments, R is H or an alkyl.
[0106] In some embodiments, an alkynyl is selected from ethynyl,
propynyl, butynyl, pentynyl, hexynyl, and the like. Non-limiting
examples of an alkynyl group include --C.ident.CH,
--C.ident.CCH.sub.3--C.ident.CCH.sub.2CH.sub.3,
--CH.sub.2C.ident.CH.
[0107] An "alkoxy" group refers to a (alkyl)O-- group, where alkyl
is as defined herein.
[0108] The term "alkylamine" refers to the --N(alkyl).sub.xH.sub.y
group, where x is 0 and y is 2, or where x is 1 and y is 1, or
where x is 2 and y is 0.
[0109] The term "aromatic" refers to a planar ring having a
delocalized it-electron system containing 4n+2 t electrons, where n
is an integer. The term "aromatic" includes both carbocyclic aryl
("aryl", e.g., phenyl) and heterocyclic aryl (or "heteroaryl" or
"heteroaromatic") groups (e.g., pyridine). The term includes
monocyclic or fused-ring polycyclic (i.e., rings which share
adjacent pairs of carbon atoms) groups.
[0110] The term "carbocyclic" or "carbocycle" refers to a ring or
ring system where the atoms forming the backbone of the ring are
all carbon atoms. The term thus distinguishes carbocyclic from
"heterocyclic" rings or "heterocycles" in which the ring backbone
contains at least one atom which is different from carbon. In some
embodiments, at least one of the two rings of a bicyclic carbocycle
is aromatic. In some embodiments, both rings of a bicyclic
carbocycle are aromatic. Carbocycle includes cycloalkyl and
aryl.
[0111] As used herein, the term "aryl" refers to an aromatic ring
wherein each of the atoms forming the ring is a carbon atom. In one
aspect, aryl is phenyl or a naphthyl. In some embodiments, an aryl
is a phenyl. In some embodiments, an aryl is a
C.sub.6-C.sub.10aryl. Depending on the structure, an aryl group is
a monoradical or a diradical (i.e., an arylene group).
[0112] The term "cycloalkyl" refers to a monocyclic or polycyclic
aliphatic, non-aromatic radical, wherein each of the atoms forming
the ring (i.e. skeletal atoms) is a carbon atom. In some
embodiments, cycloalkyls are spirocyclic or bridged compounds. In
some embodiments, cycloalkyls are optionally fused with an aromatic
ring, and the point of attachment is at a carbon that is not an
aromatic ring carbon atom. In some embodiments, cycloalkyl groups
include groups having from 3 to 10 ring atoms. In some embodiments,
cycloalkyl groups include groups having from 3 to 6 ring atoms. In
some embodiments, cycloalkyl groups are selected from among
cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl,
cyclohexenyl, cycloheptyl, cyclooctyl, spiro[2.2]pentyl, norbornyl
and bicycle[0.1.1.1]pentyl. In some embodiments, a cycloalkyl is a
C.sub.3-C.sub.6cycloalkyl. In some embodiments, a cycloalkyl is a
monocyclic cycloalkyl. Monocyclic cycloalkyls include, but are not
limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl,
cycloheptyl, and cyclooctyl. Polycyclic cycloalkyls include, for
example, adamantyl, norbornyl (i.e., bicyclo[2.2.1]heptanyl),
norbornenyl, decalinyl, 7,7-dimethyl-bicyclo[2.2.1]heptanyl, and
the like.
[0113] The term "cycloalkylene" refers to a monocyclic or
polycyclic aliphatic, non-aromatic divalent radical, wherein each
of the atoms forming the ring (i.e. skeletal atoms) is a carbon
atom. In some embodiments, cycloalkylene are spirocyclic or bridged
compounds. In some embodiments, cycloalkylenes are optionally fused
with an aromatic ring, and the point of attachment is at a carbon
that is not an aromatic ring carbon atom. In some embodiments,
cycloalkylene groups include groups having from 3 to 10 ring atoms.
In some embodiments, cycloalkylene groups include groups having
from 3 to 6 ring atoms.
[0114] The term "halo" or, alternatively, "halogen" or "halide"
means fluoro, chloro, bromo or iodo. In some embodiments, halo is
fluoro, chloro, or bromo.
[0115] The term "haloalkyl" refers to an alkyl in which one or more
hydrogen atoms are replaced by a halogen atom. In one aspect, a
fluoralkyl is a C.sub.1-C.sub.6fluoroalkyl.
[0116] The term "fluoroalkyl" refers to an alkyl in which one or
more hydrogen atoms are replaced by a fluorine atom. In one aspect,
a fluoralkyl is a C.sub.1-C.sub.6fluoroalkyl. In some embodiments,
a fluoroalkyl is selected from trifluoromethyl, difluoromethyl,
fluoromethyl, 2,2,2-trifluoroethyl, 1-fluoromethyl-2-fluoroethyl,
and the like.
[0117] The term "heteroalkyl" refers to an alkyl group in which one
or more skeletal atoms of the alkyl are selected from an atom other
than carbon, e.g., oxygen, nitrogen (e.g. --NH--, --N(alkyl)-,
sulfur, or combinations thereof. A heteroalkyl is attached to the
rest of the molecule at a carbon atom of the heteroalkyl. In one
aspect, a heteroalkyl is a C.sub.1-C.sub.6heteroalkyl.
[0118] The term "heteroalkylene" refers to an alkylene group in
which one or more skeletal atoms of the alkylene are selected from
an atom other than carbon, e.g., oxygen, nitrogen (e.g. --NH--,
--N(alkyl)-, sulfur, or combinations thereof. In some embodiments,
a heteroalkylene is attached to the rest of the molecule at a
carbon atom of the heteroalkylene. In one aspect, a heteroalkylene
is a C.sub.1-C.sub.6heteroalkylene.
[0119] As used herein, the term "heteroatom" refers to an atom of
any element other than carbon or hydrogen. In some embodiments, the
heteroatom is nitrogen, oxygen, or sulfur. In some embodiments, the
heteroatom is nitrogen or oxygen. In some embodiments, the
heteroatom is nitrogen.
[0120] The term "heterocycle" or "heterocyclic" refers to
heteroaromatic rings (also known as heteroaryls) and
heterocycloalkyl rings (also known as heteroalicyclic groups)
containing one to four heteroatoms in the ring(s), where each
heteroatom in the ring(s) is selected from O, S and N, wherein each
heterocyclic group has from 3 to 10 atoms in its ring system, and
with the proviso that any ring does not contain two adjacent O or S
atoms. In some embodiments, heterocycles are monocyclic, bicyclic,
polycyclic, spirocyclic or bridged compounds. Non-aromatic
heterocyclic groups (also known as heterocycloalkyls) include rings
having 3 to 10 atoms in its ring system and aromatic heterocyclic
groups include rings having 5 to 10 atoms in its ring system. The
heterocyclic groups include benzo-fused ring systems. Examples of
non-aromatic heterocyclic groups are pyrrolidinyl,
tetrahydrofuranyl, dihydrofuranyl, tetrahydrothienyl,
oxazolidinonyl, tetrahydropyranyl, dihydropyranyl,
tetrahydrothiopyranyl, piperidinyl, morpholinyl, thiomorpholinyl,
thioxanyl, piperazinyl, aziridinyl, azetidinyl, oxetanyl,
thietanyl, homopiperidinyl, oxepanyl, thiepanyl, oxazepinyl,
diazepinyl, thiazepinyl, 1,2,3,6-tetrahydropyridinyl,
pyrrolin-2-yl, pyrrolin-3-yl, indolinyl, 2H-pyranyl, 4H-pyranyl,
dioxanyl, 1,3-dioxolanyl, pyrazolinyl, dithianyl, dithiolanyl,
dihydropyranyl, dihydrothienyl, dihydrofuranyl, pyrazolidinyl,
imidazolinyl, imidazolidinyl, 3-azabicyclo[3.1.0]hexanyl,
3-azabicyclo[4.1.0]heptanyl, 3H-indolyl, indolin-2-onyl,
isoindolin-1-onyl, isoindoline-1,3-dionyl,
3,4-dihydroisoquinolin-1(2H)-onyl, 3,4-dihydroquinolin-2(1H)-onyl,
isoindoline-1,3-dithionyl, benzo[d]oxazol-2(3H)-onyl,
1H-benzo[d]imidazol-2(3H)-onyl, benzo[d]thiazol-2(3H)-onyl, and
quinolizinyl. Examples of aromatic heterocyclic groups are
pyridinyl, imidazolyl, pyrimidinyl, pyrazolyl, triazolyl,
pyrazinyl, tetrazolyl, furyl, thienyl, isoxazolyl, thiazolyl,
oxazolyl, isothiazolyl, pyrrolyl, quinolinyl, isoquinolinyl,
indolyl, benzimidazolyl, benzofuranyl, cinnolinyl, indazolyl,
indolizinyl, phthalazinyl, pyridazinyl, triazinyl, isoindolyl,
pteridinyl, purinyl, oxadiazolyl, thiadiazolyl, furazanyl,
benzofurazanyl, benzothiophenyl, benzothiazolyl, benzoxazolyl,
quinazolinyl, quinoxalinyl, naphthyridinyl, and furopyridinyl. The
foregoing groups are either C-attached (or C-linked) or N-attached
where such is possible. For instance, a group derived from pyrrole
includes both pyrrol-1-yl (N-attached) or pyrrol-3-yl (C-attached).
Further, a group derived from imidazole includes imidazol-1-yl or
imidazol-3-yl (both N-attached) or imidazol-2-yl, imidazol-4-yl or
imidazol-5-yl (all C-attached). The heterocyclic groups include
benzo-fused ring systems. Non-aromatic heterocycles are optionally
substituted with one or two oxo (.dbd.O) moieties, such as
pyrrolidin-2-one. In some embodiments, at least one of the two
rings of a bicyclic heterocycle is aromatic. In some embodiments,
both rings of a bicyclic heterocycle are aromatic.
[0121] The terms "heteroaryl" or, alternatively, "heteroaromatic"
refers to an aryl group that includes one or more ring heteroatoms
selected from nitrogen, oxygen and sulfur. Illustrative examples of
heteroaryl groups include monocyclic heteroaryls and bicyclcic
heteroaryls. Monocyclic heteroaryls include pyridinyl, imidazolyl,
pyrimidinyl, pyrazolyl, triazolyl, pyrazinyl, tetrazolyl, furyl,
thienyl, isoxazolyl, thiazolyl, oxazolyl, isothiazolyl, pyrrolyl,
pyridazinyl, triazinyl, oxadiazolyl, thiadiazolyl, and furazanyl.
Bicyclic heteroaryls include indolizine, indole, benzofuran,
benzothiophene, indazole, benzimidazole, purine, quinolizine,
quinoline, isoquinoline, cinnoline, phthalazine, quinazoline,
quinoxaline, 1,8-naphthyridine, and pteridine. In some embodiments,
a heteroaryl contains 0-4 N atoms in the ring. In some embodiments,
a heteroaryl contains 1-4 N atoms in the ring. In some embodiments,
a heteroaryl contains 0-4 N atoms, 0-1 O atoms, and 0-1 S atoms in
the ring. In some embodiments, a heteroaryl contains 1-4 N atoms,
0-1 O atoms, and 0-1 S atoms in the ring. In some embodiments,
heteroaryl is a C.sub.1-C.sub.9heteroaryl. In some embodiments,
monocyclic heteroaryl is a C.sub.1-C.sub.8heteroaryl. In some
embodiments, monocyclic heteroaryl is a 5-membered or 6-membered
heteroaryl. In some embodiments, bicyclic heteroaryl is a
C.sub.6-C.sub.9heteroaryl.
[0122] A "heterocycloalkyl" or "heteroalicyclic" group refers to a
cycloalkyl group that includes at least one heteroatom selected
from nitrogen, oxygen and sulfur. In some embodiments, a
heterocycloalkyl is a spirocyclic or bridged compound. In some
embodiments, a heterocycloalkyl is fused with an aryl or
heteroaryl. In some embodiments, the heterocycloalkyl is
oxazolidinonyl, pyrrolidinyl, tetrahydrofuranyl, tetrahydrothienyl,
tetrahydropyranyl, tetrahydrothiopyranyl, piperidinyl, morpholinyl,
thiomorpholinyl, piperazinyl, piperidin-2-onyl,
pyrrolidine-2,5-dithionyl, pyrrolidine-2,5-dionyl, pyrrolidinonyl,
imidazolidinyl, imidazolidin-2-onyl, or thiazolidin-2-onyl. The
term heteroalicyclic also includes all ring forms of the
carbohydrates, including but not limited to the monosaccharides,
the disaccharides and the oligosaccharides. In one aspect, a
heterocycloalkyl is a C.sub.2-C.sub.10heterocycloalkyl. In another
aspect, a heterocycloalkyl is a C.sub.4-C.sub.10heterocycloalkyl.
In some embodiments, a heterocycloalkyl contains 0-2 N atoms in the
ring. In some embodiments, a heterocycloalkyl contains 0-2 N atoms,
0-2 O atoms and 0-1 S atoms in the ring.
[0123] The term "bond" or "single bond" refers to a chemical bond
between two atoms, or two moieties when the atoms joined by the
bond are considered to be part of larger substructure. In one
aspect, when a group described herein is a bond, the referenced
group is absent thereby allowing a bond to be formed between the
remaining identified groups.
[0124] The term "moiety" refers to a specific segment or functional
group of a molecule.
[0125] Chemical moieties are often recognized chemical entities
embedded in or appended to a molecule.
[0126] The term "optionally substituted" or "substituted" means
that the referenced group is optionally substituted with one or
more additional group(s) individually and independently selected
from D, halogen, --CN, --NH.sub.2, --NH(alkyl),
--CH.sub.2N(alkyl).sub.2, --N(alkyl).sub.2, --OH, --CO.sub.2H,
--CO.sub.2alkyl, --CH.sub.2NH.sub.2, --C(.dbd.O)NH.sub.2,
--C(.dbd.O)NH(alkyl), --C(.dbd.O)N(alkyl).sub.2,
--S(.dbd.O).sub.2NH.sub.2, --S(.dbd.O).sub.2NH(alkyl),
--S(.dbd.O).sub.2N(alkyl).sub.2, alkyl, cycloalkyl, fluoroalkyl,
heteroalkyl, alkoxy, fluoroalkoxy, heterocycloalkyl, aryl,
heteroaryl, aryloxy, alkylthio, arylthio, alkylsulfoxide,
arylsulfoxide, alkylsulfone, and arylsulfone. In some other
embodiments, optional substituents are independently selected from
D, halogen, --CN, --NH.sub.2, --NH(CH.sub.3), --N(CH.sub.3).sub.2,
--OH, --CO.sub.2H, --CO.sub.2(C.sub.1-C.sub.4alkyl),
--CH.sub.2NH.sub.2, --C(.dbd.O)NH.sub.2,
--C(.dbd.O)NH(C.sub.1-C.sub.4alkyl),
--C(.dbd.O)N(C.sub.1-C.sub.4alkyl).sub.2,
--S(.dbd.O).sub.2NH.sub.2,
--S(.dbd.O).sub.2NH(C.sub.1-C.sub.4alkyl),
--S(.dbd.O).sub.2N(C.sub.1-C.sub.4alkyl).sub.2,
C.sub.1-C.sub.4alkyl, C.sub.3-C.sub.6cycloalkyl,
C.sub.1-C.sub.4fluoroalkyl, C.sub.1-C.sub.4heteroalkyl,
C.sub.1-C.sub.4alkoxy, C.sub.1-C.sub.4fluoroalkoxy,
--SC.sub.1-C.sub.4alkyl, --S(.dbd.O)C.sub.1-C.sub.4alkyl, and
--S(.dbd.O).sub.2C.sub.1-C.sub.4alkyl. In some embodiments,
optional substituents are independently selected from D, halogen,
--CN, --NH.sub.2, --OH, --NH(CH.sub.3), --N(CH.sub.3).sub.2,
--CH.sub.3, --CH.sub.2CH.sub.3, --CH.sub.2NH.sub.2, --CF.sub.3,
--OCH.sub.3, and --OCF.sub.3. In some embodiments, substituted
groups are substituted with one or two of the preceding groups. In
some embodiments, an optional substituent on an aliphatic carbon
atom (acyclic or cyclic) includes oxo (.dbd.O).
[0127] A "tautomer" refers to a molecule wherein a proton shift
from one atom of a molecule to another atom of the same molecule is
possible. The compounds presented herein may, in certain
embodiments, exist as tautomers. In circumstances where
tautomerization is possible, a chemical equilibrium of the
tautomers will exist. The exact ratio of the tautomers depends on
several factors, including physical state, temperature, solvent,
and pH. Some examples of tautomeric equilibrium include:
##STR00022##
[0128] "Optional" or "optionally" means that a subsequently
described event or circumstance may or may not occur and that the
description includes instances when the event or circumstance
occurs and instances in which it does not. For example, "optionally
substituted aryl" means that the aryl radical may or may not be
substituted and that the description includes both substituted aryl
radicals and aryl radicals having no substitution.
[0129] "Pharmaceutically acceptable salt" includes both acid and
base addition salts. A pharmaceutically acceptable salt of any one
of the pyrazole compounds described herein is intended to encompass
any and all pharmaceutically suitable salt forms. Preferred
pharmaceutically acceptable salts of the compounds described herein
are pharmaceutically acceptable acid addition salts and
pharmaceutically acceptable base addition salts.
[0130] "Pharmaceutically acceptable acid addition salt" refers to
those salts which retain the biological effectiveness and
properties of the free bases, which are not biologically or
otherwise undesirable, and which are formed with inorganic acids
such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric
acid, phosphoric acid, hydroiodic acid, hydrofluoric acid,
phosphorous acid, and the like. Also included are salts that are
formed with organic acids such as aliphatic mono- and dicarboxylic
acids, phenyl-substituted alkanoic acids, hydroxy alkanoic acids,
alkanedioic acids, aromatic acids, aliphatic and. aromatic sulfonic
acids, etc. and include, for example, acetic acid, trifluoroacetic
acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid,
maleic acid, malonic acid, succinic acid, fumaric acid, tartaric
acid, citric acid, benzoic acid, cinnamic acid, mandelic acid,
methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid,
salicylic acid, and the like. Exemplary salts thus include
sulfates, pyrosulfates, bisulfates, sulfites, bisulfites, nitrates,
phosphates, monohydrogenphosphates, dihydrogenphosphates,
metaphosphates, pyrophosphates, chlorides, bromides, iodides,
acetates, trifluoroacetates, propionates, caprylates, isobutyrates,
oxalates, malonates, succinate suberates, sebacates, fumarates,
maleates, mandelates, benzoates, chlorobenzoates, methylbenzoates,
dinitrobenzoates, phthalates, benzenesulfonates, toluenesulfonates,
phenylacetates, citrates, lactates, malates, tartrates,
methanesulfonates, and the like.
[0131] Also contemplated are salts of amino acids, such as
arginates, gluconates, and galacturonates (see, for example, Berge
S. M. et al., "Pharmaceutical Salts," Journal of Pharmaceutical
Science, 66:1-19 (1997)). Acid addition salts of basic compounds
may be prepared by contacting the free base forms with a sufficient
amount of the desired acid to produce the salt according to methods
and techniques with which a skilled artisan is familiar.
[0132] "Pharmaceutically acceptable base addition salt" refers to
those salts that retain the biological effectiveness and properties
of the free acids, which are not biologically or otherwise
undesirable. These salts are prepared from addition of an inorganic
base or an organic base to the free acid. Pharmaceutically
acceptable base addition salts may be formed with metals or amines,
such as alkali and alkaline earth metals or organic amines. Salts
derived from inorganic bases include, but are not limited to,
sodium, potassium, lithium, ammonium, calcium, magnesium, iron,
zinc, copper, manganese, aluminum salts and the like. Salts derived
from organic bases include, but are not limited to, salts of
primary, secondary, and tertiary amines, substituted amines
including naturally occurring substituted amines, cyclic amines and
basic ion exchange resins, for example, isopropylamine,
trimethylamine, diethylamine, triethylamine, tripropylamine,
ethanolamine, diethanolamine, 2-dimethylaminoethanol,
2-diethylaminoethanol, dicyclohexylamine, lysine, arginine,
histidine, caffeine, procaine, N,N-dibenzylethylenediamine,
chloroprocaine, hydrabamine, choline, betaine, ethylenediamine,
ethylenedianiline, N-methylglucamine, glucosamine, methylglucamine,
theobromine, purines, piperazine, piperidine, N-ethylpiperidine,
polyamine resins and the like. See Berge et al., supra.
[0133] "Prodrug" is meant to indicate a compound that may be
converted under physiological conditions or by solvolysis to a
biologically active compound described herein. Thus, the term
"prodrug" refers to a precursor of a biologically active compound
that is pharmaceutically acceptable. A prodrug may be inactive when
administered to a subject, but is converted in vivo to an active
compound, for example, by hydrolysis. The prodrug compound often
offers advantages of solubility, tissue compatibility or delayed
release in a mammalian organism (see, e.g., Bundgard, H., Design of
Prodrugs (1985), pp. 7-9, 21-24 (Elsevier, Amsterdam).
[0134] A discussion of prodrugs is provided in Higuchi, T., et al.,
"Pro-drugs as Novel Delivery Systems," A.C.S. Symposium Series,
Vol. 14, and in Bioreversible Carriers in Drug Design, ed. Edward
B. Roche, American Pharmaceutical Association and Pergamon Press,
1987.
[0135] The term "prodrug" is also meant to include any covalently
bonded carriers, which release the active compound in vivo when
such prodrug is administered to a mammalian subject. Prodrugs of an
active compound, as described herein, may be prepared by modifying
functional groups present in the active compound in such a way that
the modifications are cleaved, either in routine manipulation or in
vivo, to the parent active compound. Prodrugs include compounds
wherein a hydroxy, amino or mercapto group is bonded to any group
that, when the prodrug of the active compound is administered to a
mammalian subject, cleaves to form a free hydroxy, free amino or
free mercapto group, respectively. Examples of prodrugs include,
but are not limited to, acetate, formate and benzoate derivatives
of alcohol or amine functional groups in the active compounds and
the like.
[0136] The term "acceptable" with respect to a formulation,
composition or ingredient, as used herein, means having no
persistent detrimental effect on the general health of the subject
being treated.
[0137] The term "modulate" as used herein, means to interact with a
target either directly or indirectly so as to alter the activity of
the target, including, by way of example only, to enhance the
activity of the target, to inhibit the activity of the target, to
limit the activity of the target, or to extend the activity of the
target.
[0138] The term "modulator" as used herein, refers to a molecule
that interacts with a target either directly or indirectly. The
interactions include, but are not limited to, the interactions of
an agonist, partial agonist, an inverse agonist, antagonist,
degrader, or combinations thereof. In some embodiments, a modulator
is an agonist.
[0139] The terms "administer," "administering", "administration,"
and the like, as used herein, refer to the methods that may be used
to enable delivery of compounds or compositions to the desired site
of biological action. These methods include, but are not limited to
oral routes, intraduodenal routes, parenteral injection (including
intravenous, subcutaneous, intraperitoneal, intramuscular,
intravascular or infusion), topical and rectal administration.
Those of skill in the art are familiar with administration
techniques that can be employed with the compounds and methods
described herein. In some embodiments, the compounds and
compositions described herein are administered orally.
[0140] The terms "co-administration" or the like, as used herein,
are meant to encompass administration of the selected therapeutic
agents to a single patient, and are intended to include treatment
regimens in which the agents are administered by the same or
different route of administration or at the same or different
time.
[0141] The terms "effective amount" or "therapeutically effective
amount," as used herein, refer to a sufficient amount of an agent
or a compound being administered, which will relieve to some extent
one or more of the symptoms of the disease or condition being
treated. The result includes reduction and/or alleviation of the
signs, symptoms, or causes of a disease, or any other desired
alteration of a biological system. For example, an "effective
amount" for therapeutic uses is the amount of the composition
comprising a compound as disclosed herein required to provide a
clinically significant decrease in disease symptoms. An appropriate
"effective" amount in any individual case is optionally determined
using techniques, such as a dose escalation study.
[0142] The terms "enhance" or "enhancing," as used herein, means to
increase or prolong either in potency or duration a desired effect.
Thus, in regard to enhancing the effect of therapeutic agents, the
term "enhancing" refers to the ability to increase or prolong,
either in potency or duration, the effect of other therapeutic
agents on a system. An "enhancing-effective amount," as used
herein, refers to an amount adequate to enhance the effect of
another therapeutic agent in a desired system.
[0143] The term "pharmaceutical combination" as used herein, means
a product that results from the mixing or combining of more than
one active ingredient and includes both fixed and non-fixed
combinations of the active ingredients. The term "fixed
combination" means that the active ingredients, e.g. a compound
described herein, or a pharmaceutically acceptable salt thereof,
and a co-agent, are both administered to a patient simultaneously
in the form of a single entity or dosage. The term "non-fixed
combination" means that the active ingredients, e.g. a compound
described herein, or a pharmaceutically acceptable salt thereof,
and a co-agent, are administered to a patient as separate entities
either simultaneously, concurrently or sequentially with no
specific intervening time limits, wherein such administration
provides effective levels of the two compounds in the body of the
patient. The latter also applies to cocktail therapy, e.g. the
administration of three or more active ingredients.
[0144] The terms "kit" and "article of manufacture" are used as
synonyms.
[0145] The term "subject" or "patient" encompasses mammals.
Examples of mammals include, but are not limited to, any member of
the Mammalian class: humans, non-human primates such as
chimpanzees, and other apes and monkey species; farm animals such
as cattle, horses, sheep, goats, swine; domestic animals such as
rabbits, dogs, and cats; laboratory animals including rodents, such
as rats, mice and guinea pigs, and the like. In one aspect, the
mammal is a human.
[0146] As used herein, "treatment" or "treating" or "palliating" or
"ameliorating" are used interchangeably herein. These terms refers
to an approach for obtaining beneficial or desired results
including but not limited to therapeutic benefit and/or a
prophylactic benefit. By "therapeutic benefit" is meant eradication
or amelioration of the underlying disorder being treated. Also, a
therapeutic benefit is achieved with the eradication or
amelioration of one or more of the physiological symptoms
associated with the underlying disorder such that an improvement is
observed in the patient, notwithstanding that the patient may still
be afflicted with the underlying disorder. For prophylactic
benefit, the compositions may be administered to a patient at risk
of developing a particular disease, or to a patient reporting one
or more of the physiological symptoms of a disease, even though a
diagnosis of this disease may not have been made.
[0147] Compounds
[0148] Compounds described herein, including pharmaceutically
acceptable salts, and pharmaceutically acceptable solvates thereof,
that modulate IRE1 mediated signaling, directly or indirectly.
[0149] Provided in one aspect is a compound of Formula (I), or a
pharmaceutically acceptable salt, or solvate thereof:
##STR00023##
wherein,
##STR00024##
is a substituted C.sub.3-C.sub.10 cycloalkyl that is substituted
with 1-3R.sup.1 and 0-3R.sup.2; [0150] each R.sup.1 is
independently --OR.sup.6, --SR.sup.6, --S(.dbd.O)R.sup.7,
--S(.dbd.O).sub.2R.sup.7, or --N(R.sup.6).sub.2; [0151] each
R.sup.2 is independently H, halogen, --CN, --OR.sup.8, --SR.sup.8,
--S(.dbd.O)R.sup.9, --S(.dbd.O).sub.2R.sup.9,
--S(.dbd.O).sub.2N(R.sup.8).sub.2,
--NR.sup.8S(.dbd.O).sub.2R.sup.9, --C(.dbd.O)R.sup.9,
--OC(.dbd.O)R.sup.9, --CO.sub.2R.sup.8, --OCO.sub.2R.sup.9,
--N(R.sup.8).sub.2, --OC(.dbd.O)N(R.sup.8).sub.2,
--NR.sup.8C(.dbd.O)R.sup.9, --NR.sup.8C(.dbd.O)OR.sup.9, optionally
substituted C.sub.1-C.sub.4alkyl, optionally substituted
C.sub.1-C.sub.4fluoroalkyl, optionally substituted
C.sub.1-C.sub.4heteroalkyl, optionally substituted
C.sub.3-C.sub.6cycloalkyl, optionally substituted aryl, or
optionally substituted heteroaryl; [0152] each R.sup.6 is
independently H, optionally substituted C.sub.1-C.sub.4alkyl,
optionally substituted C.sub.1-C.sub.4heteroalkyl, optionally
substituted C.sub.1-C.sub.4fluoroalkyl, --X-optionally substituted
C.sub.1-C.sub.4alkyl, --X-optionally substituted
C.sub.1-C.sub.4heteroalkyl, --X-optionally substituted
C.sub.1-C.sub.4fluoroalkyl, optionally substituted
C.sub.3-C.sub.6cycloalkyl, optionally substituted
C.sub.2-C.sub.10heterocycloalkyl, optionally substituted aryl, or
optionally substituted heteroaryl; [0153] or two R.sup.6 are taken
together with the N atom to which they are attached to form an
optionally substituted heterocycle; [0154] X is --(C.dbd.O)--;
[0155] each R.sup.7 is independently optionally substituted
C.sub.1-C.sub.4alkyl, optionally substituted
C.sub.1-C.sub.4heteroalkyl, optionally substituted
C.sub.1-C.sub.4fluoroalkyl, optionally substituted
C.sub.3-C.sub.6cycloalkyl, optionally substituted
C.sub.2-C.sub.10heterocycloalkyl, optionally substituted aryl, or
optionally substituted heteroaryl; [0156] each R.sup.8 is
independently H, optionally substituted C.sub.1-C.sub.4alkyl,
optionally substituted C.sub.1-C.sub.4heteroalkyl, optionally
substituted C.sub.1-C.sub.4fluoroalkyl, optionally substituted
C.sub.3-C.sub.6cycloalkyl, optionally substituted
C.sub.2-C.sub.10heterocycloalkyl, optionally substituted aryl, or
optionally substituted heteroaryl; [0157] or two R.sup.8 are taken
together with the N atom to which they are attached to form an
optionally substituted heterocycle; [0158] each R.sup.9 is
independently optionally substituted C.sub.1-C.sub.4alkyl,
optionally substituted C.sub.1-C.sub.4heteroalkyl, or optionally
substituted C.sub.1-C.sub.4fluoroalkyl, optionally substituted
C.sub.3-C.sub.6cycloalkyl, optionally substituted
C.sub.2-C.sub.10heterocycloalkyl, optionally substituted aryl, or
optionally substituted heteroaryl; [0159] A.sup.2 is N or CR.sup.A;
[0160] R.sup.A, R.sup.A1, R.sup.A2, and R.sup.A3 are each
independently H, halogen, optionally substituted
C.sub.1-C.sub.4alkyl, optionally substituted
C.sub.1-C.sub.4fluoroalkyl, optionally substituted aryl, or
--OR.sup.10 [0161] R.sup.10 is independently H, optionally
substituted C.sub.1-C.sub.4alkyl, optionally substituted
C.sub.1-C.sub.4fluoroalkyl, optionally substituted
C.sub.1-C.sub.4heteroalkyl, optionally substituted
C.sub.3-C.sub.6cycloalkyl, optionally substituted
C.sub.2-C.sub.10heterocycloalkyl, optionally substituted aryl, or
optionally substituted heteroaryl; [0162] ring A is a monocyclic
carbocycle or a monocyclic heterocycle; [0163] each R.sup.3 is
independently H, halogen, --CN, --OR.sup.11, --SR.sup.11,
--N(R.sup.11).sub.2, optionally substituted C.sub.1-C.sub.4alkyl,
optionally substituted C.sub.1-C.sub.4fluoroalkyl, optionally
substituted C.sub.1-C.sub.4heteroalkyl, optionally substituted
C.sub.3-C.sub.6cycloalkyl, optionally substituted
C.sub.2-C.sub.10heterocycloalkyl, optionally substituted aryl, or
optionally substituted heteroaryl; [0164] each R.sup.11 is
independently H, optionally substituted C.sub.1-C.sub.4alkyl,
optionally substituted C.sub.1-C.sub.4fluoroalkyl, optionally
substituted C.sub.1-C.sub.4heteroalkyl, optionally substituted
C.sub.3-C.sub.6cycloalkyl, optionally substituted
C.sub.2-C.sub.10heterocycloalkyl, optionally substituted aryl, or
optionally substituted heteroaryl; [0165] n is 0, 1, 2, 3, or 4;
[0166] R.sup.4 and R.sup.5 are each independently H, halogen, --CN,
--OR.sup.12, --SR.sup.12, --N(R.sup.12).sub.2, optionally
substituted C.sub.1-C.sub.4alkyl, optionally substituted
C.sub.1-C.sub.4fluoroalkyl, optionally substituted
C.sub.1-C.sub.4heteroalkyl, optionally substituted
C.sub.3-C.sub.6cycloalkyl, optionally substituted
C.sub.2-C.sub.10heterocycloalkyl, optionally substituted aryl, or
optionally substituted heteroaryl; and [0167] R.sup.12 is
independently H, optionally substituted C.sub.1-C.sub.4alkyl,
optionally substituted C.sub.1-C.sub.4fluoroalkyl, optionally
substituted C.sub.1-C.sub.4heteroalkyl, optionally substituted
C.sub.3-C.sub.6cycloalkyl, optionally substituted
C.sub.2-C.sub.10heterocycloalkyl, optionally substituted aryl, or
optionally substituted heteroaryl.
[0168] In some embodiments,
##STR00025##
is substituted C.sub.4-C.sub.7 cycloalkyl that is substituted with
1-3R.sup.1 and 0-3R.sup.2.
[0169] In some embodiments,
##STR00026##
and q is 0, 1, 2, or 3.
[0170] In some embodiments,
##STR00027##
[0171] q is 0, 1, 2, or 3.
[0172] In some embodiments,
##STR00028##
and
[0173] q is 0, 1, 2, or 3.
[0174] In some embodiments, q is 0 or 1. In some embodiments, each
R.sup.6 is independently H, optionally substituted
C.sub.1-C.sub.4alkyl, optionally substituted
C.sub.1-C.sub.4heteroalkyl, optionally substituted
C.sub.1-C.sub.4fluoroalkyl, --X-optionally substituted
C.sub.1-C.sub.4alkyl, --X-optionally substituted
C.sub.1-C.sub.4heteroalkyl, or --X-optionally substituted
C.sub.1-C.sub.4fluoroalkyl. In some embodiments, each R.sup.6 is
independently H. In some embodiments, each R.sup.2 is independently
H, optionally substituted C.sub.1-C.sub.4alkyl, optionally
substituted C.sub.1-C.sub.4heteroalkyl, or optionally substituted
C.sub.1-C.sub.4fluoroalkyl.
[0175] In some embodiments
##STR00029##
R.sup.6 is H, optionally substituted C.sub.1-C.sub.4alkyl,
optionally substituted C.sub.1-C.sub.4heteroalkyl, optionally
substituted C.sub.1-C.sub.4fluoroalkyl, --X-optionally substituted
C.sub.1-C.sub.4alkyl, --X-optionally substituted
C.sub.1-C.sub.4heteroalkyl, or --X-optionally substituted
C.sub.1-C.sub.4fluoroalkyl; q is 0 or 1; and R.sup.2 is H,
optionally substituted C.sub.1-C.sub.4alkyl, optionally substituted
C.sub.1-C.sub.4heteroalkyl, or optionally substituted
C.sub.1-C.sub.4fluoroalkyl.
[0176] In some embodiments, R.sup.6 is H. In some embodiments,
A.sup.2 is N. In some embodiments, A.sup.2 is CR.sup.A. In some
embodiments, R.sup.A is H, optionally substituted
C.sub.1-C.sub.4alkyl, or optionally substituted
C.sub.1-C.sub.4fluoroalkyl. In some embodiments, R.sup.A is H. In
some embodiments, R.sup.A1 is H, optionally substituted
C.sub.1-C.sub.4alkyl, or optionally substituted
C.sub.1-C.sub.4fluoroalkyl. In some embodiments, R.sup.A1 is H. In
some embodiments, R.sup.A2 is H, optionally substituted
C.sub.1-C.sub.4alkyl, or optionally substituted
C.sub.1-C.sub.4fluoroalkyl. In some embodiments, R.sup.A2 is H. In
some embodiments, R.sup.A3 is H, halogen, optionally substituted
C.sub.1-C.sub.4alkyl, optionally substituted
C.sub.1-C.sub.4fluoroalkyl, optionally substituted aryl, or
--OR.sup.10. In some embodiments, R.sup.A3 is H, halogen,
optionally substituted C.sub.1-C.sub.4alkyl, optionally substituted
C.sub.1-C.sub.4fluoroalkyl, or --OR.sup.10. In some embodiments,
R.sup.A3 is optionally substituted C.sub.1-C.sub.4alkyl. In some
embodiments, R.sup.A3 is methyl, ethyl, propyl or butyl. In some
embodiments, R.sup.A3 is --OR.sup.10 and R.sup.10 is methyl, ethyl,
propyl or butyl. In some embodiments, ring A is phenylene or a
monocyclic C.sub.3-C.sub.8cycloalkylene that is selected from
cyclopropylene, cyclobutylene, cyclopentylene, cyclohexylene,
cycloheptylene, and cyclooctylene. In some embodiments, ring A is
phenylene.
[0177] In some embodiments,
##STR00030##
[0178] In some embodiments, ring A is a monocyclic
C.sub.1-C.sub.8heteroarylene containing 1-4 N atoms, and 0 or 1 O
or S atom, or a monocyclic C.sub.1-C.sub.5heteroarylene containing
0-4 N atoms, and 1 O or S atom. In some embodiments, ring A is a
monocyclic 6-membered heteroarylene selected from pyridinylene,
pyrimidinylene, pyrazinylene, and pyridazinylene. In some
embodiments, ring A is pyridinylene.
[0179] In some embodiments,
##STR00031##
[0180] In some embodiments,
##STR00032##
[0181] In some embodiments, ring A is a monocyclic 5-membered
heteroarylene selected from furanylene, thienylene, pyrrolylene,
oxazolylene, thiazolylene, imidazolylene, pyrazolylene,
triazolylene, tetrazolylene, isoxazolylene, isothiazolylene,
oxadiazolylene, and thiadiazolylene. In some embodiments, ring A is
oxazolylene, thiazolylene, imidazolylene, pyrazolylene, or
oxadiazolylene. In some embodiments, ring A is pyrazolylene.
[0182] In some embodiments,
##STR00033## ##STR00034##
[0183] In some embodiments
##STR00035##
[0184] In some embodiments
##STR00036##
[0185] In some embodiments, ring A is a ring A is a monocyclic
C.sub.2-C.sub.8heterocycloalkylene containing at least 1 N atom in
the ring that is selected from aziridinylene, azetidinylene,
pyrrolidinylene, piperidinylene, piperazinylene, and azepanylene.
In some embodiments, each R.sup.3 is independently H, halogen,
--CN, --OR.sup.11, --SR.sup.11, optionally substituted
C.sub.1-C.sub.4alkyl, or optionally substituted
C.sub.1-C.sub.4fluoroalkyl; and n is 1, 2, or 3. In some
embodiments, R.sup.3 is optionally substituted
C.sub.1-C.sub.4alkyl.
[0186] In some embodiments, R.sup.3 is methyl, ethyl, propyl, or
butyl. In some embodiments, R.sup.3 is --OR.sup.11. In some
embodiments, R.sup.11 is H, optionally substituted
C.sub.1-C.sub.4alkyl, or optionally substituted
C.sub.1-C.sub.4fluoroalkyl. In some embodiments, R.sup.11 is
methyl, ethyl, propyl, or butyl. In some embodiments, R.sup.11 is
--CF.sub.3 or --CH.sub.2CF.sub.3. In some embodiments, R.sup.4 is
H, halogen, --CN, --OR.sup.12, --SR.sup.12, --N(R.sup.12).sub.2,
optionally substituted C.sub.1-C.sub.4alkyl, or optionally
substituted C.sub.1-C.sub.4fluoroalkyl. In some embodiments,
R.sup.4 is H. In some embodiments, R.sup.4 is halogen. In some
embodiments, R.sup.4 is --Cl, --Br, --F, or --I. In some
embodiments, R.sup.4 is --OR.sup.12. In some embodiments, R.sup.12
is H, optionally substituted C.sub.1-C.sub.4alkyl, or optionally
substituted C.sub.1-C.sub.4fluoroalkyl. In some embodiments,
R.sup.4 is optionally substituted C.sub.1-C.sub.4alkyl. In some
embodiments, R.sup.4 is methyl, ethyl, propyl, or butyl. In some
embodiments, R.sup.4 is optionally substituted
C.sub.1-C.sub.4fluoroalkyl. In some embodiments, R.sup.4 is
--CF.sub.3 or --CH.sub.2CF.sub.3. In some embodiments, R.sup.5 is
H, halogen, --CN, --OR.sup.12, --SR.sup.12, --N(R.sup.12).sub.2,
optionally substituted C.sub.1-C.sub.4alkyl, or optionally
substituted C.sub.1-C.sub.4fluoroalkyl. In some embodiments,
R.sup.5 is H. In some embodiments, R.sup.5 is halogen. In some
embodiments, R.sup.5 is --Cl, --Br, --F, or --I. In some
embodiments, R.sup.5 is --OR.sup.12. In some embodiments, R.sup.12
is H, optionally substituted C.sub.1-C.sub.4alkyl, or optionally
substituted C.sub.1-C.sub.4fluoroalkyl. In some embodiments,
R.sup.5 is optionally substituted C.sub.1-C.sub.4alkyl. In some
embodiments, R.sup.5 is methyl, ethyl, propyl, or butyl. In some
embodiments, R.sup.5 is optionally substituted
C.sub.1-C.sub.4fluoroalkyl. In some embodiments, R.sup.5 is
--CF.sub.3 or --CH.sub.2CF.sub.3.
[0187] In some embodiments, the compound has the structure of
formula (Ia)
##STR00037##
[0188] In some embodiments, the compound has the structure of
formula (Ib)
##STR00038##
[0189] In some embodiments, the compound has the structure of
formula (Ic)
##STR00039##
[0190] In some embodiments,
##STR00040##
and q is 0 or 1.
[0191] In some embodiments, each R.sup.6 is independently H,
optionally substituted C.sub.1-C.sub.4alkyl, optionally substituted
C.sub.1-C.sub.4heteroalkyl, optionally substituted
C.sub.1-C.sub.4fluoroalkyl, --X-optionally substituted
C.sub.1-C.sub.4alkyl, --X-optionally substituted
C.sub.1-C.sub.4heteroalkyl, or --X-optionally substituted
C.sub.1-C.sub.4fluoroalkyl. In some embodiments, each R.sup.6 is
independently H. In some embodiments, each R.sup.2 is independently
H, optionally substituted C.sub.1-C.sub.4alkyl, optionally
substituted C.sub.1-C.sub.4heteroalkyl, or optionally substituted
C.sub.1-C.sub.4fluoroalkyl. In some embodiments, A.sup.2 is N. In
some embodiments, A.sup.2 is CR.sup.A. In some embodiments, R.sup.A
is H, optionally substituted C.sub.1-C.sub.4alkyl, or optionally
substituted C.sub.1-C.sub.4fluoroalkyl. In some embodiments,
R.sup.A is H. In some embodiments, R.sup.A1 is H, optionally
substituted C.sub.1-C.sub.4alkyl, or optionally substituted
C.sub.1-C.sub.4fluoroalkyl. In some embodiments, R.sup.A1 is H. In
some embodiments, R.sup.A2 is H, optionally substituted
C.sub.1-C.sub.4alkyl, or optionally substituted
C.sub.1-C.sub.4fluoroalkyl. In some embodiments, R.sup.A2 is H. In
some embodiments, R.sup.A3 is H, halogen, optionally substituted
C.sub.1-C.sub.4alkyl, optionally substituted
C.sub.1-C.sub.4fluoroalkyl, optionally substituted aryl, or
--OR.sup.10. In some embodiments, R.sup.A3 is H, halogen,
optionally substituted C.sub.1-C.sub.4alkyl, optionally substituted
C.sub.1-C.sub.4fluoroalkyl, or --OR.sup.10. In some embodiments,
R.sup.A3 is optionally substituted C.sub.1-C.sub.4alkyl. In some
embodiments, R.sup.A3 is methyl, ethyl, propyl, or butyl. In some
embodiments, R.sup.A3 is ethyl. In some embodiments, ring A is
phenylene. In some embodiments, ring A is a monocyclic 6-membered
heteroarylene selected from pyridinylene, pyrimidinylene,
pyrazinylene, and pyridazinylene. In some embodiments, ring A is
pyridinylene. In some embodiments, ring A is a monocyclic
5-membered heteroarylene selected from furanylene, thienylene,
pyrrolylene, oxazolylene, thiazolylene, imidazolylene,
pyrazolylene, triazolylene, tetrazolylene, isoxazolylene,
isothiazolylene, oxadiazolylene, and thiadiazolylene. In some
embodiments, ring A is pyrazolylene. In some embodiments, each
R.sup.3 is independently H, --OR.sup.11, optionally substituted
C.sub.1-C.sub.4alkyl, or optionally substituted
C.sub.1-C.sub.4fluoroalkyl; and n is 1, 2, or 3. In some
embodiments, R.sup.11 is H, optionally substituted
C.sub.1-C.sub.4alkyl, or optionally substituted
C.sub.1-C.sub.4fluoroalkyl. In some embodiments, R.sup.4 and
R.sup.5 are each independently H, halogen, --CN, --OR.sup.12,
--SR.sup.12, --N(R.sup.12).sub.2, optionally substituted
C.sub.1-C.sub.4alkyl, or optionally substituted
C.sub.1-C.sub.4fluoroalkyl.
[0192] In some embodiments, the compound has the structure of
formula (Id)
##STR00041##
and R.sup.A3 is optionally substituted C.sub.1-C.sub.4 alkyl.
[0193] In some embodiments, the compound has the structure of
formula (Ie)
##STR00042##
[0194] In some embodiments, the compound has the structure of
formula (If)
##STR00043##
[0195] In some embodiments, ring A is phenylene, pyridinylene,
pyrazolylene, thiazolylene, imidazolylene, oxazolylene, or
oxadiazolylene. In some embodiments, R.sup.4 and R.sup.5 are each
independently H, halogen, --CN, --OR.sup.12, --SR.sup.12,
--N(R.sup.12).sub.2, optionally substituted C.sub.1-C.sub.4alkyl,
or optionally substituted C.sub.1-C.sub.4fluoroalkyl.
[0196] In exemplary embodiments, provided herein is a compound of
Formula (I), or a pharmaceutically acceptable salt, or solvate
thereof:
##STR00044##
[0197] wherein,
##STR00045##
and q is 0, 1, 2, or 3;
[0198] each R.sup.6 is independently H, optionally substituted
C.sub.1-C.sub.4alkyl, optionally substituted
C.sub.1-C.sub.4heteroalkyl, optionally substituted
C.sub.1-C.sub.4fluoroalkyl, --X-optionally substituted
C.sub.1-C.sub.4alkyl, --X-optionally substituted
C.sub.1-C.sub.4heteroalkyl, or --X-optionally substituted
C.sub.1-C.sub.4fluoroalkyl;
[0199] each R.sup.2 is independently H, optionally substituted
C.sub.1-C.sub.4alkyl, optionally substituted
C.sub.1-C.sub.4heteroalkyl, or optionally substituted
C.sub.1-C.sub.4fluoroalkyl;
[0200] A.sup.2 is N;
[0201] R.sup.A1 is H;
[0202] R.sup.A2 is H, optionally substituted C.sub.1-C.sub.4alkyl,
or optionally substituted C.sub.1-C.sub.4fluoroalkyl;
[0203] R.sup.A3 is methyl, ethyl, propyl or butyl;
[0204] ring A is a monocyclic 6-membered heteroarylene selected
from pyridinylene, pyrimidinylene, pyrazinylene, and
pyridazinylene;
[0205] R.sup.3 is independently H, halogen, --CN, --OR.sup.11,
--SR.sup.11, optionally substituted C.sub.1-C.sub.4alkyl, or
[0206] optionally substituted C.sub.1-C.sub.4fluoroalkyl; and n is
1, 2, or 3; R.sup.11 is independently H, optionally substituted
C.sub.1-C.sub.4alkyl, optionally substituted
C.sub.1-C.sub.4fluoroalkyl, optionally substituted
C.sub.1-C.sub.4heteroalkyl, optionally substituted
C.sub.3-C.sub.6cycloalkyl, optionally substituted
C.sub.2-C.sub.10heterocycloalkyl, optionally substituted aryl, or
optionally substituted heteroaryl
[0207] R.sup.4 is --Cl, --Br, --F, or --I;
[0208] and R.sup.5 is hydrogen.
[0209] In exemplary embodiments, provided herein is a compound of
Formula (I), or a pharmaceutically acceptable salt, or solvate
thereof:
##STR00046##
[0210] wherein,
##STR00047##
and q is 0, 1, 2, or 3;
[0211] each R.sup.6 is independently H, optionally substituted
C.sub.1-C.sub.4alkyl, optionally substituted
C.sub.1-C.sub.4heteroalkyl, optionally substituted
C.sub.1-C.sub.4fluoroalkyl, --X-optionally substituted
C.sub.1-C.sub.4alkyl, --X-optionally substituted
C.sub.1-C.sub.4heteroalkyl, or --X-optionally substituted
C.sub.1-C.sub.4fluoroalkyl;
[0212] each R.sup.2 is independently H, optionally substituted
C.sub.1-C.sub.4alkyl, optionally substituted
C.sub.1-C.sub.4heteroalkyl, or optionally substituted
C.sub.1-C.sub.4fluoroalkyl;
[0213] A.sup.2 is N;
[0214] R.sup.A1 is H;
[0215] R.sup.A2 is H;
[0216] R.sup.A3 is methyl, ethyl, propyl or butyl;
[0217] ring A is pyridinylene;
[0218] R.sup.3 is methyl, ethyl, propyl, or butyl and n is 1, 2 or
3;
[0219] R.sup.4 is --Cl, --Br, --F, or --I;
[0220] and R.sup.5 is hydrogen.
[0221] In exemplary embodiments, provided herein is a compound of
Formula (I), or a pharmaceutically acceptable salt, or solvate
thereof:
##STR00048##
[0222] wherein.
##STR00049##
and q is 0, 1, 2, or 3;
[0223] each R.sup.6 is independently H, optionally substituted
C.sub.1-C.sub.4alkyl, optionally substituted
C.sub.1-C.sub.4heteroalkyl, optionally substituted
C.sub.1-C.sub.4fluoroalkyl, --X-optionally substituted
C.sub.1-C.sub.4alkyl, --X-optionally substituted
C.sub.1-C.sub.4heteroalkyl, or --X-optionally substituted
C.sub.1-C.sub.4fluoroalkyl;
[0224] each R.sup.2 is independently H, optionally substituted
C.sub.1-C.sub.4alkyl, optionally substituted
C.sub.1-C.sub.4heteroalkyl, or optionally substituted
C.sub.1-C.sub.4fluoroalkyl;
[0225] A.sup.2 is N;
[0226] R.sup.A1 is H;
[0227] R.sup.A2 is H;
[0228] R.sup.A3 is methyl, ethyl, propyl or butyl;
[0229] wherein ring A is pyridinylene;
[0230] R.sup.3 is --OR.sup.11 and n is 1, 2 or 3;
[0231] R.sup.11 is methyl, ethyl, propyl, or butyl
[0232] R.sup.4 is --Cl, --Br, --F, or --I;
[0233] and R.sup.5 is hydrogen.
[0234] In exemplary embodiments, provided herein is a compound of
Formula (I), or a pharmaceutically acceptable salt, or solvate
thereof:
##STR00050##
[0235] wherein,
##STR00051##
and q is 0, 1, 2, or 3;
[0236] each R.sup.6 is independently H, optionally substituted
C.sub.1-C.sub.4alkyl, optionally substituted
C.sub.1-C.sub.4heteroalkyl, optionally substituted
C.sub.1-C.sub.4fluoroalkyl, --X-optionally substituted
C.sub.1-C.sub.4alkyl, --X-optionally substituted
C.sub.1-C.sub.4heteroalkyl, or --X-optionally substituted
C.sub.1-C.sub.4fluoroalkyl;
[0237] each R.sup.2 is independently H, optionally substituted
C.sub.1-C.sub.4alkyl, optionally substituted
C.sub.1-C.sub.4heteroalkyl, or optionally substituted
C.sub.1-C.sub.4fluoroalkyl;
[0238] A.sup.2 is N;
[0239] R.sup.A1 is H;
[0240] R.sup.A2 is H;
[0241] R.sup.A3 is methyl, ethyl, propyl or butyl;
[0242] wherein ring A is pyridinylene;
[0243] R.sup.3 is --OR.sup.11 and n is 1, 2 or 3;
[0244] R.sup.11 is CF.sub.3 or --CH.sub.2CF.sub.3
[0245] R.sup.4 is --Cl, --Br, --F, or --I;
[0246] and R.sup.5 is hydrogen.
[0247] In some embodiments, a compound described herein is selected
from any one of the compounds from Table 1.
TABLE-US-00001 TABLE 1 Compound No. Structure Name 1 ##STR00052##
N-(5-(2-(((1r,4r)-4- aminocyclohexyl)amino)
quinazolin-6-yl)-1-methyl- 1H-pyrazol-3-yl)-2-
chlorobenzenesulfonamide 2 ##STR00053## N-(4-(2-(((1r,4r)-4-
aminocyclohexyl)amino) quinazolin-6-yl)-3- methylphenyl)-2-
chlorobenzenesulfonamide 3 ##STR00054## N-(4-(2-(((1r,4r)-4-
aminocyclohexyl)amino)-8- ethylquinazolin-6-yl)-3- methylphenyl)-2-
chlorobenzenesulfonamide 4 ##STR00055## N-(5-(2-(((1r,4r)-4-
aminocyclohexyl)amino)-8- ethylquinazolin-6-yl)-4-
methylpyridin-2-yl)-2- chlorobenzenesulfonamide 5 ##STR00056##
N-(5-(2-(((1r,4r)-4- aminocyclohexyl)amino) quinazolin-6-yl)-4-
methylpyridin-2-yl)-2- chlorobenzenesulfonamide 6 ##STR00057##
N-(5-(2-(((1r,4r)-4- aminocyclohexyl)amino)-8-
ethylquinazolin-6-yl)-1- methyl-1H-pyrazol-3-yl)-2-
chlorobenzenesulfonamide 7 ##STR00058## N-(4-(2-(((1r,4r)-4-
aminocyclohexyl)amino)-8- ethylquinazolin-6-yl)-3- methylphenyl)-2-
(trifluoromethyl) benzenesulfonamide 8 ##STR00059##
N-(4-(2-(((1r,4r)-4- aminocyclohexyl)amino)-8-
ethylquinazolin-6-yl)-3- methylphenyl)-2- (trifluoromethoxy)
benzenesulfonamide 9 ##STR00060## N-(4-(2-(((1r,4r)-4-
aminocyclohexyl)amino)-8- ethylquinazolin-6-yl)-3-
methylphenyl)-2,5- dichlorobenzenesulfonamide 10 ##STR00061##
N-(4-(2-(((1r,4r)-4- aminocyclohexyl)amino)-8-
ethylquinazolin-6-yl)-3- methylphenyl)-2- fluorobenzenesulfonamide
11 ##STR00062## N-(4-(2-(((1r,4r)-4- aminocyclohexyl)amino)
quinazolin-6-yl)-3- methylphenyl)-3- chlorobenzenesulfonamide 12
##STR00063## N-(4-(2-(((1r,4r)-4- aminocyclohexyl)amino-8-
ethylquinazolin-6-yl)-3- methylphenyl)-4- chlorobenzenesulfonamide
13 ##STR00064## N-(4-(2-(((1r,4r)-4- aminocyclohexyl)amino-8-
ethylquinazolin-6-yl)-3- methylphenyl)-2- methoxybenzenesulfonamide
14 ##STR00065## N-(4-(2-(((1r,4r)-4- aminocyclohexyl)amino)-8-
ethylquinazolin-6-yl)-3- (trifluoromethyl)phenyl)-2-
chlorobenzenesulfonamide 15 ##STR00066## N-(4-(2-(((1r,4r)-4-
aminocyclohexyl)amino)-8- ethylquinazolin-6-yl)-3- methylphenyl)
benzenesulfonamide 16 ##STR00067## N-(5-(2-(((1r,4r)-4-
aminocyclohexyl)amino)-8- ethylquinazolin-6-yl)-6-
methylpyridin-2-yl)-2- chlorobenzenesulfonamide 17 ##STR00068##
N-(4-(2-(((1r,4r)-4- aminocyclohexyl)amino)-8-
ethylquinazolin-6-yl)-3- chlorophenyl)-2- chlorobenzenesulfonamide
18 ##STR00069## N-(4-(2-(((1r,4r)-4- aminocyclohexyl)amino)-8-
ethylquinazolin-6-yl)phenyl)- 2-chlorobenzenesulfonamide 19
##STR00070## N-(4-(2-(((1r,4r)-4- aminocyclohexyl)amino)-8-
ethylquinazolin-6-yl)-3- methoxyphenyl)-2- chlorobenzenesulfonamide
20 ##STR00071## N-(6-2-(((1r,4r)-4- aminocyclohexyl)amino)-8-
ethylquinazolin-6-yl)-5- methylpyridin-3-yl)-2-
chlorobenzenesulfonamide 21 ##STR00072## N-(4-(2-(((1r,4r)-4-
aminocyclohexyl)amino)-8- ethylquinazolin-6-yl)-
2-fluoro-5-methylphenyl)-2- chlorobenzenesulfonamide 22
##STR00073## N-(4-(2-(((1r,4r)-4- aminocyclohexyl)amino)-8-
ethylquinazolin-6-yl)-2,3- dimethylphenyl)-2-
chlorobenzenesulfonamide 23 ##STR00074## N-(5-(2-(((1r,4r)-4-
aminocyclohexyl)amino)-8- ethylquinazolin-6-yl)-4-
methylpyrimidin-2-yl)-2- chlorobenzenesulfonamide 24 ##STR00075##
N-(4-(2-(((1r,4r)-4- aminocyclohexyl)amino-8-
ethylquinazolin-6-yl)-2- fluorophenyl)-2- chlorobenzenesulfonamide
25 ##STR00076## N-(5-(2-(((1r,4r)-4- aminocyclohexyl)amino)-8-
ethylquinazolin-6-yl)pyrazin- 2-yl)-2- chlorobenzenesulfonamide 26
##STR00077## N-(4-(2-(((1r,4r)-4- aminocyclohexyl)amino)
quinazolin-6-yl)phenyl-2- chlorobenzenesulfonamide 27 ##STR00078##
N-(5-(2-(((1r,4r)-4- aminocyclohexyl)amino)-8-
ethylquinazolin-6-yl)pyridin- 2-yl)-2- chlorobenzenesulfonamide 28
##STR00079## N-(6-(2-(((1r,4r)-4- aminocyclohexyl)amino)-8-
ethylquinazolin-6-yl)pyridin- 3-yl)-2- chlorobenzenesulfonamide 29
##STR00080## N-(5-(2-(((1r,4r)-4- aminocyclohexyl)amino)-8-
ethylquinazolin-6-yl)-1H- pyrazol-3-yl)-2- chlorobenzenesulfonamide
30 ##STR00081## N-(4-(2-(((1r,4r)-4- aminocyclohexyl)amino)-8-
hydroxyquinazolin-6-yl)-3- methylphenyl)-2-chloro-N-
methylbenzenesulfonamide 31 ##STR00082## N-(4-(2-(((1r,4r)-4-
aminocyclohexyl)amino)-8- ethylquinazolin-6-yl)-3-
methylphenyl)-2-chloro-N- methylbenzenesulfonamide 32 ##STR00083##
N-(6-(2-(((1r,4r)-4- aminocyclohexyl)amino)-8- ethylquinazolin-6-
yl)pyridazin-3-yl)-2- chlorobenzenesulfonamide 33 ##STR00084##
N-(2-(2-(((1r,4r)-4- aminocyclohexyl)amino)-8- ethylquinazolin-6-
yl)pyrimidin-5-yl)-2- chlorobenzenesulfonamide 34 ##STR00085##
N-(4-(2-(((1r,4r)-4- aminocyclohexyl)amino)-8-
ethylquinazolin-6-yl)-3- ethylphenyl)-2- chlorobenzenesulfonamide
35 ##STR00086## N-(4-(2-(((1r,4r)-4- aminocyclohexyl)amino)-8-
ethylquinazolin-6-yl)-3- fluorophenyl)-2- chlorobenzenesulfonamide
36 ##STR00087## N-(4-(2-(((1r,4r)-4- aminocyclohexyl)amino)-8-
methoxyquinazolin-6-yl)-3- methylphenyl)-2-
chlorobenzenesulfonamide 37 ##STR00088## N-(5-(2-(((1r,4r)-4-
aminocyclohexyl)amino)-8- ethylquinazolin-6-yl)-6-
methoxypyridin-2-yl)-2- chlorobenzenesulfonamide 38 ##STR00089##
N-(5-(2-(((1r,4r)-4- aminocyclohexyl)amino)-8-
ethylquinazolin-6-yl)-4- methylthiazol-2-yl)-2-
chlorobenzenesulfonamide 39 ##STR00090## N-(5-(2-(((1r,4r)-4-
aminocyclohexyl)amino)-8- ethylquinazolin-6- yl)pyrimidin-2-yl)-2-
chlorobenzenesulfonamide 40 ##STR00091## N-(5-(2-(((1r,4r)-4-
aminocyclohexyl)amino)-8- isopropylquinazolin-6-yl)-1-
methyl-1H-pyrazol-3-yl)-2- chlorobenzenesulfonamide 41 ##STR00092##
N-(5-(2-(((1r,4r)-4- aminocyclohexyl)amino)-8-
ethylquinazolin-6-yl)thiazol-2- yl)-2- chlorobenzenesulfonamide 42
##STR00093## N-(4-(2-(((1r,4r))-4- aminocyclohexyl)amino)-8-
ethylquinazolin-6-yl)-2-fluoro- 5-methoxyphenyl)-2-
chlorobenzenesulfonamide 43 ##STR00094## N-(1-(2-(((1r,4r)-4-
aminocyclohexyl)amino)-8- ethylquinazolin-6-yl)-1H-
pyrazol-4-yl)-2- chlorobenzenesulfonamide 44 ##STR00095##
N-(5-(2-(((1r,4r)-4- aminocyclohexyl)amino)-8-
ethylquinazolin-6-yl)isoxazol- 3-yl)-2- chlorobenzenesulfonamide 45
##STR00096## N-(5-(2-(((1r,4r)-4- aminocyclohexyl)amino)-8-
methoxyquinazolin-6-yl)-1- methyl-1H-pyrazol-3-yl)-2-
chlorobenzenesulfonamide 46 ##STR00097## N-(5-(2-(((1r,4r)-4-
aminocyclohexyl)amino)-8- ethylquinazolin-6-yl)-4-
methoxypyrimidin-2-yl)-2- chlorobenzenesulfonamide 47 ##STR00098##
N-(5-(2-(((1r,4r)-4- aminocyclohexyl)amino)-8-
propylquinaozlin-6-yl)-1- methyl-1H-pyrazol-3-yl)-2-
chlorobenzenesulfonamide 48 ##STR00099## N-(4-(2-(((1r,4r)-4-
aminocyclohexyl)amino) quinazolin-6-yl)-3- fluorophenyl)-2-
chlorobenzenesulfonamide 49 ##STR00100## N-(6-(2-(((1r,4r)-4-
aminocyclohexyl)amino) quinazolin-6-yl)pyridazin- 3-yl)-2-
chlorobenzenesulfonamide 50 ##STR00101## N-(4-(2-(((1r,4r)-4-
aminocyclohexyl)amino) quinazolin-6-yl)-2- fluorophenyl)-2-
chlorobenzenesulfonamide 51 ##STR00102## N-(6-(2-(((1r,4r)-4-
aminocyclohexyl)amino) quinazolin-6-yl)-5- fluoropyridin-3-yl)-2-
chlorobenzenesulfonamide 52 ##STR00103## N-(6-(2-(((1r,4r)-4-
aminocyclohexyl)amino)-8- ethylquinazolin-6-yl)-5-
fluoropyridin-3-yl)-2- chlorobenzenesulfonamide 53 ##STR00104##
N-(4-(2-(((1r,4r)-4- aminocyclohexyl)amino) quinazolin-6-yl)-2,5-
difluorophenyl)-2- chlorobenzenesulfonamide 54 ##STR00105##
N-(5-(2-(((1r,4r)-4- aminocyclohexyl)amino) quinazolin-6-yl)-3-
fluoropyridin-2-yl)-2- chlorobenzenesulfonamide 55 ##STR00106##
N-(5-(2-(((1r,4r)-4- aminocyclohexyl)amino)-8-
ethylquinazolin-6-yl)-3- fluoropyridin-2-yl)-2-
chlorobenzenesulfonamide 56 ##STR00107## N-(4-(2-(((1r,4r)-4-
aminocyclohexyl)amino) quinazolin-6-yl)-2,3- difluorophenyl)-2-
chlorobenzenesulfonamide 57 ##STR00108## N-(4-(3-(((1r,4r)-4-
aminocyclohexyl)amino) isoquinolin-7-yl)-2- fluorophenyl)-2-
chlorobenzenesulfonamide 58 ##STR00109##
(S)-2-amino-N-((1r,4S)-4-((6- (4-((2- chlorophenyl)sulfonamido)-3-
fluorophenyl)-8- ethylquinazolin-2- yl)amino)cyclohexyl)-3-
methylbutanamide 59 ##STR00110## N-((1r,4r)-4-((6-(4-((2-
chlorophenyl)sulfonamido)-3- fluorophenyl)-8- ethylquinazolin-2-
yl)amino)cyclohexyl) acetamide 60 ##STR00111##
2-chloro-N-(4-(8-ethyl-2- (((1r,4r)-4- (methylamino)cyclohexyl)
amino)quinazolin-6-yl)-2- fluorophenyl) benzenesulfonamide 62
##STR00112## N-(4-(2-(((1r,4r)-4- aminocyclohexyl)amino)
quinazolin-6-yl)-3,5- difluorophenyl)-2- chlorobenzenesulfonamide
63 ##STR00113## N-(4-(2-(((1r,4r)-4- aminocyclohexyl)amino-8-
ethylquinazolin-6-yl)-2,6- difluorophenyl)-2-
chlorobenzenesulfonamide 65 ##STR00114## N-(6-(2-(((1r,4r)-4-
aminocyclohexyl)amino)-8- ethylquinaolin-6-yl)-5-
methoxypyridazin-3-yl)-2- chlorobenzenesulfonamide 66 ##STR00115##
N-(6-(2-(((1r,4r)-4- aminocyclohexyl)amino)-8-
ethylquinazolin-6-yl)-4- methxoypyridazin-3-yl)-2-
chlorobenzenesulfonamide 67 ##STR00116## N-(6-(2-(((1r,4r)-4-
aminocyclohexyl)amino)-8- ethylquinazolin-6-yl)-5-
methylpyridazin-3-yl)-2- chlorobenzenesulfonamide 68 ##STR00117##
N-(5-(2-(((1r,4r)-4- aminocyclohexyl)amino) quinazolin-6-yl)-4-
methylpyrimidin-2-yl)-2- chlorobenzenesulfonamide 69 ##STR00118##
2-chloro-N-(4-(2-(((1r,4r)-4- (dimethylamino)cyclohexyl)
amino)-8-ethylquinazolin- 6-yl)-2- fluorophenyl) benzenesulfonamide
70 ##STR00119## N-(4-(2-(((1R,3R,4S)-4- amino-3-
methylcyclohexyl)amino)-8- ethylquinazolin-6-yl)-2-
fluorophenyl)-2- chlorobenzenesulfonamide 71 ##STR00120##
N-(4-(2-(((1r,4r)-4- aminocyclohexyl)amino)-8-
ethylquinazolin-6-yl)-2-fluoro- 3-methylphenyl)-2-
chlorobenzenesulfonamide 72 ##STR00121## N-(4-(2-(((1R,3S)-3-
aminocyclohexyl)amino)-8- ethylquinazolin-6-yl)-2- fluorophenyl)-2-
chlorobenzenesulfonamide 73 ##STR00122##
(S)-2-chloro-N-(4-(8-ethyl-2- (piperidin-3-
ylamino)quinazolin-6-yl)-2- fluorophenyl) benzenesulfonamide 74
##STR00123## N-(4-(2-(((1R,3R,4R)-4- amino-3-
methylcyclohexyl)amino)-8- ethylquinazolin-6-yl)-2-
fluorophenyl)-2- chlorobenzenesulfonamide 75 ##STR00124##
N-(4-(2-(((1R,3S)-3- aminocyclohexyl)amino) quinazolin-6-yl)-2-
fluorophenyl)-2- chlorobenzenesulfonamide 76 ##STR00125##
(S)-2-chloro-N-(2-fluoro-4-(2- (piperidin-3- ylamino)quinazolin-6-
yl)phenyl)benzenesulfonamide
77 ##STR00126## N-(4-(2-(((1R,3R)-3- aminocyclopentyl)amino)
quinazolin-6-yl)-2- fluorophenyl)-2- chlorobenzenesulfonamide 78
##STR00127## N-(4-(2-(((1R,3R)-3- aminocyclopentyl)amino)-8-
ethylquinazolin-6-yl)-2- fluorophenyl)-2- chlorobenzenesulfonamide
79 ##STR00128## N-(4-(2-(((1R,3S)-3- aminocyclopentyl)amino)-8-
ethylquinazolin-6-yl)-2- fluorophenyl)-2- chlorobenzenesulfonamide
80 ##STR00129## N-(4-(2-(((1R,3S)-3- aminocyclopentyl)amino)
quinazolin-6-yl)-2- fluorophenyl)-2- chlorobenzenesulfonamide 81
##STR00130## N-(4-(2-((4- aminobicyclo[2.2.2]octan-1-
yl)amino)quinazolin-6-yl)-2- fluorophenyl)-2-
chlorobenzenesulfonamide 82 ##STR00131## N-(4-(2-(((2r,5r)-5-
aminooctahydropentalen-2- yl)amino)-8-ethylquinazolin-
6-yl)-2-fluorophenyl)-2- chlorobenzenesulfonamide 83 ##STR00132##
N-(4-(2-(((2r,5r)-5- aminooctahydropentalen-2-
yl)amino)-8-ethylquinazolin- 6-yl-2-fluorophenyl)-2-
chlorobenzenesulfonamide 84 ##STR00133## N-(4-(2-(((2s,5s)-5-
aminooctahydropentalen-2- yl)amino)-8-ethylquinazolin-
6-yl)-2-fluorophenyl)-2- chlorobenzenesulfonamide 85 ##STR00134##
N-(4-(2-(((2s,5s)-5- aminooctahydropentalen-2-
yl)amino)quinazolin-6-yl)-2- fluorophenyl)-2-
chlorobenzenesulfonamide 86 ##STR00135## N-(4-(2-((4-
aminobicyclo[2.2.1]heptan-1- yl)amino)quinazolin-6-yl)-2-
fluorophenyl)-2- chlorobenzenesulfonamide 87 ##STR00136##
N-(4-(2-((4- aminobicyclo[2.2.2]octan-1-
yl)amino)-8-ethylquinazolin- 6-yl)-2-fluorophenyl)-2-
chlorobenzenesulfonamide 88 ##STR00137## 2-chloro-N-(4-(8-ethyl-2-
(((1r,4r)-4-(pyrrolidin-1- yl)cyclohexyl)amino) quinazolin-6-yl)-2-
fluorophenyl) benzenesulfonamide 89 ##STR00138##
N-(5-(2-(((1r,4r)-4- aminocyclohexyl)amino) quinazolin-6-yl)-1,3,4-
thiadiazol-2-yl)-2- chlorobenzenesulfonamide 90 ##STR00139##
N-(4-(2-(((1r,4r)-4- aminocyclohexyl)amino)-7-
methylquinazolin-6-yl)-2- fluorophenyl)-2- chlorobenzenesulfonamide
92 ##STR00140## N-(5-(2-(((1r,4r)-4- aminocyclohexyl)amino)-8-
ethylquinazolin-6-yl)-4- methoxypyridin-2-yl)-2-
chlorobenzenesulfonamide 93 ##STR00141## N-(6-(2-(((1r,4r)-4-
aminocyclohexyl)amino)-8- ethylquinazolin-6-yl)-5-
methoxypyridin-3-yl)-2- chlorobenzenesulfonamide 94 ##STR00142##
N-(5-(2-(((1r,4r)-4- aminocyclohexyl)amino)-8-
ethylquinazolin-6-yl)-6- methylpyrazin-2-yl)-2-
chlorobenzenesulfonamide 96 ##STR00143## N-(6-(2-(((1r,4r)-4-
aminocyclohexyl)amino)-8- ethylquinazolin-6-yl)-5-
ethylpyridazin-3-yl)-2- chlorobenzenesulfonamide 98 ##STR00144##
N-(5-(2-(((1r,4r)-4- aminocyclohexyl)amino)-8-
ethylquinazolin-6-yl)-6- methxoypyrazin-2-yl)-2-
chlorobenzenesulfonamide 100 ##STR00145## N-(6-(2-(((1r,4r)-4-
aminocyclohexyl)amino)-8- ethylquinazolin-6-yl)-4-
ethylpyridazin-3-yl)-2- chlorobenzenesulfonamide 101 ##STR00146##
2-chloro-N-(5-(8-ethyl-2- (((1r,4r)-4- hydroxycyclohexyl)amino)
quinazolin-6-yl)-6- metthoxypyridin-2- yl)benzenesulfonamide 102
##STR00147## N-(5-(2-(((1r,4r)-4- aminocyclohexyl)amino)-7-
methylquinazolin-6-yl)-6- methoxypyridin-2-yl)-2-
cyanobenzenesulfonamide 103 ##STR00148## N-(5-(2-(((1r,4r)-4-
aminocyclohexyl)amino)-8- ethylquinazolin-6-yl)-6-
methoxypyridin-2-yl)-2- methylbenzenesulfonamide 104 ##STR00149##
N-(5-(2-(((1r,4r)-4- aminocyclohexyl)amino)-7-
methylquinazolin-6-yl)-6- methoxypyridin-2-yl)-2-
chlorobenzenesulfonamide 105 ##STR00150## N-(5-(2-(((1r,4r)-4-
aminocyclohexyl)amino)-7- methylquinazolin-6-yl)-6-
ethylpyridin-2-yl)-2- chlorobenzenesulfonamide 106 ##STR00151##
N-(5-(2-(((1r,4r)-4- aminocyclohexyl)amino)-7-
methylquinazolin-6-yl)-6- methylpyridin-2-yl)-2-
chlorobenzenesulfonamide 107 ##STR00152## N-(5-(2-(((1r,4r)-4-
aminocyclohexyl)amino)-8- ethylquinazolin-6-yl)-6-
(trifluoromethoxy)pyridin-2- yl)-2- chlorobenzenesulfonamide 109
##STR00153## N-(5-(2-(((1r,4r)-4- aminocyclohexyl)amino)-8-
ethylquinazolin-6-yl)-6- methoxypyridin-2-yl)-2-
methoxybenzenesulfonamide 110 ##STR00154## N-(5-(2-(((1r,4r)-4-
aminocyclohexyl)amino)-7- ethylquinazolin-6-yl)-6-
methoxypyridin-2-yl)-2- chlorobenzenesulfonamide 111 ##STR00155##
N-(5-(2-(((1r,4r)-4- aminocyclohexyl)amino)-8-
ethylquinazolin-6-yl)-6- methylpyridin-2- yl)benzenesulfonamide 112
##STR00156## N-(5-(2-(((1r,4r)-4- aminocyclohexyl)amino)-8-
ethylquinazolin-6-yl)-6- methylpyridin-2-yl)-2-
methylbenzenesulfonamide 113 ##STR00157## N-(5-(2-(((1r,4r)-4-
aminocyclohexyl)amino)-8- ethylquinazolin-6-yl)-6-
methylpyridin-2-yl)-3- methylbenzenesulfonamide 114 ##STR00158##
N-(5-(2-(((1r,4r)-4- aminocyclohexyl)amino)-5-
methylquinazolin-6-yl)-6- methoxypyridin-2-yl)-2-
chlorobenzenesulfonamide 115 ##STR00159## N-(5-(2-(((1r,4r)-4-
aminocyclohexyl)amino)-8- methylquinazolin-6-yl)-6-
methoxypyridin-2-yl)-2- chlorobenzenesulfonamide 120 ##STR00160##
2-chloro-N-(4-(2-(((1r,4r)-4- (dimethylamino)cyclohexyl)
amino)-8-ethylquinazolin- 6-yl)-2-fluoro-5- methoxyphenyl)
benzenesulfonamide 121 ##STR00161## 2-chloro-N-(4-(8-ethyl-2-
(((1r,4r)-4- (methylamino)cyclohexyl) amino)quinazolin-6-yl)-2-
fluoro-5- methoxyphenyl) benzenesulfonamide 123 ##STR00162##
N-(5-(2-(((1r,4r)-4- aminocyclohexyl)amino)-8-
(1,1-difluoroethyl)quinazlin- 6-yl)-6-methoxypyridin-2-yl)-
2-chlorobenzenesulfonamide 129 ##STR00163## N-(5-(2-(((1r,4r)-4-
aminocyclohexyl)amino)-8- (methoxymethyl)quinazolin-6-
yl)-6-methoxypyridin-2-yl)-2- chlorobenzenesulfonamide 134
##STR00164## N-(5-(2-(((1r,4r)-4- aminocyclohexyl)amino)-8-
(trifluoromethyl)quinazolin-6- yl)-6-methoxypyridin-2-yl)-2-
chlorobenzenesulfonamide 136 ##STR00165## 2-chloro-N-(5-(2-((4-
(dimethylamino)bicyclo[2.2.2] octan-1-yl)amino)-8-
ethylquinazolin-6-yl)-6- ethylpyridin-2- yl)benzenesulfonamide 138
##STR00166## N-(5-(2-(((1s,4s)-4- aminocyclohexyl)amino)-8-
methylquinazlin-6-yl)-6- methoxypyridin-2-yl)-2-
chlorobenzenesulfonamide 140 ##STR00167## N-(5-(2-(((1s,4s)-4-
aminocyclohexyl)amino)-8- ethylquinazolin-6-yl)-6-
methoxypyridin-2-yl)-2- chlorobenzenesulfonamide 143 ##STR00168##
2-chloro-N-(5-(2-(((1s,4s)-4- (dimethylamino)-4-
methylcyclohexyl)amino)-8- ethylquinazolin-6-yl)-6-
methoxypyridin-2- yl)benzenesulfonamide 144 ##STR00169##
2-chloro-N-(5-(2-(((1s,4s)-4- (dimethylamino)-4-
methylcyclohexyl)amino)-8- ethylquinazolin-6-yl)-3-fluoro-
6-methoxypyridin-2- yl)benzenesulfonamide 146 ##STR00170##
N-(5-(2-(((1s,4s)-4- aminocyclohexyl)amino)-8-
methylquinazlin-6-yl)-3- fluoro-6-methoxypyridin-2- yl)-2-
chlorobenzenesulfonamide
IRE1-like Family of Proteins
[0248] In some embodiments, a compound disclosed herein selectively
binds to a protein of the serine/threonine-protein
kinase/endoribonuclease inositol-requiring enzyme 1 (IRE1) family
of proteins. In humans, IRE1 is encoded by the ERN1 gene. Exemplary
IRE1 family proteins include isoforms IRE1 and IRE1a. Other
exemplary IRE1 family proteins include IRE1 homologues or
orthologues in other organisms. Exemplary organisms include human,
non-human primate, mouse, rat, chicken, fruit fly, yeast, and
others listed in Table 2. In some embodiments, the IRE1 protein is
human IRE1a.
TABLE-US-00002 TABLE 2 Organism Accession # Homo sapiens
NP_001424.3 Mus musculus NP_076402.1 Rattus norvegicus
XP_006247696.1
[0249] In some embodiments, a compound disclosed herein selectively
binds to an IRE1 family protein comprising a kinase domain and/or
an RNase domain. In some embodiments, the kinase domain is a
trans-autophosphorylation kinase domain. In some embodiments, the
IRE1 family protein is IRE1a. An example arrangement of domains
within an IRE1a protein is depicted in FIG. 1. An example alignment
of IRE1 family protein orthologues is depicted in FIG. 2.
[0250] In some embodiments, a compound disclosed herein selectively
binds to a trans-autophosphorylation kinase domain region of IRE1a.
In some embodiments, a compound disclosed herein selectively binds
to a trans-autophosphorylation kinase domain region of IRE1a, for
example within amino acid residues 568-833 of SEQ ID NO: 1, or
equivalent amino acid residues thereof.
[0251] In some embodiments, a compound disclosed herein selectively
binds to an ATP-binding pocket within a trans-autophosphorylation
kinase domain region of IRE1a. In some embodiments, a compound
disclosed herein selectively binds to an ATP-binding pocket within
a trans-autophosphorylation kinase domain region of IRE1a, for
example, one or more of amino acid resides 577-711, 577-586, 597,
599, 626, 642-643, 645, 648, 688, 692-693, 695, or 711 of SEQ ID
NO: 1, or equivalent amino acid residues thereof.
[0252] In some embodiments, a compound disclosed herein selectively
binds to an activation loop within a trans-autophosphorylation
kinase domain region of IRE1a. In some embodiments, a compound
disclosed herein selectively binds to an activation loop within a
trans-autophosphorylation kinase domain region of IRE1a, for
example, one or more of amino acid residues 710-736, 710-725, or
729-736 of SEQ ID NO: 1, or equivalent amino acid residues
thereof.
[0253] In some embodiments, a compound disclosed herein selectively
binds to an RNase domain region of IRE1a. In some embodiments, a
compound disclosed herein selectively binds to an RNase domain
region of IRE1a, for example within amino acid residues 835-963 of
SEQ ID NO: 1, or equivalent amino acid residues thereof.
[0254] In some embodiments, a compound disclosed herein selectively
binds to a kinase domain dimer interface amino acid residue. In
some embodiments, a compound disclosed herein selectively binds to
a kinase domain dimer interface amino acid residue, such as one or
more of amino acid residues 569-701, 569, 591, 592, 594, 617,
620,627, 628, 631, 674, 678, or 701 of SEQ ID NO: 1.
[0255] In some embodiments, a compound disclosed herein selectively
binds to a first IRE1a and blocks dimerization between kinase
domain dimer interface amino acid residues of the first IRE1a and a
second IRE1a. In some embodiments, a compound disclosed herein
selectively binds to a first IRE1a, and inhibit dimerization at one
or more of amino acid residues 569-701, 569, 591, 592, 594, 617,
620,627, 628, 631, 674, 678, or 701 of SEQ ID NO: 1.
[0256] In some embodiments, a compound disclosed herein selectively
binds to a kinase-extension nuclease (KEN) domain dimer interface
amino acid residue of an IRE1a. In some embodiments, a compound
disclosed herein selectively binds to a KEN domain dimer interface
amino acid residue, such as one or more of amino acid residues
840-925, 840, 844, 851, 908, 912, or 925 of SEQ ID NO: 1.
[0257] In some embodiments, a compound disclosed herein selectively
binds to amino acid residues of a nuclease active site. In some
embodiments, a compound disclosed herein selectively binds to amino
acid residues of a nuclease active site, such as one or more of
amino acid residues 847-910, 847, 850, 886, 888, 889, 890, 892,
902, 905, 906, or 910 of SEQ ID NO: 1.
[0258] In some embodiments, a compound disclosed herein selectively
binds to an RNase domain and a trans-autophosphorylation kinase
domain region of IRE1a. In some embodiments, a compound disclosed
herein selectively binds to an RNase domain and an ATP-binding
pocket within a trans-autophosphorylation kinase domain region of
IRE1a. In some embodiments, a compound disclosed herein selectively
binds to an RNase domain and an activation loop within a trans
autophosphorylation kinase domain region of IRE1a.
[0259] In some embodiments, a compound disclosed herein selectively
binds to IRE1a at two sites located in an RNase domain,
trans-autophosphorylation kinase domain region, ATP-binding pocket,
activation loop, or any combination thereof. In some embodiments, a
compound disclosed herein selectively binds to IRE1a at two or more
sites. In some embodiments, a compound disclosed herein selectively
binds to IRE1a at two or more sites located in an RNase domain,
trans-autophosphorylation kinase domain region, ATP-binding pocket,
activation loop, or any combination thereof. In some embodiments, a
compound disclosed herein selectively binds to IRE1a at three sites
located in an RNase domain, trans-autophosphorylation kinase domain
region, ATP-binding pocket, activation loop, or any combination
thereof.
[0260] In some embodiments, a compound disclosed herein selectively
binds to IRE1a at a first site located in an RNase domain,
trans-autophosphorylation kinase domain region, ATP-binding pocket,
or activation loop. In some embodiments, a first site comprises one
or more of any amino acid residue within amino acid residues
465-977 of SEQ ID NO: 1. In some embodiments, a compound disclosed
herein selectively binds to IRE1a at a second site located in an
RNase domain, trans-autophosphorylation kinase domain region,
ATP-binding pocket, or activation loop. In some examples, the first
site is located within the same domain or region as the second
site. In some examples, the first site is located within a
different domain or region as the second site.
[0261] In some embodiments, a compound disclosed herein selectively
binds to first IRE1a, thereby blocking dimerization of the first
IRE1a to a second IRE1a. In some embodiments, a compound disclosed
herein selectively binds to first IRE1a, thereby blocking
auto-transphosphorylation of the first IRE1a or a second IRE1a to
which the first IRE1a is dimerized. In some embodiments, a compound
disclosed herein selectively binds to a first IRE1a, thereby
blocking activation of the first IRE1a or a second IRE1a to which
the first IRE1a is dimerized. In some embodiments, a compound
disclosed herein selectively binds to a first IRE1a, thereby
blocking kinase activity of the first IRE1a or a second IRE1a to
which the first IRE1a is dimerized. In some embodiments, a compound
disclosed herein selectively binds to a first IRE1a, thereby
blocking RNase activity of the first IRE1a or a second IRE1a to
which the first IRE1a is dimerized.
[0262] In some embodiments, a compound disclosed herein selectively
binds to IRE1a when in a homo-dimerized conformation. In some
embodiments, a compound disclosed herein selectively binds to IRE1a
when in an oligomerized conformation. In some embodiments, a
compound disclosed herein selectively binds to IRE1a when in a
non-oligomerized or non-dimerized conformation. In some
embodiments, a compound disclosed herein selectively binds to IRE1a
when in an ATP-bound state. In some embodiments, a compound
disclosed herein selectively binds to a IRE1 family protein when in
a non-ATP-bound state. In some embodiments, the compound is a
pharmaceutically acceptable salt, or solvate thereof.
IRE1 Signaling Pathway
[0263] In some embodiments, a compound disclosed herein selectively
binds to an IRE1 family protein and alters a downstream signaling
pathway. In some embodiments, a compound disclosed herein
selectively binds to an IRE1 family protein and alters signaling of
immunoglobulin heavy-chain binding protein (BIP), protein kinase R
(PKR)-like endoplasmic reticulum kinase (PERK), glucose regulate
protein 78 (Grp78), eukaryotic translation initiation factor
2.alpha. (eIF2.alpha.), X-box binding protein 1 (XBP1), activating
transcription factor 6a (ATF6.alpha.), C/EBP homologous protein
(CHOP), growth arrest and DNA damage-inducible protein 34 (GADD34),
tumor necrosis factor receptor-associated factor 2 (TRAF2), JUN
N-terminal kinase (JNK), regulated IRE1-dependent decay (RIDD),
transcriptionally active XBP1 (XBP1s), or unspliced XBP1 (XBP1u).
In some embodiments, a compound disclosed herein selectively binds
to an IRE1 family protein and alters a downstream cellular process.
In some embodiments, an IRE1 family protein is IRE1, IRE1a, or
ERN1.
[0264] In some embodiments, a compound disclosed herein selectively
binds to an IRE1 family protein and decreases or blocks a
downstream signaling pathway. In some embodiments, a compound
disclosed herein selectively binds to an IRE1 family protein and
decreases or blocks activity or signaling of TXNIP, Caspase 1,
Interleukin 1-beta, JNK, Bim, cytochrome C, Caspase 3, Caspase 8,
mRNA degradation, miRNA degradation, apoptotosis-inducing proteins,
or inflammation-inducing proteins. In some embodiments, a compound
disclosed herein selectively binds to an IRE1 family protein and
decreases XBP1 mRNA levels. In some embodiments, a compound
disclosed herein selectively binds to an IRE1 family protein and
decreases transcriptionally active XBP1 (XBP1s) mRNA levels. In
some embodiments, a compound disclosed herein selectively binds to
an IRE1 family protein and decreases spliced XBP1 mRNA levels. In
some embodiments, an IRE1 family protein is IRE1, IRE1a, or
ERN1.
[0265] In some embodiments, a compound disclosed herein selectively
binds to an IRE1 family protein and increases, activates, or
removes a block of a downstream signaling pathway. In some
embodiments, a compound disclosed herein selectively binds to an
IRE1 family protein and increases, activates, or removes a block of
activity or signaling of Bcl2, Bcl-XL, Mcl-1, Bax, Bak, other
anti-apoptotic proteins, or an mRNA translocon proteins. In some
embodiments, an IRE1 family protein is IRE1, IRE1a, or ERN1.
[0266] In some embodiments, a compound disclosed herein selectively
binds to an IRE family protein and disrupts binding with an
effector protein. In some cases, the effector protein binds to the
IRE1 family protein when in a dimerized or oligomerized state. In
some cases, the effector protein binds to the IRE1 family protein
when in a non-dimerized or non-oligomerized state. In some cases,
the effector protein is immunoglobulin heavy-chain binding protein
(BIP), protein kinase R (PKR)-like endoplasmic reticulum kinase
(PERK), glucose regulate protein 78 (Grp78), tumor necrosis factor
receptor-associated factor 2 (TRAF2), JUN N-terminal kinase (JNK),
transcriptionally active XBP1 (XBP1s), unspliced XBP1 (XBP1u),
regulated IRE1-dependent decay (RIDD), Heat shock protein 90 kDa
alpha (HSP 90-alpha), or misfolded protein. In some embodiments, an
IRE1 family protein is IRE1, IRE1a, or ERN1.
[0267] In some embodiments, a compound disclosed herein selectively
binds to an IRE1 family protein and alters activity of a cellular
process or cellular function, such as regulated
[0268] IRE1-dependent decay (RIDD), RNA decay, translation,
autophagy, cell survival, ER protein folding, ERAD, reactive oxygen
species generation, transport, ER-associated protein degradation
(ERAD), protein synthesis, or apoptosis. In some embodiments, where
an altered or lack of a cellular process or cellular function is
associate with a disease state, selective binding of a compound
disclosed herein results in inhibiting or alleviating the disease
state, or inhibiting a deleterious activity associated with the
disease state. In some embodiments, an IRE1 family protein is IRE1,
IRE1a, or ERN1.
Diseases Associated with Altered IRE1 Pathway Signaling
[0269] In some cases, a compound disclosed herein is used to treat
or ameliorate a disease associated with altered IRE1a pathway
signaling when administered to a subject in need thereof. In some
cases, a compound disclosed herein is used to treat or ameliorate
the effects of a disease associated with altered IRE1a pathway
signaling when administered to a subject in need thereof. Exemplary
disease associated with altered IRE1a signaling include cancer. In
some cases, a compound disclosed herein is used to treat or
ameliorate a cancer when administered to a subject in need thereof.
Exemplary cancers include tumors, solid and hematologic cancers. In
some cases, a compound disclosed herein is used to treat or
ameliorate a cell proliferative disorder when administered to a
subject in need thereof. In some cases, the cell proliferative
disorder is a cancer. In some cases, the cancer is ovarian cancer,
lung cancer, bladder cancer, breast cancer, or triple negative
breast cancer (TNBC).
[0270] An IRE1a pathway can be involved in a variety of
pathological conditions, including neurodegenerative diseases,
inflammation, metabolic disorders, liver dysfunction, brain
ischemia, heart ischemia, autoimmune diseases, and cancer. In some
cases, modulation of this pathway provides therapeutic methods
useful for treatment of such diseases.
[0271] In some instances, a compound disclosed herein is used to
reinforce anti-tumor mechanisms. In some cases, an anti-tumor
mechanism comprises direct inhibition of tumor growth. In some
cases, an anti-tumor mechanism comprises induction of anti-tumor
immunity. In some cases, anti-tumor mechanisms comprise direct
inhibition of tumor growth and simultaneous induction of anti-tumor
immunity. In some cases, a compound disclosed herein can prevent
lipid accumulation in myeloid cells exposed to ovarian
cancer-derived ascites supernatants. In some cases, a compound
disclosed herein can block myeloid cell immunosuppression mediated
by tumor-associated factors. In some cases, a compound disclosed
herein can be employed as therapeutic compound that enhances
dendritic cell and T cell anti-tumor activity in mammals. For
example, the compounds disclosed herein can be used to treat murine
and human ovarian cancers.
Methods of Dosing and Treatment Regimens
[0272] In one embodiment, the compounds described herein, or a
pharmaceutically acceptable salt thereof, are used in the
preparation of medicaments for the treatment of diseases or
conditions in a mammal that would benefit from administration of
any one of the compounds disclosed. Methods for treating any of the
diseases or conditions described herein in a mammal in need of such
treatment, involves administration of pharmaceutical compositions
that include at least one compound described herein or a
pharmaceutically acceptable salt, active metabolite, prodrug, or
pharmaceutically acceptable solvate thereof, in therapeutically
effective amounts to said mammal.
[0273] In certain embodiments, the compositions containing the
compound(s) described herein are administered for prophylactic
and/or therapeutic treatments. In certain therapeutic applications,
the compositions are administered to a patient already suffering
from a disease or condition, in an amount sufficient to cure or at
least partially arrest at least one of the symptoms of the disease
or condition. Amounts effective for this use depend on the severity
and course of the disease or condition, previous therapy, the
patient's health status, weight, and response to the drugs, and the
judgment of the treating physician. Therapeutically effective
amounts are optionally determined by methods including, but not
limited to, a dose escalation and/or dose ranging clinical
trial.
[0274] In prophylactic applications, compositions containing the
compounds described herein are administered to a patient
susceptible to or otherwise at risk of a particular disease,
disorder or condition. Such an amount is defined to be a
"prophylactically effective amount or dose." In this use, the
precise amounts also depend on the patient's state of health,
weight, and the like. When used in patients, effective amounts for
this use will depend on the severity and course of the disease,
disorder or condition, previous therapy, the patient's health
status and response to the drugs, and the judgment of the treating
physician. In one aspect, prophylactic treatments include
administering to a mammal, who previously experienced at least one
symptom of the disease being treated and is currently in remission,
a pharmaceutical composition comprising a compound described
herein, or a pharmaceutically acceptable salt thereof, in order to
prevent a return of the symptoms of the disease or condition.
[0275] In certain embodiments wherein the patient's condition does
not improve, upon the doctor's discretion the administration of the
compounds are administered chronically, that is, for an extended
period of time, including throughout the duration of the patient's
life in order to ameliorate or otherwise control or limit the
symptoms of the patient's disease or condition.
[0276] In certain embodiments wherein a patient's status does
improve, the dose of drug being administered is temporarily reduced
or temporarily suspended for a certain length of time (e.g., a
"drug holiday"). In specific embodiments, the length of the drug
holiday is between 2 days and 1 year, including by way of example
only, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 10 days, 12
days, 15 days, 20 days, 28 days, or more than 28 days. The dose
reduction during a drug holiday is, by way of example only, by
10%-100%, including by way of example only 10%, 15%, 20%, 25%),
30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%,
95%, and 100%.
[0277] Once improvement of the patient's conditions has occurred, a
maintenance dose is administered if necessary. Subsequently, in
specific embodiments, the dosage or the frequency of
administration, or both, is reduced, as a function of the symptoms,
to a level at which the improved disease, disorder or condition is
retained. In certain embodiments, however, the patient requires
intermittent treatment on a long-term basis upon any recurrence of
symptoms.
[0278] The amount of a given agent that corresponds to such an
amount varies depending upon factors such as the particular
compound, disease condition and its severity, the identity (e.g.,
weight, sex) of the subject or host in need of treatment, but
nevertheless is determined according to the particular
circumstances surrounding the case, including, e.g., the specific
agent being administered, the route of administration, the
condition being treated, and the subject or host being treated.
[0279] In general, however, doses employed for adult human
treatment are typically in the range of 0.01 mg to 5000 mg per day.
In one aspect, doses employed for adult human treatment are from
about 1 mg to about 1000 mg per day. In one embodiment, the desired
dose is conveniently presented in a single dose or in divided doses
administered simultaneously or at appropriate intervals, for
example as two, three, four or more sub-doses per day.
[0280] In one embodiment, the daily dosages appropriate for the
compound described herein, or a pharmaceutically acceptable salt
thereof, are from about 0.01 mg/kg to about 50 mg/kg per body
weight. In some embodiments, the daily dosage or the amount of
active in the dosage form are lower or higher than the ranges
indicated herein, based on a number of variables in regard to an
individual treatment regime. In various embodiments, the daily and
unit dosages are altered depending on a number of variables
including, but not limited to, the activity of the compound used,
the disease or condition to be treated, the mode of administration,
the requirements of the individual subject, the severity of the
disease or condition being treated, and the judgment of the
practitioner.
[0281] Toxicity and therapeutic efficacy of such therapeutic
regimens are determined by standard pharmaceutical procedures in
cell cultures or experimental animals, including, but not limited
to, the determination of the LD50 and the ED50. The dose ratio
between the toxic and therapeutic effects is the therapeutic index
and it is expressed as the ratio between LD50 and ED50. In certain
embodiments, the data obtained from cell culture assays and animal
studies are used in formulating the therapeutically effective daily
dosage range and/or the therapeutically effective unit dosage
amount for use in mammals, including humans. In some embodiments,
the daily dosage amount of the compounds described herein lies
within a range of circulating concentrations that include the ED50
with minimal toxicity. In certain embodiments, the daily dosage
range and/or the unit dosage amount varies within this range
depending upon the dosage form employed and the route of
administration utilized.
[0282] In any of the aforementioned aspects are further embodiments
in which the effective amount of the compound described herein, or
a pharmaceutically acceptable salt thereof, is: (a) systemically
administered to the mammal; and/or (b) administered orally to the
mammal; and/or (c) intravenously administered to the mammal; and/or
(d) administered by injection to the mammal; and/or (e)
administered topically to the mammal; and/or (f) administered
non-systemically or locally to the mammal.
[0283] In any of the aforementioned aspects are further embodiments
comprising single administrations of the effective amount of the
compound, including further embodiments in which (i) the compound
is administered once a day; or (ii) the compound is administered to
the mammal multiple times over the span of one day, e.g., two,
three, four or more times daily.
[0284] In any of the aforementioned aspects are further embodiments
comprising multiple administrations of the effective amount of the
compound, including further embodiments in which (i) the compound
is administered continuously or intermittently: as in a single
dose; (ii) the time between multiple administrations is every 6
hours; (iii) the compound is administered to the mammal every 8
hours; (iv) the compound is administered to the mammal every 12
hours; (v) the compound is administered to the mammal every 24
hours. In further or alternative embodiments, the method comprises
a drug holiday, wherein the administration of the compound is
temporarily suspended or the dose of the compound being
administered is temporarily reduced; at the end of the drug
holiday, dosing of the compound is resumed. In one embodiment, the
length of the drug holiday varies from 2 days to 1 year.
[0285] In certain instances, it is appropriate to administer at
least one compound described herein, or a pharmaceutically
acceptable salt thereof, in combination with one or more other
therapeutic agents. In one embodiment, the therapeutic
effectiveness of one of the compounds described herein is enhanced
by administration of an adjuvant {i.e., by itself the adjuvant has
minimal therapeutic benefit, but in combination with another
therapeutic agent, the overall therapeutic benefit to the patient
is enhanced). Or, in some embodiments, the benefit experienced by a
patient is increased by administering one of the compounds
described herein with another agent (which also includes a
therapeutic regimen) that also has therapeutic benefit.
[0286] It is understood that the dosage regimen to treat, prevent,
or ameliorate the condition(s) for which relief is sought, is
modified in accordance with a variety of factors (e.g. the disease,
disorder or condition from which the subject suffers; the age,
weight, sex, diet, and medical condition of the subject). Thus, in
some instances, the dosage regimen actually employed varies and, in
some embodiments, deviates from the dosage regimens set forth
herein.
[0287] For combination therapies described herein, dosages of the
co-administered compounds vary depending on the type of co-drug
employed, on the specific drug employed, on the disease or
condition being treated and so forth. In additional embodiments,
when co-administered with one or more other therapeutic agents, the
compound provided herein is administered either simultaneously with
the one or more other therapeutic agents, or sequentially.
[0288] In combination therapies, the multiple therapeutic agents
(one of which is one of the compounds described herein) are
administered in any order or even simultaneously. If administration
is simultaneous, the multiple therapeutic agents are, by way of
example only, provided in a single, unified form, or in multiple
forms (e.g., as a single pill or as two separate pills).
[0289] The compounds described herein, or a pharmaceutically
acceptable salt thereof, as well as combination therapies, are
administered before, during or after the occurrence of a disease or
condition, and the timing of administering the composition
containing a compound varies. Thus, in one embodiment, the
compounds described herein are used as a prophylactic and are
administered continuously to subjects with a propensity to develop
conditions or diseases in order to prevent the occurrence of the
disease or condition. In another embodiment, the compounds and
compositions are administered to a subject during or as soon as
possible after the onset of the symptoms. In specific embodiments,
a compound described herein is administered as soon as is
practicable after the onset of a disease or condition is detected
or suspected, and for a length of time necessary for the treatment
of the disease. In some embodiments, the length required for
treatment varies, and the treatment length is adjusted to suit the
specific needs of each subject. For example, in specific
embodiments, a compound described herein or a formulation
containing the compound is administered for at least 2 weeks, about
1 month to about 5 years.
Examples
I. Chemical Synthesis
[0290] In some embodiments, the compounds that modulate IRE1
mediated signaling disclosed herein are synthesized according to
the following examples. The examples are intended to illustrate but
not limit the disclosed embodiments.
Example 1A: Synthesis of tert-butyl
((1r,4r)-4-((6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)quinazolin-2--
yl)amino)cyclohexyl)carbamate (1A)
##STR00171##
[0291] Step 1: 6-bromoquinazolin-2-amine (1A-2)
[0292] To a solution of 5-bromo-2-fluoro-benzaldehyde (20.0 g, 98.5
mmol) in DMA (700 mL) was added guanidine-carbonic acid (26.6 g,
147.7 mmol). The mixture was stirred at 160.degree. C. for 0.5 h,
cooled to rt and concentrated. The residue was diluted with
H.sub.2O (300 mL) and extracted with ethyl acetate (200
mL.times.3). The combined organic layers were washed with brine
(100 mL.times.3), dried over Na.sub.2SO.sub.4, filtered and
concentrated under reduced pressure to give a residue. The residue
was washed with DCM (300 mL) to get compound 1A-2 (4.0 g,
crude).
Step 2: 6-bromo-2-iodoquinazoline (1A-3)
[0293] To a solution of compound 1A-2 (2.0 g, 8.9 mmol) in THF
(20.0 mL) under N.sub.2 were added of isoamylnitrite (3.1 g, 26.8
mmol, 3.6 mL), diiodomethane (11.9 g, 44.7 mmol, 3.6 mL) and CuI
(1.7 g, 8.9 mmol). The mixture was stirred at 80.degree. C. for 2
h, cooled to rt, quenched by addition of ice water (100 mL), and
extracted with ethyl acetate (100 mL.times.3). The combined organic
layers were washed with brine (100 mL.times.3), dried over
anhydrous Na.sub.2SO.sub.4, filtered and concentrated. The residue
was purified by column chromatography (SiO.sub.2) to afford
compound 1A-3 (2.1 g, crude).
Step 3: 1-tert-butyl ((1r,
4r)-4-((6-bromoquinazolin-2-yl)amino)cyclohexyl)carbamate
(1A-4)
[0294] To a solution of compound 1A-3 (4.0 g, 11.9 mmol) in IPA
(120.0 mL) was added DIEA (4.6 g, 35.8 mmol, 6.2 mL) and tert-butyl
((1r,4r)-4-aminocyclohexyl)carbamate (7.6 g, 35.8 mmol). The
mixture was stirred at 80.degree. C. for 12 h, cooled to rt and
filtered. The collected solid was washed with
Dichloromethane/Methanol (10/1, 60 mL). The combined filtrate was
concentrated to give a residue which was purified by column
chromatography (SiO.sub.2) to afford compound 1A-4 (3.6 g, 6.8
mmol, 57.2% yield). M+H.sup.+=421.1 (LCMS); .sup.1H NMR
(CHLOROFORM-d, 400 MHz) .delta. 8.87 (s, 1H), 7.78 (d, J=1.8 Hz,
1H), 7.71 (dd, J=2.0, 9.0 Hz, 1H), 7.44 (d, J=9.2 Hz, 1H), 5.19 (br
d, J=7.9 Hz, 1H), 4.43 (br s, 1H), 3.93 (br d, J=7.5 Hz, 1H), 3.49
(br s, 1H), 2.27-2.00 (m, 4H), 1.46 (s, 9H), 1.40-1.29 (m, 4H)
Step 4: tert-butyl
((1r,4r)-4-((6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)quinazolin-2--
yl)amino)cyclohexyl)carbamate (1A)
[0295] A mixture of compound 1A-4 (2.0 g, 4.7 mmol),
4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3,2-
-dioxaborolane (1.3 g, 5.2 mmol), AcOK (1.4 g, 14.2 mmol) and
Pd(dppf)Cl.sub.2 (347 mg, 474.6 umol) in dioxane (50 mL) was
degassed and purged with N.sub.2 three times, and heated at
90.degree. C. for 12 h under N.sub.2. The reaction was cooled to rt
and concentrated to give a residue. The residue was purified by
column chromatography (SiO.sub.2) to afford compound 1A (2.7 g,
crude). M+H.sup.+=469.2 (LCMS).
Example 2A: Synthesis of tert-butyl
((1r,4r)-4-((8-ethyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)quina-
zolin-2-yl)amino)cyclohexyl)carbamate (2A)
##STR00172##
[0296] Step 1: 1-(5-bromo-2-fluorophenyl)ethan-1-ol (2A-2)
[0297] A solution of 5-bromo-2-fluoro-benzaldehyde (55.0 g, 270.9
mmol) in THF (500.0 mL) was cooled to 0.degree. C. Then MeMgBr (3
M, 94.8 mL) was added. The mixture was stirred at 0.degree. C. for
0.5 h, quenched with NH.sub.4Cl (500 mL) and extracted with ethyl
acetate (500 mL.times.3). The combined organic layers were washed
with brine (500 mL.times.3), dried over Na.sub.2SO.sub.4, filtered
and concentrated under reduced pressure to give a residue. The
residue was purified by column chromatography (SiO.sub.2) to afford
compound 2A-2 (46.0 g, crude).
Step 2: 4-bromo-2-ethyl-1-fluorobenzene (2A-3)
[0298] To a solution of compound 2A-2 (46.0 g, 210.0 mmol) and
triethylsilane (48.8 g, 420.0 mmol, 66.9 mL) in DCM (500.0 mL) was
added BF.sub.3.Et.sub.2O (59.6 g, 420.0 mmol, 51.8 mL) at 0.degree.
C. The mixture was stirred at 25.degree. C. for 2 h, concentrated,
quenched by addition of Sat.NaHCO.sub.3 (200 mL) at 0.degree. C.,
and extracted with ethyl acetate (200 mL.times.3). The combined
organic layers were washed with brine (200 mL.times.3), dried over
Na.sub.2SO.sub.4, filtered and concentrated. The residue was
purified by column chromatography (SiO.sub.2) to afford compound
2A-3 (24.0 g, crude). H NMR (CHLOROFORM-d, 400 MHz) .delta. 7.31
(dd, J=2.2, 6.6 Hz, 1H), 7.27-7.21 (m, 1H), 6.87 (t, J=9.2 Hz, 1H),
2.62 (q, J=7.5 Hz, 2H), 1.20 (t, J=7.6 Hz, 3H).
Step 3: 5-bromo-3-ethyl-2-fluorobenzaldehyde (2A-4)
[0299] To a solution of compound 2A-3 (24.0 g, 82.7 mmol) in THF
(500 mL) was added LDA (2 M, 49.6 mL) at -78.degree. C. The mixture
was stirred at -78.degree. C. for 1 h. Then dimethyl formamide (7.8
g, 107.5 mmol, 8.3 mL) was added and stirred for 1 h at -78.degree.
C. The reaction mixture was quenched by addition of NH.sub.4Cl (100
mL) and the resulting mixture was extracted with ethyl acetate (200
mL.times.3). The combined organic layers were washed with brine
(100 mL.times.3), dried over Na.sub.2SO.sub.4, filtered and
concentrated under reduced pressure to give a residue. The residue
was purified by column chromatography (SiO.sub.2) to afford
compound 2A-4 (13.0 g, crude). .sup.1H NMR (CDCl.sub.3, 400 MHz)
.delta. 10.30 (s, 1H), 7.81 (dd, J=2.6, 5.7 Hz, 1H), 7.58 (dd,
J=2.6, 6.4 Hz, 1H), 2.73 (q, J=7.6 Hz, 2H), 1.30-1.25 (m, 3H)
Step 4: 6-bromo-8-ethylquinazolin-2-amine (2A-5)
[0300] To a solution of carbonic acid-guanidine (3.5 g, 19.4 mmol)
and DIEA (5.0 g, 38.9 mmol, 6.8 mL) in DMA (20 mL) was added a
solution of compound 2A-4 (3.0 g, 12.98 mmol) in DMA (5 mL). The
mixture was stirred at 160.degree. C. for 1 h, poured into ice
water (30 mL) and extracted with ethyl acetate (40 mL.times.3). The
combined organic layers were washed with brine (30 mL.times.3),
dried over Na.sub.2SO.sub.4, filtered and concentrated under
reduced pressure to give a residue. The residue was purified by
column chromatography (SiO.sub.2) to afford compound 2A-5 (1.2 g,
crude). .sup.1H NMR (DMSO-d.sub.6, 400 MHz) .delta. 9.03 (s, 1H),
7.85 (d, J=2.4 Hz, 1H), 7.60 (d, J=2.4 Hz, 1H), 6.94 (s, 2H),
2.98-2.88 (m, 2H), 1.22-1.17 (m, 3H)
Step 5: 6-bromo-8-ethyl-2-iodoquinazoline (2A-6)
[0301] To a mixture of compound 2A-5 (1.2 g, 4.76 mmol) and
CH.sub.2I.sub.2(6.3 g, 23.8 mmol, 1.92 mL) in tetrahydrofuran (24.0
mL) were added CuI (906 mg, 4.7 mmol) and isoamyl nitrite (1.6 g,
14.3 mmol, 2.0 mL). After the mixture was stirred at 80.degree. C.
for 2 h under N.sub.2, NH.sub.3.H.sub.2O (30 mL) was added. The
resulting mixture was extracted with ethyl acetate (50 mL.times.3)
and the combined organic layers were washed with brine (50
mL.times.3), dried over Na.sub.2SO.sub.4, filtered and
concentrated. The residue was purified by column chromatography
(SiO.sub.2) to afford compound 2A-6 (400 mg, crude).
Step 6: tert-butyl
((1r,4r)-4-((6-bromo-8-ethylquinazolin-2-yl)amino)cyclohexyl)carbamate
(2A-7)
[0302] To a mixture of compound 2A-6 (350 mg, 964.2 umol) and DIEA
(373 mg, 2.8 mmol, 505.2 uL) in isopropanol (10 mL) was added
tert-butyl ((1r,4r)-4-aminocyclohexyl)carbamate (413 mg, 1.9 mmol).
The mixture was stirred at 80.degree. C. for 12 h, cooled to rt and
concentrated. The residue was purified by prep-TLC (SiO.sub.2) to
afford compound 2A-7 (350 mg, crude).
Step 7: tert-butyl
((1r,4r)-4-((8-ethyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)quina-
zolin-2-yl)amino)cyclohexyl)carbamate (2A)
[0303] To a mixture of compound 2A-7 (150 mg, 333.7 umol) and KOAc
(98 mg, 1.0 mmol) in dioxane (2 mL) were added
4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3,2-
-dioxaborolane (101 mg, 400.5 umol) and Pd(dppf)Cl.sub.2 (24 mg,
33.3 umol). The mixture was stirred at 90.degree. C. for 12 h under
N.sub.2, cooled to rt and concentrated. The residue was purified by
prep-TLC (SiO.sub.2) to afford compound 2A (100 mg, crude).
Example 1: Synthesis of
N-(5-(2-(((1r,4r)-4-aminocyclohexyl)amino)quinazolin-6-yl)-1-methyl-1H-py-
razol-3-yl)-2-chlorobenzenesulfonamide (1)
##STR00173##
[0304] Step 1
[0305] To a solution of tert-butyl
((1r,4r)-4-((6-bromoquinazolin-2-yl)amino)cyclohexyl)carbamate (700
mg, 1.6 mmol) in Boc.sub.2O (46.0 mL) was added TEA (505 mg, 5.0
mmol, 690.9 uL) and DMAP (406 mg, 3.3 mmol). The mixture was
stirred at 100.degree. C. for 12 h, cooled to rt and diluted with
DCM (50 mL). Silica gel was added and the resulting suspension was
concentrated to give residue which was purified by column
chromatography (SiO2) to afford tert-butyl
((1r,4r)-4-(bis(tert-butoxycarbonyl)amino)cyclohexyl)(6-bromoquinazolin-2-
-yl)carbamate (340 mg, 437.6 umol, 43.9% yield). 1H NMR
(CHLOROFORM-d, 400 MHz): .delta. 9.25 (s, 1H), 8.06 (d, J=1.8 Hz,
1H), 7.96-7.91 (m, 1H), 7.86-7.81 (m, 1H), 4.25 (br t, J=11.6 Hz,
1H), 3.89 (br t, J=11.8 Hz, 1H), 2.08-1.93 (m, 4H), 1.87-1.73 (m,
4H), 1.46 (s, 18H), 1.41 (s, 9H).
Step 2
[0306] A mixture of tert-butyl
((1r,4r)-4-(bis(tert-butoxycarbonyl)amino)cyclohexyl)(6-bromoquinazolin-2-
-yl)carbamate (340 mg, 547.0 umol),
4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3,2-
-dioxaborolane (153 mg, 601.7 umol), AcOK (161 mg, 1.6 mmol) and
Pd(dppf)Cl.sub.2 (40 mg, 54.7 umol) in dioxane (5.0 mL) was
degassed and purged with N.sub.2 three times, and then the mixture
was stirred at 90.degree. C. for 12 h under N.sub.2. The reaction
was cooled to rt and concentrated to give a residue which was
purified by column chromatography (SiO.sub.2) to afford
(2-(((1r,4r)-4-(bis(tert-butoxycarbonyl)amino)cyclohexyl)(tert-butoxycarb-
onyl)amino)quinazolin-6-yl)boronic acid (400 mg, 504.7 umol, 92.2%
yield).
Step 3
[0307] A mixture of
(2-(((1r,4r)-4-(bis(tert-butoxycarbonyl)amino)cyclohexyl)(tert-butoxycarb-
onyl)amino)quinazolin-6-yl)boronic acid (330 mg, 562.6 umol),
5-bromo-1-methyl-1H-pyrazol-3-amine (119 mg, 675.2 umol),
K.sub.2CO.sub.3 (233 mg, 1.6 mmol) and Pd(dppf)Cl.sub.2 (41 mg,
56.2 umol) in dioxane (15.0 mL) and H.sub.2O (1.5 mL) was degassed
and purged with N.sub.2 three times, and the mixture was stirred at
90.degree. C. for 12 h under N.sub.2. The reaction was concentrated
and the residue was purified by column chromatography (SiO.sub.2)
to afford tert-butyl
(6-(3-amino-1-methyl-1H-pyrazol-5-yl)quinazolin-2-yl)((1r,4r)-4-(bis(tert-
-butoxycarbonyl)amino)cyclohexyl)carbamate (120 mg, crude).
Step 4
[0308] To a solution of tert-butyl
(6-(3-amino-1-methyl-1H-pyrazol-5-yl)quinazolin-2-yl)((1r,4r)-4-(bis(tert-
-butoxycarbonyl)amino)cyclohexyl)carbamate (60 mg, 94.0 umol) in
pyridine (2.0 mL) was added TEA (29 mg, 282.2 umol, 39.1 uL) and
2-chlorobenzenesulfonyl chloride (50 mg, 235.2 umol, 32.0 uL). The
mixture was stirred at 25.degree. C. for 12 h and concentrated. The
residue was purified by prep-TLC (SiO.sub.2) to afford tert-butyl
((1r,4r)-4-(bis(tert-butoxycarbonyl)amino)cyclohexyl)(6-(3-((2-chloro
phenyl)sulfonamido)-1-methyl-1H-pyrazol-5-yl)quinazolin-2-yl)carbamate
(80 mg, crude).
Step 5
[0309] To a solution of tert-butyl
((1r,4r)-4-(bis(tert-butoxycarbonyl)amino)cyclohexyl)(6-(3-((2-chloro
phenyl)
sulfonamido)-1-methyl-1H-pyrazol-5-yl)quinazolin-2-yl)carbamate (80
mg, 98.4 umol) in DCM (2.0 mL) was added TFA (1.0 mL). The mixture
was stirred at 25.degree. C. for 15 min and concentrated to give a
residue. The residue was dissolved in MeOH (2.0 mL), basified with
NH.sub.3.H.sub.2O (0.02 mL, 25% solution) and concentrated to give
a residue. The residue was purified by prep-HPLC to afford
N-(5-(2-(((1r,4r)-4-aminocyclohexyl)amino)quinazolin-6-yl)-1-methyl-1H-py-
razol-3-yl)-2-chlorobenzenesulfonamide (36.1 mg, 61.5 umol, 62.4%
yield, FA). M+H.sup.+=512.3 (LCMS). .sup.1H NMR (METHANOL-d.sub.4,
400 MHz): .delta. 9.05 (s, 1H), 8.33 (br s, 1H), 8.07 (dd, J=1.1,
7.9 Hz, 1H), 7.77 (d, J=1.8 Hz, 1H), 7.68 (dd, J=2.0, 8.8 Hz, 1H),
7.60-7.50 (m, 3H), 7.42 (ddd, J=1.9, 6.6, 8.1 Hz, 1H), 6.11 (s,
1H), 4.01-3.88 (m, 1H), 3.70 (s, 3H), 3.13 (tdd, J=4.0, 7.8, 11.6
Hz, 1H), 2.26-2.05 (m, 4H), 1.66-1.39 (m, 4H).
[0310] The following compound was synthesized according to
procedures described in example 1 above for the preparation of
compound 1.
TABLE-US-00003 Comp Mass .sup.1H NMR (MeOD, 400 ID Structure
Chemical Name (M + H.sup.+) MHz) 6 ##STR00174## N-(5-(2-
(((1r,4r)-4- aminocyclohexyl) amino)-8- ethylquinazolin-
6-yl)-1-methyl- 1H-pyrazol-3-yl)- 2- chlorobenzene- sulfonamide,
Calc'd for C.sub.26H.sub.31ClN.sub.7O.sub.2S: 540.2; Found: 540.2
.delta. 9.01 (s, 1H), 8.48 (br s, 1H), 8.09 (dd, J = 1.1, 7.9 Hz,
1H), 7.63-7.49 (m, 4H), 7.43 (dt, J = 1.9, 7.3 Hz, 1H), 6.10 (s,
1H), 4.04-3.91 (m, 1H), 3.71 (s, 3H), 3.16 (tt, J = 3.6, 11.4 Hz,
1H), 3.05 (q, J = 7.5 Hz, 2H), 2.30 (br d, J = 11.2 formate Hz,
2H), 2.14 (br d, J = salt 11.7 Hz, 2H), 1.69- 1.41 (m, 4H), 1.31
(t, J = 7.5 Hz. 3H)
Example 2: Synthesis of
N-(4-(2-(((1r,4r)-4-aminocyclohexyl)amino)quinazolin-6-yl)-3-methylphenyl-
)-2-chlorobenzenesulfonamide (2)
##STR00175##
[0311] Step 1
[0312] To a solution of 2-chlorobenzenesulfonyl chloride (170 mg,
806.2 umol, 109.7 uL) in DCM (2.0 mL) was added pyridine (63 mg,
806.2 umol, 65.0 uL) and 4-bromo-3-methyl-aniline (100 mg, 537.4
umol). The mixture was stirred at 45.degree. C. for 2 h. The
reaction mixture was concentrated under reduced pressure. The
residue was purified by prep-TLC (SiO2) to afford
N-(4-bromo-3-methylphenyl)-2-chlorobenzenesulfonamide (190 mg,
447.8 umol, 83.3% yield).
Step 2
[0313] A mixture of
N-(4-bromo-3-methylphenyl)-2-chlorobenzenesulfonamide (50 mg, 138.6
umol), tert-butyl
((1r,4r)-4-((6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)quinazolin-2--
yl)amino)cyclohexyl)carbamate (64 mg, 138.6 umol), K.sub.2CO.sub.3
(57 mg, 415.9 umol), Pd(dppf)Cl.sub.2 (10 mg, 13.8 umol) in dioxane
(2.0 mL) and H.sub.2O (0.2 mL) was degassed and purged with N.sub.2
three times, and then the mixture was stirred at 90.degree. C. for
12 h under N.sub.2 atmosphere. The reaction mixture was
concentrated under reduced pressure. The residue was purified by
prep-TLC (SiO.sub.2) to afford tert-butyl
((1r,4r)-4-((6-(4-(2-chlorophenylsulfonamido)-2-methylphenyl)quinazolin-2-
-yl)amino)cyclohexyl)carbamate (30 mg, crude). M+H.sup.+=622.2
(LCMS).
Step 3
[0314] To a solution of tert-butyl
((1r,4r)-4-((6-(4-(2-chlorophenylsulfonamido)-2-methylphenyl)quinazolin-2-
-yl)amino)cyclohexyl)carbamate (30 mg, 48.2 umol) in DCM (2.0 mL)
was added TFA (1.0 mL). The mixture was stirred at 25.degree. C.
for 0.5 h. The reaction mixture was concentrated under reduced
pressure. The residue was added dichloromethane (2.0 mL) and
NH.sub.3.H.sub.2O (25% solution) to pH 7, concentrated under
reduced pressure again. The residue was purified by prep-HPLC to
give
N-(4-(2-(((1r,4r)-4-aminocyclohexyl)amino)quinazolin-6-yl)-3-methylphenyl-
)-2-chlorobenzenesulfonamide (6.9 mg, 12.1 umol, 25.2% yield, FA).
M+H.sup.+=522.0 (LCMS); .sup.1H NMR (400 MHz, METHANOL-d.sub.4)
.delta. 9.04 (s, 1H), 8.57 (s, 1H), 8.23-8.04 (m, 1H), 7.66-7.53
(m, 5H), 7.50-7.43 (m, 1H), 7.14-7.04 (m, 3H), 4.10-3.87 (m, 1H),
3.16 (tt, J=3.9, 11.6 Hz, 1H), 2.25 (br d, J=10.5 Hz, 2H), 2.20 (s,
3H), 2.14 (br d, J=12.1 Hz, 2H), 1.70-1.39 (m, 4H).
[0315] The following compound was synthesized according to
procedures described in example 2 above for the preparation of
compound 2.
TABLE-US-00004 Comp Mass .sup.1H NMR (MeOD, 400 ID Structure
Chemical Name (M + H.sup.+) MHz) 5 ##STR00176## N-(5-(2-
(((1r,4r)-4- aminocyclohexyl) amino) quinazolin-6-yl)-
4-methylpyridin- 2-yl)-2- chlorobenzene- Calc'd for
C.sub.26H.sub.28ClN.sub.6O.sub.2S: 523.2; Found: 523.2 .delta. 9.05
(s, 1H), 8.52 (br s, 1H), 8.22 (d, J = 7.5 Hz, 1H), 7.82 (s, 1H),
7.69 (d, J = 1.8 Hz, 1H), 7.67-7.62 (m, 1H), 7.61-7.55 (m, 1H),
7.55-7.52 (m, 1H), 7.50-7.45 (m, 1H), sulfonamide, 7.38-7.30 (m,
1H), formate 7.15 (s, 1H), 4.06-3.90 salt (m, 1H), 3.24-3.05 (m,
1H), 2.31-2.20 (m, 5H), 2.12 (br d, J = 12.3 Hz, 2H), 1.69-1.40 (m,
4H)
Example 3: Synthesis of
N-(4-(2-(((1r,4r)-4-aminocyclohexyl)amino)-8-ethylquinazolin-6-yl)-3-meth-
ylphenyl)-2-chlorobenzenesulfonamide (3)
##STR00177##
[0316] Step 1
[0317] A mixture of
N-(4-bromo-3-methylphenyl)-2-chlorobenzenesulfonamide (29 mg, 80.5
umol), tert-butyl
((1r,4r)-4-((8-ethyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)quina-
zolin-2-yl)amino)cyclohexyl)carbamate (40 mg, 80.5 umol),
K.sub.2CO.sub.3 (16 mg, 120.8 umol), Pd(dppf)Cl.sub.2 (5 mg, 8.0
umol) in dioxane (2.0 mL) and water (0.2 mL) was degassed and
purged with N.sub.2 three times. The mixture was stirred at
90.degree. C. for 12 h under N.sub.2, cooled to rt, and
concentrated. The residue was purified by prep-TLC (SiO2) to give
tert-butyl
((1r,4r)-4-((6-(4-(2-chlorophenylsulfonamido)-2-methylphenyl)-8-ethylquin-
azolin-2-yl)amino)cyclohexyl)carbamate (47 mg, 58.6 umol, 72.7%
yield). M+H.sup.+=650.3 (LCMS).
Step 2
[0318] To a solution of tert-butyl
((1r,4r)-4-((6-(4-(2-chlorophenylsulfonamido)-2-methylphenyl)-8-ethylquin-
azolin-2-yl)amino)cyclohexyl)carbamate (47 mg, 72.2 umol) in DCM
(2.0 mL) was added TFA (1.0 mL). The resulting mixture was stirred
at 15.degree. C. for 0.5 h and concentrated. The residue was
dissolved in MeOH (2.0 mL), basified pH to 8 with NH.sub.3.H.sub.2O
(25% solution) and purified by prep-HPLC to give
N-(4-(2-(((1r,4r)-4-aminocyclohexyl)amino)-8-ethylquinazolin-6-yl)-3-meth-
ylphenyl)-2-chlorobenzenesulfonamide (10.2 mg, 17.2 umol, 23.8%
yield, FA). M+H.sup.+=550.2 (LCMS); .sup.1H NMR (400 MHz,
METHANOL-d.sub.4): .delta. 8.95 (d, J=4.2 Hz, 1H), 8.39 (br s, 1H),
8.09 (d, J=7.7 Hz, 1H), 7.60-7.51 (m, 2H), 7.47-7.37 (m, 3H),
7.11-7.01 (m, 3H), 4.01-3.91 (m, 1H), 3.17 (tt, J=3.7, 11.4 Hz,
1H), 3.04 (q, J=7.5 Hz, 2H), 2.31 (brd, J=11.9 Hz, 2H), 2.19-2.10
(m, 5H), 1.66-1.54 (m, 2H), 1.54-1.43 (m, 2H), 1.34-1.27 (m,
3H).
[0319] The following compounds were synthesized according to
procedures described in example 3 above for the preparation of
compound 3.
TABLE-US-00005 Comp Mass .sup.1H NMR (MeOD, 400 ID Structure
Chemical Name (M + H.sup.+) MHz) 4 ##STR00178## N-(5-(2-
(((1r,4r)-4- aminocyclohexyl) amino)-8- ethylquinazlin-6- yl)-4-
methylpyridin-2- yl)-2- chlorobenzene- sulfonamide, Calc'd for
C.sub.28H.sub.32ClN.sub.6O.sub.2S: 551.2 Found: 551.2 .delta. 9.00
(s, 1 H), 8.49 (br s, 1 H), 8.22 (d, J = 7.34 Hz, 1 H), 7.80 (s, 1
H), 7.45-7.58 (m, 5 H), 7.14 (s, 1 H), 3.91-4.03 (m, 1 H),
3.10-3.21 (m, 1 H), 3.06 (q, J = 7.66 Hz, 2 H), 2.31 (br d, J =
13.20 Hz, 2 H), 2.25 (s, 3 H), 2.13 (br d, J = formate 12.23 Hz, 2
H), 1.44- salt 1.64 (m, 4 H), 1.31 (t, J = 7.58 Hz, 3 H) 14
##STR00179## N-(4-(2- (((1r,4r)-4- aminocyclohexyl) amino)-8-
ethylquinazlin-6- yl)-3- (trifluoromethyl) phenyl)-2-
chlorobenzene- sulfonamide, Calc'd for
C.sub.29H.sub.30ClF.sub.3N.sub.5O.sub.2S: 604.2; Found: 604.2
.delta. 8.95 (br s, 1H), 8.55 (br s, 1H), 8.15 (d, J = 7.7 Hz, 1H),
7.63-7.53 (m, 3H), 7.48 (br dd, J = 4.3, 7.2 Hz, 1H), 7.41 (br d, J
= 7.9 Hz, 3H), 7.26 (br d, J = 8.4 Hz, 1H), 4.02-3.92 (m, 1H),
3.21-3.11 (m, 1H), 3.03 (q, J = 7.3 Hz, formate 2H), 2.31 (br d, J
= 11.7 salt Hz, 2H), 2.14 (br d, J = 11.5 Hz, 2H), 1.65- 1.55 (m,
2H), 1.54- 1.43 (m, 2H), 1.29 (t, J = 7.5 Hz, 3H). 16 ##STR00180##
N-(5-(2- (((1r,4r)-4- aminocyclohexyl) amino)-8- ethylquinazolin-
6-yl)-6- methylpyridin-2- yl)-2- chlorobenzene- sulfonamide, Calc'd
for C.sub.28H.sub.32ClN.sub.6O.sub.2S: 551.2; Found: 551.1 .delta.
9.02 (s, 1H), 8.56 (br s, 1H), 8.33-8.19 (m, 1H), 7.69 (d, J = 8.9
Hz, 1H), 7.61-7.44 (m, 5H), 7.22 (br d, J = 8.8 Hz, 1H), 4.08-3.89
(m, 1H), 3.25-3.15 (m, 1H), 3.09 (q, J = 7.5 Hz, 2H), 2.40 (s, 3H),
2.33 (br d, J = 11.5 Hz, 2H), formate salt 2.17 (br d, J = 11.5 Hz,
2H), 1.70-1.46 (m, 4H), 1.34 (t, J = 7.5 Hz, 3H). 17 ##STR00181##
N-(4-(2- (((1r,4r)-4- aminocyclohexyl) amino)-8- ethylquinazolin-
6-yl)-3- chlorophenyl)-2- chlorobenzene- sulfonamide, formate salt
Calc'd for C.sub.28H.sub.30Cl.sub.2N.sub.5O.sub.2S: 570.1; Found:
570.1 .delta. 8.97 (s, 1H), 8.56 (br s, 1H), 8.14 (d, J = 8.4 Hz,
1H), 7.63-7.56 (m, 2H), 7.56-7.52 (m, 2H), 7.48 (ddd, J = 3.3, 5.3,
8.2 Hz, 1H), 7.33- 7.23 (m, 2H), 7.17 (dd, J = 2.2, 8.4 Hz, 1H),
4.05- 3.90 (m, 1H), 3.20- 3.10 (m, 1H), 3.04 (q, J = 7.4 Hz, 2H),
2.31 (br d, J = 11.7 Hz, 2H), 2.13 (br d, 7= 11.9 Hz, 2H),
1.65-1.54 (m, 2H), 1.54-1.43 (m, 2H), 1.31 (t, J = 7.5 Hz, 3H) 19
##STR00182## N-(4-(2- (((1r,4r)-4- aminocyclohexyl) amino)-8-
ethylquinazolin- 6-yl)-3- methoxyphenyl)- 2- chlorobenzene-
sulfonamide, Calc'd for C.sub.29H.sub.33ClN.sub.5O.sub.3S: 566.2;
Found: 566.2 .delta. 8.94 (s, 1 H), 8.51 (br s, 1 H), 8.10-8.18 (m,
1 H), 7.63 (d, J = 1.76 Hz, 1 H), 7.54-7.60 (m, 3 H), 7.46 (ddd, J
= 8.16, 5.84, 2.76 Hz, 1 H), 7.18 (d, J = 8.16 Hz, 1 H), 6.90 (d, J
= 1.98 Hz, 1 H), 6.81 (dd, J = 8.16, 1.98 Hz, 1 H), 3.91- formate
4.04 (m, 1 H), 3.73 (s, 3 salt H), 3.12-3.23 (m, 1 H), 3.03 (q, J =
7.57 Hz, 2 H), 2.31 (br d, J = 11.03 Hz, 2H), 2.14 (br d, J = 12.13
Hz, 2 H), 1.43- 1.67 (m, 4 H), 1.30 (t, J = 7.39 Hz, 3 H) 20
##STR00183## N-(6-(2- (((1r,4r)-4- aminocyclohexyl) amino)-8-
ethylquinazlin-6- yl)-5- methylpyridin-3- yl)-2- chlorobenzene-
sulfonamide, Calc'd for C.sub.28H.sub.32ClN.sub.6O.sub.2S: 551.2;
Found: 551.2 .delta. 9.00 (s, 1 H), 8.53 (br s, 1 H), 8.23 (s, 1
H), 8.14 (d, J = 7.94 Hz, 1 H), 7.57-7.64 (m, 4 H), 7.55 (s, 1 H),
7.45-7.51 (m, 1 H), 3.90-4.05 (m, 1 H), 3.16 (br t, J = 11.36 Hz, 1
H), 3.07 (q, J = 7.64 Hz, 2 H), 2.26- 2.36 (m, 5 H), 2.14 (br
formate d, J = 10.80 Hz, 2 H), salt 1.44-1.68 (m, 4 H), 1.32 (t, J
= 7.50 Hz, 3 H) 21 ##STR00184## N-(4-(2- (((1r,4r)-4-
aminocyclohexyl) amino)-8- ethylquinazolin- 6-yl-2-f-luoro-5-
methylphenyl)-2- chlorobenzene- sulfonamide, formate salt Calc'd
for C.sub.29H.sub.33ClFN.sub.5O.sub.3S: 568.2; Found: 568.2 .delta.
8.96 (s, 1H), 8.51 (br s, 1H), 8.01 (d, J = 7.7 Hz, 1H), 7.66-7.50
(m, 2H), 7.49-7.37 (m, 3H), 7.30 (d, J = 7.9 Hz, 1H), 6.99-6.88 (m,
1H), 4.03-3.90 (m, 1H), 3.17 (br t, J = 11.5 Hz, 1H), 3.04 (q, J =
7.4 Hz, 2H), 2.31 (br d, J = 11.5 Hz, 2H), 2.15 ( , 5H), 1.67-1.55
(m, 2H), 1.54-1.43 (m, 2H), 1.30 (t, J = 7.4 Hz, 3H) 22
##STR00185## N-(4-(2- (((1r,4r)-4- aminocyclohexyl) amino)-8-
ethylquinazlin- 6-yl)-2,3- dimethylphenyl)- 2- chlorobenzene-
sulfonamide, Calc'd for C.sub.30H.sub.35ClN.sub.5O.sub.2S: 564.2;
Found: 564.2 .delta. 8.97 (s, 1 H), 8.55 (br s, 1 H), 7.88 (dd, J =
8.31, 1.47 Hz, 1 H), 7.64-7.68 (m, 1 H), 7.56-7.61 (m, 1 H),
7.38-7.44 (m, 3 H), 6.90-6.93 (m, 1 H), 6.82-6.88 (m, 1 H),
3.93-4.02 (m, 1 H), 3.12-3.21 (m, 1 H), formate 3.06 (q, J = 7.34
Hz, 2 salt H), 2.32 (br d, J = 11.74 Hz, 2 H), 2.26 (s, 3 H), 2.14
(m, 5 H), 1.44- 1.67 (m, 4 H), 1.31 (t, J = 7.34 Hz, 3 H)
Example 4: Synthesis of
N-(4-(2-(((1r,4r)-4-aminocyclohexyl)amino)-8-ethylquinazolin-6-yl)phenyl)-
-2-chlorobenzenesulfonamide (18)
##STR00186##
[0320] Step 1
[0321] A mixture of 4-bromoaniline (33 mg, 193.3 umol), tert-butyl
((1r,4r)-4-((8-ethyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)quina-
zolin-2-yl)amino)cyclohexyl)carbamate (80 mg, 161.1 umol),
K.sub.2CO.sub.3 (33 mg, 241.7 umol), Pd(dppf)Cl.sub.2 (11 mg, 16.1
umol) in dioxane (2.0 mL) and water (0.2 mL) was degassed and
purged with N.sub.2. The resulting mixture was stirred at
90.degree. C. for 12 h under N.sub.2. Additional 4-bromoaniline (13
mg) and Pd(dppf)Cl.sub.2 (10 mg) were added, and the mixture was
stirred at 90.degree. C. for 4 h, cooled to rt and concentrated.
The residue was purified by prep-TLC (SiO.sub.2) to give tert-butyl
((1r,4r)-4-((6-(4-aminophenyl)-8-ethylquinazolin-2-yl)amino)-cyclohexyl)c-
arbamate (40 mg, 65.2 umol, 40% yield). M+H.sup.+=462.3 (LCMS).
Step 2
[0322] To a solution of tert-butyl
((1r,4r)-4-((6-(4-aminophenyl)-8-ethylquinazolin-2-yl)amino)-cyclohexyl)c-
arbamate (40 mg, 86.6 umol) in DCM (2.0 mL) was added pyridine (20
mg, 259.9 umol, 20.9 uL) and 2-chlorobenzenesulfonyl chloride (18
mg, 86.6 umol, 11.8 uL). The mixture was stirred at 45.degree. C.
for 12 h, cooled to rt and concentrated to give tert-butyl
((1r,4r)-4-((6-(4-(2-chlorophenylsulfonamido)phenyl)-8-ethylquinazolin-2--
yl)amino)cyclohexyl)carbamate (50 mg, crude).
Step 3
[0323] To a solution of tert-butyl
((1r,4r)-4-((6-(4-(2-chlorophenylsulfonamido)phenyl)-8-ethylquinazolin-2--
yl)amino)cyclohexyl)carbamate (50 mg, 78.5 umol) in DCM (2.0 mL)
was added TFA (1.0 mL). The mixture was stirred at 15.degree. C.
for 0.5 h and concentrated. The residue was dissolved in MeOH (2.0
mL), basified pH to 8 with NH.sub.3.H.sub.2O (25% solution) and
purified by prep-HPLC to give
N-(4-(2-(((1r,4r)-4-aminocyclohexyl)amino)-8-ethylquinazolin-6-yl)phenyl)-
-2-chlorobenzenesulfonamide (8.7 mg, 14.9 umol, 18.9% yield, FA).
M+H.sup.+=536.2 (LCMS); .sup.1H NMR (400 MHz, METHANOL-d.sub.4)
.delta. 9.00 (s, 1H), 8.50 (br s, 1H), 8.12-8.03 (m, 1H), 7.74 (dd,
J=1.9, 16.2 Hz, 2H), 7.60-7.48 (m, 4H), 7.47-7.38 (m, 1H), 7.24 (d,
J=8.6 Hz, 2H), 4.02-3.92 (m, 1H), 3.17 (tt, J=3.9, 11.5 Hz, 1H),
3.07 (q, J=7.4 Hz, 2H), 2.31 (br d, J=11.9 Hz, 2H), 2.14 (br d,
J=11.7 Hz, 2H), 1.67-1.55 (m, 2H), 1.54-1.42 (m, 2H), 1.33 (t,
J=7.5 Hz, 3H). The following compounds were synthesized according
to procedures described in example 4 above for the preparation of
compound 18.
TABLE-US-00006 Comp Mass .sup.1H NMR (MeOD, ID Structure Chemical
Name (M + H.sup.+) 400 MHz) 7 ##STR00187## N-(4-(2-(((1r,4r)- 4-
aminocyclohexyl) amino)-8- ethylquinazolin-6- yl)-3-
methylphenyl)-2- (trifluoromethyl) benzene- sulfonamide, formate
salt Calc'd for C.sub.30H.sub.33F.sub.3N.sub.5O.sub.2S: 584.2;
Found: 584.2 .delta. 8.96 (s, 1H), 8.53 (br s, 1H), 8.18- 8.11 (m,
1H), 7.97- 7.90 (m, 1H), 7.80- 7.68 (m, 2H), 7.43 (d, J = 6.2 Hz,
2H), 7.15-7.08 (m, 1H), 7.07-6.97 (m, 2H), 4.05-3.90 (m, 1H), 3.16
(tt, J = 3.8, 11.5 Hz, 1H), 3.05 (q, J = 7.5 Hz, 2H), 2.31 (br d, J
= 11.7 Hz, 2H), 2.21-2.08 (m, 5H), 1.68-1.40 (m, 4H), 1.30 (t, J =
7.5 Hz, 3H) 8 ##STR00188## N-(4-(2-(((1r,4r)- 4- aminocyclohexyl)
amino)-8- ethylquinazolin-6- yl)-3- methylphenyl)-2- (trifluoro-
methoxy) benzene- sulfonamide, formate salt Calc'd for
C.sub.30H.sub.33F.sub.3N.sub.5O.sub.3S: 600.2; Found: 600.2 .delta.
8.95 (s, 1H), 8.57 (br s, 1H), 8.02 (dd, J = 1.7, 7.8 Hz, 1H),
7.73-7.62 (m, 1H), 7.52-7.34 (m, 4H), 7.12-6.95 (m, 3H), 4.03-3.88
(m, 1H), 3.20-3.09 (m, 1H), 3.04 (q, J = 7.5 Hz, 2H), 2.30 (br d, J
= 11.7 Hz, 2H), 2.19- 2.06 (m, 5H), 1.65- 1.40 (m, 4H), 1.30 (t, J
= 7.4 Hz, 3H) 9 ##STR00189## N-(4-(2-(((1r,4r)- 4- aminocyclohexyl)
amino)-8- ethylquinazolin-6- yl)-3- methylphenyl)- 2,5-
dichlorobenzene- sulfonamide, formate salt Calc'd for
C.sub.29H.sub.32Cl.sub.2N.sub.5O.sub.3S: 584.2; Found: 584.1
.delta. 8.95 (s, 1H), 8.56 (br s, 1H), 8.07- 8.00 (m, 1H), 7.59-
7.53 (m, 2H), 7.47- 7.39 (m, 2H), 7.14- 7.00 (m, 3H), 4.02- 3.89
(m, 1H), 3.18- 3.08 (m, 1H), 3.04 (q, J = 7.5 Hz, 2H), 2.35-2.25
(m, 2H), 2.19 (s, 3H), 2.12 (br d, J = 11.9 Hz, 2H), 1.64-1.40 (m,
4H), 1.30 (t, J = 7.5 Hz, 3H) 10 ##STR00190## N-(4-(2-(((1r,4r)- 4-
aminocyclohexyl) amino)-8- ethylquinazolin-6- yl)-3-
methylphenyl)-2- fluorobenzene- sulfonamide, formate salt Calc'd
for C.sub.29H.sub.33FN.sub.5O.sub.3S: 534.2; Found: 534.1 .delta.
8.96 (s, 1 H), 8.57 (br s, 1 H), 7.88 (td, J = 7.55, 1.65 Hz, 1 H),
7.46-7.72 (m, 2 H), 7.43 (dd, J = 8.71, 1.87 Hz, 2 H), 7.25-7.33
(m, 2 H), 7.03-7.10 (m, 2 H), 3.91-4.05 (m, 1 H), 3.10-3.20 (m, 1
H), 2.98-3.09 (m, 2 H), 2.28-2.34 (m, 2 H), 2.07-2.22 (m, 5 H),
1.42-1.65 (m, 4 H), 1.28-1.37 (m, 3 H) 11 ##STR00191##
N-(4-(2-(((1r,4r)- 4- aminocyclohexyl) amino)-8-ethyl-
quinazolin-6-yl)- 3- methylphenyl)-3- chlorobenzene- sulfonamide,
formate salt Calc'd for C.sub.29H.sub.33ClN.sub.5O.sub.3S: 550.2;
Found: 550.2 .delta. 8.98 (s, 1H), 8.56 (br s, 1H), 7.81- 7.77 (m,
1H), 7.73 (d, J = 7.9 Hz, 1H), 7.60 (br d, J = 7.9 Hz, 1H), 7.52
(d, J = 7.9 Hz, 1H), 7.49-7.45 (m, 2H), 7.17-7.12 (m, 1H),
7.07-6.99 (m, 2H), 4.04-3.91 (m, 1H), 3.18-3.10 (m, 1H), 3.06 (q, J
= 7.5 Hz, 2H), 2.32 (br d, J = 10.5 Hz, 2H), 2.21 (s, 3H), 2.13 (br
d, J = 12.3 Hz, 2H), 1.64-1.42 (m, 4H), 1.32 (t, J = 7.5 Hz, 3H) 12
##STR00192## N-(4-(2-(((1r,4r)- 4- aminocyclohexyl) amino)-8-ethyl-
quinazolin-6-yl)- 3- methylphenyl)-4- chlorobenzene- sulfonamide,
formate salt Calc'd for C.sub.29H.sub.33ClN.sub.5O.sub.3S: 550.2;
Found: 550.2 .delta. 8.98 (s, 1 H), 8.54 (br s, 1 H), 7.74- 7.82
(m, 2 H), 7.53 (d, J = 8.82 Hz, 2 H), 7.44-7.48 (m, 2 H), 7.13 (d,
J = 7.72 Hz, 1 H), 6.98-7.05 (m, 2 H), 3.92-4.04 (m, 1 H),
3.11-3.25 (m, 1 H), 3.01-3.09 (m, 2 H), 2.32 (br d, J = 10.36 Hz, 2
H), 2.20 (s, 3 H), 2.15 (br d, J = 11.69 Hz, 2 H), 1.43-1.66 (m, 4
H), 1.32 (t, J = 7.39 Hz, 3 H) 13 ##STR00193## N-(4-(2-(((1r,4r)-
4- aminocyclohexyl) amino)-8- ethylquinazolin-6- yl)-3-
methylphenyl)-2- methoxybenzene- sulfonamide, formate salt Calc'd
for C.sub.30H.sub.36N.sub.5O.sub.3S: 546.2; Found: 546.2 .delta.
9.01 (br s, 1H), 7.84 (dd, J = 1.5, 7.7 Hz, 1H), 7.64- 7.49 (m,
2H), 7.42 (d, J = 7.0 Hz, 2H), 7.15 (d, J = 8.3 Hz, 1H), 7.12-6.95
(m, 4H), 3.99 (m, 4H), 3.20-3.00 (m, 3H), 2.31 (m, 2H), 2.17 (m,
5H), 1.63-1.39 (m, 4H), 1.30 (t, J = 7.5 Hz, 3H) 15 ##STR00194##
N-(4-(2-(((1r,4r)- 4- aminocyclohexyl) amino)-8- ethylquinazolin-6-
yl)-3- methylphenyl) benzene- sulfonamide, formate salt Calc'd for
C.sub.29H.sub.34N.sub.5O.sub.3S: 516.2; Found: 516.2 .delta.
8.95-8.75 (m, 1H), 8.35 (br s, 1H), 7.76-7.70 (m, 2H), 7.51-7.44
(m, 1H), 7.43-7.37 (m, 2H), 7.32 (dd, J = 1.8, 14.6 Hz, 2H),
7.02-6.97 (m, 1H), 6.95-6.90 (m, 2H), 3.89 (tdd, J = 3.8, 7.5, 11.1
Hz, 1H), 3.09 (br t, J = 11.5 Hz, 1H), 2.95 (q, J = 7.5 Hz, 2H),
2.22 (br d, J = 11.1 Hz, 2H), 2.14-2.01 (m, 5H), 1.63-1.30 (m, 4H),
1.21 (t, J = 7.5 Hz, 3H)
[0324] Exemplary compounds were synthesized according to procedures
described herein. For compounds that do not have a specific
synthetic scheme described herein, such compounds can be routinely
synthesized by a skilled artisan armed with the guidance presented
herein and skill in the art.
TABLE-US-00007 Comp Mass .sup.1H NMR (MeOD, 400 ID Structure
Chemical Name (M + H.sup.+) MHz) 23 ##STR00195## N-(5-(2-(((1r,4r)-
4- aminocyclohexyl) amino)-8- ethylquinazolin- 6-yl)-4-
methylpyrimidin- 2-yl)-2- chlorobenzene- sulfonamide Calc'd for
C.sub.27H.sub.31ClN.sub.7O.sub.2S: 552.1; Found: 552.1 .delta. 9.01
(s, 1H), 8.58 (br s, 1H), 8.34 (br d, J = 7.0 Hz, 1H), 8.23 (br s,
1H), 7.61-7.46 (m, 5H), 4.05-3.89 (m, 1H), 3.26-3.13 (m, 1H), 3.07
(q, J = 7.5 Hz, 2H), 2.31 (m, 5H), 2.16 (br d, J = 10.6 Hz, 2H),
1.71-1.43 (m, 4H), 1.33 (t, J = 7.5 Hz, 3H) 24 ##STR00196##
N-(4-(2-(((1r,4r)- 4- aminocyclohexyl) amino)-8- ethylquinazolin-
6-yl)-2- fluorophenyl)-2- chlorobenzene- sulfonamide Calc'd for
C.sub.28H.sub.30ClFN.sub.5O.sub.2S: 554.2; Found: 554.1 .delta.
9.03 (s, 1H), 8.56 (br s, 1H), 8.03 (dd, J = 1.3, 7.9 Hz, 1H), 7.80
(s, 2H), 7.68-7.54 (m, 2H), 7.54-7.34 (m, 4H), 4.05-3.91 (m, 1H),
3.25-3.15 (m, 1H), 3.09 (q, J = 7.4 Hz, 2H), 2.33 (br d, J = 11.5
Hz, 2H), 2.16 (br d, J = 11.7 Hz, 2H), 1.71- 1.43 (m, 4H), 1.41-
1.27 (m, 3H) 25 ##STR00197## N-(5-(2-(((1r,4r)- 4- aminocyclohexyl)
amino)-8- ethylquinazolin- 6-yl)pyrazin-2- yl)-2- chlorobenzene-
sulfonamide Calc'd for C.sub.26H.sub.29ClN.sub.7O.sub.2S: 538.2;
Found: 538.1 .delta. 9.03 (s, 1H), 8.58 (br s, 2H), 8.33-8.23 (m,
2H), 8.13 (d, J = 1.7 Hz, 1H), 8.08 (d, J = 1.8 Hz, 1H), 7.57-7.44
(m, 3H), 4.06-3.91 (m, 1H), 3.26-3.14 (m, 1H), 3.08 (q, J = 7.4 Hz,
2H), 2.32 (br d, J = 10.5 Hz, 2H), 2.16 (br d, J = 13.0 Hz, 2H),
1.73- 1.44 (m, 4H), 1.38- 1.27 (m, 3H) 26 ##STR00198##
N-(4-(2-(((1r,4r)- 4- aminocyclohexyl) amino)quinazolin-
6-yl)phenyl)-2- chlorobenzene- sulfonamide M + H.sup.+ = 508.1
(LCMS) .sup.1H NMR (400 MHz, METHANOL-d.sub.4) .delta. 9.06 (s,
1H), 8.41 (br s, 1H), 8.14-8.06 (m, 1H), 7.99-7.88 (m, 2H),
7.62-7.49 (m, 5H), 7.43 (m, 1H), 7.25 (d, J = 8.7 Hz, 2H), 4.02-
3.89 (m, 1H), 3.21- 3.10 (m, 1H), 2.23 (br d, J = 12.0 Hz, 2H),
2.12 (br d, J = 11.0 Hz, 2H), 1.67-1.55 (m, 2H), 1.53-1.41 (m, 2H)
27 ##STR00199## N-(5-(2-(((1r,4r)- 4- aminocyclohexyl) amino)-8-
ethylquinazolin- 6-yl)pyridin-2- yl)-2- chlorobenzene- sulfonamide
Calc'd for C.sub.27H.sub.30ClN.sub.6O.sub.2S: 537.2; Found: 537.1
.delta. 9.03 (s, 1 H), 8.55 (br s, 1 H), 8.40 (d, J = 2.45 Hz, 1
H), 8.05-8.15 (m, 3 H), 7.80 (d, J = 8.80 Hz, 1 H), 7.68 (dd, J =
8.56, 2.69 Hz, 1 H), 7.53- 7.61 (m, 2 H), 7.41- 7.50 (m, 1 H),
3.92- 4.03 (m, 1 H), 3.12- 3.21 (m, 1 H), 3.08 (q, J = 7.34 Hz, 2
H), 2.31 (br d, J = 11.25 Hz, 2 H), 2.14 (br d, J = 11.74 Hz, 2 H),
1.42-1.64 (m, 4 H), 1.34 (t, J = 7.58 Hz, 3H) 28 ##STR00200##
N-(6-(2-(((1r,4r)- 4- aminocyclohexyl) amino)-8- ethylquinazolin-
6-yl)pyridin-3- yl)-2- chlorobenzene- sulfonamide Calc'd for
C.sub.27H.sub.30ClN.sub.6O.sub.2S: 537.2; Found: 537.2 .delta. 9.00
(s, 1H), 8.53 (br s, 1H), 8.30 (s, 1H), 8.23 (d, J = 7.7 Hz, 1H),
8.06 (dd, J = 2.0, 8.8 Hz, 1H), 7.76 (s, 2H), 7.55- 7.44 (m, 3H),
7.29 (d, J = 9.0 Hz, 1H), 4.01- 3.90 (m, 1H), 3.21-3.11 (m, 1H),
3.07 (q, J = 7.4 Hz, 2H), 2.30 (br d, J = 10.8 Hz, 2H), 2.13 (br d,
J = 12.1 Hz, 2H), 1.66- 1.40 (m, 4H), 1.33 (t, J = 7.5 Hz, 3H) 29
##STR00201## N-(5-(2-(((1r,4r)- 4- aminocyclohexyl) amino)-8-
ethylquinazolin- 6-yl)-1H-pyrazol- 3-yl)-2- chlorobenzene-
sulfonamide Calc'd for C.sub.25H.sub.29ClN.sub.7O.sub.2S: 526.2;
Found: 526.1 .delta. 8.99 (s, 1H), 8.09 (d, J = 7.3 Hz, 1H), 7.78
(br s, 2H), 7.62-7.52 (m, 2H), 7.43 (t, J = 7.2 Hz, 1H), 6.37 (s,
1H), 3.96 (m, 1H), 3.17 (m, 1H), 3.05 (q, J = 7.3 Hz, 2H), 2.30 (br
d, J = 11.5 Hz, 2H), 2.14 (br d, J = 11.9 Hz, 2H), 1.65-1.54 (m,
2H), 1.53-1.43 (m, 2H), 1.33 (t, J = 7.5 Hz, 3H) 30 ##STR00202##
N-(4-(2-(((1r,4r)- 4- aminocyclohexyl) amino)-8- hydroxyquinazolin-
6-yl)-3- methylphenyl)-2- chloro-N- methylbenzene- sulfonamide M +
H.sup.+ = 552.2 .delta. 8.99 (s, 1H), 8.51 (s, 1H), 7.92 (d, J =
7.9 Hz, 1H), 7.68-7.53 (m, 2H), 7.43 (t, J = 7.0 Hz, 1H), 7.22-7.06
(m, 4H), 7.01 (s, 1H), 4.09 (br s, 1H), 3.42 (s, 3H), 3.15 (br t, J
= 11.6 Hz, 1H), 2.30-2.20 (m, 5H), 2.12 (br d, J = 12.7 Hz, 2H),
1.73-1.55 (m, 2H), 1.53-1.35 (m, 2H). 31 ##STR00203##
N-(4-(2-(((1r,4r)- 4- aminocyclohexyl) amino)-8- ethylquinazolin-
6-yl)-3- methylphenyl)-2- chloro-N- methylbenzene- sulfonamide M +
H.sup.+ = 564.2 .delta. 8.98 (s, 1H), 8.51 (br s, 1H), 7.91 (d, J =
7.9 Hz, 1H), 7.65-7.55 (m, 2H), 7.49-7.39 (m, 3H), 7.19-7.14 (m,
2H), 7.12-7.07 (m, 1H), 3.98 (br t, J = 11.0 Hz, 1H), 3.42 (d, J =
1.8 Hz, 3H), 3.17 (br t, J = 11.4 Hz, 1H), 3.06 (q, J = 7.3 Hz,
2H), 2.32 (br d, J = 11.8 Hz, 2H), 2.20 (s, 3H), 2.15 (br d, J =
12.3 Hz, 2H), 1.69- 1.43 (m, 4H), 1.37- 1.28 (m, 3H). 32
##STR00204## N-(6-(2-(((1r,4r)- 4- aminocyclohexyl) amino)-8-
ethylquinazolin- 6-yl)pyridazin-3- yl)-2- chlorobenzene-
sulfonamide Calc'd for C.sub.26H.sub.29ClN.sub.7O.sub.2S: 538.2;
Found: 538.2 .delta. 9.03 (s, 1H), 8.53 (br s, 1H), 8.24-8.18 (m,
2H), 8.15 (d, J = 1.8 Hz, 1H), 8.10 (d, J = 2.2 Hz, 1H), 7.95 (d, J
= 10.1 Hz, 1H), 7.56-7.43 (m, 3H), 4.03-3.91 (m, 1H), 3.23-3.11 (m,
1H), 3.06 (q, J = 7.5 Hz, 2H), 2.30 (br d, J = 10.1 Hz, 2H), 2.14
(br d, J = 11.8 Hz, 2H), 1.67- 1.43 (m, 4H), 1.33 (t, J = 7.5 Hz,
3H) 33 ##STR00205## N-(2-(2-(((1r,4r)- 4- aminocyclohexyl)
amino)-8- ethylquinazolin- 6-yl)pyrimidin-5- yl)-2- chlorobenzene-
sulfonamide Calc'd for C.sub.26H.sub.29ClN.sub.7O.sub.2S: 538.2;
Found: 538.1 .delta. 9.06 (s, 1H), 8.61 (s, 2H), 8.55-8.43 (m, 3H),
8.20-8.12 (m, 1H), 7.66-7.54 (m, 2H), 7.54-7.45 (m, 1H), 4.06-3.95
(m, 1H), 3.24-3.14 (m, 1H), 3.09 (q, J = 7.5 Hz, 2H), 2.33 (br d, J
= 12.5 Hz, 2H), 2.16 (br d, J = 10.8 Hz, 2H), 1.72- 1.42 (m, 4H),
1.36 (t, J = 7.5 Hz, 3H) 34 ##STR00206## N-(4-(2-(((1r,4r)- 4-
aminocyclohexyl) amino)-8- ethylquinazolin- 6-yl)-3-
ethylphenyl)-2- chlorobenzene- sulfonamide M + H.sup.+ = 564.2
.delta. 8.95 (s, 1H), 8.56 (br s, 1H), 8.14-8.06 (m, 1H), 7.60-7.52
(m, 2H), 7.45 (m, 1H), 7.40 (d, J = 2.9 Hz, 2H), 7.11 (d, J = 1.8
Hz, 1H), 7.08- 6.99 (m, 2H), 4.03- 3.85 (m, 1H), 3.16- 2.97 (m,
3H), 2.51 (q, J = 7.5 Hz, 2H), 2.30 (br d, J = 10.6 Hz, 2H), 2.12
(br d, J = 12.1 Hz, 2H), 1.62-1.42 (m, 4H), 1.30 (t, J = 7.5 Hz,
3H), 0.98 (t, J = 7.5 Hz, 3H) 35 ##STR00207## N-(4-(2-(((1r,4r)- 4-
aminocyclohexyl) amino)-8- ethylquinazolin- 6-yl)-3-
fluorophenyl)-2- chlorobenzene- sulfonamide Calc'd for
C.sub.28H.sub.30ClFN.sub.5O.sub.2S: 554.2; Found: 554.1 .delta.
8.97 (br d, J = 3.1 Hz, 1H), 8.55 (br s, 1H), 8.15 (br dd, J = 2.6,
7.5 Hz, 1H), 7.64 (br s, 2H), 7.57 (br d, J = 3.1 Hz, 2H),
7.51-7.43 (m, 1H), 7.37 (dt, J = 3.5, 8.6 Hz, 1H), 7.07-6.97 (m,
2H), 4.02-3.90 (m, 1H), 3.20-3.11 (m, 1H), 3.04 (br dd, J = 3.1,
7.3 Hz, 2H), 2.30 (br d, J = 11.2 Hz, 2H), 2.13 (br d, J = 11.2 Hz,
2H), 1.66-1.40 (m, 4H), 1.31 (dt, J = 3.6, 7.3 Hz, 3H) 36
##STR00208## N-(4-(2-(((1r,4r)- 4- aminocyclohexyl) amino)-8-
methoxyquinazolin- 6-yl)-3- methylphenyl)-2- chlorobenzene-
sulfonamide M + H.sup.+ = 552.1 .delta. 8.98 (s, 1H), 8.47 (s, 1H),
8.15-8.04 (m, 1H), 7.58-7.52 (m, 2H), 7.44 (ddd, J = 2.6, 5.9, 8.1
Hz, 1H), 7.16 (d, J = 1.8 Hz, 1H), 7.12- 7.03 (m, 4H), 4.05 (br t,
J = 11.2 Hz, 1H), 3.95 (s, 3H), 3.14 (ddd, J = 3.9, 7.7, 11.6 Hz,
1H), 2.27-2.17 (m, 5H), 2.11 (br d, J = 11.4 Hz, 2H), 1.67-1.53 (m,
2H), 1.52-1.38 (m, 2H) 37 ##STR00209## N-(5-(2-(((1r,4r)- 4-
aminocyclohexyl) amino)-8- ethylquinazolin- 6-yl)-6-
methoxypyridin- 2-yl)-2- chlorobenzene- sulfonamide M + H.sup.+ =
567.2 .delta. 8.95 (s, 1 H), 8.54 (br s, 1 H), 8.31 (d, J = 7.72
Hz, 1 H), 7.65 (t, J = 7.50 Hz, 3 H), 7.56- 7.60 (m, 2 H), 7.48-
7.54 (m, 1 H), 6.63 (d, J = 7.94 Hz, 1 H), 3.91- 4.01 (m, 1 H),
3.65 (s, 3 H), 3.10-3.21 (m, 1 H), 3.03 (q, J = 7.35 Hz, 2 H), 2.30
(br d, J = 12.13 Hz, 2 H), 2.13 (br d, J = 12.13 Hz, 2 H), 1.44-
1.65 (m, 4 H), 1.30 (t, J = 7.50 Hz, 3 H) 38 ##STR00210##
N-(5-(2-(((1r,4r)- 4- aminocyclohexyl) amino)-8- ethylquinazolin-
6-yl)-4- methylthiazol-2- yl)-2- chlorobenzene- sulfonamide M +
H.sup.+ = 557.2 .delta. 9.02 (s, 1 H) 8.52 (br s, 1 H) 8.15 (d, J =
7.06 Hz, 1 H) 7.64 (s, 1 H) 7.51-7.59 (m, 3 H) 7.43-7.49 (m, 1 H)
3.92-4.04 (m, 1 H) 3.02-3.21 (m, 3 H) 2.30 (s, 5 H) 2.14 (br d, J =
12.13 Hz, 2 H) 1.44- 1.64 (m, 4 H) 1.33 (t, J = 7.50 Hz, 3 H) 39
##STR00211## N-(5-(2-(((1r,4r)- 4- aminocyclohexyl) amino)-8-
ethylquinazolin- 6-yl)pyrimidin-2- yl)-2- chlorobenzene-
sulfonamide M + H.sup.+ = 538.1 .delta. 9.02 (br s, 1H), 8.51 (br
s, 2H), 8.19 (s, 1H), 8.04 (br s, 1H), 7.78 (br d, J = 6.8 Hz, 2H),
7.36 (br s, 4H), 3.78 (br s, 1H), 3.03 (br s, 1H), 2.94 (q, J = 7.4
Hz, 2H), 2.09 (br s, 2H), 1.99 (br d, J = 10.8 Hz, 2H), 1.52 (br s,
2H), 1.42- 1.30 (m, 2H), 1.23 (t, J = 7.4 Hz, 3H) 40 ##STR00212##
N-(5-(2-(((1r,4r)- 4- aminocyclohexyl) amino)-8-
isopropylquinazolin- 6-yl)-1-methyl- 1H-pyrazol-3-yl)- 2-
chlorobenzene- sulfonamide M + H.sup.+ = 554.2 .delta. 9.01 (s,
1H), 8.53 (br s, 1H), 8.12-8.07 (m, 1H), 7.60 (dd, J = 1.8, 10.5
Hz, 2H), 7.57- 7.54 (m, 1H), 7.52 (d, J = 1.8 Hz, 1H), 7.47- 7.41
(m, 1H), 6.09 (s, 1H), 4.03-3.87 (m, 2H), 3.71 (s, 3H), 3.17 (br t,
J = 11.4 Hz, 1H), 2.30 (br d, J = 11.8 Hz, 2H), 2.14 (br d, J =
11.0 Hz, 2H), 1.68-1.41 (m, 5H), 1.34 (d, J = 7.0 Hz, 6H) 41
##STR00213## N-(5-(2-(((1r,4r)- 4- aminocyclohexyl) amino)-8-
ethylquinazolin- 6-yl)thiazol-2-yl)- 2- chlorobenzene- sulfonamide
M + H.sup.+ = 543.1 .delta. 8.98 (s, 1H), 8.51 (br s, 1H), 8.17 (d,
J = 7.0 Hz, 1H), 7.73 (s, 1H), 7.65 (s, 1H), 7.58-7.40 (m, 4H),
4.01-3.89 (m, 1H), 3.19-2.98 (m, 3H), 2.30 (br d, J = 12.3 Hz, 2H),
2.13 (br d, J = 13.2 Hz, 2H), 1.66- 1.41 (m, 4H), 1.33 (t, J = 7.5
Hz, 3H) 42 ##STR00214## N-(4-(2-(((1r,4r)- 4- aminocyclohexyl)
amino)-8- ethylquinazolin- 6-yl)-2-fluoro-5- methoxyphenyl)- 2-
chlorobenzene- sulfonamide M + H.sup.+ = 584.2 .delta. 8.95 (s, 1
H), 8.55 (br s, 1 H), 8.09 (d, J = 7.28 Hz, 1 H), 7.54-7.67 (m, 4
H), 7.41-7.47 (m, 1 H), 7.05-7.11 (m, 2 H), 3.96 (br t, J = 11.36
Hz, 1 H), 3.70 (s, 3 H), 3.10- 3.19 (m, 1 H), 3.03 (q, J = 7.72 Hz,
2 H), 2.30 (br d, J = 12.57 Hz, 2 H), 2.13 (br d, J = 11.47 Hz, 2
H), 1.42-1.65 (m, 4 H), 1.31 (t, J = 7.39 Hz, 3 H) 43 ##STR00215##
N-(1-(2-(((1r,4r)- 4- aminocyclohexyl) amino)-8- ethylquinazolin-
6-yl)-1H-pyrazol- 4-yl)-2- chlorobenzene- sulfonamide M + H.sup.+ =
526.0 .delta. 9.09 (br s, 1H), 8.40 (br s, 1H), 8.05 (s, 1H),
8.01-7.95 (m, 2H), 7.88 (d, J = 2.3 Hz, 1H), 7.65-7.47 (m, 2H),
7.44-7.34 (m, 2H), 3.77 (br s, 1H), 3.05- 2.90 (m, 3H), 2.12- 1.96
(m, 4H), 1.49- 1.24 (m, 7H) 44 ##STR00216## N-(5-(2-(((1r,4r)- 4-
aminocyclohexyl) amino)-8- ethylquinazolin- 6-yl)isoxazol-3- yl)-2-
chlorobenzene- sulfonamide M + H.sup.+ = 527.1 .delta. 9.13 (br s,
1H), 8.39 (br s, 1H), 8.06-7.90 (m, 2H), 7.79 (d, J = 1.6 Hz, 1H),
7.55 (br s, 1H), 7.46-7.40 (m, 1H), 7.39-7.29 (m, 2H), 6.53 (s,
1H), 3.80 (br s, 1H), 2.98 (q, J = 7.4 Hz, 3H), 2.17-1.94 (m, 4H),
1.53-1.32 (m, 4H), 1.31-1.22 (m, 3H). 45 ##STR00217##
N-(5-(2-(((1r,4r)- 4- aminocyclohexyl) amino)-8- methoxyquinazolin-
6-yl)-1-methyl- 1H-pyrazol-3-yl)- 2- chlorobenzene- sulfonamide M +
H.sup.+ = 542.2 .delta. 9.05 (br s, 1H), 8.33 (br s, 2H), 8.02 (d,
J = 7.7 Hz, 1H), 7.60-7.34 (m, 5H), 7.10 (br s, 1H), 6.02 (s, 1H),
3.89 (br s, 4H), 3.68 (s, 3H), 2.96 (br s, 1H), 1.97 (br s, 4H),
1.49-1.26 (m, 4H). 46 ##STR00218## N-(5-(2-(((1r,4r)- 4-
aminocyclohexyl) amino)-8- ethylquinazolin- 6-yl)-4-
methoxypyrimidin- 2-yl)-2- chlorobenzene- sulfonamide M + H.sup.+ =
568.2 .delta. 8.98 (s, 1 H), 8.50 (br s, 1 H), 8.33 (d, J = 7.94
Hz, 1 H), 8.14 (s, 1 H), 7.61-7.68 (m, 2 H), 7.48-7.58 (m, 3 H),
3.91-4.02 (m, 1 H), 3.71 (s, 3 H), 3.11-3.23 (m, 1 H), 3.04 (q, J =
7.72 Hz, 2 H), 2.31 (br d, J = 11.69 Hz, 2 H), 2.14 (br d, J =
11.47 Hz, 2 H), 1.43-1.66 (m, 4 H), 1.31 (t, J = 7.50 Hz, 3 H) 47
##STR00219## N-(5-(2-(((1r,4r)- 4- aminocyclohexyl) amino)-8-
propylquinazolin- 6-yl)-1-methyl- 1H-pyrazol-3-yl)- 2-
chlorobenzene- sulfonamide M + H.sup.+ = 554.2 .delta. 9.02 (s,
1H), 8.48 (br s, 1H), 8.09 (dd, J = 1.3, 7.9 Hz, 1H), 7.62 (d, J =
2.0 Hz, 1H), 7.61-7.54 (m, 2H), 7.52 (d, J = 2.0 Hz, 1H), 7.44
(ddd, J = 1.9, 6.7, 8.1 Hz, 1H), 6.10 (s, 1H), 4.00-3.90 (m, 1H),
3.72 (s, 3H), 3.23-3.12 (m, 1H), 3.05-2.96 (m, 2H), 2.32 (br d, J =
11.7 Hz, 2H), 2.15 (br d, J = 11.2 Hz, 2H), 1.76 (qd, J = 7.4, 15.0
Hz, 2H), 1.67- 1.41 (m, 4H), 1.01 (t, J = 7.3 Hz, 3H) 48
##STR00220## N-(4-(2-(((1r,4r)- 4- aminocyclohexyl)
amino)quinazolin- 6-yl)-3- fluorophenyl)-2- chlorobenzene-
sulfonamide M + H.sup.+ = 526.1 .delta. 9.06 (s, 1H), 8.50 (br s,
1H), 8.18 (d, J = 7.6 Hz, 1H), 7.91-7.80 (m, 2H), 7.62-7.56 (m,
3H), 7.53-7.48 (m, 1H), 7.46-7.40 (m, 1H), 7.11-7.02 (m, 2H),
4.04-3.93 (m, 1H), 3.22-3.11 (m, 1H), 2.25 (br d, J = 13.0 Hz, 2H),
2.14 (br d, J = 11.9 Hz, 2H), 1.71- 1.40 (m, 4H) 49 ##STR00221##
N-(6-(2-(((1r,4r)- 4- aminocyclohexyl) amino)quinazolin-
6-yl)pyridazin-3- yl)-2- chlorobenzene- sulfonamide M + H.sup.+ =
510.1 .delta. 9.13 (s, 1H), 8.42 (br s, 1H), 8.37-8.27 (m, 3H),
8.23 (d, J = 6.7 Hz, 1H), 8.07 (d, J = 10.0 Hz, 1H), 7.68-7.44 (m,
4H), 4.01 (br t, J = 11.2 Hz, 1H), 3.24-3.11 (m, 1H), 2.33-2.10 (m,
4H), 1.72-1.44 (m, 4H) 50 ##STR00222## N-(4-(2-(((1r,4r)- 4-
aminocyclohexyl) amino)quinazolin- 6-yl)-2- fluorophenyl)-2-
chlorobenzene- sulfonamide M + H.sup.+ = 526.1 .delta. 9.08 (br s,
1H), 8.25 (s, 1H), 8.00-7.91 (m, 3H), 7.50-7.29 (m, 5H), 7.24-7.12
(m, 2H), 3.81 (br d, J = 8.1 Hz, 1H), 3.03 (br d, J = 10.9 Hz, 1H),
2.11- 1.92 (m, 4H), 1.53- 1.29 (m, 4H) 51 ##STR00223##
N-(6-(2-(((1r,4r)- 4- aminocyclohexyl) amino)quinazolin- 6-yl)-5-
fluoropyridin-3- yl)-2- chlorobenzene- sulfonamide M + H.sup.+ =
527.1 .delta. 9.08 (s, 1H), 8.45 (br s, 1H), 8.29 (s, 1H), 8.24-
8.15 (m, 3H), 7.64- 7.55 (m, 3H), 7.54- 7.45 (m, 2H), 3.98 (br t, J
= 11.4 Hz, 1H), 3.21- 3.09 (m, 1H), 2.24 (br d, J = 11.7 Hz, 2H),
2.13 (br d, J = 11.7 Hz, 2H), 1.71-1.41 (m, 4H) 52 ##STR00224##
N-(6-(2-(((1r,4r)- 4- aminocyclohexyl) amino)-8- ethylquinazolin-
6-yl)-5- fluoropyridin-3- yl)-2- chlorobenzene- sulfonamide M +
H.sup.+ = 555.2 .delta. 9.02 (s, 1H), 8.51 (br s, 1H), 8.28 (s,
1H), 8.19 (d, J = 7.9 Hz, 1H), 8.05 (br d, J = 7.5 Hz, 2H),
7.64-7.56 (m, 2H), 7.54-7.42 (m, 2H), 3.99 (br t, J = 11.0 Hz, 1H),
3.18 (br t, J = 11.5 Hz, 1H), 3.08 (q, J = 7.5 Hz, 2H), 2.32 (br d,
J = 11.2 Hz, 2H), 2.15 (br d, J = 11.2 Hz, 2H), 1.70- 1.43 (m, 4H),
1.34 (t, J = 7.4 Hz, 3H). 53 ##STR00225## N-(4-(2-(((1r,4r)- 4-
aminocyclohexyl) amino)quinazolin- 6-yl)-2,5- difluorophenyl)- 2-
chlorobenzene- sulfonamide M + H.sup.+ = 544.1 .delta. 9.10 (br s,
1 H), 8.17 (br s, 1 H), 7.97 (dd, J = 7.28,
1.98 Hz, 1 H), 7.85- 7.89 (m, 1 H), 7.80 (br d, J = 8.82 Hz, 1 H),
7.36-7.47 (m, 4 H), 7.13-7.23 (m, 1 H), 6.98 (br dd, J = 14.33,
7.50 Hz, 1 H), 3.80 (br s, 1 H), 3.03 (br s, 1 H), 1.88-2.12 (m, 4
H), 1.22-1.57 (m, 4 H) 54 ##STR00226## N-(5-(2-(((1r,4r)- 4-
aminocyclohexyl) amino)quinazolin- 6-yl)-3- fluoropyridin-2- yl)-2-
chlorobenzene- sulfonamide M + H.sup.+ = 527.1 .delta. 9.10 (s,
1H), 8.29 (br dd, J = 2.1, 5.6 Hz, 3H), 8.23 (d, J = 1.8 Hz, 1H),
8.02-7.91 (m, 2H), 7.63-7.57 (m, 2H), 7.57-7.51 (m, 1H), 3.99 (br
t, J = 11.2 Hz, 1H), 3.21-3.09 (m, 1H), 2.25 (br d, J = 12.3 Hz,
2H), 2.14 (br d, J = 12.0 Hz, 2H), 1.71- 1.41 (m, 4H) 55
##STR00227## N-(5-(2-(((1r,4r)- 4- aminocyclohexyl) amino)-8-
ethylquinazolin- 6-yl)-3- fluoropyridin-2- yl)-2- chlorobenzene-
sulfonamide M + H.sup.+ = 555.2 ) .delta. 9.00 (s, 1H), 8.49 (br s,
1H), 8.25 (d, J = 8.1 Hz, 1H), 8.16 (s, 1H), 7.85 (br d, J = 11.6
Hz, 1H), 7.76 (br s, 2H), 7.57-7.51 (m, 2H), 7.51-7.44 (m, 1H),
4.01-3.87 (m, 1H), 3.22-3.12 (m, 1H), 3.06 (q, J = 7.5 Hz, 2H),
2.30 (br d, J = 11.5 Hz, 2H), 2.14 (br d, J = 12.2 Hz, 2H),
1.72-1.41 (m, 4H), 1.32 (t, J = 7.5 Hz, 3H) 56 ##STR00228##
N-(4-(2-(((1r,4r)- 4- aminocyclohexyl) amino)quinazolin- 6-yl)-2,3-
difluorophenyl)- 2- chlorobenzene- sulfonamide M + H.sup.+ = 544.1
.delta. 9.06 (s, 1H), 8.42 (br s, 1H), 8.08-8.02 (m, 1H), 7.89 (s,
1H), 7.83 (br d, J = 9.0 Hz, 1H), 7.65-7.55 (m, 3H), 7.48-7.41 (m,
1H), 7.32-7.20 (m, 2H), 4.04-3.91 (m, 1H), 3.21-3.08 (m, 1H), 2.23
(br d, J = 11.2 Hz, 2H), 2.12 (br d, J = 12.3 Hz, 2H), 1.68-1.38
(m, 4H) 57 ##STR00229## N-(4-(3-(((1r,4r)- 4- aminocyclohexyl)
amino)isoquinolin- 7-yl)-2- fluorophenyl)-2- chlorobenzene-
sulfonamide M + H.sup.+ = 525.1 .delta. 8.83 (s, 1H), 8.46 (br s,
1H), 8.05-7.93 (m, 2H), 7.71 (dd, J = 1.9, 8.7 Hz, 1H), 7.62-7.53
(m, 3H), 7.50-7.44 (m, 1H), 7.44-7.37 (m, 3H), 6.68 (s, 1H), 3.68
(tt, J = 3.8, 11.2 Hz, 1H), 3.16 (tt, J = 3.9, 11.7 Hz, 1H), 2.29-
2.18 (m, 2H), 2.12 (br d, J = 12.1 Hz, 2H), 1.61 (dq, J = 3.1, 12.6
Hz, 2H), 1.48-1.33 (m, 2H) 58 ##STR00230## (S)-2-amino-N-
((1r,4S)-4-((6-(4- ((2- chlorophenyl) sulfonamido)-3-
fluorophenyl)-8- ethylquinazolin- 2- yl)amino)cyclo- hexyl)-3-
methylbutanamide M + H.sup.+ = 653.2 .delta. 8.98 (s, 1H), 8.54 (br
s, 1H), 8.02 (dd, J = 1.2, 7.9 Hz, 1H), 7.73 (br d, J = 4.3 Hz,
2H), 7.64- 7.52 (m, 2H), 7.50- 7.44 (m, 1H), 7.44- 7.34 (m, 3H),
3.96 (br s, 1H), 3.80 (br s, 1H), 3.52 (br d, J = 6.0 Hz, 1H), 3.06
(q, J = 7.3 Hz, 2H), 2.24 (br s, 2H), 2.15 (br dd, J = 6.6, 13.2
Hz, 1H), 2.05 (br s, 2H), 1.50 (br d, J = 8.6 Hz, 4H), 1.33 (br t,
J = 7.4 Hz, 3H), 1.07 (br dd, J = 4.0, 6.7 Hz, 6H). 59 ##STR00231##
N-((1r,4r)-4-((6- (4-((2- chlorophenyl) sulfonamido)-3-
fluorophenyl)-8- ethylquinazolin- 2- yl)amino)cyclo-
hexyl)acetamide M + H+ = 596.1 .delta. 8.98 (s, 1H), 8.00 (dd, J =
1.5, 7.9 Hz, 1H), 7.75 (s, 2H), 7.63-7.52 (m, 2H), 7.50-7.44 (m,
1H), 7.43-7.36 (m, 3H), 3.98-3.88 (m, 1H), 3.68 (br d, J = 15.7 Hz,
1H), 3.06 (q, J = 7.4 Hz, 2H), 2.20 (br d, J = 11.7 Hz, 2H), 1.99
(br d, J = 9.3 Hz, 2H), 1.93 (s, 3H), 1.50-1.37 (m, 4H), 1.33 (t, J
= 7.5 Hz, 3H). 60 ##STR00232## 2-chloro-N-(4-(8- ethyl-2-(((1r,4r)-
4- (methylamino) cyclohexyl)amino) quinazolin-6-yl)-
2-fluorophenyl) benzenesulfonamide M + H.sup.+ = 568.2 .delta. 9.05
(br s, 1H), 8.25 (br s, 1H), 7.95 (dd, J = 2.0, 7.5 Hz, 1H), 7.80
(d, J = 1.3 Hz, 2H), 7.47- 7.43 (m, 1H), 7.41- 7.30 (m, 4H), 7.20-
7.13 (m, 2H), 3.79 (br s, 1H), 2.98 (q, J = 7.6 Hz, 2H), 2.91 (br
s, 1H), 2.55 (s, 3H), 2.09 (br d, J = 9.3 Hz, 4H), 1.46- 1.33 (m,
4H), 1.28 (t, J = 7.4 Hz, 3H) 62 ##STR00233## N-(4-(2-(((1r,4r)- 4-
aminocyclohexyl) amino)quinazolin- 6-yl)-3,5- difluorophenyl)- 2-
chlorobenzene- sulfonamide M + H.sup.+ = 544.1 .delta. 8.93 (s,
1H), 8.42 (br s, 1H), 8.18-8.04 (m, 1H), 7.67 (s, 1H), 7.61- 7.55
(m, 1H), 7.53- 7.50 (m, 2H), 7.48- 7.39 (m, 2H), 6.82- 6.75 (m,
2H), 3.96- 3.83 (m, 1H), 3.06 (tt, J = 3.9, 11.6 Hz, 1H), 2.15 (br
d, J = 11.0 Hz, 2H), 2.03 (br d, J = 12.2 Hz, 2H), 1.59-1.46 (m,
2H), 1.44-1.31 (m, 2H). 63 ##STR00234## N-(4-(2-(((1r,4r)- 4-
aminocyclohexyl) amino)-8- ethylquinazolin- 6-yl)-2,6-
difluorophenyl)- 2- chlorobenzene- sulfonamide M + H.sup.+ = 572.2
.delta. 9.04 (br s, 1H), 8.43 (br s, 2H), 7.95 (br d, J = 7.8 Hz,
1H), 7.82 (br d, J = 15.6 Hz, 2H), 7.70-7.57 (m, 2H), 7.43 (br t, J
= 7.4 Hz, 1H), 7.33 (br d, J = 8.9 Hz, 2H), 3.99 (br s, 1H),
3.25-3.03 (m, 3H), 2.33 (br d, J = 10.3 Hz, 2H), 2.17 (br d, J =
9.8 Hz, 2H), 1.70-1.46 (m, 4H), 1.36 (br t, J = 7.2 Hz, 3H). 65
##STR00235## N-(6-(2-(((1r,4r)- 4- aminocyclohexyl) amino)-8-
ethylquinazolin- 6-yl)-5- methoxypyridazin- 3-yl)-2- chlorobenzene-
sulfonamide M + H.sup.+ = 568.2 (LCMS) .sup.1H NMR (400 MHz,
METHANOL-d.sub.4) .delta. 9.04 (s, 1H), 8.52 (br s, 1H), 8.24 (dd,
J = 1.5, 7.7 Hz, 1H), 8.06 (d, J = 2.0 Hz, 1H), 7.98-7.91 (m, 1H),
7.61-7.45 (m, 3H), 7.34 (s, 1H), 4.05- 3.95 (m, 4H), 3.19 (br t, J
= 11.4 Hz, 1H), 3.07 (q, J = 7.5 Hz, 2H), 2.32 (br d, J = 11.1 Hz,
2H), 2.17 (br d, J = 11.4 Hz, 2H), 1.70-1.43 (m, 4H), 1.39-1.27 (m,
3H) 66 ##STR00236## N-(6-(2-(((1r,4r)- 4- aminocyclohexyl)
amino)-8- ethylquinazolin- 6-yl)-4- methoxypyridazin- 3-yl)-2-
chlorobenzene- sulfonamide M + H.sup.+ = 568.2 (LCMS) .sup.1H NMR
(400 MHz, METHANOL-d.sub.4) .delta. 8.96 (s, 1H), 8.35 (br s, 1H),
8.19-8.05 (m, 3H), 7.52-7.32 (m, 4H), 4.03-3.79 (m, 4H), 3.14-2.93
(m, 3H), 2.21 (br d, J = 11.0 Hz, 2H), 2.05 (br d, J = 10.6 Hz,
2H), 1.61-1.33 (m, 4H), 1.25 (t, J = 7.5 Hz, 3H) 67 ##STR00237##
N-(6-(2-(((1r,4r)- 4- aminocyclohexyl) amino)-8- ethylquinazolin-
6-yl)-5- methylpyridazin- 3-yl)-2- chlorobenzene- sulfonamide M +
H.sup.+ = 552.1 (LCMS) .sup.1H NMR (400 MHz, METHANOL-d.sub.4)
.delta. 9.04 (s, 1H), 8.56 (br s, 1H), 8.22 (br d, J = 7.3 Hz, 1H),
7.75 (s, 1H), 7.68 (br s, 2H), 7.57-7.41 (m, 3H), 3.98 (br t, J =
11.0 Hz, 1H), 3.22- 3.01 (m, 3H), 2.41- 2.25 (m, 5H), 2.14 (br d, J
= 11.5 Hz, 2H), 1.70- 1.42 (m, 4H), 1.33 (br t, J = 7.5 Hz, 3H) 68
##STR00238## N-(5-(2-(((1r,4r)- 4- aminocyclohexyl)
amino)quinazolin- 6-yl)-4- methylpyrimidin- 2-yl)-2- chlorobenzene-
sulfonamide M + H.sup.+ = 524 .delta. = 9.04 (s, 1H), 8.50 (br s,
1H), 8.31 (dd, J = 1.3, 7.7 Hz, 1H), 8.22 (s, 1H), 7.71-7.61 (m,
2H), 7.60-7.47 (m, 4H), 4.03-3.90 (m, 1H), 3.15 (tt, J = 3.9, 11.6
Hz, 1H), 2.29 (s, 3H), 2.23 (br d, J = 11.5 Hz, 2H), 2.12 (br d, J
= 12.6 Hz, 2H), 1.66- 1.40 (m, 4H). 69 ##STR00239##
2-chloro-N-(4-(2- (((1r,4r)-4- (dimethylamino) cyclohexyl)amino)-
8- ethylquinazolin- 6-yl)-2- fluorophenyl) benzenesulfonamide M +
H.sup.+ = 582.2 (LCMS) .sup.1H NMR (400 MHz, METHANOL-d.sub.4)
.delta. 9.01 (s, 1H), 8.56 (br s, 1H), 8.03 (d, J = 7.7 Hz, 1H),
7.77 (br s, 2H), 7.66- 7.54 (m, 2H), 7.51- 7.34 (m, 4H), 3.98 (br
t, J = 11.6 Hz, 1H), 3.22- 3.02 (m, 3H), 2.82 (s, 6H), 2.39 (br d,
J = 12.0 Hz, 2H), 2.18 (br d, J = 12.1 Hz, 2H), 1.78- 1.63 (m, 2H),
1.57- 1.41 (m, 2H), 1.34 (t, J = 7.5 Hz, 2H) 70 ##STR00240##
N-(4-(2- (((1R,3R,4S)-4- amino-3- methylcyclohexyl) amino)-8-
ethylquinazolin- 6-yl)-2- fluorophenyl)-2- chlorobenzene-
sulfonamide M + H.sup.+ = 568.2 (LCMS) .sup.1H NMR (400 MHz,
METHANOL-d.sub.4) .delta. 9.04 (s, 1H), 8.55 (br s, 1H), 8.03 (dd,
J = 1.3, 7.9 Hz, 1H), 7.79 (s, 2H), 7.65-7.55 (m, 2H), 7.52-7.32
(m, 4H), 4.07 (ddd, J = 3.9, 7.6, 11.4 Hz, 1H), 3.46 (br s, 1H),
3.16-3.02 (m, 2H), 2.27-2.04 (m, 4H), 2.03-1.88 (m, 1H), 1.52-1.26
(m, 5H), 1.11 (d, J = 6.8 Hz, 3H) 71 ##STR00241##
N-(4-(2-(((1r,4r)- 4- aminocyclohexyl) amino)-8- ethylquinazolin-
6-yl)-2-fluoro-3- methylphenyl)-2- chlorobenzene- sulfonamide M +
H.sup.+ = 568.0 (LCMS) .sup.1H NMR (400 MHz, METHANOL-d.sub.4)
.delta. 8.98 (s, 1H), 8.53 (br s, 1H), 8.03 (dd, J = 1.2, 8.0 Hz,
1H), 7.66-7.53 (m, 2H), 7.49-7.39 (m, 3H), 7.28 (t, J = 8.2 Hz,
1H), 6.97 (d, J = 8.4 Hz, 1H), 4.04-3.91 (m, 1H), 3.23-3.12 (m,
1H), 3.06 (q, J = 7.5 Hz, 2H), 2.32 (br d, J = 11.9 Hz, 2H),
2.20-2.05 (m, 5H), 1.67-1.42 (m, 4H), 1.31 (t, J = 7.4 Hz, 3H). 72
##STR00242## N-(4-(2- (((1R,3S)-3- aminocyclohexyl) amino)-8-
ethylquinazolin- 6-yl)-2- fluorophenyl)-2- chlorobenzene-
sulfonamide M + H.sup.+ = 554.3 (LCMS) .sup.1H NMR (400 MHz,
METHANOL-d.sub.4) .delta. 9.00 (s, 1H), 8.55 (br s, 1H), 8.02 (dd,
J = 1.4, 8.0 Hz, 1H), 7.79-7.71 (m, 2H), 7.64-7.50 (m, 2H),
7.49-7.27 (m, 4H), 4.08 (ddd, J = 4.0, 7.7, 11.5 Hz, 1H), 3.23
(ddd, J = 3.9, 8.2, 11.8 Hz, 1H), 3.17-2.97 (m, 2H), 2.52 (br d, J
= 11.2 Hz, 1H), 2.27-1.88 (m, 3H), 1.66-1.46 (m, 1H), 1.43-1.26 (m,
6H) 73 ##STR00243## (S)-2-chloro-N- (4-(8-ethyl-2- (piperidin-3-
ylamino)quinazolin- 6-yl)-2- fluorophenyl) benzenesulfonamide M +
H.sup.+ = 540.2 (LCMS) .sup.1H NMR (400 MHz, METHANOL-d.sub.4)
.delta. 9.08 (s, 1H), 8.51 (br s, 1H), 8.01 (dd, J = 1.3, 7.9 Hz,
1H), 7.81 (s, 2H), 7.66-7.34 (m, 6H), 4.45-4.24 (m, 1H), 3.66 (br
dd, J = 3.3, 12.1 Hz, 1H), 3.20-2.97 (m, 4H), 2.24-2.06 (m, 2H),
1.97-1.76 (m, 2H), 1.34 (t, J = 7.5 Hz, 3H) 74 ##STR00244##
N-(4-(2- (((1R,3R,4R)-4- amino-3- methylcyclohexyl) amino)-8-
ethylquinazolin- 6-yl)-2- fluorophenyl)-2- chlorobenzene-
sulfonamide M + H.sup.+ = 568.2 (LCMS) .sup.1H NMR (400 MHz,
METHANOL-d.sub.4) .delta. 9.04 (s, 1H), 8.56 (br s, 1H), 8.09-7.99
(m, 1H), 7.80 (s, 2H), 7.66-7.54 (m, 2H), 7.54-7.38 (m, 4H), 4.05
(br t, J = 11.6 Hz, 1H), 3.17-3.04 (m, 2H), 2.83 (dt, J = 3.9, 10.9
Hz, 1H), 2.37- 2.25 (m, 2H), 2.16 (br dd, J = 3.5, 12.3 Hz, 1H),
1.76 (br s, 1H), 1.67-1.41 (m, 2H), 1.38-1.19 (m, 4H), 1.14 (d, J =
6.5 Hz, 3H). 75 ##STR00245## N-(4-(2- (((1R,3S)-3- aminocyclohexyl)
amino)quinazolin- 6-yl)-2- fluorophenyl)-2- chlorobenzene-
sulfonamide M + H.sup.+ = 526.1 (LCMS) .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. 9.08 (s, 1H), 8.22 (br s, 1H), 7.98-7.88 (m,
3H), 7.46-7.28 (m, 5H), 7.18-7.11 (m, 2H), 3.93 (brs, 1H), 2.27 (br
s, 1H), 1.91 (br s, 2H), 1.79 (br d, J = 12.8 Hz, 1H), 1.49-1.11
(m, 4H) 76 ##STR00246## (S)-2-chloro-N- (2-fluoro-4-(2-
(piperidin-3- ylamino)quinazolin- 6- yl)phenyl)benzene- sulfonamide
M + H.sup.+ = 512.1 (LCMS) .sup.1H NMR (400 MHz, METHANOL-d.sub.4)
.delta. 9.11 (s, 1H), 8.56 (br s, 1H), 8.06-7.91 (m, 3H), 7.62-7.52
(m, 3H), 7.50-7.44 (m, 1H), 7.44-7.38 (m, 3H), 4.42-4.24 (m, 1H),
3.60 (br dd, J = 3.1, 12.1 Hz, 1H), 3.30 (br s, 1H), 3.04-2.94 (m,
2H), 2.24-2.01 (m, 2H), 1.95-1.67 (m, 2H). 77 ##STR00247## N-(4-(2-
(((1R,3R)-3- aminocyclopentyl) amino)quinazolin- 6-yl)-2-
fluorophenyl)-2- chlorobenzene- sulfonamide M + H.sup.+ = 512.1
(LCMS) .sup.1H NMR (400 MHz, METHANOL-d.sub.4) .delta. 9.05 (s,
1H), 8.52 (br s, 1H), 8.00 (dd, J = 1.3, 7.9 Hz, 1H), 7.95-7.88 (m,
2H), 7.61-7.51 (m, 3H), 7.50-7.43 (m, 1H), 7.43-7.34 (m, 3H),
4.66-4.56 (m, 1H), 3.81 (quin, J = 6.9 Hz, 1H), 2.40-2.25 (m, 2H),
2.15 (t, J = 6.9 Hz, 2H), 1.84-1.66 (m, 2H). 78 ##STR00248##
N-(4-(2- (((1R,3R)-3- aminocyclopentyl) amino)-8- ethylquinazolin-
6-yl)-2- fluorophenyl)-2- chlorobenzene- sulfonamide M + H.sup.+ =
540.1 (LCMS) .sup.1H NMR (400 MHz, METHANOL-d.sub.4) .delta. 9.00
(s, 1H), 8.48 (br s, 1H), 8.00 (dd, J = 1.3, 7.9 Hz, 1H), 7.75 (s,
2H), 7.61-7.51 (m, 2H), 7.49-7.34 (m, 4H), 4.60 (quin, J = 6.6 Hz,
1H), 3.80 (quin, J = 7.1 Hz, 1H), 3.08 (q, J = 7.4 Hz, 2H),
2.41-2.28 (m, 2H), 2.27-2.12 (m, 2H), 1.88-1.67 (m, 2H), 1.32 (t, J
= 7.5 Hz, 3H) 79 ##STR00249## N-(4-(2- (((1R,3S)-3-
aminocyclopentyl) amino)-8- ethylquinazolin- 6-yl)-2-
fluorophenyl)-2- chlorobenzene- sulfonamide M + H.sup.+ = 540.1
(LCMS) .sup.1H NMR (400 MHz, METHANOL-d.sub.4) .delta. 9.05 (s,
1H), 8.56 (br s, 1H), 8.03 (d, J = 7.9 Hz, 1H), 7.83-7.78 (m, 2H),
7.66-7.53 (m, 2H), 7.52-7.37 (m, 4H), 4.48 (quin, J = 7.0 Hz, 1H),
3.72 (quin, J = 7.2 Hz, 1H), 3.11 (q, J = 7.4 Hz, 2H), 2.85-2.71
(m, 1H), 2.33-2.14 (m, 2H), 2.01-1.81 (m, 2H), 1.76-1.64 (m, 1H),
1.39-1.31 (m, 3H) 80 ##STR00250## N-(4-(2- (((1R,3S)-3-
aminocyclopentyl) amino)quinazolin- 6-yl)-2- fluorophenyl)-2-
chlorobenzene- sulfonamide M + H.sup.+ = 512.1 (LCMS) .sup.1H NMR
(400 MHz, METHANOL-d.sub.4) .delta. 9.11 (s, 1H), 8.54 (br s, 1H),
8.08-7.95 (m, 3H), 7.67-7.37 (m, 7H), 4.55-4.39 (m, 1H), 3.80-3.66
(m, 1H), 2.77-2.61 (m, 1H), 2.29-2.11 (m, 2H), 2.05-1.83 (m, 2H),
1.77-1.63 (m, 1H) 81 ##STR00251## N-(4-(2-((4- aminobicyclo[2.2.2]
octan-1- yl)amino)quinazolin- 6-yl)-2- fluorophenyl)-2-
chlorobenzene- sulfonamide M + H.sup.+ = 552.1 (LCMS) .sup.1H NMR
(400 MHz, METHANOL-d.sub.4) .delta. 9.02 (s, 1H), 8.44 (br s, 1H),
8.00 (d, J = 7.9 Hz, 1H), 7.93 (br s, 2H), 7.62- 7.52 (m, 3H),
7.51- 7.44 (m, 1H), 7.41 (br d, J = 8.2 Hz, 3H), 2.35- 2.27 (m,
6H), 1.99- 1.92 (m, 6H) 82 ##STR00252## N-(4-(2-(((2r,5r)- 5-
aminooctahydro- pentalen-2- yl)amino)-8- ethylquinazolin- 6-yl)-2-
fluorophenyl)-2- chlorobenzene- sulfonamide M + H.sup.+ = 580.1
(LCMS) .sup.1H NMR (400 MHz, METHANOL-d.sub.4) .delta. 8.91 (s,
1H), 8.40 (br s, 1H), 7.91 (dd, J = 1.3, 7.9 Hz, 1H), 7.68 (s, 2H),
7.54-7.44 (m, 2H), 7.41-7.25 (m, 4H), 4.50-4.41 (m, 2H), 3.00 (q, J
= 7.4 Hz, 2H), 2.68-2.55 (m, 2H), 2.36-2.22 (m, 2H), 1.97 (br dd, J
= 5.9, 12.5 Hz, 2H), 1.66 (td, J = 9.0, 12.5 Hz, 2H), 1.38- 1.21
(m, 5H) 83 ##STR00253## N-(4-(2-(((2r,5r)- 5- aminooctahydro-
pentalen-2- yl)amino)-8- ethylquinazolin- 6-yl)-2- fluorophenyl)-2-
chlorobenzene- sulfonamide M + H.sup.+ = 580.2 (LCMS) .sup.1H NMR
(400 MHz, METHANOL-d.sub.4) .delta. 8.99 (s, 1H), 8.54 (br s, 1H),
8.00 (d, J = 7.9 Hz, 1H), 7.76 (s, 2H), 7.62-7.52 (m, 2H),
7.49-7.36 (m, 4H), 4.38-4.17 (m, 1H), 3.83-3.66 (m, 1H), 3.13-3.00
(m, 2H), 2.73 (br s, 2H), 2.55-2.46 (m, 2H), 1.94 (br dd, J = 6.4,
12.5 Hz, 2H), 1.85-1.74 (m, 2H), 1.32 (t, J = 7.5 Hz, 3H),
1.28-1.21 (m, 2H) 84 ##STR00254## N-(4-(2-(((2s,5s)- 5-
aminooctahydro- pentalen-2- yl)amino)-8- ethylquinazolin- 6-yl)-2-
fluorophenyl)-2- chlorobenzene- sulfonamide M + H.sup.+ = 580.1
(LCMS) .sup.1H NMR (400 MHz, METHANOL-d.sub.4) .delta. 8.99 (s,
1H), 8.48 (br s, 1H), 8.00 (dd, J = 1.3, 7.9 Hz, 1H), 7.75 (s, 2H),
7.62-7.52 (m, 2H), 7.50-7.36 (m, 4H), 4.50-4.38 (m, 1H), 3.57-3.45
(m, 1H), 3.06 (q, J = 7.6 Hz, 2H), 2.67-2.57 (m, 2H), 2.52 (br dd,
J = 6.4, 12.5 Hz, 2H), 2.44-2.33 (m, 2H), 1.59-1.39 (m, 4H), 1.32
(t, J = 7.5 Hz, 3H) 85 ##STR00255## N-(4-(2-(((2s,5s)- 5-
aminooctahydro- pentalen-2- yl)amino)quinazolin- 6-yl)-2-
fluorophenyl)-2- chlorobenzene- sulfonamide M + H.sup.+ = 552.1
(LCMS) .sup.1H NMR (400 MHz, METHANOL-d.sub.4) .delta. 9.06 (s,
1H), 8.47 (br s, 1H), 8.06-7.89 (m, 3H), 7.64-7.53 (m, 3H),
7.52-7.36 (m, 4H), 4.52-4.38 (m, 1H), 3.60-3.44 (m, 1H), 2.72-2.53
(m, 2H), 2.53-2.31 (m, 4H), 1.55-1.37 (m, 4H).
86 ##STR00256## N-(4-(2-((4- aminobicyclo[2.2.1] heptan-1-
yl)amino)quinazolin- 6-yl)-2- fluorophenyl)-2- chlorobenzene-
sulfonamide M + H.sup.+ = 538.1 (LCMS) .sup.1H NMR (400 MHz,
METHANOL-d.sub.4) .delta. 9.06 (s, 1H), 8.59-8.47 (m, 1H),
8.08-7.87 (m, 3H), 7.63-7.34 (m, 7H), 2.48-2.28 (m, 4H), 2.06-1.85
(m, 6H) 87 ##STR00257## N-(4-(2-((4- aminobicyclo[2.2.2] octan-1-
yl)amino)-8- ethylquinazolin- 6-yl)-2- fluorophenyl)-2-
chlorobenzene- sulfonamide M + H.sup.+ = 580.2 (LCMS) .sup.1H NMR
(400 MHz, METHANOL-d.sub.4) .delta. 8.98 (s, 1H), 8.49 (br s, 1H),
8.02 (dd, J = 1.4, 7.9 Hz, 1H), 7.77 (dd, J = 1.9, 12.2 Hz, 2H),
7.63- 7.55 (m, 2H), 7.51- 7.38 (m, 4H), 3.10 (q, J = 7.5 Hz, 2H),
2.42- 2.32 (m, 6H), 2.04- 1.94 (m, 6H), 1.36 (t, J = 7.5 Hz, 3H) 88
##STR00258## 2-chloro-N-(4-(8- ethyl-2-(((1r,4r)- 4-(pyrrolidin-1-
yl)cyclohexyl)amino) quinazolin-6- yl)-2- fluorophenyl)
benzenesulfonamide M + H.sup.+ = 608.3 (LCMS) .sup.1H NMR (400 MHz,
METHANOL-d.sub.4) .delta. 9.02 (s, 1H), 8.57 (br s, 1H), 8.03 (d, J
= 7.9 Hz, 1H), 7.79 (s, 2H), 7.64-7.54 (m, 2H), 7.51-7.39 (m, 4H),
3.98 (br t, J = 11.4 Hz, 1H), 3.33-3.29 (m, 4H), 3.12-3.01 (m, 3H),
2.44-2.24 (m, 4H), 2.07 (br s, 4H), 1.73-1.59 (m, 2H), 1.54-1.42
(m, 2H), 1.35 (t, J = 7.5 Hz, 3H) 89 ##STR00259##
N-(5-(2-(((1r,4r)- 4- aminocyclohexyl) amino)quinazolin-
6-yl)-1,3,4- thiadiazol-2-yl)- 2- chlorobenzene- sulfonamide M +
H.sup.+ = 516.1 (LCMS) .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta.
9.13 (br s, 1H), 8.19 (s, 1H), 8.10 (br d, J = 9.3 Hz, 1H), 8.02
(d, J = 2.0 Hz, 1H), 7.96 (dd, J = 1.9, 7.6 Hz, 1H), 7.50-7.31 (m,
5H), 3.80 (br d, J = 12.1 Hz, 1H), 2.98 (br s, 1H), 2.05-1.90 (m,
4H), 1.48-1.27 (m, 4H). 90 ##STR00260## N-(4-(2-(((1r,4r)- 4-
aminocyclohexyl) amino)-7- methylquinazolin- 6-yl)-2-
4-fluorophenyl)-2- chlorobenzene- sulfonamide M + H.sup.+ = 540.3
(LCMS) .sup.1H NMR (400 MHz, METHANOL-d.sub.4) .delta. 8.95 (s,
1H), 8.07 (dd, J = 1.6, 7.8 Hz, 1H), 7.60- 7.47 (m, 3H), 7.43- 7.32
(m, 3H), 7.07- 6.94 (m, 2H), 4.00- 3.89 (m, 1H), 3.0 2.93 (m, 1H),
2.34 (s, 3H), 2.23-2.16 (m, 2H), 2.12-2.03 (m, 2H), 1.59-1.41 (m,
4H) 92 ##STR00261## N-(5-(2-(((1r,4r)- 4- aminocyclohexyl)
amino)-8- ethylquinazolin- 6-yl)-4- methoxypyridin- 2-yl)-2-
chlorobenzene- sulfonamide M + H.sup.+ = 567.1 (LCMS) .sup.1H NMR
(400 MHz, METHANOL-d.sub.4) .delta. 8.99 (s, 1H), 8.40 (br s, 1H),
8.31-8.21 (m, 1H), 7.84 (s, 1H), 7.66-7.45 (m, 5H), 6.83 (s, 1H),
4.03-3.92 (m, 1H), 3.88 (s, 3H), 3.23-3.12 (m, 1H), 3.05 (q, J =
7.4 Hz, 2H), 2.31 (br d, J = 12.3 Hz, 2H), 2.14 (br d, J = 12.1 Hz,
2H), 1.68- 1.42 (m, 4H), 1.31 (t, J = 7.5 Hz, 3H) 93 ##STR00262##
N-(6-(2-(((1r,4r)- 4- aminocyclohexyl) amino)-8- ethylquinazolin-
6-yl)-5- methoxypyridin- 3-yl)-2- chlorobenzene- sulfonamide M +
H.sup.+ = 567.2 (LCMS) .sup.1H NMR (400 MHz, METHANOL-d.sub.4)
.delta. 8.98 (s, 1H), 8.48 (br s, 1H), 8.20-8.12 (m, 1H), 8.06-7.91
(m, 3H), 7.64-7.54 (m, 2H), 7.49 (ddd, J = 2.6, 5.8, 8.0 Hz, 1H),
7.34 (d, J = 2.2 Hz, 1H), 4.02-3.92 (m, 1H), 3.84 (s, 3H),
3.24-3.12 (m, 1H), 3.05 (q, J = 7.6 Hz, 2H), 2.30 (br d, J = 11.0
Hz, 2H), 2.14 (br d, J = 11.9 Hz, 2H), 1.66-1.41 (m, 4H), 1.32 (t,
J = 7.4 Hz, 3H) 94 ##STR00263## N-(5-(2-(((1r,4r)- 4-
aminocyclohexyl) amino)-8- ethylquinazolin- 6-yl)-6-
methylpyrazin-2- yl)-2- chlorobenzene- sulfonamide M + H.sup.+ =
552.2 (LCMS) .sup.1H NMR (400 MHz, METHANOL-d.sub.4) .delta. 9.00
(s, 1H), 8.50 (br s, 1H), 8.30 (d, J = 7.3 Hz, 1H), 8.15 (s, 1H),
7.68 (s, 2H), 7.59-7.47 (m, 3H), 4.03-3.92 (m, 1H), 3.22-3.12 (m,
1H), 3.06 (q, J = 7.5 Hz, 2H), 2.37 (s, 3H), 2.30 (br d, J = 11.0
Hz, 2H), 2.14 (br d, J = 11.9 Hz, 2H), 1.66-1.42 (m, 4H), 1.31 (t,
J = 7.5 Hz, 3H)
Example 5: Synthesis of
N-(6-(2-(((1r,4r)-4-aminocyclohexyl)amino)-8-ethylquinazolin-6-yl)-5-ethy-
lpyridazin-3-yl)-2-chlorobenzenesulfonamide (96)
##STR00264##
[0325] Step 1
[0326] To a solution of 2-chlorobenzene-1-sulfonyl chloride (2.0 g,
9.5 mmol, 1.3 mL) in THF (20.0 mL) was added NH3.H2O (3.3 g, 28.4
mmol, 3.7 mL, 25% solution) at 0.degree. C. The mixture was stirred
at 0.degree. C. for 10 min and then warmed to 20.degree. C. for 2
h. The reaction mixture was concentrated to afford
2-chlorobenzenesulfonamide (1.8 g, 9.4 mmol, 99.1% yield). 1H NMR
(400 MHz, DMSO-d.sub.6) .delta. 7.96 (dd, J=1.4, 7.8 Hz, 1H),
7.65-7.55 (m, 2H), 7.54-7.34 (m, 7H).
Step 2
[0327] A mixture of 3,6-dichloro-4-ethylpyridazine (500 mg, 2.8
mmol), 2-chlorobenzenesulfonamide (595 mg, 3.1 mmol),
Cs.sub.2CO.sub.3 (2.7 g, 8.5 mmol),
dicyclohexyl-[2-(2,6-diisopropoxyphenyl)phenyl]phosphane (132 mg,
282.4 umol) and
[2-(2-aminoethyl)phenyl]-chloro-palladium;ditert-butyl-[2-(2,4,6-triisopr-
opylphenyl)phenyl]phosphane (194 mg, 282.4 umol) in THF (30.0 mL)
was degassed and purged with N.sub.2 for 3 times, and then the
mixture was stirred at 80.degree. C. for 12 h under N.sub.2
atmosphere. The reaction was concentrated to give a residue. The
residue was purified by column chromatography (SiO.sub.2) to give a
crude product (280 mg). The crude product was purified by prep-HPLC
(TFA condition) to afford
2-chloro-N-(6-chloro-5-ethylpyridazin-3-yl)benzenesulfonamide (20
mg, 54.2 umol, 1.9% yield). .sup.1H NMR (400 MHz, METHANOL-d.sub.4)
.delta. 8.20 (d, J=7.7 Hz, 1H), 7.64 (br s, 1H), 7.57-7.53 (m, 2H),
7.52-7.46 (m, 1H), 2.71 (q, J=7.5 Hz, 2H), 1.23 (t, J=7.4 Hz, 3H);
and 2-chloro-N-(6-chloro-4-ethylpyridazin-3-yl)benzenesulfonamide
(100 mg, 270.9 umol, 10.7% yield). .sup.1H NMR (400 MHz,
METHANOL-d.sub.4) .delta. 8.21 (d, J=7.6 Hz, 1H), 7.60-7.56 (m,
2H), 7.56-7.48 (m, 2H), 2.61 (br d, J=6.7 Hz, 2H), 1.18 (br t,
J=7.2 Hz, 3H).
Step 3
[0328] A mixture of
2-chloro-N-(6-chloro-4-ethylpyridazin-3-yl)benzenesulfonamide (54
mg, 161.1 umol), tert-butyl
((1r,4r)-4-((8-ethyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)quina-
zolin-2-yl)amino)cyclohexyl)carbamate (80 mg, 161.1 umol),
K.sub.3PO.sub.4 (0.5 M, 644.6 uL) and
[2-(2-aminophenyl)phenyl]-chloro-palladium;bis(1-adamantyl)-butyl-phospha-
ne (11 mg, 16.1 umol) were degassed and purged with N.sub.2 for 3
times and taken up into a microwave tube in 2-methyltetrahydrofuran
(2.5 mL). The sealed tube was heated at 120.degree. C. for 180 min
under microwave. The reaction was concentrated to give a residue.
The residue was purified by prep-TLC (SiO.sub.2) to give tert-butyl
((1r,4r)-4-((6-(6-((2-chlorophenyl)sulfonamido)-4-ethylpyridazin-3-yl)-8--
ethylquinazolin-2-yl)amino)cyclohexyl)carbamate (60 mg, crude).
M+H.sup.+=666.3 (LCMS).
Step 4
[0329] To a solution of tert-butyl
((1r,4r)-4-((6-(6-(2-chlorophenylsulfonamido)-4-ethylpyridazin-3-yl)-8-et-
hylquinazolin-2-yl)amino)cyclohexyl)carbamate (60 mg, 90.1 umol) in
DCM (2.0 mL) was added TFA (1.0 mL). The mixture was stirred at
20.degree. C. for 0.5 h. The reaction was concentrated to give a
residue. The residue was dissolved in MeOH (1.0 mL) and basified pH
to 7 with NH.sub.3.H.sub.2O (25% solution). The residue was
purified by prep-HPLC (FA condition) to afford
N-(6-(2-(((1r,4r)-4-aminocyclohexyl)amino)-8-ethylquinazolin-6-yl)-5-ethy-
lpyridazin-3-yl)-2-chlorobenzenesulfonamide (5.1 mg, 7.9 umol, 8.8%
yield, FA). M+H.sup.+=566.2 (LCMS); .sup.1H NMR (400 MHz,
METHANOL-d.sub.4) .delta. 9.08 (br s, 1H), 8.23 (br s, 1H),
8.03-7.38 (m, 7H), 3.99 (br s, 1H), 3.23-3.01 (m, 3H), 2.67 (br s,
2H), 2.31 (br d, J=10.1 Hz, 2H), 2.14 (br d, J=11.0 Hz, 2H),
1.66-1.44 (m, 4H), 1.33 (br t, J=7.4 Hz, 3H), 1.10 (br t, J=7.1 Hz,
3H).
Example 6: Synthesis of
N-(6-(2-(((1r,4r)-4-aminocyclohexyl)amino)-8-ethylquinazolin-6-yl)-4-ethy-
lpyridazin-3-yl)-2-chlorobenzenesulfonamide (100)
##STR00265##
[0331] The title compound was synthesized according to the
synthetic procedure reported for the preparation of compound
N-(6-(2-(((1r,4r)-4-aminocyclohexyl)amino)-8-ethylquinazolin-6-yl)-5-ethy-
lpyridazin-3-yl)-2-chlorobenzenesulfonamide. (13.7 mg, 22.4 umol,
21.3% yield, FA). M+H.sup.+=566.2 (LCMS); .sup.1H NMR (400 MHz,
METHANOL-d.sub.4) .delta. 9.06 (s, 1H), 8.57 (br s, 1H), 8.29-8.19
(m, 2H), 8.16 (d, J=2.0 Hz, 1H), 8.05 (s, 1H), 7.59-7.46 (m, 3H),
4.05-3.94 (m, 1H), 3.24-3.14 (m, 1H), 3.09 (q, J=7.5 Hz, 2H), 2.71
(q, J=7.4 Hz, 2H), 2.32 (br d, J=11.4 Hz, 2H), 2.16 (br d, J=11.1
Hz, 2H), 1.69-1.44 (m, 4H), 1.36 (t, J=7.5 Hz, 3H), 1.26 (t, J=7.5
Hz, 3H).
Example 7: Synthesis of
N-(5-(2-(((1r,4r)-4-aminocyclohexyl)amino)-8-ethylquinazolin-6-yl)-6-meth-
oxypyrazin-2-yl)-2-chlorobenzenesulfonamide (98)
##STR00266##
[0332] Step 1
[0333] To a solution of 6-methoxypyrazin-2-amine (100 mg, 799.2
umol) in CHCl.sub.3 (5.0 mL) was added NCS (107 mg, 799.2 umol).
The mixture was stirred at 40.degree. C. for 12 h. The reaction was
concentrated to give a residue. The residue was purified by
prep-TLC (SiO.sub.2) to give 5-chloro-6-methoxypyrazin-2-amine (25
mg, 141.0 umol, 17.6% yield). .sup.1H NMR (400 MHz, CHLOROFORM-d)
.delta. 7.33 (s, 1H), 4.42 (br s, 2H), 3.96 (s, 3H).
Step 2
[0334] To a solution of 5-chloro-6-methoxypyrazin-2-amine (25 mg,
156.7 umol) in DCM (2.0 mL) was added pyridine (37 mg, 470.0 umol,
37.9 uL) and 2-chlorobenzenesulfonyl chloride (50 mg, 235.0 umol,
32.0 uL). The mixture was stirred at 45.degree. C. for 12 h. The
reaction was concentrated to give a residue. The residue was
purified by column chromatography (SiO.sub.2) to afford
2-chloro-N-(5-chloro-6-methoxypyrazin-2-yl)benzenesulfonamide (110
mg). M+H.sup.+=333.8 (LCMS).
Step 3
[0335] A mixture of tert-butyl
((1r,4r)-4-((8-ethyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)quina-
zolin-2-yl)amino)cyclohexyl)carbamate (80 mg, 161.1 umol),
2-chloro-N-(5-chloro-6-methoxypyrazin-2-yl)benzenesulfonamide (54
mg, 161.1 umol), K.sub.3PO.sub.4 (0.5 M, 644.6 uL),
[2-(2-aminophenyl)phenyl]-chloro-palladium;bis(1-adamantyl)-butyl-phospha-
ne (11 mg, 16.1 umol) in THF (2.0 mL) was degassed and purged with
N.sub.2 for 3 times, and then the mixture was stirred at 80.degree.
C. for 12 h under N.sub.2 atmosphere. The reaction was concentrated
to give a residue. The residue was purified by prep-TLC (SiO.sub.2)
to give tert-butyl
((1r,4r)-4-((6-(5-(2-chlorophenylsulfonamido)-3-methoxypyrazin-2-yl)-8-et-
hylquinazolin-2-yl)amino)cyclohexyl)carbamate (50 mg, 17.6 umol,
10.9% yield). M+H.sup.+=668.1 (LCMS).
Step 4
[0336] To a solution of tert-butyl
((1r,4r)-4-((6-(5-(2-chlorophenylsulfonamido)-3-methoxypyrazin-2-yl)-8-et-
hylquinazolin-2-yl)amino)cyclohexyl)carbamate (50 mg, 74.8 umol) in
DCM (2.0 mL) was added TFA (1.0 mL). The mixture was stirred at
20.degree. C. for 10 min. The reaction was concentrated to give a
residue. The residue was dissolved in MeOH (1.0 mL) and basified pH
to 7 with NH.sub.3.H.sub.2O (25% solution). The residue was
purified by prep-HPLC (FA condition) to afford
N-(5-(2-(((1r,4r)-4-aminocyclohexyl)amino)-8-ethylquinazolin-6-yl)-6-meth-
oxypyrazin-2-yl)-2-chlorobenzenesulfonamide (6.4 mg, 10.1 umol,
13.6% yield, FA). M+H.sup.+=568.2 (LCMS); .sup.1H NMR (400 MHz,
METHANOL-d.sub.4) .delta. 8.97 (s, 1H), 8.48 (br s, 1H), 8.33 (d,
J=7.3 Hz, 1H), 8.13 (br d, J=3.7 Hz, 2H), 7.87 (s, 1H), 7.64-7.44
(m, 3H), 3.96 (br t, J=11.4 Hz, 1H), 3.74 (s, 3H), 3.23-3.10 (m,
1H), 3.04 (q, J=7.4 Hz, 2H), 2.30 (br d, J=12.3 Hz, 2H), 2.13 (br
d, J=11.2 Hz, 2H), 1.65-1.41 (m, 4H), 1.31 (t, J=7.5 Hz, 3H).
Example 8: Synthesis of
2-chloro-N-(5-(8-ethyl-2-(((1r,4r)-4-hydroxycyclohexyl)amino)quinazolin-6-
-yl)-6-methoxypyridin-2-yl)benzenesulfonamide (101)
##STR00267##
[0337] Step 1
[0338] To a solution of 6-bromo-8-ethyl-2-iodoquinazoline (0.18 g,
495.8 umol) in n-BuOH (10.0 mL) was added 4-aminocyclohexanol (114
mg, 991.7 umol) and DIEA (192 mg, 1.4 mmol, 259.1 uL). The mixture
was stirred at 100.degree. C. for 12 h. The mixture was
concentrated to get crude residue. The residue was purified by
column chromatography (SiO.sub.2) to afford
(1r,4r)-4-((6-bromo-8-ethylquinazolin-2-yl)amino)cyclohexanol (160
mg, 381.8 umol, 77.0% yield).
[0339] M+H.sup.+=352.1 (LCMS).
Step 2
[0340] To a solution of
2-chloro-N-(6-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyri-
din-2-yl)benzenesulfonamide (145 mg, 342.6 umol) and
K.sub.2CO.sub.3 (71 mg, 513.9 umol) in dioxane (2.0 mL) and
H.sub.2O (0.2 mL) were added
(1r,4r)-4-((6-bromo-8-ethylquinazolin-2-yl)amino)cyclohexanol (60
mg, 171.3 umol) and Pd(dppf)Cl.sub.2 (12 mg, 17.1 umol). The
mixture was stirred at 90.degree. C. for 12 h under N.sub.2. The
mixture was concentrated to get crude residue. The residue was
purified by prep-TLC (SiO.sub.2). The residue was purified by
prep-HPLC (FA condition) to afford
2-chloro-N-(5-(8-ethyl-2-(((1r,4r)-4-hydroxycyclohexyl)amino)quina-
zolin-6-yl)-6-methoxypyridin-2-yl)benzenesulfonamide (24.0 mg, 38.7
umol, 22.6% yield, FA) as. M+H.sup.+=568.1 (LCMS); .sup.1H NMR
(METHANOL-d.sub.4, 400 MHz) 8.92 (s, 1H), 8.34-8.26 (m, 1H),
7.67-7.61 (m, 3H), 7.61-7.55 (m, 2H), 7.54-7.48 (m, 1H), 6.64 (d,
J=7.9 Hz, 1H), 3.99-3.85 (m, 1H), 3.71-3.56 (m, 4H), 3.03 (q, J=7.5
Hz, 2H), 2.18 (br d, J=9.3 Hz, 2H), 2.02 (br d, J=9.8 Hz, 2H),
1.51-1.34 (m, 4H), 1.30 (t, J=7.5 Hz, 3H).
Example 9: Synthesis of
N-(5-(2-(((1r,4r)-4-aminocyclohexyl)amino)-8-ethylquinazolin-6-yl)-6-meth-
oxypyridin-2-yl)-2-methylbenzenesulfonamide (103)
##STR00268##
[0341] Step 1
[0342] To a solution of 5-bromo-6-methoxypyridin-2-amine (50 mg,
246.2 umol) and 2-methylbenzene-1-sulfonyl chloride (70.4 mg, 369.3
umol, 53.3 uL) in DCM (3.0 mL) was added pyridine (58.4 mg, 738.7
umol, 59.6 uL), the mixture was stirred at 45.degree. C. for 12 h.
The reaction mixture was concentrated under reduced pressure to
give a residue. The residue was purified by prep-TLC (SiO.sub.2) to
give N-(5-bromo-6-methoxypyridin-2-yl)-2-methylbenzenesulfonamide
(80 mg, 208.2 umol, 84.5% yield). M+H.sup.+=359.1 (LCMS).
Step 2
[0343] A mixture of
N-(5-bromo-6-methoxypyridin-2-yl)-2-methylbenzenesulfonamide (29
mg, 83.9 umol), tert-butyl
((1r,4r)-4-((8-ethyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)quina-
zolin-2-yl)amino)cyclohexyl)carbamate (50 mg, 100.7 umol),
K.sub.2CO.sub.3 (34 mg, 251.7 umol), and Pd(dppf)Cl.sub.2 (6 mg,
8.3 umol) in dioxane (2.0 mL) and H.sub.2O (0.2 mL) was degassed
and purged with N.sub.2 for 3 times, and then the mixture was
stirred at 90.degree. C. for 12 h under N.sub.2 atmosphere. The
reaction mixture was concentrated under reduced pressure to give a
residue.
[0344] The residue was purified by prep-TLC (SiO.sub.2) to give
tert-butyl
((1r,4r)-4-((8-ethyl-6-(2-methoxy-6-(2-methylphenylsulfonamido)pyridin-3--
yl)quinazolin-2-yl)amino)cyclohexyl)carbamate (30 mg, 36.5 umol,
43.4% yield). M+H.sup.+=647.4 (LCMS).
Step 3
[0345] To a solution of tert-butyl
((1r,4r)-4-((8-ethyl-6-(2-methoxy-6-(2-methylphenylsulfonamido)pyridin-3--
yl)quinazolin-2-yl)amino)cyclohexyl)carbamate (30 mg, 46.3 umol) in
TFA (1.0 mL) and DCM (2.0 mL) was stirred at 20.degree. C. for 0.5
h. The mixture was concentrated under reduced pressure to give a
residue. The residue was dissolved in MeOH (2.0 mL) and basified pH
to 8 with NH.sub.3.H.sub.2O (25% solution), concentrated to give a
residue. The residue was purified by pre-HPLC (FA condition) to
afford
N-(5-(2-(((1r,4r)-4-aminocyclohexyl)amino)-8-ethylquinazolin-6-yl)-6-meth-
oxypyridin-2-yl)-2-methylbenzenesulfonamide (21.3 mg, 35.5 umol,
76.7% yield, FA). M+H.sup.+=547.3 (LCMS); .sup.1H NMR (400 MHz,
METHANOL-d.sub.4) .delta. 8.94 (s, 1H), 8.54 (br s, 1H), 8.16 (d,
J=7.5 Hz, 1H), 7.69-7.59 (m, 3H), 7.53-7.46 (m, 1H), 7.41-7.32 (m,
2H), 6.64 (d, J=7.9 Hz, 1H), 4.02-3.90 (m, 1H), 3.71 (s, 3H),
3.22-3.11 (m, 1H), 3.03 (q, J=7.5 Hz, 2H), 2.70 (s, 3H), 2.30 (br
d, J=11.0 Hz, 2H), 2.14 (br d, J=11.7 Hz, 2H), 1.67-1.40 (m, 4H),
1.30 (t, J=7.5 Hz, 3H).
Example 10: Synthesis of
N-(5-(2-(((1r,4r)-4-aminocyclohexyl)amino)-8-ethylquinazolin-6-yl)-6-meth-
ylpyridin-2-yl)-2-methylbenzenesulfonamide (112)
##STR00269##
[0347] The title compound was synthesized according to the
synthetic procedure reported for the preparation of
N-(5-(2-(((1r,4r)-4-aminocyclohexyl)amino)-8-ethylquinazolin-6-yl)-6-meth-
oxypyridin-2-yl)-2-methylbenzenesulfonamide (18.1 mg, 22.0% yield,
FA). M+H.sup.+=531.2 (LCMS); .sup.1H NMR (400 MHz,
METHANOL-d.sub.4) .delta. 8.99 (s, 1H), 8.55 (br s, 1H), 8.09 (d,
J=7.5 Hz, 1H), 7.62 (d, J=8.8 Hz, 1H), 7.52-7.39 (m, 3H), 7.37-7.30
(m, 2H), 7.15 (d, J=8.8 Hz, 1H), 4.04-3.92 (m, 1H), 3.22-3.12 (m,
1H), 3.06 (q, J=7.4 Hz, 2H), 2.72 (s, 3H), 2.43-2.26 (m, 5H), 2.14
(br d, J=11.9 Hz, 2H), 1.68-1.42 (m, 4H), 1.32 (t, J=7.5 Hz,
3H).
Example 11: Synthesis of
N-(5-(2-(((1r,4r)-4-aminocyclohexyl)amino)-7-methylquinazolin-6-yl)-6-met-
hoxypyridin-2-yl)-2-cyanobenzenesulfonamide (102)
##STR00270##
[0349] The title compound was synthesized according to the
synthetic procedure reported for the preparation of
N-(5-(2-(((1r,4r)-4-aminocyclohexyl)amino)-8-ethylquinazolin-6-yl)-6-meth-
oxypyridin-2-yl)-2-methylbenzenesulfonamide (5.6 mg, 9.4 umol,
15.1% yield, FA). M+H.sup.+=544.3 (LCMS); .sup.1H NMR (400 MHz,
METHANOL-d.sub.4) .delta. 8.92 (s, 1H), 8.51 (br s, 1H), 8.34 (d,
J=7.7 Hz, 1H), 7.97 (d, J=7.7 Hz, 1H), 7.91-7.73 (m, 2H), 7.49-7.33
(m, 3H), 6.67 (d, J=7.9 Hz, 1H), 4.00-3.89 (m, 1H), 3.50 (s, 3H),
3.21-3.09 (m, 1H), 2.28-2.07 (m, 7H), 1.68-1.39 (m, 4H).
Example 12: Synthesis of
N-(5-(2-(((1r,4r)-4-aminocyclohexyl)amino)-8-ethylquinazolin-6-yl)-6-(tri-
fluoromethoxy)pyridin-2-yl)-2-chlorobenzenesulfonamide (107)
##STR00271##
[0350] Step 1
[0351] To a solution of LDA (2 M, 2.5 mL) in THF (27.0 mL) was
added dropwise a solution of 2-chloro-6-(trifluoromethoxy)pyridine
(900 mg, 4.6 mmol) in THF (9.0 mL) at -78.degree. C. under N.sub.2.
The mixture was stirred at -78.degree. C. for 2 h. A solution of
I.sub.2 (1.3 g, 5.0 mmol, 1.0 mL) in THF (9.0 mL) was added at
-78.degree. C. Then the mixture was slowly warmed to 25.degree. C.
and stirred for 12 h. The reaction was quenched with saturated
NH.sub.4Cl (15.0 mL) and extracted with ethyl acetate (15.0
mL.times.3). The combined organic phase was washed with brine (15
mL.times.3), dried over anhydrous Na.sub.2SO.sub.4, filtered and
concentrated to give a residue. The residue was purified by
prep-TLC (SiO.sub.2) to give
6-chloro-3-iodo-2-(trifluoromethoxy)pyridine (1.2 g, 3.0 mmol,
65.2% yield). .sup.1H NMR (400 MHz, CHLOROFORM-d) .delta. 8.10 (d,
J=8.1 Hz, 1H), 7.03 (d, J=8.1 Hz, 1H).
Step 2
[0352] A mixture of 6-chloro-3-iodo-2-(trifluoromethoxy)pyridine
(63 mg, 193.4 umol), tert-butyl
((1r,4r)-4-((8-ethyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)quina-
zolin-2-yl)amino)cyclohexyl)carbamate (80 mg, 161.1 umol),
K.sub.2CO.sub.3 (34 mg, 241.7 umol) and Pd(dppf)Cl.sub.2 (12 mg,
16.1 umol) in dioxane (2.0 mL) and H.sub.2O (0.2 mL) was degassed
and purged with N.sub.2 for 3 times, and then the mixture was
stirred at 80.degree. C. for 12 h under N.sub.2 atmosphere. The
reaction was concentrated to give a residue. The residue was
purified by prep-TLC (SiO.sub.2) to afford tert-butyl
((1r,4r)-4-((6-(6-chloro-2-(trifluoromethoxy)pyridin-3-yl)-8-ethylquinazo-
lin-2-yl)amino)cyclohexyl)carbamate (90 mg, 96.8 umol, 60.1%
yield). M+H.sup.+=566.1 (LCMS).
Step 3
[0353] A mixture of tert-butyl
((1r,4r)-4-((6-(6-chloro-2-(trifluoromethoxy)pyridin-3-yl)-8-ethylquinazo-
lin-2-yl)amino)cyclohexyl)carbamate (90 mg, 159.0 umol),
2-chlorobenzenesulfonamide (34 mg, 174.9 umol), Cs.sub.2CO.sub.3
(155 mg, 477.0 umol),
dicyclohexyl-[2-(2,6-diisopropoxyphenyl)phenyl]phosphane (8 mg,
15.9 umol) and
[2-(2-aminoethyl)phenyl]-chloro-palladium;ditert-butyl-[2-(2,4,6-triisopr-
opylphenyl) phenyl]phosphane (11 mg, 15.9 umol) in THF (5.0 mL) was
degassed and purged with N.sub.2 for 3 times, and then the mixture
was stirred at 80.degree. C. for 12 h under N.sub.2 atmosphere. The
reaction was concentrated to give a residue. The residue was
purified by prep-TLC (SiO.sub.2) to give tert-butyl
((1r,4r)-4-((6-(6-(2-chlorophenylsulfonamido)-2-(trifluoromethoxy)pyridin-
-3-yl)-8-ethylquinazolin-2-yl)amino)cyclohexyl)carbamate (80 mg,
33.3 umol, 20.9% yield). M+H.sup.+=721.3 (LCMS).
Step 4
[0354] To a solution of tert-butyl
((1r,4r)-4-((6-(6-(2-chlorophenylsulfonamido)-2-(trifluoromethoxy)pyridin-
-3-yl)-8-ethylquinazolin-2-yl)amino)cyclohexyl)carbamate (80 mg,
110.9 umol) in DCM (2.0 mL) was added TFA (1.0 mL). The mixture was
stirred at 20.degree. C. for 15 min. The reaction was concentrated
to give a residue. The residue was dissolved in MeOH (2.0 mL) and
basified pH to 7 with NH.sub.3.H.sub.2O (25% solution). The residue
was purified by prep-HPLC (FA condition) to afford
N-(5-(2-(((1r,4r)-4-aminocyclohexyl)amino)-8-ethylquinazolin-6-yl)-6-(tri-
fluoromethoxy)pyridin-2-yl)-2-chlorobenzenesulfonamide (14 mg, 20.6
umol, 18.6% yield, FA). M+H.sup.+=621.2 (LCMS); .sup.1H NMR (400
MHz, METHANOL-d.sub.4) .delta. 8.99 (s, 1H), 8.50 (br s, 1H),
8.33-8.24 (m, 1H), 7.88 (d, J=8.2 Hz, 1H), 7.64-7.47 (m, 5H), 7.04
(d, J=8.2 Hz, 1H), 3.99 (tt, J=3.9, 11.2 Hz, 1H), 3.19 (tt, J=3.9,
11.5 Hz, 1H), 3.06 (q, J=7.5 Hz, 2H), 2.32 (br d, J=11.6 Hz, 2H),
2.16 (br d, J=11.9 Hz, 2H), 1.68-1.42 (m, 4H), 1.32 (t, J=7.5 Hz,
3H).
Example 13: Synthesis of
N-(5-(2-(((1r,4r)-4-aminocyclohexyl)amino)-8-ethylquinazolin-6-yl)-6-meth-
oxypyridin-2-yl)-2-methoxybenzenesulfonamide (109)
##STR00272##
[0355] Step 1
[0356] To a solution of 5-bromo-6-chloro-pyridin-2-amine (500 mg,
2.41 mmol) in THF (8.0 mL) was added NaH (144 mg, 3.6 mmol, 60%)
stirred for 30 min, then 2-methoxybenzenesulfonyl chloride (498 mg,
2.4 mmol) in THF (2.0 mL) was added. The mixture was stirred at
25.degree. C. for 2 h. The reaction mixture was quenched by
addition saturated ammonium chloride solution (10.0 mL), and then
added H2O (10.0 mL) and extracted with ethyl acetate (30.0
mL.times.3). The combined organic layers were washed with brine
(30.0 mL), dried over Na.sub.2SO.sub.4, filtered and concentrated
under reduced pressure to give a residue. The residue was purified
by column chromatography (SiO.sub.2) to afford
N-(5-bromo-6-chloropyridin-2-yl)-2-methoxybenzenesulfonamide (200
mg, 490.4 umol, 20.3% yield). M+H.sup.+=379.0 (LCMS).
Step 2
[0357] A solution of
N-(5-bromo-6-chloropyridin-2-yl)-2-methoxybenzenesulfonamide (200
mg, 529.6 umol) in NaOMe (5 mL, 30% solution) was stirred at
70.degree. C. for 3 h. The reaction mixture was added H.sub.2O
(30.0 mL) and extracted with ethyl acetate (20.0 mL.times.3). The
combined organic phase was washed with brine (10.0 mL.times.3),
dried with anhydrous Na.sub.2SO.sub.4, filtered and concentrated in
vacuum to give a residue. The residue was purified by prep-TLC
(SiO.sub.2) to afford
N-(5-bromo-6-methoxypyridin-2-yl)-2-methoxybenzenesulfonamide (100
mg, 219.7 umol, 41.4% yield). M+H.sup.+=372.9 (LCMS).
Step 3
[0358] A mixture of
N-(5-bromo-6-methoxypyridin-2-yl)-2-methoxybenzenesulfonamide (100
mg, 267.9 umol), tert-butyl
((1r,4r)-4-((8-ethyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)quina-
zolin-2-yl)amino)cyclohexyl)carbamate (159 mg, 321.5 umol),
K.sub.2CO.sub.3 (111 mg, 803.8 umol), Pd(dppf)Cl.sub.2 (19 mg,
26.79 umol) in dioxane (2.0 mL) and H.sub.2O (0.2 mL) was degassed
and purged with N.sub.2 for 3 times, and then the mixture was
stirred at 90.degree. C. for 12 h under N.sub.2 atmosphere. The
reaction mixture was concentrated under reduced pressure. The
residue was purified by prep-TLC (SiO.sub.2) to afford tert-butyl
((1r,4r)-4-((8-ethyl-6-(2-methoxy-6-(2-methoxyphenyl
sulfonamido)pyridin-3-yl)quinazolin-2-yl)amino)cyclohexyl)carbamate
(160 mg, 91.4 umol, 34.1% yield). M+H.sup.+=663.4 (LCMS).
Step 4
[0359] To a solution of tert-butyl
((1r,4r)-4-((8-ethyl-6-(2-methoxy-6-(2-methoxyphenyl
sulfonamido)pyridin-3-yl)quinazolin-2-yl)amino)cyclohexyl)carbamate
(160 mg, 241.4 umol) in DCM (2.0 mL) was added TFA (1.5 g, 13.5
mmol, 1 mL). The mixture was stirred at 25.degree. C. for 0.5 h.
The reaction mixture was concentrated under reduced pressure. The
residue was diluted with MeOH, (2.0 mL), then used the ammonium
hydroxide (25% solution) to adjust the pH to 7-8, then filtered.
The mixture was purified by prep-HPLC (FA condition) to afford
N-(5-(2-(((1r,4r)-4-aminocyclohexyl)amino)-8-ethylquinazolin-6-yl)-6-meth-
oxypyridin-2-yl)-2-methoxybenzenesulfonamide (14.7 mg, 23.9 umol,
9.9% yield, FA). M+H.sup.+=563.2 (LCMS); .sup.1H NMR
(METHANOL-d.sub.4, 400 MHz) .delta. 8.96 (s, 1H), 8.57 (br s, 1H),
8.04 (dd, J=1.5, 7.8 Hz, 1H), 7.76-7.54 (m, 4H), 7.28-7.01 (m, 2H),
6.72 (d, J=7.9 Hz, 1H), 3.96 (s, 4H), 3.76 (s, 3H), 3.18 (br t,
J=11.3 Hz, 1H), 3.04 (q, J=7.5 Hz, 2H), 2.32 (br d, J=11.5 Hz, 2H),
2.16 (br d, J=10.9 Hz, 2H), 1.69-1.41 (m, 4H), 1.32 (t, J=7.5 Hz,
3H).
Example 14: Synthesis of
N-(5-(2-(((1r,4r)-4-aminocyclohexyl)amino)-8-ethylquinazolin-6-yl)-6-meth-
ylpyridin-2-yl)-3-methylbenzenesulfonamide (113)
##STR00273##
[0361] The title compound was synthesized according to the
synthetic procedure reported for the preparation of
N-(5-(2-(((1r,4r)-4-aminocyclohexyl)amino)-8-ethylquinazolin-6-yl)-6-meth-
oxypyridin-2-yl)-2-methoxybenzenesulfonamide. 16.4 mg, 22.3% yield.
M+H.sup.+=531.3 (LCMS); .sup.1HNMR (DMSO-d.sub.6, 400 MHz) .delta.
9.02 (br s, 1H), 7.70-7.60 (m, 2H), 7.47 (br d, J=8.6 Hz, 2H),
7.39-7.27 (m, 4H), 6.80 (br d, J=8.6 Hz, 1H), 6.62 (br d, J=6.6 Hz,
1H), 6.06 (br s, 1H), 3.77 (s, 1H), 3.23 (s, 1H), 2.95 (q, J=7.4
Hz, 2H), 2.34 (s, 3H), 2.29-2.21 (m, 3H), 2.03 (brs, 2H), 1.85 (br
s, 2H), 1.41-1.28 (m, 4H), 1.24 (br t, J=7.4 Hz, 3H).
Example 15: Synthesis of
N-(5-(2-(((1r,4r)-4-aminocyclohexyl)amino)-7-ethylquinazolin-6-yl)-6-meth-
oxypyridin-2-yl)-2-chlorobenzenesulfonamide (110)
##STR00274##
[0362] Step 1
[0363] To a solution of 1-(2-bromo-5-fluoro-phenyl)ethanone (9.2 g,
42.3 mmol) in MeOH (92.0 mL) was cooled to 0.degree. C. and added
NaBH.sub.4 (2.2 g, 59.3 mmol). The mixture was stirred at
25.degree. C. for 1 h. The reaction mixture was concentrated under
reduced pressure to give a residue. The residue was diluted with
saturated NaHCO.sub.3 solution (100.0 mL) and the mixture was
extracted with ethyl acetate (100.0 mL.times.3). The combined
organic layers were washed with brine (50.0 mL.times.3), dried over
Na.sub.2SO.sub.4, filtered and concentrated to afford
1-(2-bromo-5-fluorophenyl)ethanol (9 g, crude).
Step 2
[0364] To a solution of 1-(2-bromo-5-fluorophenyl)ethanol (9 g,
41.0 mmol) and Et.sub.3SiH (9.5 g, 82.1 mmol, 13.1 mL) in DCM
(100.0 mL) was added BF.sub.3.Et.sub.2O (11.6 g, 82.1 mmol, 10.1
mL) at 0.degree. C. The mixture was stirred at 35.degree. C. for 36
h. The mixture was quenched by addition Sat.NaHCO.sub.3 (100.0 mL)
at 0.degree. C., extracted with DCM (100.0 mL.times.3). The
combined organic layers were washed with brine (50.0 mL.times.3),
dried over Na.sub.2SO.sub.4, filtered and concentrated under
reduced pressure to give a residue. The residue was purified by
column chromatography (SiO.sub.2) to afford
1-bromo-2-ethyl-4-fluorobenzene (6.3 g, 24.8 mmol, crude). .sup.1H
NMR (CHLOROFORM-d, 400 MHz): .delta. 7.53-7.43 (m, 1H), 6.97 (dd,
J=2.9, 9.5 Hz, 1H), 6.79 (dt, J=3.0, 8.3 Hz, 1H), 2.74 (q, J=7.5
Hz, 2H), 1.34-1.16 (m, 6H).
Step 3
[0365] To a solution of 1-bromo-2-ethyl-4-fluorobenzene (2.0 g, 9.8
mmol) in THF (35.0 mL) was added LDA (2 M, 5.9 mL) at -78.degree.
C. The mixture was stirred at -78.degree. C. for 1 h. And then DMF
(935 mg, 12.8 mmol, 985.1 uL) was added at -78.degree. C. for 1 h.
The reaction mixture was diluted with NH.sub.4Cl (30.0 mL) and
extracted with ethyl acetate (10.0 mL.times.3). The combined
organic layers were washed with brine (10.0 mL.times.3), dried over
Na.sub.2SO.sub.4, filtered and concentrated under reduced pressure
to give a residue. The residue was purified by column
chromatography (SiO.sub.2) to afford
5-bromo-4-ethyl-2-fluorobenzaldehyde (1.0 g, 3.4 mmol, 35.1%
yield). .sup.1H NMR (CHLOROFORM-d, 400 MHz): .delta. 10.25 (s, 1H),
8.02 (d, J=7.0 Hz, 1H), 7.08 (d, J=11.0 Hz, 1H), 2.80 (q, J=7.5 Hz,
2H), 1.27 (t, J=7.5 Hz, 3H).
Step 4
[0366] To a solution of guanidine (262 mg, 2.1 mmol,
H.sub.2CO.sub.3) and DIEA (839 mg, 6.4 mmol, 1.1 mL) in DMA (10.0
mL) was added a solution of 5-bromo-4-ethyl-2-fluorobenzaldehyde
(0.5 g, 2.1 mmol) in DMA (1.5 mL). Then the mixture was stirred at
160.degree. C. for 2 h. The mixture was concentrated to get crude
residue and then H.sub.2O (30.0 mL) was added. It was extracted
with ethyl acetate (30.0 mL.times.3). The combined organic layers
were washed with brine (20.0 mL.times.3), dried over
Na.sub.2SO.sub.4, filtered and concentrated under reduced pressure
to give a residue. The residue was purified by column
chromatography (SiO.sub.2) to afford
6-bromo-7-ethylquinazolin-2-amine (130 mg, 217.2 umol, 10.0%
yield). M+H.sup.+=251.9 (LCMS).
Step 5
[0367] To a solution of 6-bromo-7-ethylquinazolin-2-amine (130 mg,
515.6 umol) and diiodomethane (690 mg, 2.5 mmol, 207.9 uL) in THF
(2.0 mL) was added CuI (98 mg, 515.6 umol) isopentyl nitrite (181
mg, 1.5 mmol, 208.3 uL). The mixture was stirred at 65.degree. C.
for 12 h. The mixture was poured into NH.sub.3.H.sub.2O (2.0 mL,
25%) and filtered. The filtrate was extracted with ethyl acetate
(5.0 mL.times.3). The combined organic layers were washed with
brine (5.0 mL.times.3), dried over Na.sub.2SO.sub.4, filtered and
concentrated under reduced pressure to give a residue. The residue
was purified by prep-TLC (SiO.sub.2) to afford
6-bromo-7-ethyl-2-iodoquinazoline (50 mg, 110.0 umol, 21.3% yield).
M+H.sup.+=362.8 (LCMS); Step 6:
[0368] To a solution of 6-bromo-7-ethyl-2-iodoquinazoline (50 mg,
137.7 umol) and DIEA (53 mg, 413.2 umol, 71.9 uL) in n-BuOH (2.0
mL) was added tert-butyl ((1r,4r)-4-aminocyclohexyl)carbamate (59
mg, 275.4 umol). The mixture was stirred at 120.degree. C. for 12
h. The mixture was concentrated to get crude residue. The residue
was purified by prep-TLC (SiO.sub.2) to afford tert-butyl
((1r,4r)-4-((6-bromo-7-ethylquinazolin-2-yl)amino)cyclohexyl)carbamate
(50 mg, crude).
Step 7
[0369] To a solution of tert-butyl
((1r,4r)-4-((6-bromo-7-ethylquinazolin-2-yl)amino)cyclohexyl)carbamate
(50 mg, 111.2 umol) and K.sub.2CO.sub.3 (15 mg, 111.2 umol) in
dioxane (2.0 mL) and H.sub.2O (0.2 mL) were added
2-chloro-N-(6-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyri-
din-2-yl)benzenesulfonamide (56 mg, 133.5 umol) and
Pd(dppf)Cl.sub.2 (81 mg, 111.2 umol). The mixture was stirred at
90.degree. C. for 12 h under N.sub.2. The mixture was concentrated
to get crude residue. The residue was purified by prep-TLC
(SiO.sub.2) to afford tert-butyl
((1r,4r)-4-((6-(6-(2-chlorophenylsulfonamido)-2-methoxypyridin-3-yl)-7-et-
hylquinazolin-2-yl)amino)cyclohexyl)carbamate (40 mg, crude).
Step 8
[0370] A solution of tert-butyl
((1r,4r)-4-((6-(6-(2-chlorophenylsulfonamido)-2-methoxypyridin-3-yl)-7-et-
hylquinazolin-2-yl)amino)cyclohexyl)carbamate (40 mg, 59.9 umol) in
TFA (1.0 mL) and DCM (2.0 mL) was stirred at 25.degree. C. for 10
min. The mixture was concentrated to get crude residue. The residue
was dissolved in MeOH (2.0 mL) and basified pH to 8 with
NH.sub.3.H.sub.2O (25% solution), concentrated to give a residue.
The residue was purified by prep-HPLC (FA condition) to afford
N-(5-(2-(((1r,4r)-4-aminocyclohexyl)amino)-7-ethylquinazolin-6-yl)-6-meth-
oxypyridin-2-yl)-2-chlorobenzenesulfonamide (14.0 mg, 22.1 umol,
36.9% yield, FA). M+H.sup.+=567.2 (LCMS); .sup.1H NMR
(METHANOL-d.sub.4, 400 MHz) .delta. 8.91 (s, 1H), 8.52 (br s, 1H),
8.33-8.27 (m, 1H), 7.61-7.56 (m, 2H), 7.53-7.46 (m, 1H), 7.44-7.37
(m, 3H), 6.62 (d, J=7.7 Hz, 1H), 4.02-3.87 (m, 1H), 3.55 (s, 3H),
3.22-3.11 (m, 1H), 2.46 (br d, J=7.1 Hz, 2H), 2.23 (br d, J=11.5
Hz, 2H), 2.17-2.05 (m, 2H), 1.67-1.55 (m, 2H), 1.52-1.41 (m, 2H),
1.06 (t, J=7.6 Hz, 3H).
Example 16: Synthesis of
N-(5-(2-(((1r,4r)-4-aminocyclohexyl)amino)-7-methylquinazolin-6-yl)-6-met-
hylpyridin-2-yl)-2-chlorobenzenesulfonamide (106)
##STR00275##
[0372] The title compound was synthesized according to the
synthetic procedure reported for the preparation of
N-(5-(2-(((1r,4r)-4-aminocyclohexyl)amino)-7-ethylquinazolin-6-yl)-6-meth-
oxypyridin-2-yl)-2-chlorobenzenesulfonamide (5.5 mg, 9.1 umol,
14.6% yield, FA). M+H.sup.+=537.3 (LCMS); .sup.1H NMR (400 MHz,
METHANOL-d.sub.4) .delta. 8.95 (s, 1H), 8.47 (br s, 1H), 8.26-8.19
(m, 1H), 7.58-7.42 (m, 6H), 7.18 (d, J=8.8 Hz, 1H), 4.02-3.88 (m,
1H), 3.14 (dt, J=4.0, 7.7 Hz, 1H), 2.28-2.05 (m, 10H), 1.72-1.53
(m, 2H), 1.52-1.39 (m, 2H).
Example 17:
N-(5-(2-(((1r,4r)-4-aminocyclohexyl)amino)-7-methylquinazolin-6-yl)-6-met-
hoxypyridin-2-yl)-2-chlorobenzenesulfonamide (104)
##STR00276##
[0374] The title compound was synthesized according to the
synthetic procedure reported for the preparation of
N-(5-(2-(((1r,4r)-4-aminocyclohexyl)amino)-7-ethylquinazolin-6-yl)-6-meth-
oxypyridin-2-yl)-2-chlorobenzenesulfonamide (11.6 mg, 19.1 umol,
24.9% yield, FA). M+H.sup.+=553.1 (LCMS); .sup.1H NMR (400 MHz,
METHANOL-d.sub.4) .delta. 8.90 (s, 1H), 8.56 (br s, 1H), 8.29 (d,
J=7.7 Hz, 1H), 7.62-7.53 (m, 2H), 7.52-7.44 (m, 1H), 7.38 (dd,
J=7.3, 15.0 Hz, 3H), 6.59 (d, J=7.7 Hz, 1H), 3.93 (tt, J=3.8, 11.3
Hz, 1H), 3.54 (s, 3H), 3.12 (tt, J=3.9, 11.7 Hz, 1H), 2.30-2.00 (m,
7H), 1.66-1.52 (m, 2H), 1.52-1.39 (m, 2H).
Example 18:
N-(5-(2-(((1r,4r)-4-aminocyclohexyl)amino)-7-methylquinazolin-6-yl)-6-eth-
ylpyridin-2-yl)-2-chlorobenzenesulfonamide (105)
##STR00277##
[0376] The title compound was synthesized according to the
synthetic procedure reported for the preparation of
N-(5-(2-(((1r,4r)-4-aminocyclohexyl)amino)-7-ethylquinazolin-6-yl)-6-meth-
oxypyridin-2-yl)-2-chlorobenzennesulfonamide. (16.2 mg, 26.9 umol,
17.6% yield, FA). M+H.sup.+=551.1 (LCMS); .sup.1H NMR (400 MHz,
METHANOL-d.sub.4) .delta. 8.94 (s, 1H), 8.47 (br s, 1H), 8.24 (d,
J=7.5 Hz, 1H), 7.61-7.38 (m, 6H), 7.09 (d, J=8.8 Hz, 1H), 3.95
(tdd, J=3.5, 7.5, 15.0 Hz, 1H), 3.21-3.10 (m, 1H), 2.53-2.40 (m,
1H), 2.33 (qd, J=7.4, 14.3 Hz, 1H), 2.26-2.06 (m, 7H), 1.68-1.54
(m, 2H), 1.53-1.38 (m, 2H), 0.98 (t, J=7.6 Hz, 3H).
Example 19: Synthesis of
N-(5-(2-(((1r,4r)-4-aminocyclohexyl)amino)-5-methylquinazolin-6-yl)-6-met-
hoxypyridin-2-yl)-2-chlorobenzenesulfonamide (114)
##STR00278##
[0378] The title compound was synthesized according to the
synthetic procedure reported for the preparation of
N-(5-(2-(((1r,4r)-4-aminocyclohexyl)amino)-7-ethylquinazolin-6-yl)-6-meth-
oxypyridin-2-yl)-2-chlorobenzenesulfonamide (5.7 mg, 9.3 umol,
20.3% yield, FA). M+H.sup.+=553.3 (LCMS); .sup.1H NMR (400 MHz,
METHANOL-d.sub.4) .delta. 9.29 (s, 1H), 8.55 (br s, 1H), 8.33 (d,
J=7.3 Hz, 1H), 7.67-7.57 (m, 2H), 7.57-7.48 (m, 1H), 7.46-7.34 (m,
3H), 6.65 (d, J=7.8 Hz, 1H), 3.97 (br t, J=11.3 Hz, 1H), 3.59 (s,
3H), 3.17 (ddd, J=4.3, 7.6, 11.5 Hz, 1H), 2.35 (s, 3H), 2.25 (br d,
J=11.5 Hz, 2H), 2.14 (br d, J=11.5 Hz, 2H), 1.69-1.56 (m, 2H),
1.55-1.42 (m, 2H).
Example 20: Synthesis of
N-(5-(2-(((1r,4r)-4-aminocyclohexyl)amino)-8-ethylquinazolin-6-yl)-6-meth-
ylpyridin-2-yl)benzenesulfonamide (111)
##STR00279##
[0379] Step 1
[0380] To a solution of 5-bromo-6-methylpyridin-2-amine (0.5 g, 2.6
mmol) in DCM (30.0 mL) was added pyridine (634 mg, 8.0 mmol, 647.3
uL) and benzenesulfonyl chloride (519 mg, 2.9 mmol, 376.4 uL). The
mixture was stirred at 45.degree. C. for 12 h. The reaction was
concentrated to give a residue. The residue was purified by flash
silica gel chromatography (SiO.sub.2) to afford
N-(5-bromo-6-methylpyridin-2-yl)benzenesulfonamide (780 mg, 1.8
mmol, 68.3% yield). M+H.sup.+=329.0 (LCMS).
Step 2
[0381] A mixture of tert-butyl
((1r,4r)-4-((8-ethyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)quina-
zolin-2-yl)amino)cyclohexyl)carbamate (60 mg, 120.8 umol),
N-(5-bromo-6-methylpyridin-2-yl)benzenesulfonamide (44 mg, 132.9
umol), K.sub.2CO.sub.3 (25 mg, 181.3 umol) and Pd(dppf)Cl.sub.2 (9
mg, 12.1 umol) in dioxane (2.0 mL) and H.sub.2O (0.2 mL) was
degassed and purged with N.sub.2 for 3 times, and then the mixture
was stirred at 90.degree. C. for 12 h under N.sub.2 atmosphere. The
reaction was concentrated to give a residue. The residue was
purified by prep-TLC (SiO.sub.2) to afford tert-butyl
((1r,4r)-4-((8-ethyl-6-(2-methyl-6-(phenylsulfonamido)pyridin-3-yl)quinaz-
olin-2-yl)amino)cyclohexyl)carbamate (60 mg, 55.9 umol, 46.3%
yield). M+H.sup.+=617.4 (LCMS).
Step 3
[0382] To a solution of tert-butyl
((1r,4r)-4-((8-ethyl-6-(2-methyl-6-(phenylsulfonamido)pyridin-3-yl)quinaz-
olin-2-yl)amino)cyclohexyl)carbamate (60 mg, 55.9 umol) in DCM (2.0
mL) was added TFA (1.0 mL). The mixture was stirred at 20.degree.
C. for 0.5 h. The reaction was concentrated to give a residue. The
residue was dissolved in MeOH (2.0 mL) and basified pH to 7 with
NH.sub.3.H.sub.2O (25% solution). The residue was purified by
prep-HPLC (FA condition) to afford
N-(5-(2-(((1r,4r)-4-aminocyclohexyl)amino)-8-ethylquinazolin-6-yl)-
-6-methylpyridin-2-yl)benzenesulfonamide (13.4 mg, 24.0 umol, 42.8%
yield, FA). M+H.sup.+=517.2 (LCMS); .sup.1H NMR (400 MHz,
METHANOL-d.sub.4) .delta. 9.00 (s, 1H), 8.58 (br s, 1H), 7.99 (br
d, J=7.1 Hz, 2H), 7.64 (d, J=8.8 Hz, 1H), 7.60-7.45 (m, 5H), 7.22
(br d, J=8.7 Hz, 1H), 4.05-3.93 (m, 1H), 3.22-3.02 (m, 3H), 2.39
(s, 3H), 2.32 (br d, J=11.6 Hz, 2H), 2.15 (br d, J=12.0 Hz, 2H),
1.69-1.43 (m, 4H), 1.39-1.28 (m, 3H).
Example 21: Synthesis of
2-chloro-N-(4-(2-(((1r,4r)-4-(dimethylamino)cyclohexyl)amino)-8-ethylquin-
azolin-6-yl)-2-fluoro-5-methoxyphenyl)benzenesulfonamide (120)
##STR00280##
[0383] Step 1
[0384] To a solution of 2-bromo-4-fluoro-5-nitrophenol (1.0 g, 4.2
mmol) in DMF (25.0 mL) was added K.sub.2CO.sub.3 (1.2 g, 8.9 mmol),
and then iodomethane (1.2 g, 8.4 mmol, 527.5 uL) at 0.degree. C.
was added dropwise and after complete addition, the reaction
mixture was warmed to 45.degree. C. and stirred for 12 h. The
mixture (contain other batch 1 g) was diluted with H.sub.2O (100
mL) and extracted with ethyl acetate (30.0 mL.times.3) and washed
with brine (30.0 mL.times.3). The organic layer was dried over
anhydrous Na.sub.2SO.sub.4, then filtered and concentrated to
afford a crude 1-bromo-5-fluoro-2-methoxy-4-nitrobenzene (2.0 g).
.sup.1H NMR (400 MHz, CHLOROFORM-d) (7.61-7.54 (m, 2H), 3.99 (s,
3H).
Step 2
[0385] To a solution of 1-bromo-5-fluoro-2-methoxy-4-nitrobenzene
(2.0 g, 8.0 mmol) in EtOH (45.0 mL) and H.sub.2O (9.0 mL) was added
Fe (2.2 g, 40.0 mmol) and NH.sub.4Cl (1.2 g, 24.0 mmol, 839.0 uL).
The mixture was stirred at 80.degree. C. for 12 h. The reaction
mixture was filtered, the filter liquor was concentrated under
reduced pressure. The residue was purified by column chromatography
(SiO.sub.2) to afford 4-bromo-2-fluoro-5-methoxyaniline (1.2 g, 4.4
mmol, 55.1% yield). M+H.sup.+=221.9 (LCMS); .sup.1H NMR (400 MHz,
CHLOROFORM-d) .delta. 7.10 (d, J=10.0 Hz, 1H), 6.29 (d, J=7.8 Hz,
1H), 3.75 (s, 3H).
Step 3
[0386] To a solution of 4-bromo-2-fluoro-5-methoxyaniline (500 mg,
2.2 mmol) in pyridine (10.0 mL) was added 2-chlorobenzenesulfonyl
chloride (575 mg, 2.7 mmol, 371.3 uL). The mixture was stirred at
45.degree. C. for 12 h. The reaction mixture was concentrated under
reduced pressure. The residue was purified by column chromatography
(SiO.sub.2) to afford
N-(4-bromo-2-fluoro-5-methoxyphenyl)-2-chlorobenzenesulfonamide
(890 mg, 1.5 mmol, 69.4% yield). .sup.1H NMR (400 MHz,
CHLOROFORM-d) .delta. 7.95 (d, J=7.6 Hz, 1H), 7.52-7.40 (m, 2H),
7.34-7.25 (m, 1H), 7.13 (d, J=9.3 Hz, 1H), 7.06 (d, J=7.0 Hz, 1H),
3.76 (s, 3H).
Step 4
[0387] A mixture of
N-(4-bromo-2-fluoro-5-methoxyphenyl)-2-chlorobenzenesulfonamide
(783 mg, 1.9 mmol),
8-ethyl-2-fluoro-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)quinazoli-
ne (500 mg, 1.6 mmol), K.sub.2CO.sub.3 (686 mg, 4.9 mmol),
Pd(dppf)Cl.sub.2 (121 mg, 165 umol) in dioxane (20.0 mL) and
H.sub.2O (2.0 mL) was degassed and purged with N.sub.2 for 3 times,
and then the mixture was stirred at 90.degree. C. for 12 h under
N.sub.2 atmosphere. The reaction mixture was concentrated under
reduced pressure. The residue was purified by column chromatography
(SiO.sub.2) to afford
2-chloro-N-(4-(8-ethyl-2-fluoroquinazolin-6-yl)-2-fluoro-5-methoxyphenyl)
benzenesulfonamide (760 mg, 1.0 mmol, 63.7% yield). M+H.sup.+=490.2
(LCMS).
Step 5
[0388] To a solution of
2-chloro-N-(4-(8-ethyl-2-fluoroquinazolin-6-yl)-2-fluoro-5-methoxyphenyl)
benzenesulfonamide (200 mg, 408.2 umol) in n-BuOH (5.0 mL) was
added DIEA (422 mg, 3.2 mmol, 568.8 uL) and
(1r,4r)-N1,N1-dimethylcyclohexane-1,4-diamine (291 mg, 1.6 mmol,
HCl). The mixture was stirred at 100.degree. C. for 12 h. The
reaction mixture was concentrated under reduced pressure. The
residue was purified by prep-HPLC (FA condition) to afford
2-chloro-N-(4-(2-(((1r,4r)-4-(dimethylamino)cyclohexyl)amino)-8-ethylquin-
azolin-6-yl)-2-fluoro-5-methoxyphenyl)benzenesulfonamide (60.4 mg,
91.4 umol, 22.3% yield, FA). M+H.sup.+=612.2 (LCMS); .sup.1H NMR
(400 MHz, METHANOL-d.sub.4) .delta. 8.98 (s, 1H), 8.53 (br s, 1H),
8.09 (dd, J=1.3, 7.9 Hz, 1H), 7.69-7.58 (m, 4H), 7.47 (ddd, J=1.8,
6.7, 8.1 Hz, 1H), 7.10 (dd, J=2.0, 8.8 Hz, 2H), 3.99 (tt, J=4.0,
11.6 Hz, 1H), 3.73 (s, 3H), 3.28-3.20 (m, 1H), 3.06 (q, J=7.5 Hz,
2H), 2.88 (s, 6H), 2.47-2.35 (m, 2H), 2.26-2.14 (m, 2H), 1.82-1.67
(m, 2H), 1.57-1.43 (m, 2H), 1.33 (t, J=7.5 Hz, 3H).
Example 22: Synthesis of
2-chloro-N-(4-(8-ethyl-2-(((1r,4r)-4-(methylamino)cyclohexyl)amino)quinaz-
olin-6-yl)-2-fluoro-5-methoxyphenyl)benzenesulfonamide (121)
##STR00281##
[0389] Step 1
[0390] To a solution of
2-chloro-N-(4-(8-ethyl-2-fluoroquinazolin-6-yl)-2-fluoro-5-methoxyphenyl)-
benzenesulfonamide (200 mg, 408.2 umol) in n-BuOH (5.0 mL) was
added DIEA (158 mg, 1.2 mmol, 213.3 uL) and tert-butyl
((1r,4r)-4-aminocyclohexyl)(methyl)carbamate (279 mg, 1.2 mmol).
The mixture was stirred at 100.degree. C. for 12 h. The reaction
mixture was concentrated under reduced pressure. The residue was
purified by column chromatography (SiO.sub.2) to afford tert-butyl
((1r,4r)-4-((6-(4-(2-chlorophenylsulfonamido)-5-fluoro-2-methoxyphenyl)-8-
-ethylquinazolin-2-yl)amino)cyclohexyl)(methyl)carbamate (175 mg,
238.1 umol, 58.3% yield). M+H.sup.+=698.4 (LCMS).
Step 2
[0391] To a solution of tert-butyl
((1r,4r)-4-((6-(4-(2-chlorophenylsulfonamido)-5-fluoro-2-methoxyphenyl)-8-
-ethylquinazolin-2-yl)amino)cyclohexyl)(methyl)carbamate (175 mg,
250.6 umol) in DCM (2.0 mL) was added TFA (1.5 g, 13.5 mmol, 1.0
mL). The mixture was stirred at 25.degree. C. for 0.5 h. The
reaction mixture was concentrated under reduced pressure. And then
the mixture in MeOH (2.0 mL) was adjusted to pH=7 by adding
NH.sub.3. H.sub.2O (25% solution). The residue was purified by
prep-HPLC (FA condition) to give
2-chloro-N-(4-(8-ethyl-2-(((1r,4r)-4-(methylamino)cyclohexyl)amino)quinaz-
olin-6-yl)-2-fluoro-5-methoxyphenyl)benzenesulfonamide (101.7 mg,
157.8 umol, 62.9% yield, FA). M+H.sup.+=598.2 (LCMS); .sup.1H NMR
(400 MHz, METHANOL-d.sub.4) .delta. 8.98 (s, 1H), 8.31 (s, 1H),
8.09 (d, J=8.1 Hz, 1H), 7.71-7.56 (m, 4H), 7.51-7.42 (m, 1H),
7.16-7.06 (m, 2H), 4.07-3.93 (m, 1H), 3.73 (s, 3H), 3.16-2.99 (m,
3H), 2.75 (s, 3H), 2.36 (br d, J=11.6 Hz, 2H), 2.26 (br d, J=11.7
Hz, 2H), 1.68-1.41 (m, 4H), 1.32 (t, J=7.5 Hz, 3H).
Example 23: Synthesis
N-(5-(2-(((1r,4r)-4-aminocyclohexyl)amino)-8-(methoxymethyl)quinazolin-6--
yl)-6-methoxypyridin-2-yl)-2-chlorobenzenesulfonamide (129)
##STR00282##
[0392] Step 1
[0393] To a solution of 6-bromo-2-fluoro-8-methylquinazoline (0.5
g, 2.2 mmol) in ACN (10.0 mL) was added AIBN (37 mg, 228.1 umol)
and NBS (487 mg, 2.7 mmol). The mixture was stirred at 90.degree.
C. for 12 h. The reaction mixture was concentrated under reduced
pressure. The residue was purified by column chromatography
(SiO.sub.2) to afford 6-bromo-8-(bromomethyl)-2-fluoroquinazoline
(0.7 g, 1.7 mmol, 78.6% yield). M+H.sup.+=320.9 (LCMS). Step 2:
[0394] To a solution of 6-bromo-8-(bromomethyl)-2-fluoroquinazoline
(150 mg, 468.8 umol) in n-BuOH (4.0 mL) was added DIEA (181 mg, 1.4
mmol, 244.9 uL), and tert-butyl N-(4-aminocyclohexyl)carbamate (100
mg, 468.8 umol,). The mixture was stirred at 25.degree. C. for 12
h. The reaction mixture was concentrated under reduced pressure to
afford tert-butyl
((1r,4r)-4-((6-bromo-8-(bromomethyl)quinazolin-2-yl)amino)cyclohexyl)carb-
amate (240 mg, crude).
Step 3
[0395] To a solution of tert-butyl
((1r,4r)-4-((6-bromo-8-(bromomethyl)quinazolin-2-yl)amino)cyclohexyl)carb-
amate (200 mg, 388.9 umol) in MeOH (2.0 mL) was added NaOMe (2.0
mL, 30% solution). The mixture was stirred at 25.degree. C. for 2
h. The reaction mixture was concentrated under reduced pressure.
The residue was purified by column chromatography (SiO.sub.2) to
afford tert-butyl
((1r,4r)-4-((6-bromo-8-(methoxymethyl)quinazolin-2-yl)amino)cyclohexyl)ca-
rbamate (60 mg, 51.5 umol, 13.2% yield). M+H.sup.+=465.3
(LCMS).
Step 4
[0396] A mixture of tert-butyl
((1r,4r)-4-((6-bromo-8-(methoxymethyl)quinazolin-2-yl)amino)cyclohexyl)ca-
rbamate (60 mg, 128.9 umol),
2-chloro-N-(6-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyri-
din-2-yl)benzenesulfonamide (54 mg, 128.9 umol), K.sub.2CO.sub.3
(53 mg, 386.7 umol), Pd(dppf)Cl.sub.2 (9 mg, 12.8 umol) in dioxane
(2.0 mL) and H.sub.2O (0.2 mL) was degassed and purged with N.sub.2
for 3 times, and then the mixture was stirred at 90.degree. C. for
12 h under N.sub.2 atmosphere. The reaction mixture was
concentrated under reduced pressure. The residue was purified by
prep-TLC (SiO.sub.2) to afford tert-butyl
((1r,4r)-4-((6-(6-(2-chlorophenylsulfonamido)-2-methoxypyridin-3-yl)-8-(m-
ethoxymethyl)quinazolin-2-yl)amino)cyclohexyl)carbamate (50 mg,
50.5 umol, 39.1% yield). M+H.sup.+=683.1 (LCMS).
Step 5
[0397] To a solution of tert-butyl
((1r,4r)-4-((6-(6-(2-chlorophenylsulfonamido)-2-methoxypyridin-3-yl)-8-(m-
ethoxymethyl)quinazolin-2-yl)amino)cyclohexyl)carbamate (50 mg,
73.1 umol) in DCM (2.0 mL) was added TFA (1.0 mL). The mixture was
stirred at 25.degree. C. for 0.5 h. The reaction mixture was
concentrated under reduced pressure. The residue was added
dichloromethane (2.0 mL) and NH.sub.3.H.sub.2O (25% solution) to pH
7, concentrated under reduced pressure again. The residue was
purified by prep-HPLC (FA condition) to afford
N-(5-(2-(((1r,4r)-4-aminocyclohexyl)amino)-8-(methoxymethyl)quinaz-
olin-6-yl)-6-methoxypyridin-2-yl)-2-chlorobenzenesulfonamide (12.4
mg, 18.5 umol, 25.2% yield, FA). M+H.sup.+=583.2 (LCMS); .sup.1H
NMR (400 MHz, METHANOL-d.sub.4) .delta. 9.00 (s, 1H), 8.56 (br s,
1H), 8.33 (br d, J=7.7 Hz, 1H), 7.88 (br s, 1H), 7.78 (br s, 1H),
7.67 (br d, J=7.5 Hz, 1H), 7.59 (br s, 2H), 7.54 (br d, J=7.1 Hz,
1H), 6.65 (br d, J=7.8 Hz, 1H), 3.97 (br s, 1H), 3.67 (s, 3H), 3.49
(s, 3H), 3.17 (br s, 1H), 2.31 (br d, J=10.5 Hz, 2H), 2.15 (br d,
J=10.8 Hz, 2H), 1.73-1.41 (m, 4H).
Example 24: Synthesis of
N-(5-(2-(((1r,4r)-4-aminocyclohexyl)amino)-8-(1,1-difluoroethyl)quinazoli-
n-6-yl)-6-methoxypyridin-2-yl)-2-chlorobenzenesulfonamide (123)
##STR00283##
[0398] Step 1
[0399] The solution of 1-(5-bromo-2-fluoro-phenyl)ethanone (1.0 g,
4.6 mmol) in DAST (12.2 g, 75.6 mmol, 10.0 mL) was stirred at
45.degree. C. for 12 h. The mixture was poured into ice Sat.
NaHCO.sub.3 (100.0 mL) and extracted with ethyl acetate (10.0
mL.times.3). The combined organic layers were washed with brine
(10.0 mL.times.3), dried over Na.sub.2SO.sub.4, filtered and
concentrated under reduced pressure to give a residue. The residue
was purified by column chromatography (SiO.sub.2, Petroleum
ether/Ethyl acetate=I/O to 100/1) to afford
4-bromo-2-(1,1-difluoroethyl)-1-fluorobenzene (1.0 g, 4.1 mmol,
90.8% yield). .sup.1H NMR (CHLOROFORM-d, 400 MHz): .delta. 7.68
(dd, J=2.4, 6.6 Hz, 1H), 7.57-7.50 (m, 1H), 7.07-6.98 (m, 1H), 1.99
(dt, J=1.1, 18.5 Hz, 3H).
Step 2
[0400] To a solution of
4-bromo-2-(1,1-difluoroethyl)-1-fluorobenzene (450 mg, 1.8 mmol) in
THF (10.0 mL) was added LDA (2 M, 1.2 mL) at -78.degree. C. The
mixture was stirred at -78.degree. C. for 1 h. Then DMF (165 mg,
2.2 mmol, 173.8 uL) was added and stirred for 1 h at -78.degree.
C.
[0401] The mixture was poured into Sat NH.sub.4Cl (10.0 mL) and
extracted with ethyl acetate (10.0 mL.times.3). The combined
organic layers were washed with brine (10.0 mL.times.3), dried over
Na.sub.2SO.sub.4, filtered and concentrated under reduced pressure
to give a residue. The residue was purified by column
chromatography (SiO.sub.2, Petroleum ether/Ethyl acetate=I/O to
10/1) to afford 5-bromo-3-(1,1-difluoroethyl)-2-fluorobenzaldehyde
(0.4 g, 1.5 mmol, 79.5% yield). .sup.1H NMR (CHLOROFORM-d, 400
MHz): .delta. 10.33 (s, 1H), 8.07 (dd, J=2.4, 5.5 Hz, 1H), 7.92
(dd, J=2.4, 6.4 Hz, 1H), 2.05 (t, J=18.6 Hz, 3H)
Step 3
[0402] To a solution of guanidine (181 mg, 1.5 mmol,
H.sub.2CO.sub.3) and K.sub.2CO.sub.3 (621 mg, 4.4 mmol, 4.8 mL) in
DMA (10.0 mL) was added a solution of
5-bromo-3-(1,1-difluoroethyl)-2-fluorobenzaldehyde (0.4 g, 1.5
mmol) in DMA (1.5 mL). Then the mixture was stirred at 160.degree.
C. for 1 h. The mixture was concentrated to get crude residue. And
then H.sub.2O (30.0 mL) was added and extracted with Ethyl acetate
(30.0 mL.times.3). The combined organic layers were washed with
brine (20.0 mL.times.3), dried over Na.sub.2SO.sub.4, filtered and
concentrated under reduced pressure to give a residue. The residue
was purified by column chromatography (SiO.sub.2, Petroleum
ether/Ethyl acetate=I/O to 5/1) to afford
6-bromo-8-(1,1-difluoroethyl)quinazolin-2-amine (0.4 g, 1.39 mmol,
92.69% yield).
Step 4
[0403] To a solution of
6-bromo-8-(1,1-difluoroethyl)quinazolin-2-amine (0.4 g, 1.3 mmol)
in pyridine (3.5 mL) was added pyridine hydrofluoride (7.7 g, 77.7
mmol, 7.00 mL) at -40.degree. C. The mixture was stirred at
-40.degree. C. for 15 min. Then tert-butyl nitrite (286 mg, 2.7
mmol, 330.2 uL) was added. The mixture was stirred at 20.degree. C.
for 12 h. The mixture was poured into ice water and adjusted pH=7
with sat NaHCO.sub.3 extracted with ethyl acetate (50.0
mL.times.3). The combined organic layers were washed with brine
(20.0 mL.times.3), dried over Na.sub.2SO.sub.4, filtered and
concentrated under reduced pressure to give a residue. The residue
was purified by column chromatography (SiO.sub.2, Petroleum
ether/Ethyl acetate=I/O to 10:1) to afford
6-bromo-8-(1,1-difluoroethyl)-2-fluoroquinazoline (0.3 g, 1.0 mmol,
74.2% yield). .sup.1H NMR (CHLOROFORM-d, 400 MHz): .delta. 9.35 (d,
J=2.4 Hz, 1H), 8.31 (s, 1H), 8.25 (d, J=2.1 Hz, 1H), 2.30 (t,
J=19.0 Hz, 3H)
Step 5
[0404] To a solution of
6-bromo-8-(1,1-difluoroethyl)-2-fluoroquinazoline (80 mg, 274.85
umol) and K.sub.2CO.sub.3 (114 mg, 824.5 umol) in dioxane (2.0 mL)
and H.sub.2O (0.2 mL) were added
2-chloro-N-(6-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyri-
din-2-yl)benzenesulfonamide (233 mg, 549.7 umol) and
Pd(dppf)Cl.sub.2 (20 mg, 27.4 umol). The mixture was stirred at
90.degree. C. for 12 h under N.sub.2. The mixture was concentrated
to get crude residue. The residue was purified by prep-TLC to give
2-chloro-N-(5-(8-(1,1-difluoroethyl)-2-fluoroquinazolin-6-yl)-6-methoxypy-
ridin-2-yl)benzenesulfonamide (100 mg, 196.5 umol, 71.4%
yield).
Step 6
[0405] To a solution of
2-chloro-N-(5-(8-(1,1-difluoroethyl)-2-fluoroquinazolin-6-yl)-6-methoxypy-
ridin-2-yl)benzenesulfonamide (50 mg, 98.2 umol) in n-BuOH (2.0 mL)
was added cyclohexane-1,4-diamine (22. mg, 196.5 umol) and DIEA (38
mg, 294.7 umol, 51.3 uL). The mixture was stirred at 100.degree. C.
for 12 h. The mixture was concentrated to get crude residue. The
residue was purified by prep-HPLC (FA condition) to afford
N-(5-(2-(((1r,4r)-4-aminocyclohexyl)amino)-8-(1,1-difluoroethyl)quinazoli-
n-6-yl)-6-methoxypyridin-2-yl)-2-chlorobenzenesulfonamide (8.0 mg,
12.1 umol, 12.4% yield, FA). M+H.sup.+=603.1 (LCMS); .sup.1H NMR
(400 MHz, METHANOL-d.sub.4) 9.01 (s, 1H), 8.55 (br s, 1H), 8.31 (d,
J=7.3 Hz, 1H), 8.04 (s, 1H), 7.88 (s, 1H), 7.65 (d, J=7.9 Hz, 1H),
7.59-7.55 (m, 2H), 7.55-7.46 (m, 1H), 6.63 (d, J=8.1 Hz, 1H), 3.90
(br s, 1H), 3.65 (s, 3H), 3.22-3.09 (m, 1H), 2.34-2.19 (m, 5H),
2.14 (br d, J=12.2 Hz, 2H), 1.68-1.42 (m, 4H).
Example 25: Synthesis of
N-(5-(2-(((1r,4r)-4-aminocyclohexyl)amino)-8-(trifluoromethyl)quinazolin--
6-yl)-6-methoxypyridin-2-yl)-2-chlorobenzenesulfonamide (134)
##STR00284##
[0406] Step 1
[0407] To a solution of 4-bromo-1-fluoro-2-(trifluoromethyl)benzene
(5.0 g, 20.5 mmol, 2.9 mL) in THF (50.0 mL) was added LDA (2 M,
13.3 mL) at -78.degree. C. The mixture was stirred at -78.degree.
C. for 1 hr. Then DMF (1.8 g, 24.6 mmol, 1.9 mL) was added and
stirred for 1 h at -78.degree. C. The mixture was poured into Sat
NH.sub.4Cl (20.0 mL) and extracted with ethyl acetate (20.0
mL.times.3). The combined organic layers were washed with brine
(20.0 mL.times.3), dried over Na.sub.2SO.sub.4, filtered and
concentrated under reduced pressure to give a residue. The residue
was purified by column chromatography (SiO.sub.2, Petroleum
ether/Ethyl acetate=I/O to 10/1) to afford
5-bromo-2-fluoro-3-(trifluoromethyl)benzaldehyde (4 g, 14.7 mmol,
71.7% yield). .sup.1H NMR (CHLOROFORM-d, 400 MHz): .delta. 10.35
(s, 1H), 8.19 (dd, J=2.5, 5.4 Hz, 1H), 7.98 (dd, J=2.1, 6.1 Hz,
1H).
Step 2
[0408] To a solution of guanidine (1.3 g, 11.0 mmol,
H.sub.2CO.sub.3) and K.sub.2CO.sub.3 (4.5 g, 33.2 mmol) in DMA
(60.0 mL) was added a solution of
5-bromo-2-fluoro-3-(trifluoromethyl)benzaldehyde (3.0 g, 11.0 mmol)
in DMA (9.0 mL). Then the mixture was stirred at 160.degree. C. for
1 h. The mixture was concentrated to get crude residue. And then
H.sub.2O (30.0 mL) was added and extracted with ethyl acetate (30.0
mL.times.3). The combined organic layers were washed with brine
(20.0 mL.times.3), dried over Na.sub.2SO.sub.4, filtered and
concentrated under reduced pressure to give a residue. The residue
was purified by column chromatography (SiO.sub.2, Petroleum
ether/Ethyl acetate=I/O to 5/1) to afford
6-bromo-8-(trifluoromethyl)quinazolin-2-amine (1.6 g, 4.6 mmol,
42.0% yield). .sup.1H NMR (DMSO-d.sub.6, 400 MHz) .delta. 9.19 (s,
1H), 8.34 (d, J=2.2 Hz, 1H), 8.12 (d, J=2.0 Hz, 1H), 7.42 (s,
2H).
Step 3
[0409] To a solution of
6-bromo-8-(trifluoromethyl)quinazolin-2-amine (1.5 g, 5.1 mmol) in
pyridine (13.0 mL) was added pyridine hydrofluoride (28.6 g, 288.5
mmol, 26.0 mL) at -40.degree. C. The mixture was stirred at
-40.degree. C. for 15 min. Then tert-butyl nitrite (1.0 g, 10.2
mmol, 1.2 mL) was added. The mixture was stirred at 20.degree. C.
for 12 h. The mixture was poured into ice water and adjusted pH=7
with sat NaHCO.sub.3, extracted with ethyl acetate (50.0
mL.times.3). The combined organic layers were washed with brine
(20.0 mL.times.3), dried over Na.sub.2SO.sub.4, filtered and
concentrated under reduced pressure to give a residue. The residue
was purified by column chromatography (SiO.sub.2, Petroleum
ether/Ethyl acetate=I/O to 10/1) to afford
6-bromo-2-fluoro-8-(trifluoromethyl)quinazoline (1.0 g, 3.3 mmol,
64.9% yield). M+H.sup.+=294.9 (LCMS).
Step 4
[0410] To a solution of
6-bromo-2-fluoro-8-(trifluoromethyl)quinazoline (0.4 g, 1.3 mmol)
in n-BuOH (20.0 mL) were added tert-butyl
N-(4-aminocyclohexyl)carbamate (349 mg, 1.6 mmol) and DIEA (350 mg,
2.7 mmol, 472.3 uL). The mixture was stirred at 100.degree. C. for
12 h. The mixture was cooled to 25.degree. C. and filtered. The
cake was washed with Petroleum ether (50.0 mL) to afford tert-butyl
((1r,4r)-4-((6-bromo-8-(trifluoromethyl)quinazolin-2-yl)amino)cyclohexyl)
carbamate (0.5 g, 1.0 mmol, 74.6% yield). M+H.sup.+=491.2
(LCMS).
Step 5
[0411] To a solution of tert-butyl
((1r,4r)-4-((6-bromo-8-(trifluoromethyl)quinazolin-2-yl)amino)cyclohexyl)
carbamate (0.3 g, 613.0 umol) and K.sub.2CO.sub.3 (254.2 mg, 1.8
mmol) in dioxane (6.0 mL) and H.sub.2O (0.6 mL) were added
2-chloro-N-(6-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyri-
din-2-yl)benzenesulfonamide (312 mg, 735.7 umol) and
Pd(dppf)Cl.sub.2 (45 mg, 61.3 umol). The mixture was stirred at
90.degree. C. for 12 h under N.sub.2. The mixture was concentrated
to get crude residue. The residue was purified by column
chromatography (SiO.sub.2, Petroleum ether/Ethyl acetate=I/O to
1/1) to give tert-butyl
((1r,4r)-4-((6-(6-(2-chlorophenylsulfonamido)-2-methoxypyridin-3-yl)-8-(t-
rifluoromethyl)quinazolin-2-yl)amino)cyclohexyl)carbamate (0.3 g,
171.1 umol, 27.9% yield). M+H.sup.+=707.1 (LCMS).
Step 6
[0412] A solution of tert-butyl
((1r,4r)-4-((6-(6-(2-chlorophenylsulfonamido)-2-methoxypyridin-3-yl)-8-(t-
rifluoromethyl)quinazolin-2-yl)amino)cyclohexyl)carbamate (0.3 g,
424.2 umol) in DCM (2.0 mL) and TFA (1.0 mL) was stirred at
25.degree. C. for 10 min. The mixture was concentrated to get crude
residue. The residue was dissolved in MeOH (2.0 mL) and basified pH
to 8 with NH.sub.3.H.sub.2O (25% solution), concentrated to give a
residue. The residue was purified by prep-HPLC (FA condition) to
afford
N-(5-(2-(((1r,4r)-4-aminocyclohexyl)amino)-8-(trifluoromethyl)quinazolin--
6-yl)-6-methoxypyridin-2-yl)-2-chlorobenzenesulfonamide (141.4 mg,
215.5 umol, 50.8% yield, FA). M+H.sup.+=607.2 (LCMS); .sup.1H NMR
(METHANOL-d.sub.4, 400 MHz) 9.06 (s, 1H), 8.53 (s, 1H), 8.32 (dd,
J=1.2, 7.8 Hz, 1H), 8.15 (s, 1H), 8.02 (d, J=1.8 Hz, 1H), 7.70 (d,
J=7.9 Hz, 1H), 7.63-7.55 (m, 2H), 7.55-7.47 (m, 1H), 6.66 (d, J=7.9
Hz, 1H), 3.99-3.83 (m, 1H), 3.68 (s, 3H), 3.23-3.08 (m, 1H), 2.31
(br d, J=8.8 Hz, 2H), 2.14 (br d, J=12.6 Hz, 2H), 1.70-1.38 (m,
4H).
Example 26: Synthesis of
N-(5-(2-(((1r,4r)-4-aminocyclohexyl)amino)-8-methylquinazolin-6-yl)-6-met-
hoxypyridin-2-yl)-2-chlorobenzenesulfonamide (115)
##STR00285##
[0414] The title compound was synthesized according to the
synthetic procedure reported for the preparation of
N-(5-(2-(((1r,4r)-4-aminocyclohexyl)amino)-8-(trifluoromethyl)quinazolin--
6-yl)-6-methoxypyridin-2-yl)-2-chlorobenzenesulfonamide (18.8 mg,
30.8 umol, 20.1% yield, FA). M+H.sup.+=553.2 (LCMS); .sup.1H NMR
(METHANOL-d.sub.4, 400 MHz) .delta. 8.95 (s, 1H), 8.55 (br s, 1H),
8.31 (d, J=7.6 Hz, 1H), 7.70-7.61 (m, 3H), 7.61-7.55 (m, 2H),
7.54-7.48 (m, 1H), 6.63 (d, J=7.9 Hz, 1H), 4.04-3.92 (m, 1H), 3.65
(s, 3H), 3.22-3.09 (m, 1H), 2.53 (s, 3H), 2.31 (br d, J=11.5 Hz,
2H), 2.13 (br d, J=11.9 Hz, 2H), 1.68-1.39 (m, 4H).
Example 27: Synthesis of
2-chloro-N-(5-(2-((4-(dimethylamino)bicyclo[2.2.2]octan-1-yl)amino)-8-eth-
ylquinazolin-6-yl)-6-ethylpyridin-2-yl)benzenesulfonamide (136)
##STR00286##
[0415] Step 1
[0416] To a solution of tert-butyl
N-(1-amino-4-bicyclo[2.2.2]octanyl)carbamate (500 mg, 2.1 mmol) and
(HCHO)n (562 mg, 6.2 mmol) in MeOH (15.0 mL) was added AcOH (125
mg, 2.1 mmol, 119 uL) to adjust pH to 5 and then the mixture was
stirred for 2 h at 30.degree. C. Then NaBH.sub.3CN (523 mg, 8.3
mmol) was added. The mixture was stirred at 45.degree. C. for 12 h.
The reaction was concentrated to give a residue. The residue was
dissolved in saturated NaHCO.sub.3 (15.0 mL) and extracted with
ethyl acetate (10 mL.times.3). The combined organic phase was dried
over anhydrous Na.sub.2SO.sub.4, filtered and concentrated to give
tert-butyl (4-(dimethylamino)bicyclo[2.2.2]octan-1-yl)carbamate
(550 mg, crude).
Step 2
[0417] The mixture of tert-butyl
(4-(dimethylamino)bicyclo[2.2.2]octan-1-yl)carbamate (500 mg, 1.8
mmol) in HCl/MeOH (4M, 10.0 mL) was stirred at 20.degree. C. for
0.5 h. The reaction was concentrated to give
N1,N1-dimethylbicyclo[2.2.2]octane-1,4-diamine (380 mg, crude,
HCl).
Step 3
[0418] To a solution of
2-chloro-N-(6-ethyl-5-(8-ethyl-2-fluoroquinazolin-6-yl)pyridin-2-yl)benze-
nesulfonamide (50 mg, 106.2 umol) in n-BuOH (4.0 mL) was added DIEA
(110 mg, 849.4 umol, 147.9 uL) and
N1,N1-dimethylbicyclo[2.2.2]octane-1,4-diamine (65 mg, 318.5 umol,
HCl). The mixture was stirred at 120.degree. C. for 12 h. The
reaction was concentrated to give a residue. The residue was
purified by prep-HPLC (HCl condition) and then was purified by
prep-HPLC (FA condition) to afford
2-chloro-N-(5-(2-((4-(dimethylamino)bicyclo[2.2.2]octan-1-yl)amino-
)-8-ethylquinazolin-6-yl)-6-ethylpyridin-2-yl)benzenesulfonamide
(2.1 mg, 2.9 umol, 2.8% yield, FA). M+H.sup.+=619.3 (LCMS); .sup.1H
NMR (400 MHz, METHANOL-d.sub.4) .delta. 8.87 (s, 1H), 8.45 (br s,
2H), 8.15 (d, J=7.5 Hz, 1H), 7.51 (br d, J=8.8 Hz, 1H), 7.45 (d,
J=3.8 Hz, 2H), 7.43-7.36 (m, 3H), 7.00 (br d, J=8.3 Hz, 1H), 2.99
(q, J=7.3 Hz, 2H), 2.71 (s, 6H), 2.53 (q, J=7.5 Hz, 2H), 2.32-2.22
(m, 6H), 2.01-1.88 (m, 6H), 1.23 (t, J=7.5 Hz, 3H), 0.99 (br t,
J=7.5 Hz, 3H).
Example 27A: Synthesis of
(1r,4r)-N1,N1-dimethylcyclohexane-1,4-diamine
##STR00287##
[0420] The title compound was synthesized according to the
synthetic procedure reported for the preparation of
N1,N1-dimethylbicyclo[2.2.2]octane-1,4-diamine (8.3 g, 46.4 mmol,
99.6% yield, HCl). .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta.
11.02 (br s, 1H), 8.31 (br s, 3H), 3.62-3.36 (m, 1H), 3.15-3.03 (m,
1H), 2.96 (br d, J=4.0 Hz, 1H), 2.65 (d, J=4.9 Hz, 6H), 2.09 (br s,
4H), 1.65-1.31 (m, 4H).
Example 27B: Synthesis of
(1s,4s)-N1,N1-dimethylcyclohexane-1,4-diamine
##STR00288##
[0422] The title compound was synthesized according to the
synthetic procedure reported for the preparation of
N1,N1-dimethylbicyclo[2.2.2]octane-1,4-diamine (1.7 g, crude, HCl).
.sup.1H NMR (400 MHz, METHANOL-d.sub.4) .delta. 3.53 (br s, 1H),
3.41-3.33 (m, 1H), 2.89 (s, 6H), 2.13-1.88 (m, 9H).
Example 28: Synthesis of
N-(5-(2-(((1s,4s)-4-aminocyclohexyl)amino)-8-methylquinazolin-6-yl)-3-flu-
oro-6-methoxypyridin-2-yl)-2-chlorobenzenesulfonamide (146)
##STR00289##
[0423] Step 1
[0424] A mixture of 6-bromo-2-fluoro-8-methylquinazoline (500 mg,
2.0 mmol),
4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(1,3,2-dioxaborolane) (632
mg, 2.4 mmol), KOAc (610 mg, 6.22 mmol), Pd(dppf)Cl.sub.2 (151 mg,
207.4 umol) in dioxane (20.0 mL) was degassed and purged with
N.sub.2 for 3 times, and then the mixture was stirred at 90.degree.
C. for 12 h under N.sub.2 atmosphere. The reaction mixture was
concentrated under reduced pressure. The residue was purified by
column chromatography (SiO.sub.2, Petroleum ether/Ethyl
acetate=100/1 to 10/1) to afford
2-fluoro-8-methyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)quinazol-
ine (590 mg, 1.9 mmol, crude). M+H.sup.+=289.2 (LCMS).
Step 2
[0425] A mixture of
2-fluoro-8-methyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)quinazol-
ine (349 mg, 1.2 mmol),
N-(5-bromo-3-fluoro-6-methoxypyridin-2-yl)-2-chlorobenzenesulfonamide
(400 mg, 1.0 mmol), K.sub.2CO.sub.3 (419 mg, 3.0 mmol),
Pd(dppf)Cl.sub.2 (73 mg, 101 umol) in dioxane (15.0 mL) and
H.sub.2O (1.5 mL) was degassed and purged with N.sub.2 for 3 times,
and then the mixture was stirred at 90.degree. C. for 12 h under
N.sub.2 atmosphere. The reaction mixture was concentrated under
reduced pressure. The residue was purified by column chromatography
(SiO.sub.2, Petroleum ether/Ethyl acetate=10/1 to 1/1) to afford
2-chloro-N-(3-fluoro-5-(2-fluoro-8-methylquinazolin-6-yl)-6-methox-
ypyridin-2-yl)benzenesulfonamide (450 mg, 802 umol, 79.3% yield).
M+H.sup.+=477.2 (LCMS).
Step 3
[0426] To a solution of (1s,4s)-cyclohexane-1,4-diamine (237 mg,
1.5 mmol, HCl) in n-BuOH (7.0 mL) was added DIEA (325 mg, 2.5 mmol,
438.3 uL) and
2-chloro-N-(3-fluoro-5-(2-fluoro-8-methylquinazolin-6-yl)-6-methoxypyridi-
n-2-yl)benzenesulfonamide (150 mg, 314.5 umol). The mixture was
stirred at 100.degree. C. for 24 h. The reaction mixture was
concentrated under reduced pressure to give a residue. The residue
was purified by prep-HPLC (FA condition) to afford
N-(5-(2-(((1s,4s)-4-aminocyclohexyl)amino)-8-methylquinazolin-6-yl)-3-flu-
oro-6-methoxypyridin-2-yl)-2-chlorobenzenesulfonamide (50.0 mg,
80.2 umol, 25.5% yield, FA). M+H.sup.+=571.2 (LCMS); .sup.1H NMR
(400 MHz, METHANOL-d.sub.4) .delta. 8.97 (s, 1H), 8.56 (br s, 1H),
8.31 (d, J=7.6 Hz, 1H), 7.68 (s, 2H), 7.62-7.54 (m, 3H), 7.54-7.45
(m, 1H), 4.21 (br s, 1H), 3.46 (s, 3H), 3.28 (br s, 1H), 2.53 (s,
3H), 2.13 (br d, J=9.8 Hz, 2H), 2.02-1.69 (m, 6H).
Example 29: Synthesis of
N-(5-(2-(((1s,4s)-4-aminocyclohexyl)amino)-8-methylquinazolin-6-yl)-6-met-
hoxypyridin-2-yl)-2-chlorobenzenesulfonamide (138)
##STR00290##
[0428] The title compound was synthesized according to the
synthetic procedure reported for the preparation of
N-(5-(2-(((1s,4s)-4-aminocyclohexyl)amino)-8-methylquinazolin-6-yl)-3-flu-
oro-6-methoxypyridin-2-yl)-2-chlorobenzenesulfonamide (40.8 mg,
67.2 umol, 21.4% yield, FA). M+H.sup.+=553.1 (LCMS); .sup.1HNMR
(400 MHz, METHANOL-d.sub.4) .delta. 8.92 (s, 1H), 8.44 (br s, 1H),
8.36-8.22 (m, 1H), 7.68-7.40 (m, 6H), 6.62 (d, J=7.9 Hz, 1H), 4.19
(br s, 1H), 3.63 (s, 3H), 3.29-3.22 (m, 1H), 2.50 (s, 3H),
2.17-2.02 (m, 2H), 2.01-1.69 (m, 6H).
Example 30: Synthesis of
N-(5-(2-(((1s,4s)-4-aminocyclohexyl)amino)-8-ethylquinazolin-6-yl)-6-meth-
oxypyridin-2-yl)-2-chlorobenzenesulfonamide (140)
##STR00291##
[0429] Step 1
[0430] To a solution of 6-bromo-8-ethylquinazolin-2-amine (10.0 g,
39.6 mmol) in Py (100 mL) was added pyridine; hydrofluoride (220.0
g, 2.2 mol, 200.0 mL) at -40.degree. C. The mixture was stirred at
-40.degree. C. for 15 min. Then tert-butyl nitrite (8.1 g, 79.3
mmol, 9.4 mL) was added. The mixture was stirred at 20.degree. C.
for 12 h. The mixture was poured into ice water and adjusted pH=7
with sat. NaHCO.sub.3, extracted with EtOAc (500.0 mL.times.3). The
combined organic layers were washed with brine (200.0 mL.times.3),
dried over Na.sub.2SO.sub.4, filtered and concentrated under
reduced pressure to give a residue. The residue was purified by
column chromatography (SiO.sub.2) to give
6-bromo-8-ethyl-2-fluoroquinazoline (11.4 g, 40.8 mmol, 55.4%
yield). M+H.sup.+=257.0 (LCMS); .sup.1H NMR (400 MHz, CHLOROFORM-d)
.delta. 9.26 (d, J=2.6 Hz, 1H), 8.00 (d, J=2.2 Hz, 1H), 7.87 (d,
J=1.1 Hz, 1H), 3.18 (q, J=7.5 Hz, 2H), 1.37 (t, J=7.5 Hz, 3H).
Step 2
[0431] A mixture of
2-chloro-N-(6-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyri-
din-2-yl)benzenesulfonamide (399 mg, 940.8 umol),
6-bromo-8-ethyl-2-fluoroquinazoline (200 mg, 784.0 umol),
Pd(dppf)Cl.sub.2 (57 mg, 78.4 umol), and K.sub.2CO.sub.3 (325 mg,
2.3 mmol) in dioxane (6.0 mL) and H.sub.2O (0.6 mL) was degassed
and purged with N.sub.2 for 3 times, and then the mixture was
stirred at 90.degree. C. for 12 h under N.sub.2 atmosphere. The
reaction mixture was concentrated under reduced pressure to give a
residue. The residue was purified by column chromatography
(SiO.sub.2) to give
2-chloro-N-(5-(8-ethyl-2-fluoroquinazolin-6-yl)-6-methoxypyridin-2-yl)ben-
zenesulfonamide (430 mg, crude).
Step 3
[0432] To a solution of (1s,4s)-cyclohexane-1,4-diamine (144 mg,
1.2 mmol, HCl) in n-BuOH (6.0 mL) was basified pH to 8 by DIEA.
Then the mixture was added
2-chloro-N-(5-(8-ethyl-2-fluoroquinazolin-6-yl)-6-methoxypyridi-
n-2-yl)benzenesulfonamide (200 mg, 422.9 umol) and DIEA (327 mg,
2.5 mmol, 441.9 uL) and stirred at 100.degree. C. for 12 h. The
reaction mixture was concentrated under reduced pressure to give a
residue. The residue was purified by pre-HPLC (FA condition) to
afford
N-(5-(2-(((1s,4s)-4-aminocyclohexyl)amino)-8-ethylquinazolin-6-yl)-6-meth-
oxypyridin-2-yl)-2-chlorobenzenesulfonamide (121.7 mg, 196.0 umol,
46.3% yield, FA). M+H.sup.+=567.2 (LCMS); .sup.1H NMR (400 MHz,
METHANOL-d.sub.4) .delta. 8.98 (s, 1H), 8.55 (s, 1H), 8.36-8.26 (m,
1H), 7.71-7.45 (m, 6H), 6.63 (d, J=8.2 Hz, 1H), 4.20 (br s, 1H),
3.65 (s, 3H), 3.26 (br dd, J=3.6, 9.8 Hz, 1H), 3.03 (q, J=7.5 Hz,
2H), 2.21-2.06 (m, 2H), 1.98-1.71 (m, 6H), 1.29 (t, J=7.5 Hz,
3H).
Example 31: Synthesis of
2-chloro-N-(5-(2-(((1s,4s)-4-(dimethylamino)-4-methylcyclohexyl)amino)-8--
ethylquinazolin-6-yl)-3-fluoro-6-methoxypyridin-2-yl)benzenesulfonamide
(144)
##STR00292##
[0433] Step 1
[0434] To a solution of tert-butyl
(1-methyl-4-oxocyclohexyl)carbamate (900 mg, 4 mmol) in EtOH (20.0
mL) was added phenylmethanamine (509 mg, 4.7 mmol, 517.9 uL) and
AcOH (238 mg, 4 mmol, 226.5 uL) at 0.degree. C. The resulting
mixture was stirred at 0.degree. C. for 15 min. Follow by
successive addition of NaBH.sub.3CN (498 mg, 7.9 mmol), the mixture
was stirred at 20.degree. C. for 12 h. The reaction was
concentrated to give a residue. The residue was dissolved in
saturated aqueous NaHCO.sub.3 (20.0 mL) and extracted with ethyl
acetate (20.0 mL.times.3). The combined organic phase was dried
over anhydrous Na.sub.2SO.sub.4, filtered and concentrated to give
tert-butyl (4-(benzylamino)-1-methylcyclohexyl)carbamate (1.3 g,
crude).
Step 2
[0435] To a solution of tert-butyl
(4-(benzylamino)-1-methylcyclohexyl)carbamate (1.2 g, 3.7 mmol) in
DMF (20.0 mL) was added K.sub.2CO.sub.3 (1.6 g, 11.3 mmol) and
bromomethylbenzene (773 mg, 4.5 mmol, 537.1 uL). The mixture was
stirred at 40.degree. C. for 12 h. The reaction was quenched with
H.sub.2O (30.0 mL) and extracted with ethyl acetate (20
mL.times.3). The combined organic was washed with brine (20
mL.times.3), dried over anhydrous Na.sub.2SO.sub.4, filtered and
concentrated to give a residue. The residue was purified by flash
silica gel chromatography (SiO.sub.2) to afford tert-butyl
(4-(dibenzylamino)-1-methylcyclohexyl)carbamate (1.5 g, 3.4 mmol,
90% yield). .sup.1H NMR (400 MHz, CHLOROFORM-d) .delta. 7.42-7.35
(m, 4H), 7.34-7.29 (m, 4H), 7.26-7.19 (m, 2H), 3.69-3.63 (m, 4H),
2.60-2.46 (m, 1H), 2.13 (br d, J=11.9 Hz, 1H), 1.94 (br d, J=9.3
Hz, 1H), 1.84-1.66 (m, 2H), 1.61-1.50 (m, 3H), 1.47-1.39 (m, 9H),
1.36-1.24 (m, 4H).
Step 3
[0436] The mixture of tert-butyl
(4-(dibenzylamino)-1-methylcyclohexyl)carbamate (500 mg, 1.2 mmol)
in HCl/MeOH (4M, 10.0 mL) was stirred at 20.degree. C. for 1 h. The
reaction was concentrated to give
N.sup.1,N.sup.1-dibenzyl-4-methylcyclohexane-1,4-diamine (400 mg,
crude, HCl).
Step 4
[0437] To a solution of
N.sup.1,N.sup.1-dibenzyl-4-methylcyclohexane-1,4-diamine (350 mg, 1
mmol, HCl) in MeOH (10.0 mL) was added TEA to basify pH to 7 and
then (HCHO)n (274 mg, 3 mmol) was added. AcOH (61 mg, 1 mmol, 58
uL) was added to adjust pH to 5 and then the mixture was stirred at
60.degree. C. for 2 h. NaBH.sub.3CN (255 mg, 4.1 mmol) was added
and the mixture was stirred at 60.degree. C. for 12 h. The reaction
was concentrated to give a residue. The residue was dissolved in
saturated NaHCO.sub.3 (10.0 mL) and extracted with ethyl acetate
(10.0 mL.times.3). The combined organic phase was dried over
anhydrous Na.sub.2SO.sub.4, filtered and concentrated to give
N.sup.4,N.sup.4-dibenzyl-N.sup.1,N.sup.1,1-trimethylcyclohexane-1,4-diami-
ne (330 mg, crude).
Step 5
[0438] To a solution of
N.sup.4,N.sup.4-dibenzyl-N.sup.1,N.sup.1,1-trimethylcyclohexane-1,4-diami-
ne (330 mg, 980.6 umol) in THF (10.0 mL) and AcOH (0.1 mL) was
added Pd(OH).sub.2/C (400 mg, 980.6 umol, 10% Pd basis) under
N.sub.2 atmosphere. The suspension was degassed and purged with
H.sub.2 for 3 times. The mixture was stirred under H.sub.2 (50 Psi)
at 50.degree. C. for 12 h. The reaction was filtered and
concentrated to give
N.sup.1,N.sup.1,1-trimethylcyclohexane-1,4-diamine (150 mg,
crude).
Step 6
[0439] To a solution of
2-chloro-N-(5-(8-ethyl-2-fluoroquinazolin-6-yl)-3-fluoro-6-methoxypyridin-
-2-yl)benzenesulfonamide (30 mg, 61.1 umol) in n-BuOH (3.0 mL) was
added DIEA (63 mg, 488.9 umol, 85.2 uL) and
N.sup.1,N.sup.1,1-trimethylcyclohexane-1,4-diamine (38 mg, 244.4
umol). The mixture was stirred at 120.degree. C. for 12 h. The
reaction was concentrated to give a residue. The residue was
purified by prep-HPLC (FA condition) to afford
2-chloro-N-(5-(2-(((1s,4s)-4-(dimethylamino)-4-methylcyclohexyl)amino)-8--
ethylquinazolin-6-yl)-3-fluoro-6-methoxypyridin-2-yl)benzenesulfonamide
(3.7 mg, 5.4 umol, 8.9% yield, FA). M+H.sup.+=627.3 (LCMS); .sup.1H
NMR (400 MHz, METHANOL-d.sub.4) .delta. 8.98 (br s, 1H), 8.53 (br
s, 1H), 8.32 (br d, J=7.8 Hz, 1H), 7.69 (s, 2H), 7.62-7.47 (m, 4H),
4.16 (br s, 1H), 3.46 (s, 3H), 3.03 (q, J=7.4 Hz, 2H), 2.85 (s,
6H), 2.13-1.92 (m, 6H), 1.86 (br d, J=5.7 Hz, 2H), 1.41 (s, 3H),
1.29 (br t, J=7.4 Hz, 3H); .sup.1H NMR (400 MHz, DMSO-d.sub.6)
.delta. 8.98 (s, 1H), 8.18-8.12 (m, 1H), 7.66 (s, 2H), 7.44-7.32
(m, 4H), 3.99 (br s, 1H), 3.31 (s, 3H), 2.96 (q, J=7.5 Hz, 2H),
2.51 (br s, 6H), 2.01-1.75 (m, 6H), 1.58-1.47 (m, 2H), 1.24 (t,
J=7.5 Hz, 3H), 1.13 (s, 3H).
Example 32: Synthesis of
2-chloro-N-(5-(2-(((1s,4s)-4-(dimethylamino)-4-methylcyclohexyl)amino)-8--
ethylquinazolin-6-yl)-6-methoxypyridin-2-yl)benzenesulfonamide
(143)
##STR00293##
[0441] The title compound was synthesized according to the
synthetic procedure reported for the preparation of
2-chloro-N-(5-(2-(((1s,4s)-4-(dimethylamino)-4-methylcyclohexyl)amino)-8--
ethylquinazolin-6-yl)-3-fluoro-6-methoxypyridin-2-yl)benzenesulfonamide
(6.4 mg, 9.4% yield). M+H.sup.+=609.3 (LCMS); .sup.1H NMR (400 MHz,
METHANOL-d.sub.4) .delta. 8.94 (s, 1H), 8.33-8.27 (m, 1H), 7.64
(dd, J=1.9, 13.4 Hz, 2H), 7.60 (d, J=8.1 Hz, 1H), 7.58-7.54 (m,
2H), 7.52-7.46 (m, 1H), 6.60 (d, J=7.9 Hz, 1H), 4.10 (br t, J=5.3
Hz, 1H), 3.62 (s, 3H), 3.02 (q, J=7.5 Hz, 2H), 2.68-2.59 (m, 6H),
2.06-1.89 (m, 6H), 1.73-1.62 (m, 2H), 1.31-1.22 (m, 6H).
II. Biological Evaluation
Example 1: In Vitro FRET Assay
[0442] In vitro FRET assay was performed to evaluate the ability of
select compounds to inhibit IRE1, the results of which are
summarized in Table 3. To perform the in vitro FRET assay, 1.times.
complete assay buffer (CAB; 1M DTT, 50 mM sodium citrate pH 7.15,
ImM magnesium acetate, 0.02% tween 20) was used to dilute
SignalChem IRE1a protein to a final concentration of 2 nM. Selected
compounds were serially diluted with DMSO in a non-binding black
384-well plate for a total of 15 ul in each well. 2 ul of the
serially diluted compound or DMSO control were then added to new
wells containing 98 ul of 1.times.CAB, for a total volume of 100
ul, 10 ul of which were then transferred to wells of a new plate. 5
ul of the diluted IRE1a was then added to each well. 5 ul of a 400
mM XBP1 RNA probe was then added to each well. Fluorescence was
then read over 30 minutes in kinetic mode (485/515 nm).
[0443] Two RNA probes were used, XBP1 wildtype (SEQ ID NO: 2) which
is able to be spliced by active IRE1a or XBP1 mutant (SEQ ID NO: 3)
which is unable to be spliced. Each probe contained a 5' 6-FAM
modification and a 3' IOWA Black FQ modification.
[0444] A second FRET assay was performed to assess ATP-mediated
inhibition. In this case, compounds and IRE1a were prepared and
combined as discussed above, with the addition of ATP up to 1 mM
final concentration. This mixture was incubated at room temperature
for 60 minutes and then 5 ul of 400 nM XBP1 wildtype or mutant RNA
probe was added. Plates were then read over 30 minutes in kinetic
mode (485/515 nm).
TABLE-US-00008 TABLE 3 Compound Ref. No. Mean IC.sub.50 1 B 2 A 3;
Formic Acid A 4 A 5 A 6 A 7 B 8 B 9 A 10 A 11 A 12 D 13 D 14;
Formic Acid D 15; Formic Acid D 16; Formic Acid A 17; Formic Acid D
18; Formic Acid A 19; Formic Acid A 20; Formic Acid A 21; Formic
Acid A 22; Formic Acid B 23; Formic Acid A 24; Formic Acid A 25;
Formic Acid A 26; Formic Acid A 27; Formic Acid A 28; Formic Acid A
29; Formic Acid A 30; Formic Acid C 31; Formic Acid D 32; Formic
Acid A 33; Formic Acid A 34; Formic Acid A 35; Formic Acid A 36;
Formic Acid A 37; HCl .sup. A 38; Formic Acid A 39; Formic Acid A
40; Formic Acid A 41; Formic Acid A 42; Formic Acid A 43; Formic
Acid A 44; Formic Acid A 45; Formic Acid C 46; Formic Acid A 47;
Formic Acid A 48; Formic Acid A 49; Formic Acid A 50; Formic Acid A
51; Formic Acid A 52; Formic Acid A 53; Formic Acid A 54; Formic
Acid A 55; Formic Acid A 56; Formic Acid A 57; Formic Acid A 58;
Formic Acid B 59; Formic Acid B 60; Formic Acid A 62; Formic Acid A
63; Formic Acid A 65; Formic Acid A 66; Formic Acid A 67; Formic
Acid A 68; Formic Acid A 69; Formic Acid A 70; Formic Acid A 71;
Formic Acid A 72; Formic Acid A 73; Formic Acid A 74; Formic Acid A
75; Formic Acid A 76; Formic Acid A 77; Formic Acid A 78; Formic
Acid A 79; Formic Acid A 80; Formic Acid A 81; Formic Acid A 82;
Formic Acid A 83; Formic Acid B 84; Formic Acid A 85; Formic Acid A
86; Formic Acid A 87; Formic Acid A 88; Formic Acid A 89; Formic
Acid A 90; Formic Acid A 92; Formic Acid A 93; Formic Acid A 94;
Formic Acid A 96; Formic Acid A 98; Formic Acid A 100; Formic Acid
A 101; Formic Acid B 102; Formic Acid A 103; Formic Acid A 104;
Formic Acid A 105; Formic Acid A 106; Formic Acid A 107; Formic
Acid A 109; Formic Acid A 110; Formic Acid A 111; Formic Acid A
112; Formic Acid A 113; Formic Acid A 114; Formic Acid B 115;
Formic Acid A 120; Formic Acid A 121; Formic Acid A 123; Formic
Acid A 129; Formic Acid A 134; Formic Acid A 136; Formic Acid A
138; Formic Acid A 140; Formic Acid A 143; Formic Acid B 144;
Formic Acid C 146; Formic Acid A Note: Biochemical assay Mean
IC.sub.50 data are designated within the following ranges: A:
.ltoreq.5 nM; B: >5 nM to .ltoreq.50 nM; C: >50 nM to
.ltoreq.100 nM; and D: >100 nM.
Example 2: In Vitro Luciferase Assay
[0445] Compounds disclosed herein were assessed for disruption of
IRE1 signaling using a IRE1a Endoribonuclease Nanoluciferase Assay.
Briefly, 2.5.times.10.sup.6 293T cells were seeded in a 10 cm.sup.2
tissue culture plate. About 24 hours later, the cells were
transfected with Effectene. In a 15 mL Tube, the following was
added: 2 ug XBP1 luciferase reporter plasmid
(PGK-Luc2-P2A-XBP1u-Nanoluciferase-PEST); 300 ul EC buffer; and 16
ul Enhancer, followed by incubation at room temp for 5 minutes.
Next, 60 ul Effectene (Qiagen 301427) was added, followed by
incubation at room temperature for 10 minutes. 2.6 mL cDMEM media
was added. Old media was aspirated from the cells, followed by
addition of 7 mL fresh media. Full transfection mixture was added
dropwise to cells. Cells were incubated for 6 hours, followed by
trypsinization, centrifugation and resuspension in 11 mL media. 100
uL of cells were plated per a well in a 96 well plate. A day later,
ER stressors of choice +/- inhibitors were added. To harvest, media
was aspirated from cells completely, then 50 uL 1.times. passive
lysis buffer (Promega: E1941) was added per well and put on shaker
(300 rpm) for 30 minutes at room temperature. Cells were
centrifuged, and 15 uL sample per well was added to a new, opaque
white 384 well plate (Corning 3570). 15 uL OneGlo (nanoluciferase
kit, Promega N1630) was added. Plates were spun down, placed on
shaker (300 rpm) for 10 minutes. Plates were read on luminometer,
1000 ms integration time per well. 15 uL Stop and Glo
(nanoluciferase kit) was added. Plates were spun down, placed on
shaker (300 rpm) for 10 minutes. Plates were read on luminometer,
1000 ms second integration time per well. Recordings are provided
below in Table 4.
TABLE-US-00009 TABLE 4 Compound Ref. No. Mean EC.sub.50 1 D 2 D 3;
Formic Acid B 4 C 5 D 6 C 11 D 16; Formic Acid A 18; Formic Acid A
19; Formic Acid A 20; Formic Acid C 21; Formic Acid B 22; Formic
Acid D 23; Formic Acid A 24; Formic Acid A 25; Formic Acid A 26;
Formic Acid A 27; Formic Acid A 28; Formic Acid A 29; Formic Acid D
32; Formic Acid A 33; Formic Acid A 34; Formic Acid B 35; Formic
Acid A 37; HCl .sup. A 44; Formic Acid A 46; Formic Acid A 47;
Formic Acid B 48; Formic Acid B 51; Formic Acid C 52; Formic Acid A
53; Formic Acid A 54; Formic Acid B 55; Formic Acid A 56; Formic
Acid A 57; Formic Acid A 58; Formic Acid A 59; Formic Acid C 60;
Formic Acid A 62; Formic Acid B 65; Formic Acid B 66; Formic Acid C
67; Formic Acid B 68; Formic Acid C 69; Formic Acid A 70; Formic
Acid A 71; Formic Acid A 72; Formic Acid D 73; Formic Acid A 74;
Formic Acid A 75; Formic Acid D 76; Formic Acid B 77; Formic Acid B
78; Formic Acid A 79; Formic Acid B 80; Formic Acid D 81; Formic
Acid A 82; Formic Acid B 83; Formic Acid C 84; Formic Acid B 85;
Formic Acid D 86; Formic Acid C 87; Formic Acid A 88; Formic Acid A
89; Formic Acid D 90; Formic Acid B 92; Formic Acid D 93; Formic
Acid A 94; Formic Acid A 98; Formic Acid A 100; Formic Acid C 102;
Formic Acid C 103; Formic Acid A 104; Formic Acid C 107; Formic
Acid A 109; Formic Acid A 110; Formic Acid A 111; Formic Acid C
112; Formic Acid B 113; Formic Acid B 115; Formic Acid A 120;
Formic Acid A 121; Formic Acid A 123; Formic Acid A 129; Formic
Acid A 134; Formic Acid A 136; Formic Acid A 138; Formic Acid C
Note: Biochemical assay Mean EC.sub.50 data are designated within
the following ranges: A: .ltoreq.5 nM; B: >5 nM to .ltoreq.50
nM; C: >50 nM to .ltoreq.100 nM; and D: >100 nM.
Example 3: Growth Assay
[0446] A growth assay was performed to evaluate the compounds
disclosed herein for cytotoxicity. Briefly, 5,000,000 293T cells
were resuspended in 18 mL of cDMEM for a final concentration of
277,777 cells/mL. 180 uL (50,000 cells) cDMEM was seeded per well
in a 96 well flat bottom plate as shown in Table 5, with "media"
wells left unfilled. In a separate 96 well dilution plate, 199 uL
cDMEM and 1 uL of DMSO or any one of the compounds disclosed herein
(shown as Test Compound 1, 2, 3, 4, 5, or 6 below) were added to
wells A4, A8, C4, C8, E4, E8, G4, and G8. 133.3 uL cDMEM was added
to wells 1, 2, 3, 5, 6, and 7 in rows A, C, E and G of the dilution
plate. Compounds were serially diluted leftwards in threefold
dilutions (66.7 uL into 133.3 uL cDMEM). 20 uL of each dilution was
transferred in duplicate (duplicates in vertical paired wells) to
the cells plated in the 96-well plate shown in Table 5, to the
total concentrations shown below. 200 uL cDMEM was added to media
wells (wells G5-H8). The plate was then placed in a humidified
chamber for a 2 day incubation, and then photographed (media was
more yellow in wells with potent cell growth). Absorbance was then
measured at about 535 nM (lower for more acidic media) and about
450 nM (higher for more acidic media). The results of the growth
assay as shown in Table 6.
TABLE-US-00010 TABLE 5 1 2 3 4 5 6 7 8 A Test Test Com- Com- pound
1 pound 5 B C Test Test Com- Com- pound 2 pound 6 D E Test DMSO
Com- pound 3 F G Test media Com- only pound 4 H Conc 0.185 0.556
1.667 5 0.185 0.5556 1.667 5 (uM)
TABLE-US-00011 TABLE 6 % % % % Compound Ref. Growth at Growth at
Growth at Growth No. 0.185 uM 0.5556 uM 1.667 uM at 5 uM 3; Formic
Acid D D C A 16; Formic Acid D D D B 18; Formic Acid D D C A 19;
Formic Acid D D C A 20; Formic Acid D D D C 21; Formic Acid D D D B
22; Formic Acid D D D A 23; Formic Acid D C C D 24; Formic Acid D D
C C 25; Formic Acid D D D D 27; Formic Acid D D C B 28; Formic Acid
D D C B 29; Formic Acid D D D D 32; Formic Acid D D C B 33; Formic
Acid D D D C 34; Formic Acid D D D A 35; Formic Acid D D C B 37;
HCl .sup. n/a D C B 46; Formic Acid D D D D 3; Formic Acid D D C A
16; Formic Acid D D D B 18; Formic Acid D D C A 19; Formic Acid D D
C A 20; Formic Acid D D D C 21; Formic Acid D D D B 22; Formic Acid
D D D A 52; Formic Acid D D D C 55; Formic Acid D D D D 65; Formic
Acid D D D C 67; Formic Acid D D C C 69; Formic Acid n/a D C C 71;
Formic Acid D D C B Note: % Growth data are designated within the
following ranges: A: .ltoreq.25%; B: >25% to .ltoreq.50%; C:
>50% to .ltoreq.75%; D: >75% to .ltoreq.100%;
Example 4: Microsome Stability Assay
[0447] The formic acid salt of Compound 3 was tested under the
microsome stability assay outlined below. Test compounds were
incubated at 37.degree. C. with liver microsomes (pooled from
multiple donors) at 1 NM in the presence of a NADPH regenerating
system at 0.5 mg/ml microsomal protein. Positive controls included
Testosterone (3A4 substrate), Propafenone (2D6) and Diclofenac
(2C9), which were incubated with microsomes in the presence of an
NADPH regenerating system. At time points (0, 5, 10, 20, 30 and 60
minutes), samples were removed and immediately mixed with cold
acetonitrile containing internal standard (IS). Test compounds
incubated with microsomes without the NADPH regenerating system for
60 min was also included. A single point for each test condition
(n=1) was obtained, and samples were analyzed by LC/MS/MS.
Disappearance of the test compound was assessed based on peak area
ratios of analyte/IS (no standard curve).
[0448] The results of the microsome stability assay are shown below
in the following table:
TABLE-US-00012 TABLE 7 Human Liver Microsome (HLM) T.sub.1/2 47.5
min Human CI 29.2 uL/min/mg HLM Remaining at 60 min 44% Mouse Liver
Microsome T.sub.1/2 43.5 min Mouse Liver Microsome CI 31.9
uL/min/mg Mouse Liver Microsome Remaining at 60 min 41% No issues
with plasma stability were observed.
Example 5: ELISA Assay
[0449] Total human or mouse CD4 T cells are isolated by negative
selection with Miltenyi MACS beads. Mouse CD4 T cells are isolated
from mouse spleen while human CD4 T cells were isolated from human
PBMCs. CD4 T cells are washed and then mixed with CD3/CD28
activator Dynabeads at 8 pm. After a 36 hour incubation, select
IRE1a inhibitor compounds or IRE1a inhibitor controls are added and
incubated for 2 hours.
[0450] After the two hour incubation, mouse or human cell-free
malignant ascites supernatants or cRPMI control are added. After a
10 hour incubation, supernatants are isolated and used in an IFN-g
ELISA assay. Trizol is added to each ELISA well containing T Cells
for isolating RNA. ELISA assay is performed with the eBioscience
Ready-Set-Go IFN-g ELISA kit according to the manufacturer's
recommended protocol.
Example 6: T Cell Metabolism Assay
[0451] Total human or mouse CD4 T cells are isolated by negative
selection with Miltenyi MACS beads. Mouse CD4 T cells are isolated
from mouse spleen while human CD4 T cells are isolated from human
PBMCs. One and a half million CD4 T cells are washed and then mixed
with CD3/CD28 activator Dynabeads at a 1:1 bead:cell ratio and
plated in complete RPMI in a 6 well plate. After a 24 hour
incubation, select IRE1a inhibitor compounds or IRE1a inhibitor
control compounds are added and incubated for 2 hours. After the
two hour incubation, mouse or human cell-free malignant ascites
supernatants or cRPMI control are added. After a 16 hour
incubation, the dynabeads are removed by magnetic separation and
mitochondrial oxygen consumption rate (OCR) and glycolytic
extracellular acidification rate (ECAR) is measured with the
Seahorse XFe96 Analyzer (Agilent). Samples are assayed in
triplicate with 150,000 viable cells plated in each well of the
assay plate. Supernatants are additionally isolated and used in
downstream IFN-g ELISA assays. IRE1a activity is also measured by
quantifying XBP1 splicing with quantitative PCR or by intracellular
flow cytometric staining with an XBP1s-specific monoclonal antibody
(clone: Q3-695; BD Pharmingen).
Example 7: DC Lipid Accumulation Assay
[0452] Approximately 3.times.10.sup.6 bone marrow cells (after RBC
lysis) are seeded in 10 mL cRPMI with 20 ng/mL GM-CSF in a petri
dish. On culture day 3, 10 mL of cRPMI+20 ng/mL GM-CSF is added. On
culture day 6, non-adherent cells from each plate are collected and
resuspended in 20 mL of fresh cRPMI+20 ng/mL GM-CSF. On culture day
7, suspension cells are harvested, counted, and the resuspended at
500,000 cells per 180 microliters in fresh cRPMI+20 ng/mL
GM-CSF+110% final concentration of IRE1a inhibitor compounds or
DMSO as a control. 180 microliters of cell suspension are added to
each well of a 96 well flat bottom TC-treated plate and incubated
for 2 hours. 20 ul of 10.times.LPS (1 ug/mL) prepared in cRPMI+20
ng/mL GM-CSF is added to indicated wells and incubated for another
6 hours. Cells are spun down and supernatant was stored in a new
96-well V-bottom plate. 200 microliters of trizol is added to
pelleted cells for subsequent RNA analysis.
Example 8: Bioavailability Studies
[0453] FIG. 3 depicts the mean plasma concentration of compound 3
(left) after intravenous (IV, lmg/kg), oral (PO, 25 mg/kg), and
intraperitoneal (IP, 25 mg/kg) dosing and compound 37 (right) after
intravenous (IV, lmg/kg), oral (PO, 30 mg/kg), and intraperitoneal
(IP, 30 mg/kg) dosing.
Example 9: Suppression of XBP1 Splicing by Compound 3
[0454] FIG. 4 shows the results of the suppression of XBP1 splicing
by Compound 3. Mice were injected with 0.25 mg/kg tunicamycin
dissolved in DMSO: PBS at a ratio of 1:3. After 2 hours, the mice
were injected with 10 mg/kg of Compound 3 dissolved in water or
water alone as a vehicle control. After an additional 4 hours, the
animals were euthanized, livers dissected out, and 2-3 mm.sup.3
liver pieces are flash frozen on dry ice. Liver pieces were then
thawed in Trizol on ice, homogenized for 3 minutes with a bead mill
at medium-high speed. RNA was then extracted from the Trizol
solution according to the manufacturer's recommendation. Gene
expression analysis was also performed via Reverse Transcription
quantitative PCR (RT-qPCR) using a Stratagene Mx3005 instrument and
SYBR green I (Life Technologies). Gene expression was measured of
the spliced Xbp1s transcript, a primer set measuring all Xbp1
transcripts, Xbp1s target genes including Sec24d and general ER
stress response markers Hspa5 (BiP) and Ddit3 (CHOP). These data
indicate that Compound 3 potently suppresses IRE1a-mediated XBP1
splicing in vivo after low-dose intraperitoneal injection.
Example 10: Inhibition of IRE1a Signaling in Cell Types within the
Tumor Microenvironment
[0455] A syngeneic mouse model for metastatic, orthotopic ovarian
cancer was used to analyze the in vivo effects of compounds
described herein. Assay conditions were similar to those described
in Example 11, administering compound 3 for comparison against
controls. As shown in the top panel of FIG. 5 shows that mice with
metastatic ovarian cancer were injected with 11 mg/kg of Compound 3
or a vehicle. After 12 hours, the ascites were drained and FACS was
used to purify the cells into four populations: tumor cells,
dendritic cells (DC), CD4+ T cells, and CD8+ T cells. Then, PCR and
qPCR was used to quantify spliced Xbp1 transcripts and total Xbp1
transcripts. The bottom panel of FIG. 5 shows that the splicing
ratio of XBP1, calculated as the amount of spliced Xbp1 transcripts
divided by the total Xbp1 transcripts, in the different cell types
of mice treated with Compound 3 was markedly reduced compared to
the vehicle-treated mice. Compound 3 can therefore inhibit
IRE1a-mediated XBP1 splicing in vivo in tumor cells and key immune
cell types found within the tumor microenvironment.
Example 11: Xbp1 Activation in ID8 Mouse Model
[0456] A syngeneic mouse model for metastatic, orthotopic ovarian
cancer is used to analyze the in vivo effects of compounds
described herein. In a first analysis, IRE1a/XBP1 activation is
assessed in the ID8 mouse model for ovarian cancer.
[0457] Parental ID8 or aggressive ID8-Defb29/Vegf-A intraperitoneal
ovarian tumors are generated. About 1-2.times.10.sup.6 tumor cells
are injected into wild type female C57BL/6 mice. After 3 weeks, a
first group of 3-5 tumor bearing mice (parental ID8 and
ID8-Defb29/Vegf-A mice) and tumor-free naive mice are injected
intraperitoneally with a compound from Table 1. Additional groups
of 3-5 tumor bearing mice and naive mice are injected with vehicle
(PBS) as a control. Tumors are resected and ascites drained from
the mice 12-24 hours after the injection for analyzing IRE1a
pathway activation in the tumor microenvironment.
[0458] Fluorescently activated cell sorting (FACS) is then
performed to purify cells from the tumors and ascites. Tumor
dendritic cells (tDCs)
(CD45.sup.+CD11c.sup.+CD11b.sup.+MHC-II.sup.+CD8.alpha..sup.low),
tumor cells (CD45-SSC.sup.hi), CD4+ T cells
(CD45.sup.+CD3.sup.+CD4.sup.+) and CD8+ T cells
(CD45.sup.+CD3.sup.+CD4.sup.+) are isolated from tumors and ascites
of parental ID8 mice and ID8-Defb29/Vegf-A mice. Control splenic
dendritic cells (sDCs) (CD45.sup.+CD11c.sup.+CD1
b.sup.+MHC-II.sup.+CD8.alpha..sup.-) or splenic T cells
(CD45.sup.+CD3.sup.+CD4.sup.+ or CD45.sup.+CD3.sup.+CD8.sup.+) are
isolated from spleens of naive mice or ID8 mice and
ID8-Defb29/Vegf-A mice. During sorting, viable cells are identified
using the LIVE/DEAD Fixable Yellow Dead Cell Stain Kit (Life
Technologies).
[0459] Total Xbp1 mRNA expression and spliced Xbp1 (Xbp1s) are
quantified in sDCs and T cells from naive mice, sDCs and T cells
from parental ID8 mice and ID8-Defb29/Vegf-A mice, and tDCs, tumor
cells, and tumor-infiltrating T cells from parental ID8 mice and
ID8-Defb29/Vegf-A mice administered either vehicle or a compound
from Table 1. Briefly, RNA from sorted cells are isolated using the
Trizol reagent. 0.1-1 ug of RNA are used to generate cDNA using the
High Capacity cDNA Reverse Transcription Kit (Life Technologies).
Mouse Xbp1 splicing assays are performed using conventional Reverse
Transcription PCR (RT-PCR) and primers shown in Table 8. Gene
expression analysis is also performed via Reverse Transcription
quantitative PCR (RT-qPCR) using a Stratagene Mx3005 instrument and
SYBR green I (Life Technologies). Gene expression is measured of
Xbp1 target genes including ERdj4, Sec24d, and Sec61a1 and general
ER stress response markers Hspa5 (BiP) and Ddit3 (CHOP). Murine
Xbp1s transcript expression is analyzed using a primer that spans
the splicing junction site.
TABLE-US-00013 TABLE 8 SEQ ID Species Gene Oligo name Sequence
5'-3' NO Purpose Mouse Xbp1 Xbp1-SA-F ACACGTTTGGGAATGGACAC Splicing
Xbp1-SA-F CCATGGGAAGATGTTCTGGG Assay Mouse Actb actb1083
CTCAGGAGGAGCAATGATCTT RT-qPCR GAT actb987 TACCACCATGTACCCAGGCA
Mouse Xbp1 Xbp1.total-F GACAGAGAGTCAAACTAACGT RT-qPCR GG
Xbp1.total-R GTCCAGCAGGCAAGAAGGT Mouse Xbp1s XBPsA406F
AAGAACACGCTTGGGAATGG RT-qPCR XBPsAa518R CTGCACCTGCTGCGGAC Mouse
Xbp1 XBP1WT205-F CCTGAGCCCGGAGGAGAA RT-qPCR (exon 2) XBP1WT272-R
CTCGAGCAGTCTGCGCTG Mouse Dnajb9/Erdj4 ERdj4-F TAAAAGCCCTGATGCTGAAGC
RT-qPCR ERdj4-R TCCGACTATTGGCATCCGA Mouse Sec61a1 Sec61a1-F
CTATTTCCAGGGCTTCCGAGT RT-qPCR Sec61a1-R AGGTGTTGTACTGGCCTCGGT Mouse
Edem1 EDEM-F AAGCCCTCTGGAACTTGCG RT-qPCR EDEM-R AACCCAATGGCCTGTCTGG
Mouse Hspa5/BiP Grp78-F TCATCGGACGCACTTGGAA RT-qPCR Grp78-R
CAACCACCTTGAATGGCAAGA Mouse Ddit3/CHOP CHOP-F GTCCCTAGCTTGGCTGACAGA
RT-qPCR CHOP-R TGGAGAGCGAGGGCTTTG Mouse Agpat6 Agpat6-F
AGCTTGATTGTCAACCTCCTG RT-qPCR
[0460] Protein analysis of XBP1S is performed by Western blot or
intracellular flow cytometric analysis of sDCs and T cells from
naive mice, sDCs and T cells from parental ID8 mice and
ID8-Defb29/Vegf-A mice, and tDCs, tumor cells and
tumor-infiltrating T cells from parental ID8 mice and
ID8-Defb29/Vegf-A mice administered either vehicle or a compound
from Table 1. Briefly, for Western blotting 5.times.10.sup.6 sDCs,
tumor cells, T cells, or tDCs are washed twice in 1.times. cold PBS
and nuclear proteins are purified using the Nuclear Extraction Kit
(Life Technologies). Proteins are quantified using the BCA method
(Pierce) and 15-20 ug of nuclear proteins are separated via
SDS-PAGE and are transferred onto nitrocellulose membranes.
Anti-mouse XBP1s (GL Biochem) is raised in rabbit using a peptide
corresponding to the XBP1s C-terminus, and is used at a 1:500
dilution for immunoblotting. Goat anti-mouse Lamin B (Santa Cruz)
is used at 1:2000. HRP-conjugated secondary antibodies to rabbit
and mouse (Santa Cruz) are used at a 1:2000 dilution. SuperSignal
West Femto (Pierce) is used as Chemiluminescent Substrate and blots
are imaged using a FluorChemE instrument (ProteinSimple). For
intracellular flow cytometry of XBP1s protein, 1-2 million
splenocytes or dissociated cells from solid tumors or ascites are
washed in cold PBS and stained with the Ghost Dye 510 fixable
viability dye diluted 1:1000 in PBS for 30 minutes on ice. The
staining reaction is quenched with 2 mL of FACS buffer (PBS with 2%
fetal bovine serum and 1 mM EDTA), cells pelleted by centrifugation
at 300.times.g for 5 minutes, and then surface stained with
antibodies directed at key lineage defining markers such as
CD45/CD3/CD4/CD8 (for T cells) or CD45/CD11c/MHC-II (for DCs) for
30 minutes in FACS buffer on ice. Cells are washed twice with FACS
buffer and then fixed and permeabilized for 30 minutes with the
eBioscience FoxP3 nuclear staining kit according to the
manufacturer's protocol. Cells are washed twice with 1.times.
permeabilization buffer, then Fc receptors are blocked with
Truestain FcX anti-mouse CD16/32 (Biolegend) for 15 minutes at room
temperature. Finally, 5 microliters of XBP1s antibody (clone
Q3-695) or an equivalent amount of isotype control antibody are
added directly to cells and stained for 30 minutes at room
temperature protected from light. Cells are washed twice with
1.times. permeabilization buffer and resuspended in FACS buffer,
then analyzed on a flow cytometer such as the BD LSR II.
Example 12: Ovarian Cancer Progression
[0461] Tumor progression is measured in parental ID8 and aggressive
ID8-Defb29/Vegf-A mice administered vehicle or a compound from
Table 1. Similar to Example 1, parental ID8 or aggressive
ID8-Defb29/Vegf-A intraperitoneal ovarian tumors are generated.
Briefly, 1-2.times.10.sup.6 tumor cells are injected into wild type
C57BL/6 mice. After 2 weeks, a first group of 8-10 tumor bearing
mice (parental ID8 and ID8-Defb29/Vegf-A mice) and a separate group
of naive mice are injected intraperitoneally once per day with a
compound from Table 1. Additional groups of tumor bearing mice and
naive mice are injected with PBS as a control. In combination
therapy studies, additional groups of mice are injected every other
day with 200 ug isotype control antibody or blocking antibodies
against CTLA-4 or PD-1. A final group of mice receives a
combination therapy consisting of compound from Table 1 and 200 ug
checkpoint blocking antibody directed against either CTLA-4 or
PD-1.
[0462] Tumor size, tumor volume, number of tumor masses as well as
spleen size are then measured from vehicle or compound treated
naive mice, parental ID8 mice, and aggressive ID8-Defb29/Vegf-A
mice. Naive mice are monitored weekly for signs of morbidity or
mortality from compound treatment. Malignant ascites accumulation
is measured weekly as the percentage of body weight gain, and
animals are euthanized once they reach 40% body weight gain.
Survival of mice bearing parental ID8 tumors or aggressive
ID8-Defb29/Vegf-A tumors that are treated with vehicle or a
compound from Table 1 is calculated as the number of days required
to reach 40% weight gain since the tumor cells are originally
injected. Compounds listed in Table 1 are assessed for reduction in
tumor-associated weight gain compared with vehicle control-treated
animals.
Example 13: Lipid Analysis and Transcriptional Profiling
[0463] Lipid peroxidation byproducts are measured in mice described
in Examples 1-2. Intracellular lipid content is evaluated via flow
cytometry using
4,4-Difluoro1,3,5,7,8-Pentamethyl-4-Bora-3a,4a-Diaza-s-Indacene
(BODIPY 493/503; Life Technologies). Briefly, 5.times.10.sup.6
splenic cells or dendritic cells from naive mice, parental ID8
mice, and aggressive ID8-Defb29/Vegf-A mice that are administered
vehicle or a compound from Table 1 are stained for surface markers
using antibodies that do not overlap with BODIPY 493/503, namely
CD1 Ic-APC, CD45-APC-Cy7, and CD11b-Pacific Blue, followed by
staining with 500 mL of BODIPY 493/503 at 0.5 mg/mL in PBS for 15
minutes at room temperature in the dark. BODIPY 493/503 staining is
then detected in the PE or FITC channel. Lipid analysis is also
performed using electron microscopy analysis and mass spectrometry.
In addition to lipid content, intracellular reactive oxygen species
(ROS) and 4-HNE adducts are measured with 2',7'-dichlorofluorescin
diacetate (DCFDA) and a competitive ELISA assay (Cell Biolabs),
respectively.
[0464] Transcriptional profiling is performed in naive mice,
parental ID8 mice, and aggressive ID8-Defb29/Vegf-A mice that are
treated with vehicle or a compound from Table 1. Gene expression of
genes that are involved in unfolded protein response
(UPR)/endoplasmic reticulum (ER) stress and genes involved in lipid
metabolism are measured in tDCs purified by FACS. These include but
are not limited to Sec24d, Sec61a1, P4hb, Fasn, Agpat4, and Agpat6.
XBP1 pathway activation and key effector functions are also
measured by quantitative PCR in tumor-infiltrating lymphocytes
purified by FACS. Compounds listed in Table 1 are assessed for
reduction in XBP1s target gene expression and BODIPY 493/503
fluorescence in tumor-associated DCs.
Example 14: T Cell Activation
[0465] T cell activation is determined in ovarian cancer bearing
mice following administration of compounds described herein. In
vivo antigen presentation experiments are performed in wild-type
C57BL/6 female mice bearing parental ID8 or ID8-Defb29/Vegf-A
ovarian tumors. After three weeks, naive mice, parental ID8 mice,
or ID8-Defb29/Vegf-A mice are intraperitoneally injected with 0.6
mg of full length endotoxin-free ovalbumin (OVA) (SIGMA, grade
VII). Mice are then injected with vehicle or a compound from Table
1 3 hours later. After 18 hours, mice receive intraperitoneally
2.times.10.sup.6 CFSE-labeled T cells negatively purified from OT-1
transgenic mice. Peritoneal wash samples (10 mL) are collected
after 72 hours and analyzed for CFSE dilution via FACS to calculate
number of T cell divisions. Data are analyzed using FlowJo version
9 or 10.
[0466] In vitro antigen presentation experiments are performed with
isolated tDCs from wild-type C57BL/6 female mice bearing parental
ID8 or ID8-Defb29/Vegf-A ovarian tumors. After 3-4 weeks of tumor
burden, tDCs are purified by FACS from the peritoneal cavity of
naive mice, parental ID8 mice, or ID8-Defb29/Vegf-A, and are pulsed
with full-length endotoxin-free ovalbumin protein (Sigma, grade
VII) in cRPMI containing 25% cell-free ovarian cancer ascites
supernatants overnight at 37.degree. C. Antigen-loaded tDCs are
then washed twice with cRPMI and co-cultured with CFSE-labeled OT-I
CD8+ T cells immunopurified from OT-1 mice at a 1:10 (DC to T cell)
ratio. After 3-5 days, cultures analyzed for CFSE dilution via FACS
to calculate number of T cell divisions. Data are analyzed using
FlowJo version 9 or 10. Isolated tDCs from animals treated with a
compound from Table 1 are assessed for enhancement of T cell
proliferation relative to tDCs isolated from vehicle-treated
controls.
Example 15: Anti-Tumor Immunity
[0467] Effects of test compounds in inducing anti-tumor immunity
are analyzed. Mice are intraperitoneally injected with
ID8-Defb29/Vegf-A ovarian cancer cells and are treated with a
compound from Table 1 (n=3-5/group) or vehicle daily starting at
day 14 after tumor challenge. After 1-2 weeks of daily treatment,
peritoneal lavage samples are analyzed for the number of metastatic
cancer cells and tumor ascites accumulation in the peritoneal
cavity.
[0468] The capacity for T cells to respond to tumor antigens is
also measured. Freshly isolated ascites cells are cultured in
96-well flat bottom plates for 6 hours in the presence of PMA,
lonomycin and Brefeldin A to induce cytokine translation and
retention within the secretory pathway. After this stimulation
period, the cells are washed twice with FACS buffer (PBS+2% FBS and
1 mM EDTA) and stained for 30 minutes with Ghost Dye 510 Violet
(Tonbo Biosciences) in PBS on ice according to the manufacturer's
protocol. Cells are then washed twice more with FACS buffer and
then stained with antibodies directed against CD45, CD3, CD4, CD8,
and CD44 on ice for 30 minutes. Fc receptors are also blocked at
this time with the TrueStain FcX Antibody (anti-CD16/32,
Biolegend). After this staining period, cells are washed twice more
with FACS buffer, resuspended in 1.times. Fix/Perm reagent
(eBioscience Foxp3/Transcription Factor Staining Buffer Set), mixed
well by pipetting 2-3 times and incubated for 30 minutes at room
temperature protected from light. Cells are then washed twice with
1.times. permeabilization buffer and stained at room temperature
with antibodies directed against murine Fc receptor CD16/32 (Fc
Block), IFN-gamma and Granzyme-B for 30 minutes. After this
incubation period, cells are washed once with 1.times.
permeabilization buffer, once with FACS buffer, and resuspended in
FACS buffer for analysis by flow cytometry. Data are analyzed using
FlowJo version 9 or 10.
[0469] Total splenic T cells or Ficoll-enriched leukocytes
(2-3.times.10.sup.5) from peritoneal wash samples are obtained 4
days after the last treatment (day 27) and are cocultured in 10%
FBS RPMI with 2-3.times.10.sup.4 bone marrow-derived DCs that are
pulsed overnight with irradiated ID8-Defb29/Vegf-A ovarian cancer
cells. Supernatants are collected after 48-72 hours of stimulation.
IFN-.gamma. and Granzyme B secretion is determined by ELISA using
the Ready-SET-Go Kit (eBioscience). Tumor-resident T cells from
animals treated with a compound from Table 1 are assessed for
increased IFN-.gamma. and Granzyme B production relative to T cells
isolated from vehicle-treated controls.
Example 16: IC.sub.50 Measurements for hERG Potassium Ion
Channel
[0470] Blockade of the cardiac ion channel coded by the hERG gene
can lead to cardiac arrhythmia. Many small compounds have been
found to bind to the hERG gene leading to problems in the QT
response. To determine the viability of the compounds disclosed
herein as pharmacological agents that would not affect the hERG
channel blockade, a standard automated planar clamp method was
employed to determine the IC.sub.50 for various test compounds on
their inhibition of the channel. An electrophysiological assay was
prepared to measure the electric current passing through the hERG
channel expressed in a stable CHO cell line by applying the planar
clamp method. This assay was performed using the automated QPatch
platform (Sophion, Denmark) which allows fast and accurate
electrophysiological characterization of the hERG ion channel and
the determination of IC.sub.50 values for the test compounds, as
shown in Table 9. The significant separation (100-1000.times.)
between effects against IRE1a-mediated XBP1 splicing in 293T cells
and the effect on hERG channels suggest that there is a good safety
margin for targeting IRE1a.
TABLE-US-00014 TABLE 9 Compound Ref. No. Mean IC.sub.50 3; Formic
Acid B 16; Formic Acid B 24; Formic Acid C 37; HCl .sup. B 69;
Formic Acid B Note: hERG channel blockade Mean IC.sub.50 data are
designated within the following ranges: A: >50 uM; B: >10 uM
to .ltoreq.50 uM, C: >1 uM to .ltoreq.10 uM; and D: .ltoreq.1
uM.
Example 17: Pharmacokinetic Studies
[0471] Compounds are tested in a pharmacokinetic ("PK") study to
determine the half-life (T.sub.1/2) in mice. A compound from Table
1 is dissolved in a vehicle to make a test antibiotic composition.
The vehicle might be, for example, a water or a 25% PEG400 in
saline solution Administration to each mouse is performed via
intravenous (IV) cannulation of the tail vein. Blood is collected
over K2-EDTA anticoagulant from the submandibular or saphenous vein
at predetermined time points. Following collection, the blood
samples are stored at -70.degree. C. until analysis by LC-MS and
comparison to a standard calibration curve results in the T.sub.1/2
for each compound.
[0472] Alternatively, on study day, the animals (fasted) usually
receive a compound from Table 1 (typically 10 or 30 mg/kg) by IP
injection (typically 10 mL/kg). The IP dose is typically delivered
via a bolus into the IP space for mice. All dosages are expressed
as target dose in mg free base/acid equivalent/kg; actual doses are
calculated for each individual animal and are recorded. The plasma
samples are then collected as above and plasma levels
determined.
Example 18: Protein Binding--Plasma Protein Binding Assay-HTD
Method
[0473] The plasma protein binding is determined according to the
following steps. Frozen plasma or freshly prepared plasma from
various subjects are used as test matrix. They are purchased from
commercial vendors or prepared in house from animals. Warfarin is
used as a positive control. Other control compound(s) may be used
according to specific requirement. One or more compounds from Table
1 are spiked into blank matrix at the final concentration of 2
.mu.M (or other test concentrations based on specific requirement).
Final organic solvent concentration is <1%. If plasma samples
are collected from in-life studies, they are used as test matrix
without spiking compounds. An appropriate volume of spiked plasma
solution is removed before incubation for recovery calculation. An
aliquot (e.g., 150 uL) of matrix sample is added to one side of the
chamber (donor chamber) in a 96-well equilibrium dialyzer plate
(HTD dialysis device) and an equal volume of dialysis buffer is
added to the other side of the chamber (receiver chamber).
Triplicate incubations are performed (or other replicate number
according to specific requirement). The dialyzer plate is placed
into a humidified incubator with 5% CO.sub.2 and incubated at
37.degree. C. for 4 to 6 hours. After incubation, samples are taken
from the donor chamber as well as the receiver chamber. The plasma
sample is matched with an appropriate volume of blank buffer; and
buffer samples are matched with an appropriate volume of blank
plasma. The matrix-matched samples are quenched with stop solution
containing internal standard. Samples are analyzed by LC/MS/MS.
Test compound concentrations in donor and receiver samples are
expressed as peak area ratios of analyte/internal standard. If a
quantitative analysis is needed, a set of calibration curve and
quality controls could be included.
Example 19: Inhibition of Triple Negative Breast Cancer
[0474] XBP1 is known to binds directly to HIFla in triple negative
breast cancer, and this cooperative binding enhances the
upregulation of HIF1a-dependent downstream target genes. Compounds
in Table 1 are screened for impact on XBP1 protein level, thereby
removing a key binding partner for HIF1a and reducing expression of
HIFla-dependent target genes such as VEGFA, PDK1, GLUT1, and
JMJD1A. Specifically, human triple-negative breast cancer cell
lines are treated with vehicle control or a compound shown in Table
1, then cultured under hypoxia (0.1% O.sub.2) for 24 hours. Cells
are then lysed with RLT buffer, RNA extracted with the RNeasy 96
kit (Qiagen) and complementary DNA generated from the pure RNA.
Semi-quantitative PCR and quantitative PCR are then used to
quantify spliced Xbp1 transcripts, total Xbp1 transcripts, target
genes regulated by XBP1s (e.g. SEC61A1, P4HB, EDEM1, AND SEC24D)
and target genes regulated by HIFla (e.g. VEGFA, PDK1, GLUT1, and
JMJD1A). The splicing ratio of XBP1 is calculated by determining
the amount of spliced Xbp1 transcripts divided by the total number
of spliced and unspliced Xbp1 transcripts, an indicator for
compounds that inhibit critical intracellular signaling required
for TNBC tumor-initiating cell function and metastatic capacity.
Compounds shown in Table 1 are assessed for downregulation of
XBP1s, XBP1 splicing ration, XBP1s-dependent target gene
expression, and HIFla target gene expression relative to DMSO
control-treated samples.
Example 20: Soft Agar Colony Formation Assay
[0475] One hundred thousand breast cancer cells are mixed 4:1 (v/v)
with 2.0% agarose in growth medium containing vehicle control or a
compound listed in Table 1 for a final concentration of 0.4%
agarose. The cell mixture is plated on top of a solidified layer of
0.8% agarose in growth medium. Cells are fed every 6-7 days with
growth medium containing 0.4% agarose and vehicle control or a
compound from Table 1, matching the initial plating conditions. The
number of colonies are counted after 20 days, with the number of
colonies visible at the end of the growth period to identify
colonies with reduced growth.
Example 21: Inhibition of Metastatic Breast Cancer
[0476] Mice with established metastatic breast cancer are
separately injected with each of the compounds in Table 1. After 12
hours, the tumors are excised, mechanically separated, and
enzymatically digested to single cell suspensions. Flow-assisted
cell sorting is then used to purify four populations of cells:
tumor cells, dendritic cells (DC), CD4+ T cells, and CD8+ T cells.
The cells are sorted directly into RLT buffer for instant cell
lysis and RNase deactivation. Then, cellular RNA is purified with
the RNeasy 96 kit (Qiagen), and complementary DNA generated from
the pure RNA. Semi-quantitative PCR and quantitative PCR are then
used to quantify spliced Xbp1 transcripts, total Xbp1 transcripts,
and target genes regulated by XBP1 s such as SEC61A1, P4HB, EDEM1,
AND SEC24D. The splicing ratio of XBP1 is calculated by determining
the amount of spliced Xbp1 transcripts divided by the total number
of spliced and unspliced Xbp1 transcripts, an indicator for
compounds that inhibit metastatic breast cancer. Compounds shown in
Table 1 are assessed for reduction in XBP1s transcripts, XBP1
splicing and downstream XBP1s target genes relative to vehicle
control-treated mice.
Example 22: Inhibition of Lung Cancer
[0477] Mice with established primary or metastatic lung cancer are
separately injected with each of the compounds in Table 1. After 12
hours, the tumors are excised, mechanically separated, and
enzymatically digested to single cell suspensions. Flow-assisted
cell sorting is then used to purify four populations of cells:
tumor cells, dendritic cells (DC), CD4+ T cells, and CD8+ T cells.
The cells are sorted directly into RLT buffer for instant cell
lysis and RNase deactivation. Then, cellular RNA is purified with
the RNeasy 96 kit (Qiagen), and complementary DNA generated from
the pure RNA. Semi-quantitative PCR and quantitative PCR are then
used to quantify spliced Xbp1 transcripts, total Xbp1 transcripts,
and target genes regulated by XBP1s such as SEC61A1, P4HB, EDEM1,
AND SEC24D. The splicing ratio of XBP1 is calculated by determining
the amount of spliced Xbp1 transcripts divided by the total number
of spliced and unspliced Xbp1 transcripts, an indicator for
compounds that inhibit primary or metastatic lung cancer. Compounds
shown in Table 1 are assessed for reduction in XBP1s transcripts
relative to vehicle control-treated mice.
Example 23: Inhibition of Bladder Cancer
[0478] Mice with established primary or metastatic bladder cancer
are separately injected with each of the compounds in Table 1.
After 12 hours, the tumors are excised, mechanically separated, and
enzymatically digested to single cell suspensions. Flow-assisted
cell sorting is then used to purify four populations of cells:
tumor cells, dendritic cells (DC), CD4+ T cells, and CD8+ T cells.
The cells are sorted directly into RLT buffer for instant cell
lysis and RNase deactivation. Then, cellular RNA is purified with
the RNeasy 96 kit (Qiagen), and complementary DNA generated from
the pure RNA. Semi-quantitative PCR and quantitative PCR are then
used to quantify spliced Xbp1 transcripts, total Xbp1 transcripts,
and target genes regulated by XBP1s such as SEC61A1, P4HB, EDEM1,
AND SEC24D. The splicing ratio of XBP1 is calculated by determining
the amount of spliced Xbp1 transcripts divided by the total number
of spliced and unspliced Xbp1 transcripts, an indicator for
compounds from that inhibit primary or metastatic bladder cancer.
Compounds shown in Table 1 are assessed for reduction in XBP1s
transcripts, XBP1 splicing and downstream XBP1s target genes
relative to vehicle control-treated mice.
[0479] While preferred embodiments of the present invention have
been shown and described herein, it will be obvious to those
skilled in the art that such embodiments are provided by way of
example only. Numerous variations, changes, and substitutions will
now occur to those skilled in the art without departing from the
invention. It should be understood that various alternatives to the
embodiments of the invention described herein may be employed in
practicing the invention. It is intended that the following claims
define the scope of the invention and that methods and structures
within the scope of these claims and their equivalents be covered
thereby.
TABLE-US-00015 SEQUENCE LISTING SEQ ID NO: 1
MPARRLLLLLTLLLPGLGIFGSTSTVTLPETLLFVSTLDGSLHAVSKRTG
SIKWTLKEDPVLQVPTHVEEPAFLPDPNDGSLYTLGSKNNEGLTKLPFTI
PELVQASPCRSSDGILYMGKKQDIWYVIDLLTGEKQQTLSSAFADSLCPS
TSLLYLGRTEYTITMYDTKTRELRWNATYFDYAASLPEDDVDYKMSHFVS
NGDGLVVTVDSESGDVLWIQNYASPVVAFYVWQREGLRKVMHINVAVETL
RYLTFMSGEVGRITKWKYPFPKETEAKSKLTPTLYVGKYSTSLYASPSMV
HEGVAVVPRGSTLPLLEGPQTDGVTIGDKGECVITPSTDVKFDPGLKSKN
KLNYLRNYWLLIGHHETPLSASTKMLERFPNNLPKHRENVIPADSEKKSF
EEVINLVDQTSENAPTTVSRDVEEKPAHAPARPEAPVDSMLKDMATIILS
TFLLIGWVAFIITYPLSMHQQQQLQHQQFQKELEKIQLLQQQQQQLPFHP
PGDTAQDGELLDTSGPYSESSGTSSPSTSPRASNHSLCSGSSASKAGSSP
SLEQDDGDEETSVVIVGKISFCPKDVLGHGAEGTIVYRGMFDNRDVAVKR
ILPECFSFADREVQLLRESDEHPNVIRYFCTEKDRQFQYIAIELCAATLQ
EYVEQKDFAHLGLEPITLLQQTTSGLAHLHSLNIVHRDLKPHNILISMPN
AHGKIKAMISDFGLCKKLAVGRHSFSRRSGVPGTEGWIAPEMLSEDCKEN
PTYTVDIFSAGCVFYYVISEGSHPFGKSLQRQANILLGACSLDCLHPEKH
EDVIARELIEKMIAMDPQKRPSAKHVLKHPFFWSLEKQLQFFQDVSDRIE
KESLDGPIVKQLERGGRAVVKMDWRENITVPLQTDLRKFRTYKGGSVRDL
LRAMRNKKHHYRELPAEVRETLGSLPDDFVCYFTSRFPHLLAHTYRAMEL
CSHERLFQPYYFHEPPEPQPPVTPDAL SEQ ID NO: 2 CAUGUCCGCAGCACAUG SEQ ID
NO: 3 CAUGUCCCCAGCACAUG
Sequence CWU 1
1
71977PRTHomo sapiens 1Met Pro Ala Arg Arg Leu Leu Leu Leu Leu Thr
Leu Leu Leu Pro Gly 1 5 10 15 Leu Gly Ile Phe Gly Ser Thr Ser Thr
Val Thr Leu Pro Glu Thr Leu 20 25 30 Leu Phe Val Ser Thr Leu Asp
Gly Ser Leu His Ala Val Ser Lys Arg 35 40 45 Thr Gly Ser Ile Lys
Trp Thr Leu Lys Glu Asp Pro Val Leu Gln Val 50 55 60 Pro Thr His
Val Glu Glu Pro Ala Phe Leu Pro Asp Pro Asn Asp Gly 65 70 75 80 Ser
Leu Tyr Thr Leu Gly Ser Lys Asn Asn Glu Gly Leu Thr Lys Leu 85 90
95 Pro Phe Thr Ile Pro Glu Leu Val Gln Ala Ser Pro Cys Arg Ser Ser
100 105 110 Asp Gly Ile Leu Tyr Met Gly Lys Lys Gln Asp Ile Trp Tyr
Val Ile 115 120 125 Asp Leu Leu Thr Gly Glu Lys Gln Gln Thr Leu Ser
Ser Ala Phe Ala 130 135 140 Asp Ser Leu Cys Pro Ser Thr Ser Leu Leu
Tyr Leu Gly Arg Thr Glu 145 150 155 160 Tyr Thr Ile Thr Met Tyr Asp
Thr Lys Thr Arg Glu Leu Arg Trp Asn 165 170 175 Ala Thr Tyr Phe Asp
Tyr Ala Ala Ser Leu Pro Glu Asp Asp Val Asp 180 185 190 Tyr Lys Met
Ser His Phe Val Ser Asn Gly Asp Gly Leu Val Val Thr 195 200 205 Val
Asp Ser Glu Ser Gly Asp Val Leu Trp Ile Gln Asn Tyr Ala Ser 210 215
220 Pro Val Val Ala Phe Tyr Val Trp Gln Arg Glu Gly Leu Arg Lys Val
225 230 235 240 Met His Ile Asn Val Ala Val Glu Thr Leu Arg Tyr Leu
Thr Phe Met 245 250 255 Ser Gly Glu Val Gly Arg Ile Thr Lys Trp Lys
Tyr Pro Phe Pro Lys 260 265 270 Glu Thr Glu Ala Lys Ser Lys Leu Thr
Pro Thr Leu Tyr Val Gly Lys 275 280 285 Tyr Ser Thr Ser Leu Tyr Ala
Ser Pro Ser Met Val His Glu Gly Val 290 295 300 Ala Val Val Pro Arg
Gly Ser Thr Leu Pro Leu Leu Glu Gly Pro Gln 305 310 315 320 Thr Asp
Gly Val Thr Ile Gly Asp Lys Gly Glu Cys Val Ile Thr Pro 325 330 335
Ser Thr Asp Val Lys Phe Asp Pro Gly Leu Lys Ser Lys Asn Lys Leu 340
345 350 Asn Tyr Leu Arg Asn Tyr Trp Leu Leu Ile Gly His His Glu Thr
Pro 355 360 365 Leu Ser Ala Ser Thr Lys Met Leu Glu Arg Phe Pro Asn
Asn Leu Pro 370 375 380 Lys His Arg Glu Asn Val Ile Pro Ala Asp Ser
Glu Lys Lys Ser Phe 385 390 395 400 Glu Glu Val Ile Asn Leu Val Asp
Gln Thr Ser Glu Asn Ala Pro Thr 405 410 415 Thr Val Ser Arg Asp Val
Glu Glu Lys Pro Ala His Ala Pro Ala Arg 420 425 430 Pro Glu Ala Pro
Val Asp Ser Met Leu Lys Asp Met Ala Thr Ile Ile 435 440 445 Leu Ser
Thr Phe Leu Leu Ile Gly Trp Val Ala Phe Ile Ile Thr Tyr 450 455 460
Pro Leu Ser Met His Gln Gln Gln Gln Leu Gln His Gln Gln Phe Gln 465
470 475 480 Lys Glu Leu Glu Lys Ile Gln Leu Leu Gln Gln Gln Gln Gln
Gln Leu 485 490 495 Pro Phe His Pro Pro Gly Asp Thr Ala Gln Asp Gly
Glu Leu Leu Asp 500 505 510 Thr Ser Gly Pro Tyr Ser Glu Ser Ser Gly
Thr Ser Ser Pro Ser Thr 515 520 525 Ser Pro Arg Ala Ser Asn His Ser
Leu Cys Ser Gly Ser Ser Ala Ser 530 535 540 Lys Ala Gly Ser Ser Pro
Ser Leu Glu Gln Asp Asp Gly Asp Glu Glu 545 550 555 560 Thr Ser Val
Val Ile Val Gly Lys Ile Ser Phe Cys Pro Lys Asp Val 565 570 575 Leu
Gly His Gly Ala Glu Gly Thr Ile Val Tyr Arg Gly Met Phe Asp 580 585
590 Asn Arg Asp Val Ala Val Lys Arg Ile Leu Pro Glu Cys Phe Ser Phe
595 600 605 Ala Asp Arg Glu Val Gln Leu Leu Arg Glu Ser Asp Glu His
Pro Asn 610 615 620 Val Ile Arg Tyr Phe Cys Thr Glu Lys Asp Arg Gln
Phe Gln Tyr Ile 625 630 635 640 Ala Ile Glu Leu Cys Ala Ala Thr Leu
Gln Glu Tyr Val Glu Gln Lys 645 650 655 Asp Phe Ala His Leu Gly Leu
Glu Pro Ile Thr Leu Leu Gln Gln Thr 660 665 670 Thr Ser Gly Leu Ala
His Leu His Ser Leu Asn Ile Val His Arg Asp 675 680 685 Leu Lys Pro
His Asn Ile Leu Ile Ser Met Pro Asn Ala His Gly Lys 690 695 700 Ile
Lys Ala Met Ile Ser Asp Phe Gly Leu Cys Lys Lys Leu Ala Val 705 710
715 720 Gly Arg His Ser Phe Ser Arg Arg Ser Gly Val Pro Gly Thr Glu
Gly 725 730 735 Trp Ile Ala Pro Glu Met Leu Ser Glu Asp Cys Lys Glu
Asn Pro Thr 740 745 750 Tyr Thr Val Asp Ile Phe Ser Ala Gly Cys Val
Phe Tyr Tyr Val Ile 755 760 765 Ser Glu Gly Ser His Pro Phe Gly Lys
Ser Leu Gln Arg Gln Ala Asn 770 775 780 Ile Leu Leu Gly Ala Cys Ser
Leu Asp Cys Leu His Pro Glu Lys His 785 790 795 800 Glu Asp Val Ile
Ala Arg Glu Leu Ile Glu Lys Met Ile Ala Met Asp 805 810 815 Pro Gln
Lys Arg Pro Ser Ala Lys His Val Leu Lys His Pro Phe Phe 820 825 830
Trp Ser Leu Glu Lys Gln Leu Gln Phe Phe Gln Asp Val Ser Asp Arg 835
840 845 Ile Glu Lys Glu Ser Leu Asp Gly Pro Ile Val Lys Gln Leu Glu
Arg 850 855 860 Gly Gly Arg Ala Val Val Lys Met Asp Trp Arg Glu Asn
Ile Thr Val 865 870 875 880 Pro Leu Gln Thr Asp Leu Arg Lys Phe Arg
Thr Tyr Lys Gly Gly Ser 885 890 895 Val Arg Asp Leu Leu Arg Ala Met
Arg Asn Lys Lys His His Tyr Arg 900 905 910 Glu Leu Pro Ala Glu Val
Arg Glu Thr Leu Gly Ser Leu Pro Asp Asp 915 920 925 Phe Val Cys Tyr
Phe Thr Ser Arg Phe Pro His Leu Leu Ala His Thr 930 935 940 Tyr Arg
Ala Met Glu Leu Cys Ser His Glu Arg Leu Phe Gln Pro Tyr 945 950 955
960 Tyr Phe His Glu Pro Pro Glu Pro Gln Pro Pro Val Thr Pro Asp Ala
965 970 975 Leu 217RNAArtificial SequenceDescription of Artificial
Sequence Synthetic probe 2cauguccgca gcacaug 17317RNAArtificial
SequenceDescription of Artificial Sequence Synthetic probe
3caugucccca gcacaug 174434PRTSaccharomyces cerevisiae 4Ser Arg Ile
Ala Asn Ile Pro Asn Phe Glu Gln Ser Leu Lys Asn Leu 1 5 10 15 Val
Val Ser Glu Lys Ile Leu Gly Tyr Gly Ser Ser Gly Thr Val Val 20 25
30 Phe Gln Gly Ser Phe Gln Gly Arg Pro Val Ala Val Lys Arg Met Leu
35 40 45 Ile Asp Phe Cys Asp Ile Ala Leu Met Glu Ile Lys Leu Leu
Thr Glu 50 55 60 Ser Asp Asp His Pro Asn Val Ile Arg Tyr Tyr Cys
Ser Glu Thr Thr 65 70 75 80 Asp Arg Phe Leu Tyr Ile Ala Leu Glu Leu
Cys Asn Leu Asn Leu Gln 85 90 95 Asp Leu Val Glu Ser Lys Asn Val
Ser Asp Glu Asn Leu Lys Leu Gln 100 105 110 Lys Glu Tyr Asn Pro Ile
Ser Leu Leu Arg Gln Ile Ala Ser Gly Val 115 120 125 Ala His Leu His
Ser Leu Lys Ile Ile His Arg Asp Leu Lys Pro Gln 130 135 140 Asn Ile
Leu Val Ser Thr Ser Ser Arg Phe Thr Ala Asp Gln Gln Thr 145 150 155
160 Gly Ala Glu Asn Leu Arg Ile Leu Ile Ser Asp Phe Gly Leu Cys Lys
165 170 175 Lys Leu Asp Ser Gly Gln Ser Ser Phe Arg Thr Asn Leu Asn
Asn Pro 180 185 190 Ser Gly Thr Ser Gly Trp Arg Ala Pro Glu Leu Leu
Glu Glu Ser Asn 195 200 205 Asn Leu Gln Thr Lys Arg Arg Leu Thr Arg
Ser Ile Asp Ile Phe Ser 210 215 220 Met Gly Cys Val Phe Tyr Tyr Ile
Leu Ser Lys Gly Lys His Pro Phe 225 230 235 240 Gly Asp Lys Tyr Ser
Arg Glu Ser Asn Ile Ile Arg Gly Ile Phe Ser 245 250 255 Leu Asp Glu
Met Lys Cys Leu His Asp Arg Ser Leu Ile Ala Glu Ala 260 265 270 Thr
Asp Leu Ile Ser Gln Met Ile Asp His Asp Pro Leu Lys Arg Pro 275 280
285 Thr Ala Met Lys Val Leu Arg His Pro Leu Phe Trp Pro Lys Ser Lys
290 295 300 Lys Leu Glu Phe Leu Leu Lys Val Ser Asp Arg Leu Glu Ile
Glu Asn 305 310 315 320 Arg Asp Pro Pro Ser Ala Leu Leu Met Lys Phe
Asp Ala Gly Ser Asp 325 330 335 Phe Val Ile Pro Ser Gly Asp Trp Thr
Val Lys Phe Asp Lys Ile Phe 340 345 350 Met Asp Asn Leu Glu Arg Tyr
Arg Lys Tyr His Ser Ser Lys Leu Met 355 360 365 Asp Leu Leu Arg Ala
Leu Arg Asn Lys Tyr His His Phe Met Asp Leu 370 375 380 Pro Glu Asp
Ile Ala Glu Leu Met Gly Pro Val Pro Asp Gly Phe Tyr 385 390 395 400
Asp Tyr Phe Ile Lys Arg Phe Pro Asn Leu Leu Ile Gly Val Tyr Met 405
410 415 Ile Val Lys Glu Asn Leu Ser Asp Asp Gln Ile Leu Arg Glu Phe
Leu 420 425 430 Tyr Ser 5424PRTHomo sapiens 5Asp Asp Gly Asp Glu
Glu Thr Ser Val Val Ile Val Gly Lys Ile Ser 1 5 10 15 Phe Cys Pro
Lys Asp Val Leu Gly His Gly Ala Glu Gly Thr Ile Val 20 25 30 Tyr
Arg Gly Met Phe Asp Asn Arg Asp Val Ala Val Lys Arg Ile Leu 35 40
45 Pro Glu Cys Phe Ser Phe Ala Asp Arg Glu Val Gln Leu Leu Arg Glu
50 55 60 Ser Asp Glu His Pro Asn Val Ile Arg Tyr Phe Cys Thr Glu
Lys Asp 65 70 75 80 Arg Gln Phe Gln Tyr Ile Ala Ile Glu Leu Cys Ala
Ala Thr Leu Gln 85 90 95 Glu Tyr Val Glu Gln Lys Asp Cys Phe Ala
His Leu Gly Leu Glu Pro 100 105 110 Ile Thr Leu Leu Gln Gln Thr Thr
Ser Gly Leu Ala His Leu His Ser 115 120 125 Leu Asn Ile Val His Arg
Asp Leu Lys Pro His Asn Ile Leu Ile Ser 130 135 140 Met Pro Asn Ala
His Gly Lys Ile Lys Ala Met Ile Ser Asp Phe Gly 145 150 155 160 Leu
Cys Lys Lys Leu Ala Val Gly Arg His Ser Phe Ser Arg Arg Ser 165 170
175 Gly Val Pro Gly Thr Glu Gly Trp Ile Ala Pro Glu Met Leu Ser Glu
180 185 190 Asp Cys Lys Glu Asn Pro Thr Tyr Thr Val Asp Ile Phe Ser
Ala Gly 195 200 205 Cys Val Phe Tyr Tyr Val Val Ser Glu Gly Ser His
Pro Phe Gly Lys 210 215 220 Ser Leu Gln Arg Gln Ala Asn Ile Leu Leu
Gly Ala Cys Ser Leu Asp 225 230 235 240 Cys Leu His Pro Glu Lys His
Glu Asp Val Ile Ala Arg Glu Leu Ile 245 250 255 Glu Lys Met Ile Ala
Met Asp Pro Gln Lys Arg Pro Ser Ala Asn Asp 260 265 270 Val Leu Lys
His Pro Phe Phe Trp Ser Leu Glu Lys Gln Leu Gln Phe 275 280 285 Phe
Gln Asp Val Ser Asp Arg Ile Glu Lys Glu Ser Leu Asp Gly Pro 290 295
300 Ile Val Lys Gln Leu Glu Arg Gly Gly Arg Ala Val Val Lys Met Asp
305 310 315 320 Trp Arg Glu Asn Ile Thr Asp Pro Leu Gln Thr Asp Leu
Arg Lys Phe 325 330 335 Arg Thr Tyr Lys Gly Gly Ser Val Arg Asp Leu
Leu Arg Ala Met Arg 340 345 350 Asn Lys Lys His His Tyr Arg Asp Leu
Pro Glu Glu Val Arg Glu Thr 355 360 365 Leu Gly Thr Leu Pro Asp Asp
Phe Val Cys Tyr Phe Thr Ser Arg Phe 370 375 380 Pro His Leu Leu Ala
His Thr Tyr Arg Ala Met Glu Leu Cys Ser His 385 390 395 400 Glu Arg
Leu Phe Gln Pro Tyr Tyr Phe His Glu Pro Pro Glu Pro Gln 405 410 415
Pro Pro Val Thr Pro Asp Ala Leu 420 6 423PRTMus musculus 6Asp Asp
Glu Asp Glu Glu Thr Arg Met Val Ile Val Gly Lys Ile Ser 1 5 10 15
Phe Cys Pro Lys Asp Val Leu Gly His Gly Ala Glu Gly Thr Ile Val 20
25 30 Tyr Lys Gly Met Phe Asp Asn Arg Asp Val Ala Val Lys Arg Ile
Leu 35 40 45 Pro Glu Cys Phe Ser Phe Ala Asp Arg Glu Val Gln Leu
Leu Arg Glu 50 55 60 Ser Asp Glu His Pro Asn Val Ile Arg Tyr Phe
Cys Thr Glu Lys Asp 65 70 75 80 Arg Gln Phe Gln Tyr Ile Ala Ile Glu
Leu Cys Ala Ala Thr Leu Gln 85 90 95 Glu Tyr Val Glu Gln Lys Asp
Phe Ala His Leu Gly Leu Glu Pro Ile 100 105 110 Thr Leu Leu His Gln
Thr Thr Ser Gly Leu Ala His Leu His Ser Leu 115 120 125 Asn Ile Val
His Arg Asp Leu Lys Pro His Asn Ile Leu Leu Ser Met 130 135 140 Pro
Asn Ala His Gly Arg Ile Lys Ala Met Ile Ser Asp Phe Gly Leu 145 150
155 160 Cys Lys Lys Leu Ala Val Gly Arg His Ser Phe Ser Arg Arg Ser
Gly 165 170 175 Val Pro Gly Thr Glu Gly Trp Ile Ala Pro Glu Met Leu
Ser Glu Asp 180 185 190 Cys Lys Asp Asn Pro Thr Tyr Thr Val Asp Ile
Phe Ser Ala Gly Cys 195 200 205 Val Phe Tyr Tyr Val Ile Ser Glu Gly
Asn His Pro Phe Gly Lys Ser 210 215 220 Leu Gln Arg Gln Ala Asn Ile
Leu Leu Gly Ala Cys Asn Leu Asp Cys 225 230 235 240 Phe His Ser Asp
Lys His Glu Asp Val Ile Ala Arg Glu Leu Ile Glu 245 250 255 Lys Met
Ile Ala Met Asp Pro Gln Gln Arg Pro Ser Ala Lys His Val 260 265 270
Leu Lys His Pro Phe Phe Trp Ser Leu Glu Lys Gln Leu Gln Phe Phe 275
280 285 Gln Asp Val Ser Asp Arg Ile Glu Lys Glu Ala Leu Asp Gly Pro
Ile 290 295 300 Val Arg Gln Leu Glu Arg Gly Gly Arg Ala Val Val Lys
Met Asp Trp 305 310 315 320 Arg Glu Asn Ile Thr Val Pro Leu Gln Thr
Asp Leu Arg Lys Phe Arg 325 330 335 Thr Tyr Lys Gly Gly Ser Val Arg
Asp Leu Leu Arg Ala Met Arg Asn 340 345 350 Lys Lys His His Tyr Arg
Glu Leu Pro Ala Glu Val Gln Glu Thr Leu 355 360 365 Gly Ser Ile Pro
Asp Asp Phe Val Arg Tyr Phe Thr Ser Arg Phe Pro 370 375 380 His Leu
Leu Ser His Thr Tyr Gln Ala Met Glu Leu Cys Arg His Glu 385 390 395
400 Arg Leu Phe Gln Thr Tyr Tyr Trp His Glu Pro Thr Glu Pro Gln Pro
405 410 415 Pro Val Ile Pro
Tyr Ala Leu 420 7423PRTRattus norvegicus 7Asp Asp Glu Asp Glu Glu
Thr Arg Met Val Ile Val Gly Lys Ile Ser 1 5 10 15 Phe Cys Pro Lys
Asp Val Leu Gly His Gly Ala Glu Gly Thr Ile Val 20 25 30 Tyr Lys
Gly Met Phe Asp Asn Arg Asp Val Ala Val Lys Arg Ile Leu 35 40 45
Pro Glu Cys Phe Ser Phe Ala Asp Arg Glu Val Gln Leu Leu Arg Glu 50
55 60 Ser Asp Glu His Pro Asn Val Ile Arg Tyr Phe Cys Thr Glu Lys
Asp 65 70 75 80 Arg Gln Phe Gln Tyr Ile Ala Ile Glu Leu Cys Ala Ala
Thr Leu Gln 85 90 95 Glu Tyr Val Glu Gln Lys Asp Phe Ala His Leu
Gly Leu Glu Pro Ile 100 105 110 Thr Leu Leu His Gln Thr Thr Ser Gly
Leu Ala His Leu His Ser Leu 115 120 125 Asn Ile Val His Arg Asp Leu
Lys Pro His Asn Ile Leu Leu Ser Met 130 135 140 Pro Asn Ala His Gly
Arg Ile Lys Ala Met Ile Ser Asp Phe Gly Leu 145 150 155 160 Cys Lys
Lys Leu Ala Val Gly Arg His Ser Phe Ser Arg Arg Ser Gly 165 170 175
Val Pro Gly Thr Glu Gly Trp Ile Ala Pro Glu Met Leu Ser Glu Asp 180
185 190 Cys Lys Glu Asn Pro Thr Tyr Thr Val Asp Ile Phe Ser Ala Gly
Cys 195 200 205 Val Phe Tyr Tyr Val Ile Ser Glu Gly Asn His Pro Phe
Gly Lys Ser 210 215 220 Leu Gln Arg Gln Ala Asn Ile Leu Leu Gly Ala
Cys Ser Leu Asp Cys 225 230 235 240 Phe His Ser Asp Lys His Glu Asp
Val Ile Ala Arg Glu Leu Ile Glu 245 250 255 Lys Met Ile Ala Met Asp
Pro Gln Gln Arg Pro Ser Ala Lys His Val 260 265 270 Leu Lys His Pro
Phe Phe Trp Ser Leu Glu Lys Gln Leu Gln Phe Phe 275 280 285 Gln Asp
Val Ser Asp Arg Ile Glu Lys Glu Ser Leu Asp Gly Pro Ile 290 295 300
Val Arg Gln Leu Glu Arg Gly Gly Arg Ala Val Val Lys Met Asp Trp 305
310 315 320 Arg Glu Asn Ile Thr Val Pro Leu Gln Thr Asp Leu Arg Lys
Phe Arg 325 330 335 Thr Tyr Lys Gly Gly Ser Val Arg Asp Leu Leu Arg
Ala Met Arg Asn 340 345 350 Lys Arg His His Tyr Arg Glu Leu Pro Leu
Glu Val Gln Glu Thr Leu 355 360 365 Gly Ser Ile Pro Asp Asp Phe Val
Arg Tyr Phe Thr Ser Arg Phe Pro 370 375 380 His Leu Leu Ser His Thr
Tyr Arg Ala Met Glu Leu Cys Arg His Glu 385 390 395 400 Arg Leu Phe
Gln Thr Tyr Tyr Trp His Glu Pro Thr Glu Ala Gln Pro 405 410 415 Pro
Gly Ile Pro Asp Ala Leu 420
* * * * *